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The public health problem of ensuring that teens and preteens receive the HPV 
vaccination series justified this study, using a convenience sample (N=122) of parents, 68 
of whom were English-speaking parents (ESP) and 54 were Spanish-speaking parents 
(SSP). Among ESP, 94.1% (n=64) were females and 5.9% (n=4) were males. Among 
SSP, 98.1% (n=53) were females and 1.9% (n=1) was male. The mean age for ESP 
(n=68) was 41.16 years (min=27, max=72, SD=6.72). The mean age for SSP (n=54) was 
38.72 years (min=26, max=55, SD=7.31). About 44.1% (n=30) of ESP were Hispanic/ 
Latino, and 98.1% (n=53) of SSP were Hispanic/Latino.  
Using backward stepwise regression analysis, in the whole sample (N=122), 
significant predictors of parents being in an action or maintenance stage for making sure 
their children received the HPV vaccination was predicted by: if child had received HPV 
vaccination (β=1.714, SEB=.599, p=.000) and yearly household income (β=.142, 
SEB=.200, p=.007) in a model accounting for 40.5% of the variance (R
2=.420, 
AdjR2=.405).  
This study determined that a linguistically and culturally tailored (i.e., in English 
or Spanish) video on HPV and HPV vaccination of preteens and teens served as a brief 
online e-health intervention that was associated with significant parental movement 
across the stages of change (i.e., from precontemplation or contemplation stage, to 
preparation stage) and increased self-efficacy for three key behaviors: (1) talking to a 
pediatrician or family practice medical provider about the Human papillomavirus (HPV) 
infection and the HPV vaccination for children; (2) making sure their preteen and teen 
children receive the HPV vaccination; and (3) making sure their preteen and teen children 
receive all required doses (e.g., at least two or three doses) of the HPV vaccination. Also, 
89.5% (n=17) of healthcare providers recommended the video. 
Qualitative data produced themes for recommending the video and improving it. 
Recommendations for an evaluation of the video intervention using a nationally 
representative sample are advanced, along with implications for widely disseminating 
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Human papillomavirus (HPV) infection is the most common sexually transmitted 
infection (STI) among women and men in the world (Newman et al., 2018). According to 
Tanveer (2017), HPV is a global health problem. There are more than 150 types of HPV 
and about 40 types are transmitted through sexual contact, infecting “the anogenital 
region and other mucosa sites of the body” (Dunne et al., 2014, p. 69). Thus, “most 
sexually active persons will acquire HPV in their lifetime” (p. 69).  
According to Van Dyne et al. (2018), from 1999 to 2015, the incidence rates of 
HPV-associated cancers increased from 30,115 to 43,371 in the United States. According 
to the Centers for Disease Control and Prevention (CDC, 2017a), human papillomavirus 
(HPV) is the most common STI in the United States. An individual can be infected with 
the virus by having sexual contact with another infected person through vaginal, anal, or 
oral sex (CDC, 2017b). About 80 million people, or one in every four, have been infected 
with HPV, and most of the HPV infections occur among individuals in their late teens 
and early 20s (CDC, 2013; CDC 2017a). According to Bakir and Skarzynski (2015), 
“epidemiological calculations project that the majority of sexually active heterosexual 
males (90%) and females (85%) will be infected with HPV in their lifetimes” (p. 2). The 






reported each year, and half of these cases occur in persons between the ages of 15 and 
24 years of age.  
Approximately 38,793 HPV-associated cancers are diagnosed in the United States 
annually (CDC, 2016e). The number of reported HPV-associated cancer diagnoses were 
higher among women than among men, at 23,000 and 15,793, respectively. Scientists 
have identified over 120 HPV types (CDC, 2016d). More than 40 types of HPV may 
cause infection of the genital tract, while 90% of HPV infections are asymptomatic and 
usually disappear within 2 years (CDC, 2016a). However, persistent infection with 
oncogenic or high-risk HPV types can progress to HPV cancers, such as cancer of the 
cervix, vulva, vagina, penis, or anus (CDC, 2016b; Holman et al., 2014).  
HPV accounts for 99% of all cervical cancer cases (CDC, 2016d; Kessels et al., 
2012). It is estimated that 50% of cervical cancer cases worldwide are caused by HPV 
type 16, while HPV types 16 and 18 are responsible for 70% of cervical cancer diagnoses 
(CDC, 2016d). HPV has also been linked to some oropharyngeal cancers (CDC, 2016c). 
Non-oncogenic or low-risk HPV types 6 and 11 can cause 90% of genital warts and 
abnormal cervical cells (CDC, 2016d; Holman et al., 2014).  
In 2015, data from cancer registries showed that the number of HPV-associated 
cancer diagnoses were higher among women than among men, at 24,432 (13.6%) and 
18,939 (10.5%) per 100,000 persons, respectively (Van Dyne et al., 2018). The data also 
revealed that oropharyngeal squamous cell carcinoma (SCC) was the most common 
HPV-associated cancer, with 15,479 cases in men and 3,438 cases in women (Van Dyne 






Disparities in HPV infection among racial and ethnic groups have been well 
documented, showing that non-Hispanic Blacks and Hispanics have a higher prevalence 
of HPV infection compared to their counterpart non-Hispanic Whites (Lin et al., 2015). 
The incidence and mortality rates for each HPV-associated cancer vary by cancer type, 
sex, age, region, and racial and ethnic minority group (Burger et al., 2016; Van Dyne et 
al. 2018). Razzaghi et al. (2018) found large disparities in HPV-associated cancer by sex, 
race, and age, such that 5-year relative survival was higher among non-Hispanic White 
patients than non-Hispanic Black patients for all HPV-associated cancers and all age 
groups (p. 203).  
Earlier data from 2013 revealed that Hispanic women had a higher prevalence rate 
of HPV-associated cervical cancer, followed by non-Hispanic Black women; mortality 
rates for cervical cancer were higher among non-Hispanic Black women (CDC, 2016f), 
often being diagnosed in an advanced stage (CDC, 2016g). Bakir and Skarzynski (2015) 
found that women “who are of Hispanic or Black heritage are 1.5-2 times more likely to 
develop cervical cancer than American women from other ethnic and racial backgrounds” 
(p. 2). Minority groups are not only affected by the burden of cervical cancer but are also 
disproportionately affected by other HPV-associated cancers. For instance, non-Hispanic 
Black men are more likely to be diagnosed with anal cancer than non-Hispanic White 
men, while Hispanic men report higher prevalence rates of penile cancer compared to 








In an effort to address the disparity gap in HPV infection, Healthy People 2020 
sought an 80% increase the proportion of females and males aged 13 to 15 years who 
complete the HPV vaccination series, with a baseline HPV status of 28.1% and 6.9%, 
respectively (U.S. Department of Health and Human Services [USDHHS], 2019). The 
U.S. Food and Drug Administration (FDA) has licensed three vaccines for use in the 
United States: Cervarix, Gardasil, and Gardasil 9 (Fontenot, Domush, & Zimet, 2015; 
Meites, Kempe, & Markowitz, 2016). The three vaccines are administered in a three-dose 
series at intervals of a range of 0, 1-2, and 6 months (Meites et al., 2016), meaning “1-2 
months between dose 1 and 2 and 6 months between dose 1 and 3” (Wilson, Brown, 
Carmody, & Fogarty, 2015, p. 396). The 9vHPV vaccine can be administered in a two-
dose series schedule for girls and boys from 9 to 14 years old (Meites et al., 2016).  
The Advisory Committee on Immunization Practices (ACIP) recommends routine 
vaccination of all three HPV vaccines for girls from the ages 11 to 12 years, but the 
vaccination series can be initiated as early as 9 years of age (CDC, 2016a; Trogdon & 
Ahn, 2015). Catch-up vaccination is also recommended for girls and young females from 
ages 13 to 26 years who have not previously received the vaccine (Laz, Rahman, & 
Berenson, 2013; Trogdon & Ahn, 2015). The ACIP also recommends routine HPV 
vaccinations of the 4vHPV and 9vHPV vaccines for teen boys between the ages of  
11 and 12 years, and through age 21 years for those who have not been previously 
vaccinated (CDC, 2016a). For specific individuals, such as men who have sex with men 
(MSM) and for young individuals with certain immunocompromised conditions (e.g., 






continuing through age 26 years, if not vaccinated previously (CDC, 2016a, 2016d, 
2016h).  
As vaccines are considered most effective when given to individuals before they 
become sexually active, it is recommended for preteens and teens to get vaccinated 
before they become sexually active (American College of Obstetricians and 
Gynecologists [ACOG], 2015; CDC, 2017c). Likewise, the vaccine has higher immunity 
response in preteens compared to older adolescents (CDC, 2015). However, teenagers are 
having sex at early ages, increasing their risk of exposure to one or more of the HPV 
types targeted by the HPV vaccines (CDC, 2017c). According to ACOG (2015), data 
indicated that one in three teenagers in ninth grade and two in three adolescents in twelfth 
grade have had sexual intercourse (ACOG, 2015). Based on the results from the 2015 
Youth Risk Behavior Surveillance System (YRBSS), 41% of U.S. high school students 
reported having sexual intercourse and 30% reported having sex in the previous 3 
months; of these, 43% did not use proper protection the last time they were sexually 
active (CDC, 2017g). Sexually active individuals can still benefit from receiving HPV 
vaccination (CDC, 2017c) because “prior sexual exposure to all vaccine types is 
unlikely” (ACOG, 2015, p. 2). 
Racial and Gender Disparities in HPV Vaccination and Potential Factors 
Despite the ACIP recommendations, HPV vaccine uptake and completion rates 
are lower than expected (Spencer, Brewer, Trogdon, Wheeler, & Dusetzina, 2018). Data 
from the 2017 National Immunization Survey-Teen (NIS-Teen) showed that 66% of 






girls and 63% of boys received their first dose of the HPV vaccine, and only 49% of teens 
completed all three recommended doses (Walker et al., 2018). Clearly, national HPV 
vaccination completion rates are far from meeting the Healthy People 2020 target of 80% 
of adolescents aged 13 to 15 years (Katz et al., 2016; Rosen, Bishop, McDonald, Kahn, & 
Kreps, 2018). 
Adolescent girls are more likely to be vaccinated than boys (CDC, 2017e). Data 
from the 2015 NIS-Teen showed that 6 out of 10 girls and 5 out of 10 boys had received 
at least one dose of the HPV vaccine (CDC, 2017e). Only about 43% of teens had 
completed all recommended doses of the HPV vaccine (CDC, 2017h). It is argued that 
delaying “completion of the series places adolescents at risk for acquiring HPV infection 
due to gaps in immunologic protection from the vaccine doses” (Wilson et al., 2015,  
p. 396).  
According to Henry, Swiecki-Sikora, Stroup, Warner, and Kepka (2018), U.S. 
HPV vaccination rates vary by race/ethnicity and socioeconomic status. Research has 
shown that the “rates of HPV vaccine initiation and completion of the three-doses are 
lower among non-Hispanics compared to Hispanics and other racial minorities” (p. 2). 
Further, rates of HPV vaccine initiation and completion of the three-dose schedule are 
lower among “teens whose families are living below the poverty line compared to their 
counterparts living above the poverty line” (p. 2).  
Further, several studies have documented disparities in HPV vaccination uptake 
and completion among racial and ethnic groups (Btoush, Brown, Fogarty, & Carmody, 
2015; Burger et al., 2016; Jeudin, Liveright, Del Carmen, & Perkins, 2014; Nelson, 






2015). Fisher, Trotter, Audrey, MacDonald-Wallis, and Hickman (2013) conducted a 
systematic review and meta-analysis, finding that young African American females were 
less likely to initiate the HPV vaccine than young White females. Other studies have also 
reported that young Black females are less likely to initiate the HPV vaccine (Beavis & 
Levinson, 2016; Gelman et al., 2013; Kramer & Dunlop, 2012; Laz, Rahman, & 
Berenson, 2013; Lefkowitz, Kelly, Vasilenko, & Maggs, 2014).  
Gelman et al. (2013) indicated that Hispanics born in the United States, foreign-
born Hispanics as well as African Americans were less likely to initiate the HPV 
vaccination series. Pérez, Agénor, Gamarel, and Operario (2018) reported that after 
adjusting for healthcare factors, foreign-born men had lower odds of HPV vaccine 
initiation, while foreign-born women had lower odds of HPV vaccine initiation and 
completion than U.S.-born women and men. This suggests that immigrants may face 
barriers other than access to healthcare that contribute to lower HPV vaccine initiation 
than their U.S.-born counterparts. For example, “foreign-born Latinos have numerous 
barriers to healthcare, including language, transportation, and documentation status, both 
at the individual and family level” (p. 257). Also, there are those immigrants who “may 
not be familiar with navigating the U.S. healthcare system,” or lack knowledge of “U.S. 
preventive medical guidelines” (p. 257). Also, some immigrants may prioritize “treating 
symptoms rather than seeking regular preventive services” (p. 257). Yet, even here, those 
immigrants who “seek care, healthcare providers have the potential to increase HPV 
vaccine uptake, as healthcare provider recommendation has been associated with HPV 






Other studies have reported higher rates of the HPV vaccine initiation among 
African American and Hispanic adolescent girls than their White counterparts (Beavis & 
Levinson, 2016; Nelson et al., 2015; Okafor et al., 2015). Henry et al. (2018) explained 
that higher rates of HPV vaccine uptake among racial/ethnic minority groups (e.g., Non-
Hispanic Black and Hispanics) living in low-income communities could be due in part to 
access to safety-net services which provide free or reduced cost vaccinations, or to the 
availability of long-term targeted interventions. Conversely, higher vaccination rates 
could be due to living among “co-ethnics in segregated areas with similar cultural norms 
that promote vaccination” (Henry et al., 2018, p. 2). 
However, African American and Hispanic individuals continue to report lower 
rates of the HPV vaccine completion than those who are White (Beavis & Levinson, 
2016; Jeudin et al., 2014; Nelson et al., 2015; Okafor et al., 2015). In this regard, Henry 
et al. (2018) indicated that economic difficulties and barriers related to access to 
healthcare among individuals living in low-income areas could also result in lower HPV 
vaccine uptake due to limited access to healthcare resources and preventive services. For 
example, language barriers and lack of awareness about the benefits of getting the HPV 
vaccine in racial/ethnic minority communities may result in lower screening rates. Henry 
et al. (2018) further stated that, given how “cancer prevention and screening activities are 
generally higher among high-income, more educated populations, conventional wisdom 
suggests that uptake for a recommended vaccine that protects against some cancers would 
also fallow this trend” (p. 2).  
According to Henry et al. (2018), HPV vaccine initiation was higher among girls 






communities. Further, HPV vaccine initiation was higher among girls living in 
communities that were predominantly Hispanic or mixed-race, compared to girls living in 
predominately non-Hispanic White communities. The odds of HPV vaccine initiation 
were highest among older girls, girls with State Children’s Health Insurance Program 
(SCHIP) or Medicaid insurance, girls with younger mothers, and girls whose mothers had 
lower educational attainment and income below the federal poverty level. Receiving a 
provider recommendation was one of the strongest factors associated with HPV vaccine 
initiation. Henry et al. (2018) also found that rates of HPV vaccine initiation were highest 
among Hispanic girls compared to non-Hispanic White, non-Hispanic Black, and other 
non-Hispanic race/ethnic groups. Results of the study showed that “racial-ethnic 
composition” and “population density were significantly associated with HPV vaccine 
initiation even after adjusting for individual-level factors” (p. 313).  
Similar to findings with girls, Henry et al. (2018) also found that the odds of HPV 
vaccine initiation and completion varied by boys’ race/ethnicity, depending on level of 
poverty and area of residence. For instance, the study results revealed that boys living in 
urban areas had higher odds of HPV vaccine initiation and completion than boys living in 
non-urban areas. Boys living in areas where the majority race/ethnicity were Hispanics 
had greater odds of HPV vaccine initiation than those boys living in areas where the 
majority were non-Hispanic Blacks and non-Hispanic Whites. The authors observed that 
the higher odds of HPV vaccine in urban areas and among racial/ethnic minorities living 
in high-poverty areas might be due to parental acceptability of HPV vaccine, greater 
proportion of providers recommending the vaccine, and parental accessibility to safety-






areas with lower levels of poverty, “irrespective of race/ethnicity, is also likely to due to 
less parental support of HPV vaccination as compared to parents from lower-SES 
groups” (p. 11). It is also possible that non-Hispanic Whites are being exposed to 
“negative sentiment or vaccination safety concerns” and may not pursue vaccinating their 
sons (p. 11).  
Patel and Berenson (2013) conducted a review on parental vaccine hesitancy and 
explained that parents who refused vaccination tended to be more educated, “have 
researched the topic extensively and overall show an interest in health-related issues”  
(p. 2650). Patel and Berenson further explained the “theory behind this observation,” 
wherein “educated parents are more often more likely to be have access to specific source 
of media, such as Internet, which may expose them to contradictory and possibly 
inaccurate information regarding the HPV vaccine” (p. 2650). Also, those “highly 
educated parents may feel more confident in their ability to interpret complex scientific 
and clinical health information, allowing then to ignore the advice of practitioners if 
contradiction exists” (p. 2650).  
In addition, it is possible that providers in more affluent areas are non-adherent to 
the recommendation guidelines on routinely offering the HPV vaccine to parents for their 
children (Henry et al., 2018). On the other hand, acculturation may play a key role in 
HPV vaccination among Hispanics. For instance, Hispanics who live in low-income 
communities tend to have a lower level of acculturation and are more likely to accept 
HPV vaccine for the children, “which may account for the differences seen among 






Reasons for racial and ethnic disparities seen in HPV vaccine uptake and 
completion rates are multifactorial (Gelman et al., 2013; Liu, Kong, & Du, 2016). Henry 
et al. (2018) indicated that low rates of HPV vaccination are attributed, in part, to the 
following: low parental knowledge about HPV infection and HPV vaccine, lack of 
provider recommendations, missed opportunities, religious beliefs and cultural factors, 
the belief that vaccinating young children against sexually transmitted disease is not 
necessary, and the belief that vaccinating adolescents may promote sexual activity at a 
young age (Henry et al., 2018).  
Others have cited individual-level factors—such as negative attitude toward the 
HPV vaccine (concern about vaccine efficacy and possible side effects); lack of 
knowledge about HPV infection; vaccine history (having received childhood 
immunization such as influenza, meningococcal positively predicts HPV vaccination); 
and lack of health insurance—as predictors of vaccination uptake and completion rates 
(de Casadevante, Cuesta, & Cantarero-Arévalo, 2015; Kessels et al., 2012; Okafor et al., 
2015). According to Gelman et al. (2013), African Americans and Hispanics are less 
likely to have continuous health insurance or to have an annual doctor’s visit in the 
previous year compared to their counterparts. A lack of trust toward healthcare facilities 
has been reported among Hispanic immigrants as well (Holman et al., 2014). Perceived 
risk for HPV infection is another personal-level factor influencing the decision of 
whether or not to vaccinate (Okafor et al., 2015). Beavis and Levinson (2016) found that 
among young women, low perceived HPV infection risk was cited as a reason for not 







Factors Related to HPV Vaccine Uptake 
Previous studies have suggested that provider recommendation is an important 
predictor for HPV vaccine uptake in girls and boys (Gilkey, Malo, Shah, Hall, & Brewer, 
2015; Kessels et al., 2012). Mohammed and colleagues (2017) found that maternal 
education is the strongest predictor of parental intent to vaccinate against HPV. In 
addition, mothers with a graduate degree, as well as non-Hispanic White parents, 
reported a lower intention to vaccinate their child (Mohammed, Vivian, Loux, & Arnold, 
2017). Even though provider recommendation was an important predictor for HPV 
vaccine intention, “the effect was not as strong as maternal education and was stronger 
for boys than girls” (p. 3).  
Interestingly, Lindley and colleagues (2016) reported an opposite finding, as 
provider recommendation was the most important predictor of vaccine intention among 
parents intending to vaccinate their boys and girls within the next year. Yet, Mohammed 
et al. (2017) found that provider recommendation was the strongest predictor of actual 
vaccine receipt rather than vaccine intention, suggesting that multiple factors influence 
vaccine intention versus action.  
Parental sexual history of sexually transmitted diseases such as HPV-related 
disease was found to be associated with vaccine intention as well (Mohammed et al., 
2017; Patel & Berenson, 2013). This may be due in part to parental understanding about 
the severity of HPV infection and the benefits associated with the HPV vaccine (Patel & 
Berenson, 2013).  
According to Beavis and Levinson (2016), parents’ knowledge about the HPV 






and the HPV vaccine have been associated with non-vaccine intention (Zimet, Rosberger, 
Fisher, Pérez, & Stupiansky, 2013) and vaccine incompletion (Lindley et al., 2016). In 
fact, Lindley and colleagues (2016) found that “more than two-thirds of parents whose 
teens were not fully vaccinated reported they did not know how many shots are in the 
HPV vaccine series” (p. 1522). On the other hand, Walhart (2012) stated that increasing 
parental knowledge about HPV infection and its sequela will not always lead to increased 
vaccine acceptance.  
Strategies aimed to increase HPV vaccine uptake and completion should consider 
the effect of parental attitudes and acceptance toward the HPV vaccine. This is important 
because the decision of whether or not to vaccinate an adolescent aged 18 years or 
younger is mainly influenced by his or her parent or caregiver (Choi, Eworuke, & Segal, 
2016). Bakir and Skarzynski (2015) explained that parental hesitancy represents a barrier 
to HPV vaccination for children between the ages of 11 and 12 years. In fact, one study 
found that parents are three times more likely to start the HPV vaccination series in 
daughters between ages 16 and 18 years than their younger daughters ages 10 to 12 years 
(Garcini, Galvan, & Barnack-Tavlaris, 2012). It is evident that vaccination completion 
increases with age (Bakir & Skarzynski, 2015).  
Shapiro et al. (2017) evaluated for parents (n=4,606) of school-aged children 
(aged 9 to 16) their attitudes, knowledge, and decision-making stage regarding HPV 
vaccination. Using a validated HPV vaccine knowledge and attitudes scales rooted in the 
Health Belief Model, the study also investigated parents’ HPV adoption stage or 
decision-making stage, i.e., (1) unaware stage (parent unaware HPV vaccine could be 






(3) undecided stage (parent undecided about vaccinating child); (4) decided not to 
vaccinate stage (parent decided not to vaccinate child); (5) decided to act/decided to 
vaccinate stage; and (6) acted/vaccinated child stage. Only a “quarter of parents” were in 
the later stage or vaccinated child stage (p. 209). Meanwhile “parents of daughters, older 
children,” and those who had received a recommendation for HPV vaccination of their 
child from a medical provider “had decreased odds of being in an earlier stage,” such as 
unaware, unengaged or undecided stage, and so on (p. 209).  
Shapiro et al. (2018) also assessed vaccine attitudes with validated scales, 
including the Vaccine Conspiracy Beliefs Scale and the Vaccine Hesitancy Scale (i.e., 
one subscale on vaccine hesitancy—lack of confidence, and one subscale on vaccine 
hesitancy—risks); they found that parents in the decided not to vaccinate stage had 
significantly greater odds of having vaccine conspiracy beliefs, as well as perceived 
harms from vaccines, lack of confidence, and risks. Of note, other research has found that 
“parents are less likely to vaccinate their child if they are not aware of, or do not know 
enough about, HPV vaccination,” or if they “believe that HPV vaccination can cause 
harm, or that vaccination is not accessible” or affordable (p. 203). Further, positive 
attitudes toward vaccines have been found to be linked to “HPV vaccine acceptance”  
(p. 203). Also, parental acceptance of vaccination has been shown to improve 
significantly where there is a “strong healthcare provider recommendation” (p. 204). 
Shapiro et al. (2018) also found that those parents “who received a HCP recommendation 
for HPV vaccination had lower odds of being unaware,” or unengaged, or undecided, or 







Toward Interventions to Increase Vaccine Uptake: Role of Videos 
Agénor, Pérez, Peitzmeier, and Borrero (2018) explained that tailored-education 
interventions, including alerts and reminders, can be used to help providers and parents of 
unvaccinated girls and young women to make an informed decision regarding HPV 
vaccination. Educational interventions should be tailored (e.g., be provided in multiple 
languages) and tested among non-Hispanic Black, Hispanic, and non-Hispanic Asian 
individuals in order to ensure the intervention’s appropriateness and effectiveness for 
those from underserved groups (Agénor et al., 2018).  
Tuong, Larsen, and Armstrong (2014) considered the impact of videos in 
modifying health behaviors, including 28 studies and 12,703 subjects in a systematic 
review of video studies. Findings showed that video “interventions were variably 
effective for modifying health behaviors depending on the target behaviors to be 
influenced,” being less effective for influencing addiction behaviors (p. 219).  
According to Tuong et al. (2014), the modification of health behaviors is crucial 
in preventing “many diseases that are associated with significant morbidity and mortality 
in the United States” (p. 219). Health information was discussed as involving “written 
pamphlets, videos, face to-face counseling, and web-based applications”; however, the 
“use of video as an educational medium offers several potential advantages” (Tuong et 
al., 2014, p. 219). Consider the many advantages cited by Tuong et al. (2014) below: 
   First, video interventions can be a less resource intensive means of delivering 
educational content. A study assessing the cost-effectiveness of a video-based 
human immunodeficiency virus (HIV) patient education program resulted in 
annual savings of US$5,544,408 for 10,000 patients in averted HIV infections. 
Second, video interventions remove inconsistencies across educators and balance 
the presentation of information to provide more standardized education. Third, 






education. Finally, video-based education can be administered in many forms, 
such as videotape, digital video/versatile disc (DVD), downloadable media files, 
and streaming videos from certain Internet websites. In particular, educational 
videos delivered through video-sharing websites can quickly reach a broad 
audience via social media. (p. 219) 
 
Findings showed that nine “video interventions resulted in significant changes in 
the targeted behaviors, such as breast self-examination, prostate cancer screening, 
sunscreen adherence, self-care in patients with heart failure, HIV testing, treatment 
compliance, and female condom use” (Tuong et al., 2014, p. 224). Recommendations 
covered how “video modeling may facilitate learning of new behaviors and can be an 
important consideration in the development of future video interventions” (p. 225). 
Relying upon the value of video modeling of new behaviors, others have created 
e-health designed as a brief online intervention, using an avatar/cartoon video with the 
intention of impacting self-efficacy and readiness to engage in the targeted health 
behavior (Chung, 2013). For example, Chung (2013) targeted mother-child dyads who 
watched a cartoon video tailored to be culturally appropriate for African American 
mothers, while actors in the video modeled the behaviors of selecting more fruit and 
vegetables and increased engagement in physical activity. Others have created e-health 
with actors modeling prostate screening behaviors (Hall, 2018). 
Statement of the Problem 
The problem that this study addressed is the need to increase HPV vaccination 
initiation and completion for male and female preteens and teens (ages 9 to 18) by virtue 
of the dissertation accomplishing the following: (1) addressing parental hesitancy about 






vaccination of their children via exposure to an innovative linguistically and culturally 
tailored e-health cartoon video intervention on HPV vaccination; and (2) enhancing 
provider recommendations to parents to vaccinate preteens and teens by providing them 
the new tool of an innovative linguistically and culturally tailored e-health cartoon video 
on HPV vaccination, which they may choose to recommend to parents, augmenting their 
own recommendation to parents to pursue and complete HPV vaccination of children. 
Purpose of the Study 
Study # 1: Parents (English- or Spanish-Speaking)—Predictors of Parents 
Having Decided to Take Action to Vaccinate Child for HPV 
The first purpose of the dissertation research (i.e., Study # 1) was to identify 
significant predictors of the Study #1 dependent variable of parents being in an action or 
maintenance stage of change for having made the decision and taken action to ensure 
their child received the HPV vaccination—as measured before parents watched a 
linguistically and culturally tailored cartoon video.  
Study # 1: Parents (English or Spanish Speaking)—Cartoon Video as a 
Potential Linguistically and Culturally Tailored Brief Intervention 
A second purpose of the dissertation research (Study #1) was to determine if a 
linguistically and culturally tailored (i.e., in English or Spanish) video on HPV and HPV 
vaccination of children can serve as a brief online e-health intervention that promotes 
significant parental movement across the stages of change (i.e., from a precontemplation 
or contemplation stage, to a preparation stage, as per the theory of Prochaska and 






Bandura [1977]) for three key behaviors of: (1) talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection, and the HPV 
vaccination for children; (2) making sure their preteen and teen children receive the HPV 
vaccination; and (3) making sure their preteen and teen children receive all the required 
doses (e.g., at least 2 or 3 doses) of the HPV vaccination. This involved a pre-video 
viewing versus post-video viewing comparison of parents’ stage of change and self-
efficacy each of these three key behaviors. In addition, changes in knowledge were 
examined for parents from pre- to post-video viewing. 
Study #2: Providers (Pediatricians or Family Practitioners)—Recommending 
the Cartoon Video to Parents or Not 
A third purpose of the dissertation research (i.e., via Study #2) was to obtain the 
Study #2 dependent variable of pediatricians/family practitioners recommending (yes/no) 
the video to parents and/or other providers so they could share it with parents, in order to 
support parental decision making about initiating and completing HPV vaccination of 
their preteen and teen children (as per the Diffusion of Innovation Theory of Rogers 
[1995]).  
Study #1 Research Questions 
Study #1 With Parents 
Given an online sample of parents (n=122) who responded to a social media 
campaign (i.e., “Go to <htpps://tinyurl.com/HPV-Video-Study-English> to take the 






win 1 of 3 $100 Amazon gift cards”) and complete the survey, Study #1 sought to answer 
the following research questions: 
1-What are the parents’ demographic characteristics (i.e., selected English or Spanish 
survey and video, gender, age, race/ethnicity, US born or not, partner status, employment 
status, annual household income, level of education, type of medical insurance)? 
Part I: Parent’s Basic Demographics (PARENTS-BD-10) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-What do parents report about their children (i.e., number of children ages 9 to 18, 
number of male and female children, child sexual orientation, type of medical insurance)? 
Part II: About Your Children (AYC-4)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-Do parents report providers having talked to them about HPV and the HPV 
vaccination, and did the providers recommend the HPV vaccination for their child? 
Part III: Parent Report on Provider Recommendation on HPV vaccination for 
Child (PARENT-R-PR-HPV-V-FC-2) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-Do parents report one or more of their children ever having received the HPV 
vaccination? 
Part IV: Parent Report on HPV vaccination for Child (PARENT-R-HPV-V-FC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
5-Do parents report one or more of their children ever having received the flu 
vaccination, and do they believe in the value of an annual (yearly) flu vaccination for 
their children? 
Part V: Parent Report on HPV vaccination for Child (PARENT-R-FLU-V-FC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
6-To what extent have parents been exposed to print or digital media providing 
information on the HPV vaccination for children? 
Part VI: Parent Exposure to Print or Other Media or Information on HPV 
Vaccination for Children (PARENT-EPOMI-HPV-VFC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 








7-What is the parents’ level of general HPV knowledge? 
Part VII: HPV General Knowledge (HPV-G-K-23) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
8-What is the parents’ level of HPV vaccine knowledge? 
Part VIII: HPV Vaccine Knowledge Scale (HPV-V-K-S-11) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
9-What are the parents’ general vaccine attitudes, including for (a) conspiracy beliefs,  
(b) vaccine hesitancy—lack of confidence, and (c) vaccine hesitancy—risks? 
Part IX: General Vaccine Attitudes-Conspiracy Beliefs, and Hesitancy due to 
Lack of Confidence or Risks (GVA-CB-HLC-R-16) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
10-What are the parents’ perceived barriers to their child completing the HPV 
vaccination series? 
Part X: Parents’ Perceived Barriers to Child’s Completion of the HPV 
vaccination Series (PARENTS-PB-CC-HPV-VS-12) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
11-Pre-video viewing, what was the parents’ knowledge of HPV, the prevalence of 
parents being in an action or maintenance stage for making sure their children received 
the HPV vaccination—as the Study #1 dependent variable—and their self-efficacy for 
doing this? 
From Item # 4 of Part XII: Pre-Video Parents’ HPV Knowledge and Stage of 
Change and Self-Efficacy for Talking to Provider and Child Receiving the HPV 
Vaccine (PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
12-Was there a change in the parents’ knowledge of HPV, as well as their stage of 
change and self-efficacy for three key behaviors [i.e., (1) talking to a pediatrician or 
family practice medical provider about the Human papillomavirus (HPV) infection, and 
the HPV vaccination for children; (2) making sure their children receive the HPV 
vaccination; and (3) making sure their children receive all the required doses (e.g., at 
least 2 or 3 doses) of the HPV vaccination] when comparing their pre-video viewing to 
post-video viewing mean scores? 
Part XII: Pre-Video Parents’ HPV Knowledge and Stage of Change and Self-








Part XIV: Post-Video Parents’ HPV Knowledge and Stage of Change and Self-
Efficacy for Talking to Provider and Child Receiving the HPV Vaccine (PRE-V-
PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
Data Analysis Plan: Paired t-tests. 
 
13-How do the parents rate the video cartoon? 
Part XV: Rate the Video for Parent (RTV-PARENTS-2) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
14-Do the parents recommend the video cartoon to other parents? 
Part XVI: Diffusion of Innovation using E-Health on HPV by Parents (DOF-
UEH-HPV-PARENTS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
15-Are there any significant differences between the responses of the English-speaking 
and Spanish-speaking parents on the study measures? 
Data Analysis Plan: Independent t-tests 
 
16-Controlling for social desirability, what are the significant predictors of parents being 
in an action or maintenance stage for making sure their children received the HPV 
vaccination—before the video—as the Study #1 dependent variable? 
Data Analysis Plan: Backward stepwise regression. 
Qualitative Portion of Study #1 
17-How do parents respond when asked why they would or would not recommend the 
video, including any comments on the strengths and weaknesses of the video, or how 
could it be improved? 
Part XVII: Qualitative Portion on Reasons for Recommending the E-Health Video 
or Not—For Parents (QP-RREHV-PARENTS-1) 
Data Analysis Plan: Identification of emergent themes. 
 
18-What additional thoughts or feelings do the parents share in reaction to the video 
and/or taking the survey? 
Part XVIII: Qualitative Portion on Reasons to Study Participation by Parents 
(QP-RSP-PARENTS-1)  









Study #2 Research Questions 
Study #2 With Providers 
 
Given an online sample of providers (n=19 pediatricians or family practitioners) 
who responded to a social media campaign (i.e., “Click <htpps://tinyurl.com/HPV-
Video-Study-For-Providers> to take 10-12 min Survey for Pediatric & Family Practice 
Providers on HPV vaccination for preteens/teens & rate a cartoon for parents on HPV”) 
and complete the survey, Study #2 answered the following research questions: 
1-What were the providers’ demographic and background characteristics (gender, age, 
race/ethnicity, US born or not, partner status, annual household income, status as a 
current job title, pediatric or family practitioner, work setting, years in current position 
pediatrics or family practice, years in health care)? 
Part I: Provider’s Basic Demographics (PROVIDERS-BD-15)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-What was the providers’ (a) level of knowledge about the Human papillomavirus 
(HPV) infection, the available HPV vaccinations, and schedule for vaccinating preteen 
and teen boys and girls—and for the behavior of recommending within their medical 
practice to parents/guardians that they vaccinate their preteen and teen boys and girls for 
HPV—and, also their (b) stage of change, (c) self-efficacy, and (d) perception of barriers 
(e.g. time) experienced during a medical visit for doing this? 
Part II: Pre-Video Providers’ Overall HPV Knowledge for Recommending HPV 
Vaccination to Parents for their Child—and Stage of Change, Self-efficacy, and 
Barriers (PRE-VIDEO-PROVIDERS-SOC-SE-B-4)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-How did the providers rate the quality of the cartoon video as a potential linguistically 
and culturally appropriate tool (i.e., available in English and Spanish) to support parents 
in their decision-making about whether or not they make sure their preteen or teen child 
receives the HPV vaccination series. 
Part III: Rate the Video for Providers (RTV-PROVIDERS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 








4-Do the providers recommend the cartoon video for parents, or to other providers so 
they could share it with parents? 
Part IV: Diffusion of Innovation using E-Health on HPV by Providers (DOF-
UEH-HPV-PROVIDERS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
 
Qualitative Portion of Study #2 
 
5-How do the providers explain why they would or would not recommend the video to 
parents or other providers, including any comments on the strengths and weaknesses of 
the video, or how could it be improved? 
Part V: Qualitative Portion on Reasons for Recommending the E-Health Video or 
not—for Providers (QP-RREHV-PROVIDERS-1) 
Data Analysis Plan: Identification of emergent themes and categories 
 
6-What additional thoughts or feelings do the providers share in response to watching the 
video and/or taking the survey? 
Part VI: Qualitative Portion on Reactions to Study Participation by Providers 
(QP-RSP-PROVIDERS-1)  
Data Analysis Plan: Identification of emergent themes and categories 
 
Study Rationale 
The rationale for the dissertation research is provided by several theories: the 
Health Belief Model (Rosenstock, 1974) for this study’s focus on knowledge, 
beliefs/attitudes about taking action, and barriers to taking action; the Stages of Change 
from the Transtheoretical Model (Prochaska & DiClemente, 1982), such as for examining 
whether a study participant is in a precontemplation, contemplation, preparation, action, 
or maintenance stage for performing behaviors of focus (e.g., parents taking action to 
vaccinate their child for HPV or providers taking action to recommend the HPV 
vaccination to parents for vaccinating their child); Self-Efficacy from Social Cognitive 
Theory (Bandura, 1977), as in self-efficacy or confidence for performing behaviors of 






recommending the video to other parents, thereby diffusing the innovation of educating 
about HPV via the brief intervention of a cartoon video. 
Rationale for Study #1 
Parents (English- or Spanish-Speaking)—Predictors of Parents Having 
Decided to Take Action to Vaccinate Child for HPV 
More specifically, there is a rationale for Study #1 with parents seeking to 
identify: significant predictors of the Study #1 dependent variable of parents being in an 
action or maintenance stage of change for having made the decision and taken action to 
ensure their child received the HPV vaccination (i.e., as per the theory of Prochaska and 
DiClemente [1982] on the stages of change)—as measured before parents watch a 
linguistically and culturally tailored cartoon video. This rationale rests in the research of 
Shapiro et al. (2017) who examined parents’ HPV adoption stage or decision-making 
stage, spanning the following: (1) unaware stage (parent unaware HPV vaccine could be 
given to child); (2) unengaged stage (parent never thought about vaccinating child);  
(3) undecided stage (parent undecided about vaccinating child); (4) decided not to 
vaccinate stage (parent decided not to vaccinate child), (5) decided to act/decided to 
vaccinate stage; and (6) acted/vaccinated child stage (p. 209).  
Shapiro et al.’s (2018) Stage #5 (decided to act/decided to vaccinate stage) is the 
equivalent of a preparation stage in the Prochaska and DiClemente (1982) model, and 
their stage #6 (acted/vaccinated child stage) is the equivalent of the combined action and 
maintenance stages in the Prochaska and DiClemente model. This study seeking to 
identify significant predictors of parents being in an action or maintenance stage of 






HPV vaccination is justified. Shapiro et al. (2018) found that only a “quarter of parents” 
were in the later stage or vaccinated child stage (p. 209). 
There is also a rationale for the selection of key independent variables in Study 
#1, including using validated HPV vaccine knowledge and attitudes scales rooted in the 
Health Belief Model, following the research of Shapiro et al. (2018) who focused on boys 
and girls aged 9 to 16 years. The present study emphasizes the need for HPV initiation 
and completion, starting with preteen children. The present study extends the age to 9 to 
18 years, for those still under the care of their parents/guardians up to age 18 years, who 
may benefit from parental decision making to vaccinate their children with HPV. In 
support of this study’s age range of 9 to 18 years, others have indicated the vaccination 
series can be initiated as early as 9 years of age (CDC, 2016a; Trogdon & Ahn, 2015); 
others have also recommended initiation and completion of the HPV vaccination series 
before youth become sexually active (ACOG, 2015; CDC, 2017c). Also, vaccination 
completion increases with age, further justifying this study’s focus on the age group 9 to 
18 years (Bakir & Skarzynski, 2015).  
Race/ethnicity is important to include, given that racial-ethnic minorities may face 
barriers to HPV vaccination that include language or lack of awareness, or may initiate 
HPV vaccination at higher rates in comparison to Whites (Henry et al., 2016). Also, 
research has found parental level of education (e.g., higher) is also important to explore, 
as is exposure to media and information on HPV, both of which might support ignoring 
provider advice to vaccinate with HPV (Patel & Berenson, 2013). On the other hand, 
lower levels of income might be associated with vaccination initiation (Henry et al., 






prior flu vaccinations, is also important to include (de Casadevante et al., 2015; Kessels, 
et al., 2012). There is also a rationale for investigating parental hesitancy as a potential 
barrier to HPV vaccination initiation (Bakir & Skarzynski, 2015; Shapiro et al., 2018). 
Moreover, HPV vaccination initiation and completion may be related to parental attitudes 
and acceptance toward the HPV vaccine (Choi et al., 2016). Another key variable 
included was provider recommendation to vaccinate children, as this has been found to be 
an important predictor for HPV vaccine intention and completion (Gilkey et al., 2015; 
Kessels et al., 2012; Mohammed et al., 2017). 
Rationale for Study #1 
Parents (English- or Spanish-Speaking)—Cartoon Video as a Potential 
Linguistically and Culturally Tailored Brief Intervention 
There is also a rationale for evaluating a linguistically and culturally tailored 
cartoon video (i.e., parents can select the English or Spanish version) designed to serve as 
a brief online e-health intervention to increase HPV vaccination initiation and completion 
among parents, starting with their preteens and before sexual activity begins. This finds 
support in the work of Agénor et al. (2018), who recommended the use of tailored-
education interventions in multiple languages in order to test for appropriateness and 
effectiveness with those from underserved groups. Also, Tuong et al. (2014) found 
evidence to support the advantages of videos for delivering health education content, 
including being less resource-intensive, removing inconsistencies across educators, 
balancing the presentation of information to provide more standardized education, and 
reaching a broad audience quickly via social media (p. 219). Also, others have found that 






efficacy for engaging in health-related behavior when comparing pre-video to post-video 
viewing (e.g., Chung, 2013), providing a rationale for the present study.  
Rationale for Study #2 
Providers (Pediatricians or Family Practitioners)—Predictors of 
Recommending the Cartoon Video to Parents or Not 
There is also a rationale for investigating significant predictors of the Study #2 
dependent variable of pediatricians/family practitioners recommending (yes versus no) 
the video to parents and/or other providers so they could share it with parents. 
Recommending the video to parents as a potential linguistically and culturally tailored 
tool to support parental decision making to initiate and complete vaccination of their 
preteen and teen children could further extend the important role of the provider. 
Consider research by Pérez et al. (2016) showing that healthcare providers have the 
potential to increase HPV vaccine initiation and completion, including among immigrant 
Latinos. Further, a healthcare provider’s recommendation has been associated with HPV 
vaccination and completion, as indicated by researchers (Gilkey et al., 2015; Kessels et 
al., 2012). 
Delimitations 
Study #1 was delimited to parents who are at least age 25, have at least one child 
between the ages of 9 and 18 years, and completed the entire survey. 
Study #2 was delimited to providers who identify as pediatricians or family 








For both Study #1 and Study #2, limitations included: the use of samples of 
convenience that access the survey via social media online, including the use of 
snowballing; the need for access to a computer with Internet service, creating bias; the 
risk of socially desirable responses, while a measure of social desirability was used so as 
to control for social desirability; the burden of time, especially for parents in Study #1, 
contributing to possible study dropout—and, also for busy pediatric and family medicine 
providers. 
Conclusion 
This chapter introduced the topic and provided an overview of HPV infection  
and HPV-associated diseases, HPV vaccine, and gender disparities in HPV vaccination, 
specifically highlighting factors associated with parental decision making on whether or 
not vaccine their children against HPV at the recommended aged (11-12 years). It also 
introduced the purpose, research questions, and rationale of this study.  
Chapter II provides a review of the literature relevant to this dissertation. Chapter 
III describes the methods of this study. Chapter IV includes the data analysis of this 
study. The dissertation concludes with Chapter V, offering a discussion of the study 











REVIEW OF THE LITERATURE 
 
This chapter provides a review of the literature covering the following topics:  
epidemiology of HPV infection; prevalence and incidence rates of HPV-associated 
cancers; HPV vaccination; disparities in HPV vaccination; individual-level factors 
influencing HPV vaccination; social determinants of HPV vaccination; provider 
recommendations for HPV vaccination; use of e-health to promote health behavior; and 
study’s theoretical framework. 
I-Epidemiology of HPV Infection 
HPV was first discovered in skin cells in the 1950s and was classified into 
genotypes based on DNA sequence. In the 1980s, Harald zur Hausen demonstrated that 
oncogenic HPV types were responsible for cervical cancer. Per Lee and Garland (2017):  
     HPV16 and HPV18 are the commonest high-risk or oncogenic genotypes in 
cervical cancer and are responsible for approximately 50% of high-grade cervical 
dysplasias and 70% of cases of cervical cancer, the fourth most common cancer in 
females globally. Oncogenic HPVs cause almost 100% of cervical cancers, 90% 
of anal, 70% of vaginal, 40% of vulvar, 50% of penile and 13% to 72% of 
oropharyngeal cancers, and HPV16 predominates in all of these non-cervical 
HPV-related cancers. HPV6 and HPV11, which are classified as low-risk 
genotypes, cause 90% of genital warts as well as the rare but debilitating recurrent 







About 90% of HPV infections clear within 2 years without medical intervention 
(Zitkute & Bumbuliene, 2016). Although women and men are both carriers, HPV may be 
less likely to persist in men; “in men, the median time to clearance of any HPV infection 
is 5.9 months, with 75% of infections clearing within 12 months” (p. 1). Persistent HPV 
infection with high-risk HPV may progress to cancer in both genders.  
HPV infection is the most common sexually transmitted infection (STI); sexually 
active individuals are likely to get HPV at least once in their lifetime. The risk of being 
infected also depends on virus pathways; genital HPV infections are contracted through 
sexual and skin-to-skin contact in the genital region, while infections responsible for oral 
or upper respiratory lesions are contracted via oral sex. HPV infections spread through 
heterosexual and homosexual relationships; gay and bisexual men are nearly 17 times 
more likely to develop anal cancer than men who only have sex with women. Alcohol 
abuse, long-term use of oral contraceptives, lack of male circumcision, and HIV infection 
are also associated with contracting HPV infection (Zitkute & Bumbuliene, 2016).  
HPV prevalence among females has been positively associated with women’s 
estimated number of lifetime male partners, or not being aware of their partner’s sexual 
history or prior HPV infection. Sexual network characteristics that increase the risk of 
transmission include “larger network size, higher contact rates and the patterns of sexual 
mixing or partner choice” (Burchell, Winer, de Sanjosé, & Franco, 2006, p. 57). Lewis, 
Markowitz, Gargano, Steinau, and Unger (2017) evaluated genital HPV prevalence 
among sexually experienced individuals ages 14 to 59 years. Males, especially non-
Hispanic Black men, reported higher prevalence of both any HPV and high-risk HPV, 






The prevalence of HPV infection also varies by age; sexually active adolescents 
and women under 25 years are at higher risk (Li & Xu, 2017). Over 40% of young 
women are infected with HPV within 2 years after first sexual activity. Due to biology, 
young women are not only more susceptible to HPV but also “more prone to persistent 
HPV infection and lasting damage” (Zitkute & Bumbuliene, 2016, p. 2). Older men are 
just as likely as younger men to be infected with HPV, perhaps because “men do not 
develop adequate immune responses to maintain protection” (Moscicki & Palefsky, 2011, 
p. 3). At all ages, HPV seroprevalence is lower among males (Moscicki & Palefsky, 
2011). 
Present-day tests allow for “more sensitive screening among women,” including 
co-testing with an HPV test and Pap smear every 5 years for low risk women ages 30 
years and older (Pytynia, Dahlstrom, & Sturgis, 2014, p. 2). Sampling methods for HPV-
DNA in men are more variable, have not been validated, and “there are difficulties 
associated with collecting cell specimens” (Burchell et al., 2006, p. 54). With an 
estimated global prevalence of genital HPV infection at 12% and a lifetime risk at 
75%, greater attention is needed to risk factors and strategies to increase vaccination 
(Li & Xu, 2017).  
Risk Factors for HPV Infection 
Despite being the main risk factor for HPV, sexual behavior is often overlooked 
when explaining disparities in HPV-associated cancers. Individual-level factors related to 
infection include age of first sexual intercourse and lifetime number of sex partners. 
Evidence has suggested differences in these factors between racial and ethnic and 






strongly associated with riskier sexual behavior and increased risk of HPV infection; it 
has also been linked with Black race and low SES. Population-level factors include 
“sexual mixing patterns between risk groups and degree of partnership concurrency” 
(Brisson, Drolet, & Malagón, 2013, p.158). As Brisson et al. (2013) wrote:  
     Differences in population-level risk factors by race may explain why, in the 
United States, HPV prevalence is sixfold higher among blacks with one lifetime 
partner than among whites…whereas the prevalence is similar across racial/ethnic 
groups among individuals with six or more lifetime partners. (p. 159)  
 
Racial and ethnic disparities in HPV infection have been documented; non-
Hispanic Blacks have the highest prevalence of HPV, followed by Hispanic and non-
Hispanic Whites. These disparities are not clearly understood, but “may be the result of 
differences in the structure of sexual networks” (p. 2). Lin et al. (2015) wrote: 
     Evidence has shown that sexual networks of black persons are more racially 
segregated and have higher rates of recurrent sexual partnerships as well as sexual 
mixing between high- and low-risk groups, which may facilitate the spread of STI 
within the community. Differences in country of birth in HPV infection among 
Hispanic populations have also been observed due to intragroup heterogeneity 
related to demographic variables and acculturation… (p. 3) 
 
Tota, Chevarie-Davis, Richardson, and Franco (2011) explained that “HPV may 
also be transmitted during childbirth from the cervix of infected mothers to the 
oropharyngeal mucosa of their children” (p. 13). Multiparity, smoking, condom use, 
nutrition, viral load, and prior HPV infection are additional risk factors.  
Treatment for HPV Infection 
There is no specific medical treatment for HPV infection; treatments depend on 
the specific clinical manifestations, such as genital warts or abnormal cervical cell 
cytology. The annual estimated cost of HPV-related sequelae, “primarily for management 






dollars, which “exceeds the economic burden of any other sexually transmitted infection” 
except HIV (CDC, 2016d, pp. 177-178).  
II-Prevalence and Incidence Rates of HPV-Associated Cancers 
According to the CDC (2018a), nearly 42,700 HPV-associated cancers were 
diagnosed in the United States between 2011 and 2015. Of those, 24,400 cases occurred 
among women and 18,300 occurred among men, suggesting higher prevalence among 
women. Cervical cancer is the most prevalent HPV-associated cancer in women, while 
oropharyngeal cancers have become the most prevalent HPV-associated cancers in men. 
Oropharyngeal cancers were traditionally thought to be caused by tobacco and alcohol 
use, but recent data have indicated that nearly 70% of oropharyngeal cancers could be 
linked to HPV or a combination of cigarette smoking, alcohol use, and HPV (CDC, 
2018a).  
Trends in HPV-associated cancers have also changed. In 1999, cervical carcinoma 
was the most common HPV-associated cancer. From 1999 to 2015, there was a decrease 
in cervical carcinoma rates by 1.6% per year, while oropharyngeal SCC rates increased 
by 2.7% in men and 0.8% in women per year (Van Dyne et al., 2018). Oropharyngeal 
SCC is now the most common HPV-associated cancer in the United States, likely 
resulting from shifting sexual behaviors such as unprotected oral sex (Van Dyne et al., 
2018). Regarding anogenital cancers, rates of anal and vulvar SCC have increased, while 
vaginal SCC has decreased, and penile SCC has remained stable (Van Dyne et al., 2018). 
The decline in cervical cancer rates is likely the result of enhanced cancer 






groups, Hispanic and non-Hispanic Black women consistently have the highest incidence 
rates of cervical carcinoma. Higher rates of anal SCC have also been observed among 
Black men. Aside from cervical cancer, there is no screening recommendation for other 
HPV-associated cancers. Van Dyne et al. (2018) write:  
     The Healthy People 2020 target for cervical cancer screening is 93%, however, 
in 2013 only 80.7% of women reported up-to-date cervical cancer screening, with 
lower rates noted among Asians, Hispanics, women aged 51-65 years, foreign-
born, uninsured, and publicly insured women. (p. 665) 
 
Therefore, “health care delivery needs of some groups are not fully met” (Van Dyne et 
al., 2018, para, 10).  
Razzaghi et al. (2018) investigated variation in survival rates of invasive cancers 
based on participants’ demographics, finding large disparities in HPV-associated cancers 
by sex, race, and age. For most HPV-associated cancers, 5-year age-standardized relative 
survival decreased with advanced age at diagnosis. Non-Hispanic Whites comprised 83% 
of the study population, yet over 85% of the HPV-associated cancer types. Five-year 
relative survival was higher among non-Hispanic White patients than non-Hispanic Black 
patients for all HPV-associated cancers and all age groups. Men were more likely to die 
from anal SCCs and rectal SCCs than women. The greatest difference in survival rates 
among men and women was observed for rectal SCCs. According to Razzaghi et al., 
“HPV vaccination and improved access to screening and treatment, especially among 
groups that experience higher incidence and lower survival, may reduce disparities in 








Vaccination is the optimal primary prevention strategy to reduce the burden of 
HPV-associated cancers (de Sanjosé, Temin, Garland, Eckert, & Arrossi, 2017). Three 
prophylactic HPV vaccines have been approved and recommended for use. The 2vHPV 
(bivalent) vaccine protects against HPV-types 16 and 18. The 4vHPV (quadrivalent) 
vaccine protects against HPV-types 6, 11, 16 and 18. The 9vHPV (nonavalent) vaccine 
protects against HPV-types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (de Sanjosé et al., 2017). 
According to the CDC (2017g), “HPV vaccines have no therapeutic effect on HPV-
related disease, nor on risk of progression to disease in persons already infected” (p. 5). 
The 4vHPV (Gardasil) and 9vHPV vaccines are licensed for females and males ages 9 to 
26 years old, while the 2vHPV (Cervarix) is licensed for use only in females ages 9 to 25 
years (CDC, 2017g). 
The ACIP developed national recommendations for use of the HPV vaccine in the 
U.S. (CDC, 2017g). Routine HPV vaccination is now recommended for boys and girls 
ages 11 to 12 years and may be initiated as early as age 9 years. ACIP recommends 
vaccination for females through 26 years of age, and for males through 21 years of age, 
who were not appropriately vaccinated (CDC, 2017g). As an update, HPV vaccination 
may now be administered in a two-dose schedule (0 and 6 months) for those under 15 
years, while a three-dose schedule is given to individuals who start the series at age 15 
years or later (0, 1-2, and 6 months). The three-dose schedule is also recommended for 
individuals who are immunocompromised (Meites et al., 2016). The 9vHPV may be used 






Regarding special populations, the ACIP recommends routine vaccination at the 
age of 9 years for children who have been sexually abused or assaulted. For men who 
have sex with men (MSM), vaccination is the same “as for all men,…through age 26” 
(Mietes et al., 2016, p. 1407). HPV vaccination is also recommended for transgender 
individuals.  
Vaccine Safety and Effectiveness  
More than 100 million doses of HPV vaccines have been distributed in the United 
States. Following rigorous testing, vaccines are continuously monitored for safety and 
effectiveness (CDC, 2018b). The most common side effects of the HPV vaccine include 
fever, pain, redness or swelling at the site of the injection, headache, tiredness, nausea, 
and muscle or joint pain. Individuals are advised to sit or lie down for 15 minutes 
following vaccination to prevent fainting or fall-related injuries (CDC, 2018b).  
Routine HPV vaccination is not recommended for pregnant women. If a woman 
becomes pregnant after starting the series, completion should be delayed; however, 
“inactivated vaccines like HPV do not affect the safety of breastfeeding for these women 
and their infants” (ACOG, 2017, p. 4). 
HPV Vaccine and Herd Protection 
Lewis and Markowitz (2018) assessed the impact of vaccination on type-specific 
HPV prevalence. Results showed that from 2011-2014, 4vHPV type prevalence 
decreased by 71% in females ages 14 to 19 years old, and by 34% in unvaccinated 






dose coverage of 50% (Lewis & Markowitz, 2018). Ali et al. (2013) also found a 
significant decline in genital warts following debut of the 4vHPV vaccine. They wrote:   
     Less than 1% of women aged under 21 years…were found to have genital 
warts in 2011, compared with 10.5% in 2006 before vaccination programme 
started. By 2011, no genital warts were diagnosed in women aged under 21 who 
reported being vaccinated. A significant decline also occurred in genital diagnoses 
in 21-30 year old women…declining diagnoses, but to a lesser magnitude was see 
in young heterosexual men. (p. 3)  
 
The observed decline in genital warts among heterosexual men was likely due to herd 
protection (Ali et al., 2013).  
It has been suggested that high vaccine coverage among girls is more cost-
effective than lower coverage for males and females. Bloem and Ogbuanu (2017) argued 
that gender-neutral immunization “should be a country-level decision based on factors 
such as disease burden, local sexual behaviour patterns, equity concerns, programmatic 
implications, cost-effectiveness, and affordability” (p. 3). Because heterosexual men 
mostly benefit from herd protection related to female vaccination, MSM are less likely to 
benefit from this effect (Bloem & Ogbuanu, 2017). Vaccinating males not only decreases 
the incidence of HPV-associated disease, but also provides herd protection for the general 
population, with the potential to decrease morbidity and mortality (Beck & Budisalich, 
2018). According to Han, Tarney, and Song (2017): 
     HPV vaccination may have a profound impact in the prevention of HPV-
related cancers in both men and women as one serves as a silent host for the other, 
in addition to being a direct cause of anogenital and oropharyngeal cancers…. 
Only when vaccination coverage is significantly increased, progress will be made 







IV-Disparities in HPV Vaccination 
Data from the 2016 NIS-Teen Survey revealed that the proportion of U.S. 
adolescents who completed the HPV vaccine before turning 13 was 16%, while 35% 
completed the vaccine series before turning 15; overall completion was 43% among 13- 
to 17-year-olds. These numbers are concerning, given that the HPV vaccine provides 
optimal protection before the onset of sexual activity. As 11% of females and 16% of 
males reported being sexually active by the age of 15, “there is the potential for HPV 
infection prior to vaccination” (Bednarczyk, Ellingson, & Omer, 2019, p. 3). Further, as 
HPV infection does not require penetrative sex, adolescents may be exposed “to HPV 
even if they do not consider themselves sexually active” (p. 3). 
Bednarczyk et al. (2019) highlighted three main benefits of completing the HPV 
vaccine, including: (a) stronger immune response when given before the age of 15 years; 
(b) requires only two doses for completion prior to age 15 years, “reducing logistical 
barriers”; and (c) one of three vaccines recommended between the ages of 11 to 12 years, 
administered with meningococcal conjugate (MenACWY) and tetanus-diphtheria-
acellular pertussis (Tdap) vaccines. Uptake and completion rates for HPV vaccination are 
lower than other childhood vaccines, with only half of adolescents up to date on the 
recommended doses (Walker et al., 2018). According to Bernstein, Bocchini, and the 
Committee on Infectious Diseases (2017): 
     There are distinct missed opportunities to administer adolescent vaccines, 
particularly HPV vaccine. If HPV vaccine had been administered during the same 
visit at which another recommended vaccine, such as Tdap, was given, the 
vaccination rate of 13-year-old girls born in 2000 for at least 1 dose of HPV 







Currently, rates of HPV vaccination coverage do not meet the Healthy People 
2020 target of 80% for adolescents ages 13 to 15. This “warrants increased attention” 
(National Vaccine Advisory Committee, 2018, p. 545). Of note from the 2016 NIS:  
 Lower HPV vaccination coverage among 17-year old males (58.6%) 
compared with females (72.7%); 
 Lower coverage among non-Hispanic White adolescents (54.7%) compared 
with Hispanic (69.8%) and non-Hispanic Black (65.9%) adolescents; 
 Lower coverage among adolescents living at or above the federal poverty 
level (70.2%); and  
 Lower coverage among those living in rural (50.4%) compared with urban 
(65.9%) settings. (p. 545) 
 
The causes of poor HPV vaccination coverage are multifactorial (National Vaccine 
Advisory Committee, 2018).  
V-Individual-Level Factors 
Parental acceptance of HPV vaccination is dependent on many factors, including 
individual knowledge and beliefs, perception of vaccine safety and effectiveness, family 
and cultural practices, ability to afford vaccination, and healthcare provider 
recommendation (Holman et la., 2014). Fontenot et al. (2015) explored parental attitudes 
about the 9vHPV vaccine among a national convenience sample of parents with both 
vaccinated and unvaccinated daughters. Parents in both groups reported less awareness 
that the vaccine was available for males and that HPV infection is responsible for cancers 
other than cervical cancer. Following the study, parents were in favor of the new vaccine, 
including those who previously did not intend to vaccinate. Fontenot et al. wrote:   
     Overwhelmingly, parents wanted their HCP to talk with them in person, 
provide written information, and utilize clear communication strategies. They also 
described wishing that HCP held information sessions at their offices and/or that 







Study findings suggest.ed a need for promotion of the HPV vaccine, while identifying 
parents’ concerns or varying beliefs based on their child’s sex. Using data from the 2011 
NIS-Teen, Burdette, Gordon-Jokinen, and Hill (2014) also found that parents of boys 
primarily delayed vaccination due to lack of provider recommendation. Johnson, Lin, 
Cabral, Kazis, and Katz (2017) called for “targeting the recommendations to address the 
unique concerns of caregivers of male and female teens” (p. 8). 
In a U.S. national representative sample of mothers (n=2,446), Donahue, Hendrix, 
Sturm, and Zimet (2015) examined both characteristics of early initiators (receiving at 
least one dose prior to the target recommended age) and predictors of initiation among 
the target age group (11 years and up). They found older age to be a significant predictor 
of HPV vaccination, while    
     A significant higher percentage of initiators were females, belong to a 
racial/ethnic minority, had public health insurance or were uninsured, had an 
older sibling who received the HPV vaccine, received the flu vaccine during the 
most recent flu season, had visited a healthcare provider in the past year, and 
typically received healthcare…in a location other than a private office. (p. 893) 
 
Many initiators also had mothers who received a provider recommendation; as the 
strength of provider recommendation increased, the predicted probability of vaccine 
initiation also increased across all ages. Healthcare provider recommendation more 
strongly impacted initiation by males, perhaps due to “the relative recency of the ACIP’s 
routine recommendation for males…less awareness of the importance of male 
vaccination among providers as well as among parents of sons” (p. 897).  
In a national representative sample (n=7,674) of diverse adults, Otanez and Torr 
(2018) investigated the effect of HPV knowledge and willingness to vaccinate among 






willing to vaccinate, while non-Hispanic Blacks were approximately 20% less willing to 
vaccinate than non-Hispanic Whites. Non-Hispanic Blacks and non-Hispanic Whites who 
mistrusted doctors were significantly less willing to vaccinate, while Hispanics who 
mistrusted doctors were more willing to vaccinate. Non-Hispanic Blacks were more 
likely to cite concerns about vaccine safety. According to Otanez and Torr (2018): 
     This is relevant for future education campaigns, as it suggests that the lower 
rates of vaccination, reflected in less favorable attitudes toward vaccination 
among Blacks, is not simply due to lack of knowledge…. Controlling for distrust 
does not eliminate the difference by race. (p. 1479) 
 
Mistrust of doctors could potentially create ambivalence about vaccination; results 
showed that non-Hispanic Blacks were more likely to be unsure of their feelings about 
vaccination than other groups. More research is needed to develop culturally sensitive 
approaches enhancing patient-provider trust and rapport, “while highlighting safety and 
addressing concerns about vaccination” (Otanez & Torr, 2018, p. 1481).  
Jeudin et al. (2014) explained that minority, immigrant, and non-English-speaking 
parents have reported lower knowledge of the HPV vaccine than English-speaking 
parents. They wrote, “parents with little knowledge about the benefits of vaccination may 
be less likely to advocate for themselves” (p. 31). Latina parents who knew where to get 
the vaccine were more likely to favor vaccination, and Latina parents who reported 
higher levels of American acculturation also reported more frequent provider 
recommendations. Common reasons for vaccine incompletion among Latina and Black 
girls included less awareness about subsequent doses, lack of time, and finding times and 
convenient clinic locations. These issues were more common among those with “limited 
English proficiency or low health literacy, hold unskilled jobs with inflexible work hours, 






Kepka et al. (2018) also assessed sociodemographic barriers and facilitators 
among racially and ethnically caregivers (n=288) of children ages 11 to 17 years old. At 
least 20% of participants had their child vaccinated with at least one dose of the HPV 
vaccine. Race and ethnicity, years in the United States, and caregiver birthplace were 
significantly associated with HPV vaccination. Kepka et al. wrote, “each minority group 
will require a unique set of tailored intervention strategies,” while paying “particular 
attention to immigrants, regardless of how long they have lived in the United States”  
(p. 229). Indeed, research has demonstrated that HPV vaccination disparities between 
foreign-born and U.S.-born children disappear “after controlling for access-to-care, 
socioeconomic, and demographic characteristics” (Healy et al., 2018, p. 7). Thus, having 
“language-appropriate educational materials available for providers who primarily treat 
foreign-born populations, are needed” to address cultural dynamics in vaccination (p. 7). 
VI-Social Determinants of HPV Vaccine Uptake  
According to Thompson, Rosen, and Maness (2019), social determinants of health 
(SDOH) provide an innovative approach to identify and address health disparities. SODH 
are conditions in which individuals are born, grow, live, work and age. In public health, 
“ignoring social level that impacts health is to ignore broad scale areas that may hamper 
or enhance efforts to individual behavior change” (p. 150). Thus, it is important to 
consider the multifaceted approach to HPV vaccine uptake and completion.  
Thompson et al. (2019) assessed HPV vaccination among young men and women 
ages 18 to 26 years (n=3595) using data from the 2016 NIS. Results revealed that 45.7% 






language, social and community factors, and health/healthcare access were significantly 
associated with HPV vaccination, while economic factors were not. Women who were 
fluent in English were more than three times as likely to be vaccinated. As noted above, it 
is imperative to design linguistically and culturally tailored interventions (Thompson et 
al., 2019). It has been argued that interventions should focus on the benefits of the HPV 
vaccination among parents of minority children, while programs to improve HPV vaccine 
uptake among parents of higher SES are also needed (Burdette et al., 2014).  
Recall from Chapter I that rates of HPV vaccine uptake and completion appeared 
to be higher among racial and ethnic minority adolescents living in disadvantaged 
neighborhoods. This could be due to distribution of safety-net services, including 
vaccination programs. Across six states, Pruitt and Schootman (2010) found that girls 
living in counties with lower SES were more likely to be vaccinated compared to girls 
living in states with lower SES. They wrote, “while girls in poorer states had overall 
lower odds, girls living in any state experienced higher odds of vaccination in higher 
poverty counties” (p. 5). Results at the county-level may be due to safety-net resources.  
Tsui et al. (2013) found that neighborhood sociodemographic factors were not 
significantly associated with HPV vaccination after controlling for individual-level 
factors. In some cases, “neighborhood context may be less important than other factors 
such as mother’s awareness of HPV vaccine and adequate insurance coverage” (p. 6). 
Those living in less impoverished neighborhoods may lack access to healthcare clinics. 
Thus, access to public health insurance may serve as a proxy for access to affordable 
care. Tsui et al. revealed that the majority of Los Angeles neighborhoods with high HPV-






poor suburban areas had to rely more on private providers’ offices with providers who 
“face low reimbursement rates for vaccination” which is “shown to impact physician 
recommendation” (p. 2095). In a Midwestern study, Rutten et al. (2017) similarly found 
that area-level measures of SES were significantly associated with vaccination, even after 
controlling for individual-level factors. Such geographic factors “can inform efforts to 
target community and clinical interventions to improve access in areas characterized by 
greater need” (p. 538).  
VII-Provider Recommendations for HPV Vaccination 
Healy et al. (2018) found that among parents of unvaccinated children, lack of 
provider recommendation was the most common reason for not vaccinating. Johnson et 
al. (2017) found that provider recommendation increased vaccine initiation, but not 
always vaccine completion, “suggesting that other unmeasured factors may be driving 
series completion” (p. 6). Further research is needed in this regard.  
Vadaparampil et al. (2011) used a nationally representative sample of family and 
obstetric providers (n=1,538) to assess recommendations for HPV vaccination. Results 
indicated that 34.6% of physicians “always” recommended the HPV vaccine to early 
adolescents (ages 11 to 12 years), 52.7% to middle adolescents (ages 13 to 17 years), and 
50.2% to late adolescents (18 to 26 years), lacking compliance with ACIP guidelines to 
vaccinate by 11 to 12 years. Lack of recommendation to younger adolescents “represents 
a missed clinical opportunity to provide both individual and population level benefits”  
(p. 6). Regardless of age, pediatricians were most likely, and family practitioners were 






Physician age was also significantly associated with vaccine recommendation. 
Physicians aged 40 to 49 years were more likely to recommend the vaccine, perhaps due 
to “a sufficient level of clinical autonomy, but…still open to adoption of new innovations 
and technologies” (Vadaparampil et al., 2011, p. 6). Physicians ages 25 to 39 years were 
likely to “always recommend” vaccination. It is possible that this “reflects greater 
emphasis on the importance of HPV in disease etiology in medical education for more 
recent graduates” (p. 4). Similarly, Warner et al. (2017) found that providers ages 30 to 
39 years and over 50 years had less HPV-related knowledge than providers ages 40 to 49 
years. They suggested “targeted opportunities for continuing education for these who 
have completed their medical or nursing training within the last 10 to 15 years” (p. 10). 
Malo et al. (2014) examined vaccine recommendations among providers of male 
patients, finding that 10.8% of physicians always recommended the vaccine for early 
adolescents, 12.9% for middle adolescents, and 13.2% for late adolescents. Pediatricians 
and FPs did not frequently recommend the HPV vaccine. This is of concern as “males 
may transition to the care of family physicians as they move through adolescence” (p. 6). 
Physicians who self-identified as innovators and early adopters of ACIP guidelines were 
more like to always recommend the HPV vaccine. According to Malo et al. (2014):  
     Identifying and supporting innovators/early adopters may facilitate diffusion of 
male HPV vaccination, given these physicians are watched by colleagues as they 
test evidence-based changes (e.g., feasibility of implementing the new guidelines 
in clinical practice) and could influence other physicians’ support…. (p. 6) 
 
Furthermore, the study found that variables such as patient payment method and 
race/ethnicity were associated with providers’ recommendation (Malo et al., 2014). As 
STI rates and HPV-associated cancers tend to be higher among minority groups, 






these disparities,” particularly when serving a diverse patient population (p. 7). Similarly, 
Vadaparampil et al. (2011) found that physicians who self-identified as Hispanic/Latino 
were more likely to “always recommend” the vaccine. This is relevant given that 
Hispanic women have the highest incidence of cervical cancer. Hispanic providers tend 
to provide medical care to Hispanic patients; thus, “they may be more sensitized to the 
importance” (p. 6). Additional research is recommended.  
Warner et al. (2017) studied demographic and practice characteristics of 
healthcare providers (n=254) in Utah, a state with low HPV vaccination rates. At the 
individual and interpersonal levels, provider specialty, practice type, and number of 
patients seen per day were associated with lower provider knowledge of HPV. For 
instance, FPs had higher HPV vaccination knowledge compared to pediatricians and 
nurse practitioners. Providers from university and primary care settings had higher HPV 
knowledge than those in private care and hospital settings. Providers who saw more than 
15 patients per day reported higher HPV knowledge than peers with fewer patients. 
Providers who did not routinely provide vaccination or were not part of the VFC program 
also reported less knowledge (Warner et al., 2017). Size of practice, resources, and acuity 
of patients may impact provider knowledge and, in turn, comfort with recommendation. 
Additional barriers included personal beliefs that the vaccination was not a priority.  
Allison et al. (2016) conducted a national provider survey regarding HPV vaccine 
administration practices. Results revealed that 99% of pediatricians and 87% of FPs 
administered the HPV vaccine to girls ages 11 to 18 years, while 98% of pediatricians 
and 81% of FPs administered the vaccine to boys ages 11 to 18 years (Allison et al., 






the vaccine to older children and to girls. The authorsd state that if “physicians do not 
discuss the vaccine, they have no opportunity to provide a strong recommendation”  
(p. 6). Lack of dialogue may relate to provider, not just parent, knowledge gaps. Indeed, 
providers may hesitate to discuss the HPV vaccine because they perceive that their 
patient population will return for future visits or are unlikely to engage in sexual activity. 
Promisingly, 88% of pediatricians and 67% of FPs reported that they were very likely to 
discuss the HPV vaccine in a future visit (Allison et al., 2016). 
Gilkey et al. (2015) found that 73% of providers reported highly recommending 
the HPV vaccine to parents with children ages 11 to 12 years. However, providers were 
more likely to highly endorse other vaccines, as both pediatricians and FPs viewed the 
HPV vaccine more negatively than other childhood immunizations. Fewer than half of 
the providers reported discussing vaccination during sick visits incompliant with 
“practice guidelines which state that mild illnesses…do not constitute grounds for 
delaying vaccination” (p. 7). Recall from above that “providers’ communication is among 
the most important strategies for increasing HPV vaccine uptake in the U.S., where the 
vast majority of HPV vaccine doses are delivered in the context of primary care” (p. 2). 
Thus, attention to a variety of personal and structural factors is needed (Gilkey et al., 
2015).  
Structural Barriers to Recommendation  
Factors such as cost, completing follow-up doses, and “infrequency of vaccinating 
at a regular well-child…visit” may impact provider recommendations (Warner et al., 
2017, p. 8). Organizational guidelines may also be of concern. Gilkey and McRee (2016) 






complex and unclear” (p. 1463). Lack of school entry requirement for HPV vaccination 
was also identified as a barrier to obtaining parental support (Gilkey et al., 2015). 
Providers in the Warner et al. (2017) study supported campaigns to inform parents 
about the “ubiquity of HPV infection in their community” and “the HPV vaccine as a 
cancer prevention mechanism,” as well as state policy changes, such as state financing of 
immunization programs (Warner et al., 2017, p. 10). According to Vadaparampil et al. 
(2011), VFC providers were more likely to recommend the vaccine: 
     VCF states (n=36) provide vaccines only for VFC providers choosing to 
enroll. Physicians who enroll as VFC providers may be responsible for 
maintaining separate vaccine stocks for VFC-eligible and non-eligible 
patients…providers willing to take on this responsibility may represent these 
groups with greater motivation to recommend vaccination…an intervention to 
increase physician’s participation in the VFC program will increase physician 
recommendation…. (p. 7) 
 
Time is another significant factor. Dempsey et al. (2016) found that 43% of 
parents reported spending five or more minutes discussing the HPV vaccine with their 
child’s provider. In the Gilkey et al. (2015) study, providers similarly reported spending 
over 3 minutes talking about the HPV vaccine, almost twice as long as for Tdap. As a 
typical doctor’s visits usually lasts 20 minutes, dedicating a large amount of time to 
HPV-related concerns may create a time burden for providers.  
Parent-Provider Dynamics and the Key Recommendation  
A systematic review by Gilkey and McRee (2016) asserted that  
quality improvement strategies aimed at strengthening provider communication 
about HPV vaccination should emphasize the need to say HPV vaccination is 
important, recommend same-day vaccination, and deliver routine 







Across all studies, providers were more likely to initiate vaccine-related conversations 
with parents. Parents were more likely to accept a strong and unambiguous provider 
recommendation. Mothers were usually responsible for making the final decision 
regarding HPV vaccination, while provider guidance was sought in the case of parent-
adolescent disagreement. Parents were less likely to refuse vaccination when a provider 
“avoided drawing special attention to it, and offered their strong endorsement,” 
normalizing it as one of several routine vaccines (p. 1462). Presenting the vaccine as 
optional resulted in higher parental hesitancy or delay (Gilkey & McRee, 2016). 
Gilkey and McRee (2016) also found disparity-related barriers in communication; 
parents of African American and Hispanic adolescents less often received HPV 
recommendations than parents of non-Hispanic White adolescents. Parents of Hispanic 
adolescents with public insurance were less likely to report collaborative communication, 
“which adversely affected HPV vaccination coverage” (p. 1462). Providers were also less 
likely to engage non-English speaking parents in communication about HPV. Parents 
from minority groups and those with lower SES were less likely to feel engaged by 
providers, yet more likely to defer to providers’ recommendations. Thus, “eliminating 
communication disparities could raise coverage for these high priority population even 
higher” while fostering a sense of collaboration (p. 1464). Indeed, providers who used a 
collaborative approach, engaging parents and adolescents in the decision-making process, 
were more likely to initiate vaccination (Gilkey & McRee, 2016).  
Dempsey et al. (2016) found that parents were more receptive to HPV-related 
communications such as “decision-making tools, pictures of preventable diseases, and a 






and providers preferred brief written materials, as well as websites, “tailored to parents’ 
cultural background, language preference, and literacy level” (p. 1463). Providers also 
suggested the use of videos as a promising educational tool.  
VIII-Use of E-Health to Promote Health Behavior 
The number of Americans who use the internet as a source of health information 
has increased. In 2002, individuals who used the internet for healthcare information did it 
an average of three times every month; half of these individuals believed this information 
improved their self-care. Indeed, e-health provides a cost-effective source for the delivery 
of health promotion interventions (Evers, 2006). Computer-based programs have the 
capability to integrate a clinical approach, “which targets large population segments or an 
entire population” (p. 1). Interactive technologies are often more appealing to participants 
who want to receive personalized feedback in a more convenient way. The use of e-
health promotion programs has the potential to optimize consistency of interventions, 
reduce personnel demands, improve interactivity and flexibility, automate data collection, 
and generate more honest responses from participants (Evers, 2006).  
Indeed, e-health activities promote participant autonomy. Participants “can 
actively search for information and generate self-care abilities in a safe, supported, and 
favorable learning environment,” while autonomy for self-care may enhance self-efficacy 
(p. 246). Tsai and Liu (2015) evaluated the effects of a health promotion website 
designed for Taiwanese nurses, comparing nurses who received the e-health intervention 
and those who received a traditional learning handbook. Nurses who received e-health 






total scores, as well as subscale scores in self-actualization, nutrition, and exercise. 
Compared to controls, nurses in the experimental group also showed significant post-
intervention decreases in BMI. Thus, e-health education is an effective and accessible 
intervention for enhancing health promoting behavior among nurses (Tsai & Liu, 2015). 
Mackert, Champlin, Holton, Muñoz, and Damásio (2014) similarly found that e-health 
interventions offering audiovisual information were more appealing to participants than 
more traditional brochures, and argued that health communication theories should be 
utilized “to improve the efficacy of the interventions and outcomes of users” (p. 517).  
Delivery of Tailored Video Health Education 
According to the CDC (2016i), “the ideas people have about health, the languages 
they use, the health literacy skills they have, and the context in which they communicate 
about health reflect their cultures” (para. 1). Culture may be defined as membership in 
racial, ethnic, linguistic or geographical groups, or as a “collection of beliefs, values, 
customs, ways of thinking, communicating, and behaving specific to groups” (para. 2). 
Therefore, it is important to tailor health education interventions to bridge cultural 
differences. The National Culturally and Linguistically Appropriate Services (CLAS) 
Standards emphasize “effective, equitable, understandable and respectful quality care and 
services that are responsive to diverse cultural health beliefs and practices, preferred 
languages, health literacy and other communication needs” (CDC, 2016i, para. 9). 
Kreuter, Strecher and Glassman (1999) defined tailored health education 
interventions “as any combination of strategies and information intended to reach one 
specific person, based on characteristics that are unique to that person, related to the 






motivational as individuals adopt and sustain behavior change (p. 277). Tailored 
messages may be delivered via video, audio, telephone, or internet. Computer-tailored 
health education is an effective strategy to convey comprehensive health promotion, 
disease prevention, and disease management information (Kreuter et al., 1999).  
Wonggom, Du, Clark (2018) defined an avatar as “an icon or a figure that 
represents a person in a computer game, on an internet forum” (p. 2668). Avatar-based 
technology has been used in the management of chronic conditions, such as cancer, 
diabetes, depression, smoking cessation, and heart disease, and has been shown to 
improve patients’ knowledge, self-efficacy, self-care behaviors and quality of life. This 
technology also has demonstrated effectiveness in patients with low health literacy 
“because it is more engaging than printed education materials and it supports learning 
though the use of audio and visual aids” (p. 2668).  
Lustria et al. (2013) conducted a meta-analysis to assess the impact of tailored 
web-based programs on health outcomes. Findings revealed that such interventions 
positively impacted behavioral outcomes. According to Lustria et al.:  
     A unique advantage of web-based delivery is the capacity to tailor 
interventions to target population characteristics (e.g., specific risk 
factors)…compared to interventions requiring face-to-face contact with health 
care providers, tailored web-based programs facilitate wider access and encourage 
self-care, which may improve efficacy and maintenance of gains over time.  
(p. 1061)  
 
Healthy People 2020 strongly supports the development of innovative and interactive 
health communication technology “geared towards making health education and services 
more accessible and engaging to the public” (p. 1061).  
Lustria et al. (2013) additionally found that tailored, web-based interventions 






require support for complex tasks involved in chronic disease management,” such as 
among specific populations like those with chronic illness (p. 1061). It is important to 
recognize that some individuals may suffer from comorbid conditions that make 
participation in certain interventions more physically or mentally difficult. For instance, 
vision or mobility impairments may impact one’s ability to use computer equipment. 
These needs should be considered when developing e-health education interventions.  
Such interventions should also weigh cultural considerations, as beliefs about 
health, disease, and treatment often vary across racial groups. Lustria et al. (2013) wrote:  
     individualism-collectivism, in addition to other cultural-related constructs (i.e., 
health locus of control or belief in who ultimately has responsibility for one’s 
health), play an important role in…health decision-making and health behavior 
and…explain some…variance in preferences for health messaging. (p. 1061)  
 
Tailored web-based interventions targeting a single health behavior were not found to be 
significantly more efficacious than those targeting multiple health behaviors (Lustria et 
al., 2013).    
Animated Avatar Videos and Health Behavior Change  
Animated avatar videos provide a unique virtual learning space in which the 
avatar serves as a model for adopting healthy behaviors (Høybye, Vesterby, & Jørgensen, 
2016). Avatar videos in e-health education may be more appealing to “patients who do 
not wish to watch realistic depictions of medical interventions,” and viewers may adopt 
behaviors that “resonates with the actual circumstance and conditions of patients’ 
everyday life” (pp. 2-3).  
LeRouge, Dickhut, Lisetti, Sangameswaran, and Malasanos (2015) used animated 






like representations of the user, who “controls the avatar’s actions or ‘tele-operates’ the 
avatar within the virtual environment” (p. 20). Virtual agents in the study represented 
teachers or coaches. Teen, parent, and provider participants expressed excitement for 
using avatars and virtual agents to assist with self-management of chronic conditions, 
while making self-care more enjoyable and motivating. Teens were receptive to receiving 
advice about health habits from their virtual agents, such as healthy food choices, and felt 
like active members of the care team. Further, the providers “viewed the knowledgeable 
virtual agent coach role as extension of the motivation and information provided in their 
interactions with teens” (LeRouge et al., 2015, p. 22). Family members endorsed the use 
of avatar agents as important social supports. These results encourage further research 
regarding avatar-based interventions among additional populations.   
Canidate and Hart (2017) studied the ways in which health information 
consumers choose and design their avatars, such as whether participants preferred an 
avatar that resembled their own gender or ethnicity. Findings revealed that “the ethnicity 
of the user and the ethnicity of the avatar were found to have the strongest connection” 
(p. 5). Regardless of age and gender, the vast majority of users chose a White female 
avatar. Furthermore, “black participants exposed to the low-diversity representation of 
Second Life were shown to create more white-looking avatars as opposed to black 
participants exposed to the high-diversity representation” (p. 5). Results suggested that 
individuals who identified with their own chosen avatar may feel more empowered and 
motivated to adopt healthy behaviors (Candidate & Hart, 2017).  
Chen, Todd, Amresh, Menon, and Szalacha (2018) evaluated a bilingual 






parents (n=46) of unvaccinated adolescents ages 11 to 17 years. Interviews were also 
conducted with healthcare providers regarding integration of the intervention into their 
clinical routine. The intervention was guided by a variety of health behavior theories with 
demonstrated use in adoption of HPV vaccination behavior (Chen et al., 2018). Results 
showed that 95% of participants reported intention to vaccinate their children, while 50% 
agreed to immediate vaccination. Most participants found the intervention to be culturally 
and linguistically appropriate, easy to understand, and easy to use. Different from some 
aforementioned studies, parents’ intention to vaccinate did not differ by child’s biological 
sex. Although the intervention was “not intended to be substitute for guidance from 
healthcare providers,” it did motivate parents to seek HPV vaccination, while increasing 
knowledge, addressing myths, and providing resources (p. 5). The intervention also 
facilitated patient-provider communication. According to Chen et al. (2018): 
     Individuals who received tailored information are more likely to remember the 
customized messages, which can lead to desired behavioral changes. Tailored 
interactive, computers-based health education can be delivered in clinic settings 
when having discussions about health may be most relevant. As healthcare 
providers often find it challenging to provide HPV education in clinical settings 
due to the competing demands, our…intervention operated by parents while 
waiting for the health services offers an innovated and feasible approach. (p. 1) 
 
Duncan-Carnesciali, Wallace, and Odlum (2018) assessed the effect of an e-health 
intervention on reducing barriers to accessing diabetes self-management education and 
evaluated perceptions of avatar-based technology among certified diabetes educators 
(CDE). They found that “age, ethnicity, and Arab/Middle Eastern, Asian, and 
White/European decent were significant predictors of high rating the quality of the video” 
(p. 223). Qualitative analysis revealed that sound quality, use of a cartoon, and simplicity 






recommend the avatar video to their patients and colleagues. Thus, specific design and 
content factors must be considered when creating avatar-based education interventions.   
Bedra, Wick, Brotman, and Finkelstein (2013) evaluated the feasibility and 
acceptance of a tablet-based interactive ileostomy education intervention. Results showed 
improved patient ileostomy knowledge and stoma care self-efficacy, with 100% of 
patients reporting that the tablet education was easy to use; 80% of patients expressed 
interest in using the tablet for future health education. Findings demonstrated that avatar-
based ileostomy education “was a good supplement to ostomy nurse teaching,” with the 
majority of participants rating their learning experience as good or excellent (Bedra et al., 
2013). As healthcare providers may experience a variety of patient education barriers, 
avatar video education supports and facilitates the delivery of important messages among 
diverse populations. It is fundamental to involve health consumers in the development 
and evaluation of these messages. Equally important is to translate animated avatars into 
different languages (Tongpeth, Du, & Clark, 2018).  
Miller and Jensen (2014) explained how avatars and animation share common 
characteristics, in that both are computer-animated images. Avatars “are computer 
animations of a human or the projection people use to depict themselves” (p. 38). While 
animation is a “general activity of illustrating motion with an object, allowing educators 
to present an activity that would be difficult to read or demonstrate with a statics picture” 
(p. 38). Thus, avatars are associated with, but not exclusive to, animation. Avatars may 







IX-Theoretical Framework  
Health Belief Model 
According to Rosenstock (1974), the Health Belief Model (HBM) was developed 
to focus on disease prevention and screening for early detection of asymptomatic 
diseases. In order for an individual to take action to prevent disease, he or she must need 
to believe he or she is personally susceptible to a disease (e.g., individual risk of 
contracting a health condition) and that “the occurrence of the disease would have at least 
moderate severity on some component of his life” (p. 330). Degree of perceived 
seriousness may be based on emotional arousal (e.g., the individual thoughts and beliefs 
about the possible difficulties he or she would experience as a result of disease exposure). 
Also involved are the acceptance of one’s susceptibility to a disease, and the plan of 
action that would be beneficial to help reduce his or her susceptibility. Rosenstock wrote:  
     The person’s beliefs about the availability and effectiveness of various courses 
of action, and not the objective facts about the effectiveness of action, determine 
the course he will take. In turn, his beliefs in this area are undoubtedly influenced 
by the norms and pressures of social groups. (p. 331) 
 
Cues to action are the necessary triggers needed for the individual to undertake 
the preferred path of action. These actions can be internal (e.g., perception of bodily 
states) or external (e.g., interpersonal interactions, the impact of the media 
communication). If an individual has low perceived susceptibility to or severity of 
disease, rather intense stimuli would be sufficient to trigger a response; with “high levels 
of perceived susceptibility and severity, even slight stimuli may be adequate” (p. 333).  
The HBM construct has been applied (Reiter, Brewer, Gottlieb, McRee, & Smith, 






likelihood of their children contracting HPV infection and HPV-associated diseases);  
(b) perceived severity (how severe the negative effects of HPV infection and HPV-
associated diseases are believed to be); (c) perceived benefits (parental perceived belief 
that vaccinating their teen boy and girl will help reduce the risk or severity of HPV 
infection and HPV-associated diseases); (d) perceived barriers (any parental perceived 
obstacles preventing them from vaccinate their children, such as not knowing where to 
get the vaccine for their child, no convenient location, or lack of time to follow-up with 
dose series completion); and (e) cues to action, such as “situational factors prompting 
HPV vaccination, such as doctor’s recommendation” (Reiter et al., 2009, p. 2). 
The Stages of Change 
Prochaska and DiClemente (1982) provided the Transtheorical Model (TTM); of 
particular interest are the stages of change (SOC), which describe “a process involving 
progress through a series of six stages” (Prochaska & Velicer, 1997, p. 38). In pre-
contemplation, people are not intending to take action in the next 6 months. People may 
be in this stage for several reasons, including lack of knowledge about the consequences 
of their behavior, or loss of confidence in their ability to change. These individuals may 
avoid thinking about their high-risk behaviors and have been characterized as resistant to 
or not ready for health promotion programs (Prochaska & Velicer, 1997). Those in the 
contemplation stage are considering change in the next 6 months (Prochaska & Velicer, 
1997). They are aware of the pros and cons of changing, but can experience ambivalence, 
which “can keep people stuck in this stage for long periods of time” (p. 39). Individuals 
in this stage are not ready to receive traditional action-oriented programs. In the 






future and have a plan of action. Hence, individuals in this stage are ready to participate 
in traditional action-oriented programs. In the action stage, people have made specific 
behavior changes within the past 6 months. Maintenance is the last stage where “people 
are working to prevent relapse but do not apply change processes as frequently as do 
people in action” (p. 39). People in this stage are less tempted to relapse and more 
confident they can sustain their behavior change. Maintenance lasts from 6 months to 
about 5 years (Prochaska & Velicer, 1997).  
According to Fernandez et al. (2013), the TTM is well-suited to assess motivation 
and decision making related to HPV vaccination. They wrote:  
     HPV vaccination is unique to other health behaviors because it lacks a 
traditional behavioral Maintenance stage and requires relatively little overt 
behavioral effort to reach the Action stage. Maintenance for HPV vaccination is 
effectively under biological control once the final dose of the vaccine is 
completed. (p. 302) 
 
For the purposes of this study, the SOC were used to examine the behaviors of 
interest among English-speaking and Spanish-speaking parents as well as healthcare 
providers.  
Social Cognitive Theory—Self-efficacy 
A central concept is self-efficacy, as per Bandura (1991):  
     People’s beliefs in their efficacy influence the choices they make, their 
aspirations, how much effort they mobilize in a given endeavor, how long they 
persevere in the face of difficulties and setbacks, whether their thought patterns 
are self-hindering or self-aiding, the amount of stress their experience in coping 
with taxing environmental demands, and their vulnerability to depression. (p. 257) 
 
Perceived self-efficacy can affect the choices made in behavioral goal setting. For 
instance, individuals are more likely to avoid threatening situations if they believe they 






more likely to engage in activities and behave with confidence when they “judge 
themselves capable of handling situations that would otherwise be intimidating” 
(Bandura, 1977, p. 194).  
Bandura (1999) also found that individuals learn by observing the behaviors, and 
consequences of behaviors, performed by others. Observational learning enables 
individuals to generate knowledge and skills via modeling. Observational learning thus 
produces innovative behavior. Social diffusion of new styles of behavior consists of three 
functions: “acquisition of new knowledge, new ideas and practices,” adoption of 
determinants, and “the social networks that tie people to one another” (p. 26).   
The construct of self-efficacy may best capture if parents feel sufficiently 
confident or empowered to discuss HPV and the HPV vaccine with providers, 
influencing the decision to vaccinate a child (Priest, Knowlden, & Sharma, 2015).  
Diffusion of Innovation Theory 
The acceptance of an innovation is dependent on social context and explains why 
often “interventions with minimal research support gain widespread acceptance” 
(Dingfelder & Mandell, 2011, p. 2). Diffusion occurs when a new practice, program, or 
policy is communicated over time within a system (Dingfelder & Mandell, 2011). 
According to Haider and Kreps (2004), communicating a new innovation is both planned 
and spontaneous. Communication of messages about new ideas requires the creation and 
sharing of information among individuals to “reach mutual understanding” (p. 4). 
Diffusion is “the process by which change occurs in the structure and function of a social 
system” (p. 4). Social change can occur due to the introduction of the invention, 






According to the DOI, “people fall into one of five adopter categories that 
describe their rate of adoption of new behavior or belief” (Haider & Kreps, 2004, p. 5). 
Innovators are those first individuals who adopt a new innovation, while early adopters 
are educated but less able to cope with uncertainty compared to innovators. The early 
majority are more likely to adopt an innovation before the average person; this group 
constitutes one-third of the members of a system. The late majority adopt an innovation 
just after the early majority and also represent one-third of the system. Yet, late majority 
members often need peer-pressure in order to adopt a new idea. Similarly, laggards are 
suspicious of innovations. Adopter characteristics, personality variables, and 
communication behavior vary by level of education, social status, and SES, which 
“influence the rate at which a new innovation diffuses” (p. 5). When developing health 
education interventions, it is essential to identify and understand the key factors 
influencing the adoption or rejection of innovations (Haider & Kreps, 2004).  
This study permits determining if parents (Study #1) and providers (Study #2) 
engage in diffusion of the innovation (i.e., recommend it to others or not) of teaching 
parents about HPV and HPV vaccination via a culturally and linguistically tailored  
e-health avatar video/cartoon. 
Conclusion 
This chapter provided a review of the literature, covering the following topics: 
epidemiology of HPV infection; prevalence and incidence rates of HPV-associated 
cancers; HPV vaccination; disparities in HPV vaccination; individual-level factors 






recommendations for HPV vaccination; use of e-health to promote health behavior; and 
the study’s theoretical framework. 
Chapter III next provides a detailed description of the methodology used in the 













This chapter provides a description of the methods and procedures used in this 
study. This includes an overview of study design and procedures, which include the 
recruitment of participants and a description of the development of the script and avatar 
video. The treatment of data including the analysis plan is also outlined.  
Overview of Study Design and Procedures 
The research used a cross-sectional design and mixed-methods approach 
(quantitative and qualitative) in this online investigation involving Study #1 with parents 
who chose to participate in English or Spanish and Study #2 with providers. According to 
Warner et al. (2017), mixed-method approaches “that combine qualitative and 
quantitative data sources provide a more complete description of a phenomenon than a 
single methodology approach alone” (p. 2).  
IRB Approval   
Study #1 and Study #2 received approval from the Institutional Review Board 
(IRB) of Teacher College, Columbia University before any data collection began. The 
IRB approval protocol number 19-172 was deemed exempt from review. See Appendix 






Development of the Video Script and Cartoon 
The animated avatar characters were created on https://www.vyond.com/ (i.e., 
Vyond, formally known as GoAnimate) while ensuring they had features to match those 
of the racially and ethnically diverse parents for whom the video was created. Two 
animated avatar videos were made: one video for the English-speaking parents and the 
other video for the Spanish-speaking parents. Every step of video script creation and 
actual video development occurred under the supervision of Dr. Barbara Wallace, 
Director of the Research Group on Disparities in Health (RGDH) and Professor of Health 
Education, Department of Health and Behavior Studies at Teachers College, Columbia 
University. The content of the script was based on the existing literature, as per Chapter 
II, Review of Literature. Numerous drafts were reviewed and edited in a close process 
involving the Principal Investigator and Dr. Wallace. A final video script in English was 
produced (see Appendix I, Video Script in English). 
Role of the Translator and Video Consultant 
Dr. Monica Stanton-Koko, Assistant Professor of Health Science in the School of 
Health and Natural Sciences at Mercy College, served as translator of the study materials, 
including the survey and other recruitment materials and messages, and of the video 
script. The process included translation and back-translation. In addition, the principal 
investigator was able to review and make suggestions for alternative translations with a 
closer meaning, as the opportunity arose, given that her native language is Spanish. This 
was performed to ensure equivalency between the translated document and the original 







Linguistically and Culturally Appropriate Video Production Team 
Dr. Stanton-Koko also played the central role in gathering a team of two other 
adults and two preteen children—as the video cast of adult and child actors—so that the 
video was created by this team using the Vyond technology. This approach permitted 
including the team members’ natural voices. The video cast consisted of five animated 
avatar characters, including a female doctor, two parents, and two children (a 12-year-old 
girl and a boy who just turned 11 years old). The setting for the video was the doctor’s 
consultation room. The final video was deemed linguistically and culturally appropriate, 
while the study permitted parents to select watching the final video in English or Spanish. 
The avatar videos were launched through YouTube See Appendix K, Screenshots of the 
Video. 
A link to the video was provided in Spanish and English for participants to choose 
from, as follows, while the link was embedded in the middle of the survey—between the 
pre- and post-video viewing measure: 
English video: https://youtu.be/0VagYrkvW0E (5:07) 
Spanish video: https://youtu.be/dVtnSANVxsc (6:25) 
The English animated avatar video was 5:07 minutes long, while the Spanish 
version of the animated avatar video was 6:25 minutes long, given the nature of the 
typical translation process from English to Spanish.  
Recruitment of Study Participants 
A social media campaign was used to recruit participants for Study #1 and Study 
#2 using Facebook, Twitter, LinkedIn, email, Instagram, texting, and postings on other 










Study # 2 used the following core recruitment message for providers: 
 
Incentives for participation in core recruitment messages. The use of the study 
incentive of having a 1 in 250 chance (i.e., original target goal for both Study #1 and 32 
of N=250, respectively, which was not achieved) of winning one of three $100 Amazon 
gift cards was codified in the core recruitment messages to enhance willingness to 
participate in the study. The uses of these core recruitment messages can be seen in all 
the following recruitment materials that were used in Study #1 or Study #2, respectively: 
  
GO TO https://tinyurl.com/HPV-Video-English if you have a child age 9-18, 
watch the video on the Human Papillomavirus (HPV), rate the video, & complete 
a survey for chance to win one of 3 $100 Amazon gift cards     [If you prefer 






Vaya a https://tinyurl.com/HPV-Video-Study-Spanish si tiene un niño de 9 a 
18 años de edad, mire el video sobre el virus del papiloma humano (VPH), 
califique el video y complete una encuesta para la oportunidad para ganar una 
de 3 tarjetas de regalo de Amazon de $ 100 




MEDICAL PROVIDERS TO YOUTH AG S 9-18 ARE 
INVITED TO JOIN THE HPV VIDEO STUDY 
***************************************** 
VOLUNTEER FOR A CONFIDENTIAL 
SHORT 10-12 MINUTE STUDY 
FOR A CHANCE TO WIN 1 of 3 $100 AMAZON GIFT CARDS 
IRB Protocol Number 19-172 
 
	
The Research Group on Disparities in Health within the Department of 
Health and Behavior Studies at Teachers College, Columbia University, in 
New York, NY is conducting a study to see how medical providers rate a new 
cartoon video on the Human Papillomavirus (HPV) and HPV vaccination that 
was designed for parents of children ages 9-18. The study seeks to 
determine how m dical providers r te and e aluat  the new cartoon video, 
and if they recommend it for parents.	
	
To learn more about the study, read the Informed Consent, and proceed to 
study participation, please: 
 
CLICK https://tinyurl.com/HPV-Video-Study-For-Providers if 
U R a medical provider to youth ages 9-18, watch & rate an 
HPV video, & complete a survey–in just 10-12 minutes-for 
chance to win 1 of 3 $100 Amazon gift cards 
 
NOTE: Participants have a 3 in 250 chance of winning 1 of 3 $100 Amazon gift cards 
 
For more information about this research study, please contact: 
Alejandri a Canelo Villafana, MS at ac3523@tc.columbia.edu or the Research Sponsor, 







 Appendix B - Study 1-Recruitment Emails 
 Appendix C - Study 2-Recruitment Email 
 Appendix D - Study 1-Text/Tweet 
 Appendix E - Study 2-Text/Tweet 
 Appendix F - Study 1-Recruitment Flyers 
 
Participants were invited to participate in the study via regular daily emails and 
posts on the various social media platforms. Also, the survey links were sent via text 
messaging. In addition, a flyer describing the study was disseminated in small businesses 
such as laundries, barbershops, beauty salons, bodegas, and faith-based organizations.  
Participants who completed the survey were invited to share the study link with 
other parents via Facebook, email, text-messages, or twitter, thus employing a 
snowballing technique.  
Healthcare providers were primarily recruited through emails sent to different 
healthcare institutions such as hospitals, family medicine practices, federally qualified 
health centers, and pediatric clinics. Healthcare institutions that received the email were 
invited to share the information about the opportunity to participate in the study with their 
providers, in particular those in pediatric or family medicine.  
Following all of these procedures, subject recruitment and the online study took 
several weeks in the winter of 2019. 
Inclusion/Exclusion Criteria Study #1 
Participants were only included if they answered “yes” to the following questions 
to determine their eligibility for the study, and Spanish-speaking parents accessed a 
translated version of these questions:  
1-Are you at least at least 25 years of age? 







2-Are you the parent/caregiver or legal guardian of at least ONE child between the 
ages of 9 and 18 years of age? 
Yes___ No____ 
 
3-Are you able to read and understand English on a 12th grade level? 
Yes___ No____ 
 
4-Are you able to devote about 35-40 minutes to this study at this time—for a 
chance to win one of three $100 Amazon gift cards? 
Yes___ No____ 
 
5-More specifically, first, are you able to spend about 20-25 minutes answering 
a set of questions? 
Yes___ No____ 
 
6-Second, are you willing to spend about 5 minutes watching a cartoon video? 
This means using a computer with an Internet connection in a convenient 
location that will allow you to play the cartoon aloud? 
Yes___ No____ 
 
7-Third, after you watch the cartoon, are you willing to rate it and answer a final 
set of questions for about another 5-10 minutes? 
Yes___ No____ 
 
If participants were not eligible, they received a message explaining why they were 
disqualified and that they could share the study link with other eligible parents.  
Inclusion/Exclusion Criteria Study #2 
Participants were asked the following questions and had to answer “yes” for study 
inclusion Study #2:  
1-Are you a medical health care provider (e.g. physicians, physician assistants, 
nurse practitioners)? ___Yes ___No 
 
2-Do you work in a pediatric or family care practice? ___Yes ___No 
 
3-Have you had direct contact with patients within the past six months? 
___Yes ___No 
 








5-Are you able to devote about 10-12 minutes to this study at this time, including 
watching a 5-minute avatar/cartoon video and stating if you recommend it to other 
parents and providers? 
Yes___ No____ 
 
If participants were not eligible, they received a message explaining why they 
were disqualified and that they could share the study link with their peers. 
Other Study Procedures 
Eligible participants from Study #1 and Study #2, who were interested in 
participating in this study, clicked on the survey link. After clicking on the survey link, 
participants read and signed the informed consent, as per their study, given these options: 
 Appendix G - Study 1-Informed Consent in English 
 Appendix H - Study 1-Informed Consent in Spanish 
 Appendix H - Study 2-Informed Consent 
 
Those eligible for study participation who completed the Informed Consent could 
proceed to the study survey, given these options: 
 Appendix L - Study 1-Survey in English 
 Appendix M - Study 1-Survey in Spanish 
 Appendix N - Study 2-Survey 
 
Video embedded in survey. Of note, located in between the pre-video viewing 
and post-video viewing surveys, the study video was embedded, whether in English or 
Spanish for parents in Study #1 or in English for providers in Study #2.  
Prize Drawing 
Upon completion of the survey, participants from Study #1 and Study #2 were 
directed to a “thank you” webpage where they were thanked for completing the study and 
were able to enter into a lottery where they had a chance to win one of three $100 






addresses into a database that was managed by Professor Wallace’s RGDH Webmaster, 
Dr. Rupananda Misra. Participants were informed that the information they provided in 
the study was not linked to their email addresses, thus ensuring participants’ 
confidentiality. Gift certificates were emailed to three participants who were randomly 
selected from the database. The gift certificates stated that participants had won the 
lottery as a result of their participation in this study.  
Description of Study Participants 
Study #1 Participants 
The number of individuals who attempted to complete the study survey was 178. 
Of those, 98 were English-speaking parents (ESP) and 80 were Spanish-speaking 
parents (SSP).  
However, of the original 178, only 68.5% (n=122) qualified to participate in the 
study and provided Informed Consent to participate in the study, given the following 
eliminations of cases from the sample;  
 10 cases were eliminated as they were associated with 10 suspicious duplicate 
IP addresses 
 3 additional suspicious duplicate IP addresses were eliminated 
 43 cases of Study #1 non-completers were eliminated for not having 
proceeded far enough into the survey to provide data for Study #1 dependent 
variable of parents being in an action or maintenance stage of change for 
having made the decision and taken action to ensure their child received the 
HPV vaccination—as measured before parents watched a linguistically and 
culturally tailored cartoon video. Of note, Study #1 dependent variable is a 
pre-video viewing question and does not depend on watching the video; 
hence, no eliminations of participants occurred due to not watching all or most 
of the video. 
 
Thus, the Study #1 final sample size was N=122, including samples of ESP n=68 and 






Comparison of Study #1 completers (n=122) to non-completers (n=43). A 
comparison of study completers (n=122) to study non-completers (n=43) using 
independent t-tests for all demographic variables showed that no comparisons were 
statistically significant. 
Study #2 Participants 
In Study #2, a total of 21 healthcare providers responded to the social media 
campaign and provided Informed Consent. Of those, 19 respondents completed the entire 
survey and watched the video. Hence, for Study #2, N=19 were providers in pediatrics or 
family medicine.  
Description of the Research Instrumentation for Study #1 
The Study #1 measure is called the Survey for Parents on HPV Vaccination for 
Children, while containing the parts described in this section.  
Study #1—Survey Part I 
The Parent’s Basic Demographics (PARENTS-BD-10) was developed by 
Professor Barbara Wallace and is a common tool used by the Research Group on 
Disparities in Health (RGDH). The 10-item scale used in this study provided information 
about sociodemographic characteristics of parents, including gender, age, race and 
ethnicity, place of birth, residence, marital status, employment, income, education, and 







Study #1—Survey Part II 
The Part II: About Your Children (AYC-4) is a new scale created by the 
Principal Investigator and her dissertation sponsor, Dr. Barbara Wallace, for use by the 
RGDH. It consists of a four-item scale which provided self-reported information from 
parents about their children. Information obtained included number of children between 
the ages of 9-18, child’s gender, child preferred gender identity, and child insurance 
status. 
Study #1—Survey Part III 
The Part III: Parent Report on Provider Recommendation on HPV 
Vaccination for Child (PARENT-R-PR-HPV-V-FC-2) is a new scale created by the 
Principal Investigator and her dissertation sponsor, Dr. Barbara Wallace, for use by 
RGDH. This is a two-item scale and asks parents to respond whether medical providers 
such as pediatricians and/or family medicine practitioners ever talked to parents about the 
HPV infection and recommended the HPV vaccine to their child. Parents responses were 
rated “yes,” “no,” and “I’m not sure” and scored as a 0 or 1. 
Study #1—Survey Part IV 
The Part IV: Parent Report on HPV vaccination for Child (PARENT-R-
HPV-V-FC-2) is a new two-item scale developed by the Principal Investigator to ask 
parents if their child ever received the HPV vaccine; it is rated “yes,” “no,” and “I’m not 
sure” and scored as a 0 or 1. If parents responded yes, they were asked to report the 
number of actual doses received. Responses were rated as “I’m not sure,” 1 dose, 2 doses, 






Study #1—Survey Part V 
The Part V: Parent Report on Flu Vaccination for Child (PARENT-R-FLU-
V-FC-1) is a new one-item scale developed by the Principal Investigator to assess if  
(a) one or more of the parents’ children received the flu vaccination; and (b) parents 
believed in the value of an annual flu vaccination for their child. Responses were rated 
“yes,” “no,” and “I’m not sure” and scored as a 0 or 1.  
Study #1—Survey Part VI 
The Part VI: Parent Exposure to Print or other Media or Information on 
HPV Vaccination for Children (PARENTEPOMI-HPV-VFC-1) is a new one-item 
scale developed by the Principal Investigator to assess if parents ever read or watched a 
video or saw anything on television or on a social media platform or on the Internet about 
information related to HPV vaccination. Responses were scored (0 to 3) as follows: 
0--No, no information at all 
1--Yes, I was exposed to a very low amount of information 
2--Yes, I was exposed to a low amount of information 
3--Yes, I was exposed to a moderate amount of information 
 
 
Study #1—Survey Part VII 
The Part VII: HPV General Knowledge (HPV-G-K-23) was taken from the 
work of Parez et al. (2016), who demonstrated that an existing HPV general and HPV 
vaccine-specific knowledge scale was valid, reliable, and comprehensive, and could be 
used to measure HPV knowledge and change over time among parents of boys, in both 
English and French. This is a 25-item scale that showed high internal consistency  
(α>0.87) and good model fit. The forced-choice response categories included 






The 25-item scale was reduced to 23 items in this Study #1, following Shapiro  
et al. (2018). Specifically, two items were dropped (“HPV usually does not need any 
treatment” and “HPV can cause herpes”), as they were also deleted from the Shapiro  
et al. study to improve the psychometric properties of the tool. 
Study #1—Survey Part VIII 
The Part VIII: HPV Vaccine Knowledge Scale (HPV-V-K-S-11) was also 
taken from Parez et al. (2016). The HPV-V-K-S is an 11-item scale that showed high 
internal consistency (α > 0.73) and good model fit. As per Shapiro et al. (2018), in their 
study’s administration of the Vaccine Knowledge Scale, “vaccines” was changed to 
“vaccine” to make the measure consistently in the singular. Slight adaptations were also 
made to ensure the items were gender-neutral (rather than directed at parents of males 
only) and updated based on policy recommendations and current generation vaccines. 
Questions #10 and 11 that were specific to Canada were deleted and replaced with new 
items #10 and #11 in the present study. See Appendix L, Study 31-Survey in English. 
Study #1—Survey Part IX 
The Part IX: General Vaccine Attitudes-Conspiracy Beliefs, and Hesitance 
due to Lack of Confidence or Risk (GVA-CB-HLC-R-16) was taken from Shapiro  
et al. (2018), who sought to examine the validity of a Vaccine Conspiracy Belief Scale 
(VCBS) and determine if this scale was associated with parents’ willingness to vaccinate 
their sons against HPV. The Factor Analysis showed the VCBS is one-dimensional with 






supported by a moderate relationship with the Conspiracy Mentality Questionnaire 
(CMQ) (r=0.44, p<0.001) (Shapiro et al., 2018). 
One item from the original scale (“immunizing children is harmful and this fact is 
‘covered up’”) was modified slightly in the Shapiro et al. (2016) study’s administration 
(to “negative vaccination effects are covered up”), as this was considered a double-
barreled question. The designation “(R)” indicates items that were reverse-coded. Each of 










Study #1—Survey Part X 
The Part X: Parent’s Perceived Barriers to Child’s Completion of the HPV 
Vaccination Series (PARENTS-PBCC-HPV-VS-12) was developed based on the 
literature on barriers associated with HPV vaccination; it was created by the Principal 
Investigator and Professor Barbara Wallace for use by the RGDH. This new scale was 
designed to assess barriers or obstacles that parents experienced that prevented them from 
getting their children vaccinated against HPV. This was scored as a continuous scale 
from 0-12, where 0=no barriers and 12=highest barriers.  
Study #1—Survey Part XI 
The Part XI: More about You (Social Desirability) (MAY-13) was created by 






respondents, followed by the 13-item short form. The original Social Desirability scale 
consisted of a 33-item scale, with 18 items keyed as true and 15 false, “making a 
response set interpretation of scores highly improbable” (p. 350). Using Kuder-
Richardson formula 20, the internal consistency coefficient for the scale was .88 and a 
test-rest correlation of .89. The short form of the original Social Desirability scale was 
used in this study.  
Study #1—Survey Part XII 
The Part XII: Pre-Video Parents’ HPV Knowledge and Stage of Change and 
Self-Efficacy for Talking to Providers and Child Receiving the HPV Vaccine (PRE-
V-PARENTSHPV-K-SOC-SE-FTP-CR-HPV-V-7) is a standard scale used in studies 
conducted by the RGDH following the work of others (e.g., Chung, 2013), permitting 
self-ratings of participants’ stage of change and self-efficacy for performing specific 
behaviors, and the behaviors assessed are specific to the study, such as the behavior of 
talking to providers about HPV in this study.  
For example, the present Study #1 inquired about three key talking behaviors of 
focus, for which stage of change and self-efficacy were measured: (1) talking to a 
pediatrician or family practice medical provider about the Human papillomavirus (HPV) 
infection, and the HPV vaccination for children; (2) making sure their preteen and teen 
children receive the HPV vaccination; and (3) making sure their preteen and teen 
children receive all the required doses (e.g. at least 2 or 3 doses) of the HPV vaccination. 
This involved a pre-video viewing versus post-video viewing comparison of parents’ 






The stage of change and self-efficacy scales typically produce very good to 
excellent internal consistency both pre- and post-video viewing—for those items 
measuring any study-specific behaviors of focus in that particular study. For example, 
consider the findings of Chung (2013) below; they show how the language of a Global 
score is often used, while subscales may also emerge. 
1-Mom’s Global Stage of Change, Knowledge, 
Self-efficacy, and Evaluation of Website for Four 
Behaviors Before E-Health Videos (M-SOC-K-SE-
EWCV-F4B) 
12 .951 
2-Mom’s Global Stage of Change, Knowledge, 
Self-efficacy, and Evaluation of Website for Four 
Behaviors After E-Health Videos (M-SOC-K-SE-
EWCV-F4B) 
12 .898 
3-Stage of Change Before E-Health Videos 
Subscale 
4 .855 
4-Stage of Change After E-Health Video Subscale 4 .865 
5-Self-efficacy Before E-Health Videos Subscale 4 .918 
6-Self-efficacy After E-Health Videos Subscale 4 .861 
 
Following Chung (2013), first parents were asked about their knowledge, using 
the following item and 6-option Likert scale as follows: 
1-Please rate what you know, or your level of knowledge about the Human 
papillomavirus (HPV) infection HPV, and the HPV vaccination for children: 
 
Very Poor Poor Fair Good Very Good Excellent 
        1     2    3     4          5                    6 
 
Next, parents were asked to rate themselves for each of the three key talking 
behaviors of interest, first, for stages of changes, and, second, for self-efficacy, while 
using the 6-option Likert scales shown below, respectively, each for stages of change and 
self-efficacy, as follows in a sample item: 
Please rate yourself for the behavior of talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection HPV, and the 






2-For doing this [measure of stage of change] 
1_____I am not thinking of doing this behavior at all 
(Score = 1-preparation stage). 
2_____I am thinking about doing this behavior. 
(Score = 2-contemplation stage). 
3_____I am preparing to do this behavior. 
(Score = 3-preparation stage). 
4_____I have been doing this behavior for less than six (6) months. 
(Score = 4-action stage). 
5_____I have been doing this behavior for more than six (6) months up to many  
            years. 
(Score = 5-maintenance stage). 
_____I cannot answer because I do not know enough about the HPV vaccination.  
 
3-And, for doing this I am [measure of self-efficacy] 
1____0% confident                2____20% confident              3  ____40% confident  
4____60% confident              5____80% confident              6 ____100% confident  
_____I cannot answer, because I do not know enough about the HPV vaccination 
 
 
Parents Watched Video 
Upon completion of the pre-video viewing survey tools, parents were asked to 
click a link embedded in the survey and watch the video in English or Spanish: 
Study #1—Survey Part XIII 
The Part XIII: Post-Video Viewing Adherence Survey for Providers (PVV-
AS-PROVIDERS-1) asked how much of the video they watched. Responses ranged 
from 0=none of the video to 3=all of the video.  
Study #1—Survey Part XIV 
The Part XIV: Post-Video Parents’ HPV Knowledge and Stage of Change 
and Self-Efficacy for Talking to Providers and Child Receiving the HPV Vaccine 






Part XII. This is the same scale but for post-video. Paired t-tests were used to analyze the 
data from pre- to post-video viewing. 
Study #1—Survey Part XV 
The Part XV: Rate the Video for Parents (RTV-PARENTS-2) scale is a 
standard tool created by Professor Wallace for use by the RGDH in all video studies to 
assess the quality of video (e.g., Chung, 2013). Participants are asked to rate the video on 
a 6-point Likert-type, as follows: 
Please think about the cartoon video you were asked to watch, and please rate the 
video: 
1. I rate the video as follows: 
Very Poor Poor Fair Good Very Good Excellent 
       1     2    3     4         5                    6 
___I feel unable to rate the video - I was not able to watch all the video. 
 
Study #1—Survey Part XVI 
The Part XVI: Diffusion of Innovation Using E-Health on HPV by Parents 
(DOF-UEH-HPV-PARENTS-1) scale is a standard tool created by Professor Wallace 
for use by the RGDH in all video studies to assess the quality of video (e.g., Chung, 
2013). Participants are asked whether or not they would recommend the video to other 
parents with children. Responses are scored as follow: 1=Yes to 0=No.  
Study #1—Survey Part XVII 
The Part XVII: Qualitative Portion on Reasons for Recommending the  
E-Health or not—for Parents (QP-RREHV-PARENTS-1) asked parents to explain 






1- Please explain why you would or would not recommend the video. Feel free to 
offer your comments on the strengths and weaknesses of the video, or how could 
it be improved. 
___I feel unable to comment on the video – as I was not able to watch all the 
video 
___I offer my comments on the video, as follows. 
 
 
Study #1—Survey Part XVIII 
This final survey part for parents, the Qualitative Portion on Reactions to Study 
Participation by parents, is a new question created by the Principal Investigator and her 
dissertation sponsor, Dr. Barbara Wallace, for use by the RGDH that simply asks: 
1-What thoughts or feelings might you share in response to watching the video 
and/or taking this survey? 
 
Description of the Research Instrumentation for Study #2 
The Study #2 measure is called the HPV Survey for Pediatric and Family 
Practice Providers. See Appendix N, Study #2-Survey. Of note, some of the measures 
are the same as those discussed above yet adapted for providers. Hence, some details on 
the origin of the scale are not repeated here. 
Study #2—Survey Part I 
The Part I: Provider’s Basic Demographics (PROVIDERS-BD-12) is a 
common tool used by the RGDH, while questions were added which were specific to 
medical providers. The 12-item scale used in this study provided information about the 
sociodemographic characteristics of medical provider’s gender, age, race and ethnicity, 
residence, place of birth, marital status, employment, income, education attainment, types 






Study #2—Survey Part II 
The Part II: Pre-Video Providers’ Overall HPV Knowledge for 
Recommending HPV Vaccination to Parents for their Child—and Stage of Change, 
Self-efficacy, and Barriers (PRE-VIDEO-PROVIDERS-SOC-SE-B-4) was created by 
the Principal Investigator and her dissertation sponsor, Dr. Barbara Wallace, for use by 
the RGDH. It is similar in structure and function to what was described earlier (i.e., Part 
XII, above) as a standard scale used in studies conducted by the RGDH following the 
work of others, such as Chung (2013). However, this scale allowed providers to rate 
themselves for knowledge, stage of change, and barriers, as shown below, including the 
associated Likert scales and scoring: 
Knowledge Item: 1-Please rate what you know, or your level of knowledge about 
the Human papillomavirus (HPV) infection, the available HPV vaccinations, and 
the schedule for vaccinating preteen and teen boys and girls? 
 
Very Poor Poor Fair Good Very Good Excellent 
       1     2    3     4         5        6 
 
Stage of Change Item: Please rate yourself for the behavior of recommending 
within my medical practice to parents/guardians that they vaccinate their preteen 
and teen boys and girls for HPV—by checking what best describes you, below. 
2-For doing this [measure of stage of change] 
1_____I am not thinking of doing this behavior at all. 
(Score = 1-preparation stage). 
2_____I am thinking about doing this behavior. 
(Score = 2-contemplation stage). 
3_____I am preparing to do this behavior. 
(Score = 3-preparation stage). 
4_____I have been doing this behavior for less than six (6) months. 
(Score = 4-action stage).  
5_____I have been doing this behavior for more than six (6) months up to many   
            years. 
(Score = 5-maintenance stage). 








Self-Efficacy Item: 3-And, for doing this I am 1-6 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident  
____I cannot answer because I do not know enough about the HPV vaccination. 
 
Barriers Item: And, the degree of barriers I (e.g,. time) experience in a medical 
visit for actually doing this is  
__(0) non-existent (none at all) __(1) extremely low __(2) very low  __(2) low 
__(3) moderate __(4) high ___(5) very high  __(6) extremely high 
 
Providers Watched Video 
After completing the above pre-video survey, the providers clicked a link and 
watched the e-health video in English for approximately 5 minutes. 
Study #2—Survey Part III 
The Part III: Post-Video Viewing Adherence Survey for Provider (PVV-AS-
PROVIDERS—1) was discussed above under Study #1—Survey Part XIII. 
Study #2—Survey Part IV 
The Part IV: Rate the Video for Providers (RTV-PROVIDERS-1) asked to 
rate the cartoon as a potential linguistically and culturally appropriate tool to support 
parents in their decision making about whether or not to make sure their preteen or teen 
child receives the HPV vaccination series. It was rated the same as the version under 







Study #2—Survey Part V  
The Part V: Diffusion of Innovation using E-Health on HPV by Providers 
(DOF-UEH-HPV-PROVIDERS-1) scale was treated as the dependent variable of the 
study, as pediatricians/family practitioners indicated whether they would recommend 
(yes/no) the video to parents and/or other providers so they could share it with parents. It 
was rated the same as the version under Study #1—Survey Part XVI. 
1- Would you recommend this cartoon video for parents, or to other providers so 
they could share it with parents? 
1-__Yes _0-_No ___NA/Unable - I was not able to watch the video. 
 
Study #2—Survey Parts VI and VII 
The Part VI: Evaluation—Qualitative Portion on Reactions to Study 
Participation by Providers (QP-RSP-PROVIDERS-1). The qualitative portion asked 
providers reasons for recommending the video and how the video can be improved. 
Treatment of the Data 
Data were downloaded from www.qualtrics.com to SPSS. The data were 
transferred and analyzed using SPSS 25.0. 
Data Analysis Plan for Study #1 With Parents  
Given an online sample of parents (n=122) who responded to a social media 
campaign (i.e., “Go to <htpps://tinyurl.com/HPV-Video-Study-English> to take the 
Survey for Parents on HPV Vaccination for Children and rate a cartoon for a chance to 
win 1 of 3 $100 Amazon gift cards”) and complete the survey, Study #1 sought to answer 







1-What are the parents’ demographic characteristics (i.e., selected English or Spanish 
survey and video, gender, age, race/ethnicity, US born or not, partner status, employment 
status, annual household income, level of education, type of medical insurance)? 
Part I: Parent’s Basic Demographics (PARENTS-BD-10) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-What do parents report about their children (i.e., number of children ages 9 to 18, 
number of male and female children, child sexual orientation, type of medical insurance)? 
Part II: About Your Children (AYC-4)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-Do parents report providers having talked to them about HPV and the HPV 
vaccination, and did the providers recommend the HPV vaccination for their child? 
Part III: Parent Report on Provider Recommendation on HPV vaccination for 
Child (PARENT-R-PR-HPV-V-FC-2) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-Do parents report one or more of their children ever having received the HPV 
vaccination? 
Part IV: Parent Report on HPV vaccination for Child (PARENT-R-HPV-V-FC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
5-Do parents report one or more of their children ever having received the flu 
vaccination, and do they believe in the value of an annual (yearly) flu vaccination for 
their children? 
Part V: Parent Report on HPV vaccination for Child (PARENT-R-FLU-V-FC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
6-To what extent have parents been exposed to print or digital media providing 
information on the HPV vaccination for children? 
Part VI: Parent Exposure to Print or Other Media or Information on HPV 
Vaccination for Children (PARENT-EPOMI-HPV-VFC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
7-What is the parents’ level of general HPV knowledge? 
Part VII: HPV General Knowledge (HPV-G-K-23) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 







8-What is the parents’ level of HPV vaccine knowledge? 
Part VIII: HPV Vaccine Knowledge Scale (HPV-V-K-S-11) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations,  
frequencies, and percentages 
 
9-What are the parents’ general vaccine attitudes, including for (a) conspiracy beliefs,  
(b) vaccine hesitancy—lack of confidence, and (c) vaccine hesitancy—risks? 
Part IX: General Vaccine Attitudes-Conspiracy Beliefs, and Hesitancy due to 
Lack of Confidence or Risks (GVA-CB-HLC-R-16) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
10-What are the parents’ perceived barriers to their child completing the HPV 
vaccination series? 
Part X: Parents’ Perceived Barriers to Child’s Completion of the HPV 
vaccination Series (PARENTS-PB-CC-HPV-VS-12) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
11-Pre-video viewing, what was the parents’ knowledge of HPV, the prevalence of 
parents being in an action or maintenance stage for making sure their children received 
the HPV vaccination—as the Study #1 dependent variable—and their self-efficacy for 
doing this? 
From Item # 4 of Part XII: Pre-Video Parents’ HPV Knowledge and Stage of 
Change and Self-Efficacy for Talking to Provider and Child Receiving the HPV 
Vaccine (PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
12-Was there a change in the parents’ knowledge of HPV, as well as their stage of 
change and self-efficacy for three key behaviors [i.e. (1) talking to a pediatrician or 
family practice medical provider about the Human papillomavirus (HPV) infection, and 
the HPV vaccination for children; (2) making sure their children receive the HPV 
vaccination; and (3) making sure their children receive all the required doses (e.g. at least 
2 or 3 doses) of the HPV vaccination] when comparing their pre-video viewing to post-
video viewing mean scores? 
Part XII: Pre-Video Parents’ HPV Knowledge and Stage of Change and Self-
Efficacy for Talking to Provider and Child Receiving the HPV Vaccine (PRE-V-
PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7)  
and  
Part XIV: Post- Video Parents’ HPV Knowledge and Stage of Change and Self-
Efficacy for Talking to Provider and Child Receiving the HPV Vaccine (PRE-V-
PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 








13-How do the parents rate the video cartoon? 
Part XV: Rate the Video for Parent (RTV-PARENTS-2) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
14-Do the parents recommend the video cartoon to other parents? 
Part XVI: Diffusion of Innovation using E-Health on HPV by Parents (DOF-
UEH-HPV-PARENTS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
15-Are there any significant differences between the responses of the English-speaking 
and Spanish-speaking parents on the study measures? 
Data Analysis Plan: Independent t-tests 
 
16-Controlling for social desirability, what are the significant predictors of parents being 
in an action or maintenance stage for making sure their children received the HPV 
vaccination—before the video—as the Study # 1 dependent variable? 
Data Analysis Plan: Backward stepwise regression 
 
 
Qualitative Portion of Study #1 
 
17-How do parents respond when asked why they would or would not recommend the 
video, including any comments on the strengths and weaknesses of the video, or how 
could it be improved? 
Part XVII: Qualitative Portion on Reasons for Recommending the E-Health Video 
or Not—For Parents (QP-RREHV-PARENTS-1) 
Data Analysis Plan: Identification of emergent themes 
 
18-What additional thoughts or feelings do the parents share in reaction to the video 
and/or taking the survey? 
Part XVIII: Qualitative Portion on Reasons to Study Participation by Parents 
(QP-RSP-PARENTS-1)  
Data Analysis Plan: Identification of emergent themes 
 
 
Study #2 With Providers 
Given an online sample of providers (n=19 pediatricians or family practitioners) 
who respond to a social media campaign (i.e. ”Click  <htpps://tinyurl.com/HPV-Video-






Providers on HPV vaccination for preteens/teens & rate a cartoon for parents on HPV”) 
and complete the survey, Study #2 answered the following research questions. 
Study #2 Research Questions 
Study #2 With Providers 
Given an online sample of providers (n=19 pediatricians or family practitioners) 
who respond to a social media campaign (i.e., ”Click <htpps://tinyurl.com/HPV-Video-
Study-For-Providers> to take 10-12 min Survey for Pediatric & Family Practice 
Providers on HPV vaccination for preteens/teens & rate a cartoon for parents on HPV”) 
and complete the survey, the study #2 answered the following research questions: 
1-What were the providers’ demographic and background characteristics (gender, age, 
race/ethnicity, US born or not, partner status, annual household income, status as a 
current job title, pediatric or family practitioner, work setting, years in current position 
pediatrics or family practice, years in health care)? 
Part I: Provider’s Basic Demographics (PROVIDERS-BD-15)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-What was the providers’ (a) level of knowledge about the Human papillomavirus 
(HPV) infection, the available HPV vaccinations, and schedule for vaccinating preteen 
and teen boys and girls—and for the behavior of recommending within their medical 
practice to parents/guardians that they vaccinate their preteen and teen boys and girls for 
HPV—and, also their (b) stage of change, (c) self-efficacy, and (d) perception of barriers 
(e.g. time) experienced during a medical visit for doing this? 
Part II: Pre-Video Providers’ Overall HPV Knowledge for Recommending HPV 
Vaccination to Parents for their Child—and Stage of Change, Self-efficacy, and 
Barriers (PRE-VIDEO-PROVIDERS-SOC-SE-B-4)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-How did the providers rate the quality of the cartoon video as a potential linguistically 
and culturally appropriate tool (i.e., available in English and Spanish) to support parents 
in their decision-making about whether or not they make sure their preteen or teen child 







Part III: Rate the Video for Providers (RTV-PROVIDERS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-Do the providers recommend the cartoon video for parents, or to other providers so 
they could share it with parents? 
Part IV: Diffusion of Innovation using E-Health on HPV by Providers (DOF-
UEH-HPV-PROVIDERS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
 
Qualitative Portion of Study #2 
 
5-How do the providers explain why they would or would not recommend the video to 
parents or other providers, including any comments on the strengths and weaknesses of 
the video, or how could it be improved? 
Part V: Qualitative Portion on Reasons for Recommending the E-Health Video or 
not—for Providers (QP-RREHV-PROVIDERS-1) 
Data Analysis Plan: Identification of emergent themes and categories 
 
6-What additional thoughts or feelings do the providers share in response to watching the 
video and/or taking the survey? 
Part VI: Qualitative Portion on Reactions to Study Participation by Providers 
(QP-RSP-PROVIDERS-1)  
Data Analysis Plan: Identification of emergent themes and categories 
Qualitative Data Analysis Strategy 
Regarding the analysis of qualitative data, the steps followed are outlined in 
Appendix O, Qualitative Data Analysis Strategy.  
Conclusion 
The chapter provided the methods used in this study, including the study design, 
procedures, and recruitment of participants. Also, this chapter described the study 
participants, research instrumentation, and treatment of the data and data analysis plan.  












This chapter provides the results of the data analysis for Study #1 and Study #2. 
The chapter is organized by research questions and includes a summary of the findings in 
tables.  
Internal Consistency of Study Scales 
The scales used in the study can be examined for the internal consistency—where 
appropriate, as shown in Appendix Q, Internal Consistency of the Study Scales. 
Data Analysis Results by Study Question for Study #1 
Results for Research Question #1 
 
What are the parents’ demographic characteristics (i.e., selected English or 
Spanish survey and video, gender, age, race/ethnicity, US born or not, partner 
status, employment status, annual household income, level of education, type of 
medical insurance)? 
 
The whole sample consisted of 122 parents who provided electronic informed 
consent and completed the entire online survey. Of the whole sample (n=122), 68 were 
English-speaking parents (ESP) and 54 were Spanish-speaking parents (SSP). Thus, the 






In the whole sample of parents (n=122), 95.9% (n=117) were females and only 
4.1% (n=5) were males. Among ESP, 94.1% (n=64) were females and 5.9% (n=4) were 
males. Among SSP, 98.1% (n=53) were females and 1.9% (n=1) was male. The mean age 
for the whole sample (n=122) was 40.08 years (min=26, max=72, SD=7.06). The mean 
age for ESP (n=68) was 41.16 years (min=27, max=72, SD=6.72). The mean age for SSP 
(n=54) was 38.72 years (min=26, max=55, SD=7.31).  
The mean household income distribution for the whole sample (n=122) was 4.09 
(min=1, max=9, SD=1.95). The mean household income distribution for ESP (n=68) was 
4.57 (min=1, max=9, SD=1.97) with the highest income ranging from $40,000 to 
$49,000 (30.9%, n=21). While the mean household income distribution for SSP (n=54) 
was 3.48 (min=1, max=7, SD=1.78), with the highest income ranging from $20,000 to 
$39,000 (27.8%, n=15).  
The mean education for the whole sample (n=121) was 4.05 (min 1, max 9,  
SD=1.98). The mean education for the ESP (n=67) was 4.72 (min 1, max 9, SD=1.88). 
The mean education for the SSP (n=54) was 3.22 (min=1, max=7, SD=1.78).  
Regarding employment status, 73.8% (n=90) of parents reported been employed, 
and of these 90 parents, 79.4% (n=54) were ESP and 66.7% (n=36) were SSP.  
Private insurance plans were the most prevalent source of health coverage 
reported among ESP (58.8%, n=40) and SSP (31.5%, n=17), respectively. Of the 42.6% 
(n=52) parents who were born in the United States, 55.9% (n=38) were ESP and 25.9% 
(n=14) were SSP.  







S1. Table 1. Parents’ Demographic Characteristics of Sample (PARENTS-BD-10) 
(N=122) 
  N % 
Gender 
Whole Sample (N=122) 
  
Female  117 95.9 
Male  5 4.1 
English-Speaking Sample (N=68)   
Female  64 94.1 
Male  4 5.9 
Spanish-Speaking Sample (N=54)   
Female   53 98.1 
Male  1 1.9 
Age 
Whole Sample (N=122) 
  
<30 13 10.7 
31-40 50 41 
41-50 51 41.8 
51-60 7 5.7 
61-72 1 .8 
M whole=40.08, SD=7.06, Min=26, Max=72   
English-Speaking Sample (N=68)   
<30  5 7.4 
31-40  26 38.2 
41-50  33 48.5 
51-60  3 4.4 
61-72  1 1.5 
M=41.16, SD=6.72, Min=27, Max=72   
Spanish-Speaking Sample (N=54)   
<30  8 14.8 
31-40  24 44.4 
41-50  18 33.3 
51-60  4 7.4 
61-72  0 0 
M=38.72, SD=7.31, Min=26, Max=55   
Household Annual Income 
Whole sample (N=122) 
  
1-Less than $9,000 16 13.1 
2-$10,000 to $19,000 14 11.5 
3-$20,000 to $39,000 20 16.4 
4-$40,000 to $49,000 9 7.4 
5-$50,000 to $99,999 36 29.5 
6-$100,000 to $199,999 15 12.3 
7-$200,000 to $299,000 9 7.4 
8-$300,000 to $399,000 1 .8 






M whole=4.09, SD=1.954, Min=1, Max=9   
English-Speaking Sample (N=68)   
1-Less than $9,000 6 8.8 
2-$10,000 to $19,000 7 10.3 
3-$20,000 to $39,000 7 10.3 
4-$40,000 to $49,000 6 8.8 
5-$50,000 to $99,999 21 30.9 
6-$100,000 to $199,999 11 16.2 
7-$200,000 to $299,000 7 10.3 
8-$300,000 to $399,000 1 1.5 
9-$400,000 to $499,000 2 2.9 
M=4.57, SD=1.972, Min=1, Max=9   
Spanish-Speaking Sample (N=54)   
1-Less than $9,000 10 18.5 
2-$10,000 to $19,000 7 13.0 
3-$20,000 to $39,000 13 24.1 
4-$40,000 to $49,000 3 5.6 
5-$50,000 to $99,999 15 27.8 
6-$100,000 to $199,999 4 7.4 
7-$200,000 to $299,000 2 3.7 
8-$300,000 to $399,000 0 0 
9-$400,000 to $499,000 0 0 
M=3.48, SD=1.78, Min=1, Max=7   
Race/Ethnicity  
Whole Sample (N=122) 
  
1-Non-Hispanic Black 14 11.5 
2- Non-Hispanic White 10 8.2 
3-Hispanic/Latino 83 68.0 
4-Asian 9 7.4 
6-Native Hawaiian/Pacific Islander 1 .8 
7- Arab American / Middle Eastern 1 .8 
8- Native American/American Indian/Alaska 
Native 
1 .8 
9- Other group(s) 7 5.7 
English-Speaking Sample (N=68)   
1-Non-Hispanic Black 14 20.6 
2- Non-Hispanic White 10 14.7 
3-Hispanic/Latino 30 44.1 
4-Asian 9 13.2 
6-Native Hawaiian/Pacific Islander 1 1.5 
7- Arab American/Middle Eastern 1 1.5 
8- Native American/American Indian/Alaska 
Native 
1 1.9 







Spanish-Speaking Sample (N=54)   
1-Non-Hispanic Black 0 0 
2- Non-Hispanic White 0 0 
3-Hispanic/Latino 53 98.1 
4-Asian 0 0 
6-Native Hawaiian/Pacific Islander 0 0 
7- Arab American/Middle Eastern 1 1.9 
8- Native American/American Indian/Alaska 
Native 
0 0 
9- Other group(s) 0 0 
Level of Education   
Whole sample (N=121)   
1-Less than High-school 10 8.2 
2-High school or high school equivalent (GED) 20 16.4 
3-Some college or a Certificate Program 29 23.8 
4-2-year college degree (Associate’s) 7 5.7 
5-4-year college degree (Bachelor’s) 24 19.7 
6-Master’s degree 23 18.9 
7- J.D. (Lawyer) 1 .8 
8-Doctoral Degree (Ph.D., Ed.D.) 3 2.5 
9-Medical Degree (M.D., D.D.S.) 4 3.3 
M whole=4.05, SD=1.98, Min=1, Max=9   
English-Speaking Sample (N=67)   
1-Less than High-school 2 2.9 
2-High school or high school equivalent (GED) 6 8.8 
3-Some college or a Certificate Program 12 17.6 
4-2-year college degree (Associate’s) 6 8.8 
5-4-year college degree (Bachelor’s) 22 32.4 
6-Master’s degree 12 17.6 
8-Doctoral Degree (Ph.D., Ed.D.) 3 4.4 
9-Medical Degree (M.D., D.D.S.) 4 5.9 
M=4.72, SD=1.88, Min=1, Max=9   
Spanish-Speaking Sample (N=54)   
1-Less than High-school 8 14.8 
2-High school or high school equivalent (GED) 14 25.9 
3-Some college or a Certificate Program 17 31.5 
4-2-year college degree (Associate’s) 1 1.9 
5-4-year college degree (Bachelor’s) 2 3.7 
6-Master’s degree 11 20.4 
7-J.D. (Lawyer) 1 1.9 
8-Doctoral Degree (Ph.D., Ed.D.) 0 0 
9-Medical Degree (M.D., D.D.S.) 0 0 







Employed   
Whole Sample (N=122)   
Yes  90 73.8 
No 13 10.7 
English-Speaking Sample (N=68)   
Yes  54 79.4 
No 7 10.3 
Spanish-Speaking Sample (N=54)   
Yes  36 66.7 
No 6 11.1 
Marital status 
Whole Sample (N=122) 
  
1-Single 19 15.6 
2-Married 66 54.1 
3-Separated 8 6.6 
4-Divorced 17 13.9 
5-Widowed 1 .8 
6-In Domestic Partnership 4 3.3 
7-Living with Significant Other 7 5.7 
English-Speaking Sample (N=68)   
1-Single 7 10.3 
2-Married 40 58.8 
3-Separated 4 5.9 
4-Divorced 12 17.6 
5-Widowed 1 1.5 
6-In Domestic Partnership 2 2.9 
7-Living with Significant Other 2 2.9 
Spanish-Speaking Sample (N=54)   
1-Single 12 22.2 
2-Married 26 48.1 
3-Separated 4 7.4 
4-Divorced 5 9.3 
5-Widowed 0 0 
6-In Domestic Partnership 2 3.7 
7-Living with Significant Other 5 9.3 
Whole Sample (N=122)   
1-Private insurance plan 57 46.7 
2- HMO insurance 16 13.1 
3-Medicaid 15 12.3 
4-Medicare 10 8.2 
5- Other insurance plan 7 5.7 
6- None 22 18.0 
English-Speaking Sample (N=68)   
1-Private insurance plan 40 58.8 
2- HMO insurance 6 8.8 






4-Medicare 6 8.8 
5- Other insurance plan 7 10.3 
6- None 6 8.8 
Spanish-Speaking Sample (N=54)   
1-Private insurance plan 17 31.5 
2- HMO insurance 10 18.5 
3-Medicaid 8 14.8 
4-Medicare 4 7.4 
5- Other insurance plan 0 0 
6- None 16 29.6 
Whole Sample (N=122)   
Yes  52 42.6 
No 70 57.4 
English-Speaking Sample (N=68)   
Yes  38 55.9 
No 30 44.1 
Spanish-Speaking Sample (N=54)   
Yes  14 25.9 
No 40 74.1 
 
 
Results for Research Question #2 
 
What do parents report about their children (i.e., number of children ages 9 
to 18, number of male and female children, child sexual orientation, type of medical 
insurance)?  
 
The mean of children aged 9-18 for the whole sample (n=122) was 1.61 (min=1, 
max=4, SD=.765). The mean of children aged 9-18 for ESP (n=68) was 1.63 (min=1, 
max=4, SD=.710). The mean of children aged 9-18 for SSP (n=54) was 1.59 (min=1, 
max=4, SD=.836).  
Some 90.2% (n=110) of the whole sample reported that 0 of their children were 
LGBTQ. 
Also, 48.4% (n=59) of parents reported that their children had a private health 
insurance plan, and of those, 58.8% (n=40) were ESP and 35.2% (n=19) were SSP.  







S1. Table 2. Children Demographic Characteristics Reported by Parents (PARENTS-BD-
10) (N=122) 
  N % 
What do parents report about the number of children aged 9 to 18? 





M whole=1.61, SD=.765, Min=1, Max=4 





M=1.63, SD=.710, Min=1, Max=4 








































What do parents report about the number of male and female children? 
Child’s gender 





M whole=.96, SD=.786, Min=0, Max=3 






M whole=1.18, SD=.863, Min=0, Max=4 





M=.94, SD=.770, Min=0, Max=3 




























































M=1.04, SD=.762, Min=0, Max=3 





M=.98, SD=.812, Min=0, Max=3 





































What do parents report about their child sexual orientation? 
How Many are Heterosexual? 








M whole=1.20, SD=1.23, Min=0, Max=5 








M=1.19, SD=1.13, Min=0, Max=5 







M=1.21, SD=1.350, Min=0, Max=4 
How many of your children are LGBTQ? 




































































M whole=.06, SD=.273, Min=0, Max=2 





M=.11, SD=.364, Min=0, Max=2 
Spanish-Speaking Sample (N=53) 
0-Child 
Missing 





























What do parents report about their children’s type of medical insurance? 
Child’s insurance status  
Whole Sample (N=122) 
1-Private insurance plan 
2- HMO insurance 
3-Medicaid 
4-Medicare 
5- None  
English-Speaking Sample (N=68) 
1-Private insurance plan 




Spanish-Speaking Sample (N=54) 
1-Private insurance plan 


















































Results for Research Question #3  
 
Do parents report providers having talked to them about HPV and the HPV 
vaccination, and did the providers recommend the HPV vaccination for their child?  
 
Some 62.3% (n=76) of parents reported that their child’s healthcare provider 
talked to them about the HPV infection and the HPV vaccine. Among these 76 parents, 
64.7% (n=44) were ESP and 59.3% (n=32) were SSP. Also, 55.9% (n=38) of ESP and 
50% (n=27) SSP reported receiving a provider recommendation to vaccinate their child.  
See Table 3. 
 
S1. Table 3: Parent Report on Provider Recommending the HPV Vaccination for 
Child (PARENT-R-PR-HPV-V-FC-2) (N=122)  
  N % 
Do parents report providers having talked to them about HPV and the HPV 
vaccination? 
Whole Sample (N=122) 
Yes 
No 
English-Speaking Sample (N=68) 
Yes 
No 





















Parent reported on provider recommending the HPV vaccination for their child 
Whole Sample (N=122) 
Yes 
No 
English-Speaking Sample (N=68) 
Yes 
No 






























Results for Research Question #4  
 
Do parents report one or more of their children ever having received the 
HPV vaccination?  
 
Some 38.5% (n=47) of parents reported that their child received one or more 
doses of the HPV vaccine. Of the 47 parents, 41.2% (n=28) were ESP and 35.2% (n=19) 
were SSP. Further, 9% (n=12) of parents reported their child received two doses, of these, 
8.8% (n=6) were ESP and 11.1% (n=6) of SSP. Among 11% (n=9) of parents who 
reported their child received three doses, 11.8% (n=8) were ESP and 5.6% (n=3) of SSP.  
See Table 4. 
S1. Table 4. Parents Reported HPV Vaccination of One or More (PARENT-R-HPV-V-
FC-1) (N=122) 
  N % 
Do parents report one or more of their children ever having received the HPV vaccination? 
Whole Sample (N=122)   
Yes  47 38.5 
No  75 61.5 
English-Speaking Sample (N=68)   
Yes  28 41.2 
No  40 58.8 
Spanish-Speaking Sample (N=54)   
Yes 19 35.2 
No 35 64.8 
For the HPV vaccination given to your child, please indicate how many doses your child 
received (i.e., returned to medical provider for dose or doses) 
Whole Sample (N=122)   
1 dose 15 12.3 
2 doses 12 9.8 
3 doses 11 9.0 
I’m not sure 9 7.4 
English-Speaking Sample (N=68)   
1 dose 9 13.2 
2 doses 6 8.8 
3 doses 8 11.8 
I’m not sure 5 7.4 
Spanish-Speaking Sample (N=54)   
1 dose 6 11.1 
2 doses 6 11.1 
3 doses 3 5.6 







Results for Research Question #5  
 
Do parents report one or more of their children ever having received the flu 
vaccination, and do they believe in the value of an annual (yearly) flu vaccination 
for their children?  
 
For the whole sample, 86.1 % (n=105) of parents reported that their child received 
the flu vaccination. Of these 105 parents, 91.2% (n=62) were ESP and 79.6% (n=43) 
were SSP. Also, 52.9% (n=36) of ESP and 83.3% (n=45) of SSP indicated that they 
believe in the value of flu vaccination.  
See Table 5. 
S1. Table 5. Parents Reported One or More of Their Children Ever Having Received 
the Flu Vaccination (PARENT-R-FLU-V-FC-1) (N=122) 
  N % 
Do parents report one or more of their children ever having received the flu 
vaccination? 
Whole Sample (N=122) 
Yes 
No 
English-Speaking Sample (N=68) 
Yes 
No 





















Do parents believe in the value of an annual (yearly) flu vaccination for their 
children? 
Whole Sample (N=122) 
Yes 
No 
English-Speaking Sample (N=68) 
Yes 
No 





























Results for Research Question #6 
 
To what extent have parents been exposed to print or digital media providing 
information on the HPV vaccination for children?  
 
The mean score for the whole sample (n=116) was 2.24 for exposed to a very low 
amount of information (min=0, max=5, SD=1.60). The mean score ESP (n=63) was 2.49 
or exposed to a very low amount of information (min=0, max=5, SD=1.66). The mean 
score for SSP (n=54) was 1.94 or closest to being exposed to a very low amount of 
information (min=0, max=5, SD=1.45).  
See Table 6. 
S1. Table 6. Parents Reported Exposure to Print or Digital Media Information on HPV 
Vaccination (PARENT-EPOMI-HPV-VFC-1) (N=122) 
  N % 
To what extent have parents been exposed to print or digital media providing 
information on the HPV vaccination for children? 
Whole Sample (N=122) 
M whole=2.24, SD=1.60, Min=0, Max=5 
English-Speaking (n=68) M=2.49, SD=1.66, Min=0, Max=5 
Spanish-Speaking (n=54) M=1.94, SD=1.45, Min=0, Max=5 
Whole Sample (N=122)    
1-No-no information at all   19 15.6 






























7-Not Applicable - I’m not sure about this   6 4.9 
English-Speaking Sample (N=68)    
1-No-no information at all   8 11.8 
2-Yes, I was exposed to a very low amount of 
information  







3-Yes, I was exposed to a low amount of 
information 
 10 14.7 
 
4- Yes, I was exposed to a moderate amount of 
information 
 16 23.5 
5- Yes, I was exposed to a large amount of 
information 
 4 5.9 
 
6- Yes, I was exposed to a very large amount of 
information 
 12 17.6 
7-Not Applicable - I’m not sure about this   5 7.4 
Spanish-Speaking Sample (N=68)    
1-No-no information at all   11 20.4 
2-Yes, I was exposed to a very low amount of 
information  
 12 22.2 
3-Yes, I was exposed to a low amount of 
information 
 10 18.5 
 
4- Yes, I was exposed to a moderate amount of 
information 
 12 22.2 
5- Yes, I was exposed to a large amount of 
information 
 5 9.3 
 
6- Yes, I was exposed to a very large amount of 
information 
 3 5.6 
7-Not Applicable - I’m not sure about this   1 1.9 
 
Results for Research Question #7 
 
What is the parents’ level of general HPV knowledge?  
 
The mean score for the whole sample (n=122) was 12.05 (min=0, max=23, 
SD=6.79) for moderate level of general HPV knowledge. 







S1. Table 7. Whole Sample: Parents’ HPV Vaccine Knowledge (HPV-G-K-23) 
(N=122) 
  N % 
What is the parents’ level of general HPV knowledge? 
Whole Sample (N=122) 
M whole=12.05, SD=6.79, Min=0, Max=23 
English-Speaking (n=68) M=13.15, SD=6.63, Min=0, Max=23 
Spanish-Speaking (n=54) M=10.67, SD=6.79, Min=0, Max=23 
The 23 General HPV Knowledge Items 
 
1-HPV is very rare 
True  18 14.8 
False  61 50.0 
I Don’t Know (missing)  43 35.2 
2-HPV always has visible signs or symptoms  
True  21 17.2 
False  58 47.5 
I Don’t Know (missing)  43 35.2 
3-HPV can cause cervical cancer 
True  93 76.2 
False  1 .8 
I Don’t Know (missing)  28 23.0 
4-HPV can be transmitted through genital skin-to-skin contact  
True  70 57.4 
False  14 11.5 
I Don’t Know (missing)  38 31.1 
5-There are many types of HPV  
True  65 53.3 
False  5 4.1 
I Don’t Know (missing)  52 42.6 
6-HPV can cause HIV/AIDS  
True  12 9.8 
False  53 43.4 
I Don’t Know (missing)  57 46.7 
7- HPV can be passed on during sexual intercourse 
True  98 80.3 
False  2 1.6 
I Don’t Know (missing)  22 18.0 
8-HPV can cause genital warts  
True  77 63.1 
False  3 2.5 
I Don’t Know (missing)  42 34.4 
9-Men cannot get HPV  
True  18 14.8 
False  76 62.3 






10-Using condoms reduces the chances of HPV transmission  
True  73 59.8 
False  13 10.7 
I Don’t Know (missing)  36 29.5 
11-HPV can be cured with antibiotics 
True  13 10.7 
False  56 45.9 
I Don’t Know (missing)  53 43.4 
12-Having many sexual partners increases the risk of getting HPV  
True  91  74.6 
False  4 3.3 
I Don’t Know (missing)  27 22.1 
13-Most sexually active people will get HPV at some point in their lives  
True  56 45.9 
False  16 13.1 
I Don’t Know (missing)  50 41.0 
14-A person could have HPV for many years without knowing it  
True  87 71.3 
False  2 1.6 
I Don’t Know (missing)  33 27 
15-Having sex at an early age increases the risk of getting HPV  
True  70 6.6 
False  8 63.9 
I Don’t Know (missing)  44 36.1 
16-HPV can cause anal cancer 
True  48 39.3 
False  9 7.4 
I Don’t Know (missing)  65 53.3 
17-HPV is a bacterial infection  
True  33 27 
False  38 31.1 
I Don’t Know (missing)  51 41.8 
18-HPV can be transmitted through oral sex 
True  59 48.4 
False  9 55.7 
I Don’t Know (missing)  54 44.3 
19-HPV can cause cancer of the penis  
True  46 37.7 
False  9 7.4 
I Don’t Know (missing)  67 54.9 
20-HPV can be transmitted through anal sex  
True  59 48.4 
False  6 4.9 







21-HPV infections always lead to health problems  
True  53 43.4 
False  26 21.3 
I Don’t Know (missing)  43 35.2 
22-HPV can cause oral cancer  
True  55 45.1 
False  8 6.6 
I Don’t Know (missing)  59 48.4 
23-A person with no symptoms cannot transmit the HPV infection  
True  23 18 
False  55 45.1 
I Don’t Know (missing)  44 36.1 
 
The mean score for HPV-G-K-23 for ESP (n=68) was 13.15 (min 0, max 23, SD 
6.63) for moderate level of general HPV knowledge; and the mean score for HPV-G-K-
23 for SSP (n= 54) was 10.67 (min=0, max=23, SD=6.79)—for moderately low level of 
general HPV knowledge. 
See Table 8. 
S1. Table 8. English-Speaking and Spanish-Speaking Parents’ HPV Vaccine 
Knowledge (HPV-G-K-23) (N=122) 
  N % 
What is the parents’ level of general HPV knowledge? 
Whole Sample (N=122) 
M whole=12.05, SD=6.785, Min=0, Max=23 
English-Speaking (n=68) M=13.15, SD=6.629, Min=0, Max=23 
Spanish-Speaking (n=54) M=10.67, SD=6.785, Min=0, Max=23 
The 23 General HPV Knowledge Items 
1-HPV is very rare 
English-Speaking Sample (N=68) 
True  9 13.2 
False  41 60.3 
I Don’t Know (missing)  18 26.5 
Spanish-Speaking Sample (N=54) 
True  9 16.7 
False  20 37.0 







2-HPV always has visible signs or symptoms  
English-Speaking Sample (N=68) 
True  7 10.3 
False  39 57.4 
I Don’t Know (missing)  22 32.4 
Spanish-Speaking Sample (N=54) 
True  14 25.9 
False  19 35.2 
I Don’t Know (missing)  21 38.9 
3-HPV can cause cervical cancer 
English-Speaking Sample (N=68) 
True  54 79.4 
False  1 1.5 
I Don’t Know (missing)  13 19.1 
Spanish-Speaking Sample (N=54) 
True  39 72.2 
False (Blank)    
I Don’t Know (missing)  15 27.8 
4-HPV can be transmitted through genital skin-to-skin contact  
English-Speaking Sample (N=68) 
True  38 55.9 
False  11 16.2 
I Don’t Know (missing)  19 27.9 
Spanish-Speaking Sample (N=54) 
True  32 59.3 
False  3 5.6 
I Don’t Know (missing)  19 35.2 
5-There are many types of HPV  
English-Speaking Sample (N=68) 
True  42 61.8 
False  3 4.4 
I Don’t Know (missing)  23 33.8 
Spanish-Speaking Sample (N=54) 
True  23 42.6 
False  2 3.7 
I Don’t Know (missing)  29 53.7 
6-HPV can cause HIV/AIDS  
English-Speaking Sample (N=68) 
True  7 10.3 
False  31 45.6 
I Don’t Know (missing)  30 44.1 
Spanish-Speaking Sample (N=54) 
True  5 9.3 
False  22 40.7 







7- HPV can be passed on during sexual intercourse 
English-Speaking Sample (N=68) 
True  57 83.8 
False  2 2.9 
I Don’t Know (missing)  9 13.2 
Spanish-Speaking Sample (N=54) 
True  41 75.9 
False (Blank)    
I Don’t Know (missing)  13 24.1 
8-HPV can cause genital warts  
English-Speaking Sample (N=68) 
True  42 61.8 
False  2 2.9 
I Don’t Know (missing)  24 35.3 
Spanish-Speaking Sample (N=54) 
True  35 64.8 
False  1 1.9 
I Don’t Know (missing)  18 33.3 
9-Men cannot get HPV 
English-Speaking Sample (N=68) 
True  7 10.3 
False  49 72.1 
I Don’t Know (missing)  12 17.6 
Spanish-Speaking Sample (N=54) 
True  11 20.4 
False  27 50.0 
I Don’t Know (missing)  16 29.6 
10-Using condoms reduces the chances of HPV transmission  
English-Speaking Sample (N=68) 
True  40 58.8 
False  10 14.7 
I Don’t Know (missing)  18 26.5 
Spanish-Speaking Sample (N=54) 
True  33 61.1 
False  3 5.6 
I Don’t Know (missing)  18 33.3 
11-HPV can be cured with antibiotics 
English-Speaking Sample (N=68) 
True  6 8.8 
False  35 51.5 
I Don’t Know (missing)  27 39.7 
Spanish-Speaking Sample (N=54) 
True  7 13.0 
False  21 38.9 







12-Having many sexual partners increases the risk of getting HPV  
English-Speaking Sample (N=68) 
True  50 73.5 
False  3 4.4 
I Don’t Know (missing)  15 22.1 
Spanish-Speaking Sample (N=54) 
True  41 75.9 
False  1 1.9 
I Don’t Know (missing)  12 22.2 
13-Most sexually active people will get HPV at some point in their lives  
English-Speaking Sample (N=68) 
True  33 48.5 
False  10 14.7 
I Don’t Know (missing)  25 36.8 
Spanish-Speaking Sample (N=54) 
True  23 42.6 
False  6 11.1 
I Don’t Know (missing)  25 46.3 
14-A person could have HPV for many years without knowing it  
English-Speaking Sample (N=68) 
True  51 75.0 
False  2 2.9 
I Don’t Know (missing)  15 22.1 
Spanish-Speaking Sample (N=54) 
True  36 66.7 
False (Blank)    
I Don’t Know (missing)  18 33.3 
15-Having sex at an early age increases the risk of getting HPV  
English-Speaking Sample (N=68) 
True  38 55.9 
False  6 8.8 
I Don’t Know (missing)  24 35.3 
Spanish-Speaking Sample (N=54) 
True  32 59.3 
False  2 3.7 
I Don’t Know (missing)  20 37.0 
16-HPV can cause anal cancer 
English-Speaking Sample (N=68) 
True  33 48.5 
False  2 2.9 
I Don’t Know (missing)  33 48.5 
Spanish-Speaking Sample (N=54) 
True  15 27.8 
False  7 13.0 







17-HPV is a bacterial infection  
English-Speaking Sample (N=68) 
True  17 25.0 
False  27 39.7 
I Don’t Know (missing)  24 35.3 
Spanish-Speaking Sample (N=54) 
True  16 29.6 
False  11 20.4 
I Don’t Know (missing)  27 50.0 
18-HPV can be transmitted through oral sex 
English-Speaking Sample (N=68) 
True  38 55.9 
False  5 7.4 
I Don’t Know (missing)  25 36.8 
Spanish-Speaking Sample (N=54) 
True  21 38.9 
False  4 7.4 
I Don’t Know (missing)  29 53.7 
19-HPV can cause cancer of the penis  
English-Speaking Sample (N=68) 
True  27 39.7 
False  5 7.4 
I Don’t Know (missing)  36 52.9 
Spanish-Speaking Sample (N=54) 
True  19 35.2 
False  4 7.4 
I Don’t Know (missing)  31 57.4 
20-HPV can be transmitted through anal sex  
English-Speaking Sample (N=68) 
True  39 57.4 
False  4 5.9 
I Don’t Know (missing)  25 36.8 
Spanish-Speaking Sample (N=54) 
True  20 37.0 
False  2 3.7 
I Don’t Know (missing)  32 59.3 
21-HPV infections always lead to health problems  
English-Speaking Sample (N=68) 
True  27 39.7 
False  17 25.0 
I Don’t Know (missing)  24 35.3 
Spanish-Speaking Sample (N=54) 
True  26 48.1 
False  9 16.7 






22-HPV can cause oral cancer  
English-Speaking Sample (N=68) 
True  36 52.9 
False  4 5.9 
I Don’t Know (missing)  28 41.2 
Spanish-Speaking Sample (N=54) 
True  19 35.2 
False  4 7.4 
I Don’t Know (missing)  31 57.4 
23-A person with no symptoms cannot transmit the HPV infection  
English-Speaking Sample (N=68) 
True  13 19.1 
False  37 54.4 
I Don’t Know (missing)  18 26.5 
Spanish-Speaking Sample (N=54) 
True  10 18.5 
False  18 33.3 
I Don’t Know (missing)  26 48.1 
 
 
Results for Research Question #8 
 
What is the parents’ level of HPV vaccine knowledge?  
 
The mean score for the whole sample (n=122) was 5.50 (min=0, max=11, 
SD=3.43) for a moderate level of HPV vaccine knowledge. 
See Table 9. 
S1. Table 9. Whole Sample: HPV Vaccine Knowledge (HPV-V-K-S-11) (N=122) 
  N % 
What is the parents’ level of HPV vaccine knowledge? 
Whole Sample (N=122) 
M whole=5.50, SD=3.43, Min=0, Max=11 
English-Speaking (n=68) M=6.03, SD=3.21, Min=0, Max=11 
Spanish-Speaking (n=54) M=4.83, SD=3.61, Min=0, Max=11 
 
Parents’ HPV Vaccine Knowledge 
1-The HPV vaccine requires at least 2 doses 
True  53 43.4 
False  13 10.7 







2-The HPV vaccines offers protection against all sexually transmitted infections 
True  15 12.3 
False  70 57.4 
I Don’t Know (missing)  37 30.3 
3-The HPV vaccines are most effective if given to people who’ve never had sex 
True  55 45.1 
False  17 13.9 
I Don’t Know (missing)  50 41.0 
4-Someone who has had the HPV vaccine cannot develop cervical cancer 
True  11 9.0 
False  55 45.1 
I Don’t Know (missing)  56 45.9 
5-The HPV vaccines offer protection against cervical cancers 
True  65 53.3 
False  16 13.1 
I Don’t Know (missing)  41 33.6 
6-The HPV vaccine offers protection against genital warts 
True  51 41.8 
False  23 18.9 
I Don’t Know (missing)  48 39.3 
7- Girls who have had an HPV vaccine do not need a Pap test when they are older 
True  8 6.6 
False  77 63.1 
I Don’t Know (missing)  37 30.3 
8- The HPV vaccine protects you from every type of HPV 
True  20 16.4 
False  46 37.7 
I Don’t Know (missing)  56 45.9 
9-You can cure HPV by getting the HPV vaccine 
True  14 11.5 
False  54 44.3 
I Don’t Know (missing)  54 44.3 
10-HPV vaccination is most effective when given to preteens and teens before they 
become sexually active 
True  77 63.1 
False  4 3.3 
I Don’t Know (missing)  41 33.6 
11-Sexually active individuals can still benefit from getting the HPV vaccines   
True  68 55.7 
False  7 5.7 








The mean score for the ESP sample’s HPV vaccine knowledge (n=68) was 6.03 
(min=0, max=11, SD=3.21) for moderately high level of HPV vaccine knowledge; the 
mean score for HPV-V-K-S-11 for SSP (n=54) was 4.83 (min=0, max=11, SD=3.61) for 
a moderate level of HPV vaccine knowledge. 
See Table 10. 
S1. Table 10. English-Speaking and Spanish-Speaking Parents’ HPV Vaccine 
Knowledge (HPV-V-K-S-11) (N=122) 
  N % 
What is the parents’ level of HPV vaccine knowledge? 
Whole Sample (N=122) 
M whole=5.50, SD=3.431, Min=0, Max=11 
English-Speaking (n=68) M=6.03, SD=3.21, Min=0, Max=11 
Spanish-Speaking (n=54) M =6.29, SD=3.61, Min=0, Max=11 
 
Parents’ HPV Vaccine Knowledge 
1-The HPV vaccine requires at least 2 doses 
English-Speaking Sample (N=68) 
True  29 42.6 
False  8 11.8 
I Don’t Know(missing)  31 45.6 
Spanish-Speaking Sample (N=54) 
True  24 44.4 
False  5 9.3 
I Don’t Know(missing)  25 46.3 
2-The HPV vaccines offers protection against all sexually transmitted infections 
English-Speaking Sample (N=68) 
True  11 16.2 
False  41 60.3 
I Don’t Know (missing)  16 23.5 
Spanish-Speaking Sample (N=54) 
True  4 7.4 
False  29 53.7 
I Don’t Know (missing)  21 38.9 
3-The HPV vaccines are most effective if given to people who’ve never had sex 
English-Speaking Sample (N=68) 
True  32 47.1 
False  11 16.2 







Spanish-Speaking Sample (N=54) 
True  23 42.6 
False  6 11.1 
I Don’t Know (missing)  25 46.3 
4-Someone who has had the HPV vaccine cannot develop cervical cancer 
English-Speaking Sample (N=68) 
True  4 5.9 
False  36 52.9 
I Don’t Know (missing)  28 41.2 
Spanish-Speaking Sample (N=54) 
True  7 13.0 
False  19 35.2 
I Don’t Know (missing)  28 51.9 
5-The HPV vaccines offer protection against cervical cancers 
English-Speaking Sample (N=68) 
True  40 58.8 
False  9 13.2 
I Don’t Know (missing)  19 27.9 
Spanish-Speaking Sample (N=54) 
True  25 46.3 
False  7 13.0 
I Don’t Know (missing)  22 40.7 
6-The HPV vaccine offers protection against genital warts 
English-Speaking Sample (N=68) 
True  28 41.2 
False  15 22.1 
I Don’t Know (missing)  25 36.8 
Spanish-Speaking Sample (N=54) 
True  23 42.6 
False  8 14.8 
I Don’t Know (missing)  23 42.6 
7- Girls who have had an HPV vaccine do not need a Pap test when they are older 
English-Speaking Sample (N=68) 
True  3 4.4 
False  50 73.5 
I Don’t Know (missing)  15 22.1 
Spanish-Speaking Sample (N=54) 
True  5 9.3 
False  27 50.0 
I Don’t Know (missing)  22 40.7 
8- The HPV vaccine protects you from every type of HPV 
English-Speaking Sample (N=68) 
True  12 17.6 
False  29 42.6 







Spanish-Speaking Sample (N=54) 
True  8 14.8 
False  17 31.5 
I Don’t Know (missing)  29 53.7 
9-You can cure HPV by getting the HPV vaccine 
English-Speaking Sample (N=68) 
True  8 11.8 
False  35 51.5 
I Don’t Know (missing)  25 36.8 
Spanish-Speaking Sample (N=54) 
True  6 11.1 
False  19 35.2 
I Don’t Know (missing)  29 53.7 
10-HPV vaccination is most effective when given to preteens and teens before they 
become sexually active 
English-Speaking Sample (N=68) 
True  49 72.1 
False  2 2.9 
I Don’t Know (missing)  17 25.0 
Spanish-Speaking Sample (N=54) 
True  28 51.9 
False  2 3.7 
I Don’t Know (missing)  24 44.4 
11-Sexually active individuals can still benefit from getting the HPV vaccines 
English-Speaking Sample (N=68)   
True  41 60.3 
False  2 2.9 
I Don’t Know (missing)  25 36.8 
Spanish-Speaking Sample (N=54) 
True  27 50.0 
False  5 9.3 
I Don’t Know (missing)  22 40.7 
 
 
Results for Research Question #9 
 
What are the parents’ general vaccine attitudes, including for (a) conspiracy 
beliefs, (b) vaccine hesitancy—lack of confidence, and (c) vaccine hesitancy—risks?  
 
The mean score for vaccine conspiracy beliefs for the whole sample (n=122)  
was 3.82 or closest to neutral (min=1, max=7, SD=1.20). The mean score for vaccine 
hesitancy—lack confidence for the whole sample (n=122) was 2.76 or closest to 






hesitancy—risks for the whole sample (n=122) was 4.48 or neutral (min=1, max=7, 
SD=1.37).  
See Table 11. 
S1. Table 11. Whole Sample: Parents’ General Vaccine Attitudes, Conspiracy Beliefs, 
and Vaccine Hesitancy (GVA-CB-HLC-R-16) (N=122) 
  N % 
What are the parents’ general vaccine attitudes, including for (a) conspiracy beliefs, 
(b) vaccine hesitancy—lack of confidence, and (c) vaccine hesitancy—risks? 
Whole Sample (N=122) 
M whole=3.82, SD=1.20, Min=1, Max=7 
English-Speaking (n=68) M=3.99, SD=1.24, Min=1, Max=7 
Spanish-Speaking (n=54) M =3.61, SD=1.13, Min=1, Max=6.29 
 
(a) The 7 Vaccine Conspiracy Beliefs Items 
1- Vaccine safety data is often fabricated 
1-Strongly disagree  19 15.6 
2-Disagree  14 11.5 
3-Somewhat disagree  11 9.0 
4-Neutral  53 43.4 
5-Somewhat agree  15 12.3 
6-Agree  7 5.7 
7-Strongly agree  3 2.5 
2- Negative vaccination effects are covered up 
1-Strongly disagree  13 10.7 
2-Disagree  17 13.9 
3-Somewhat disagree  12 9.8 
4-Neutral  39 32.0 
5-Somewhat agree  28 23.0 
6-Agree  10 8.2 
7-Strongly agree  3 2.5 
3- Pharmaceutical companies cover up the dangers of vaccines 
1-Strongly disagree  16 13.1 
2-Disagree  13 10.7 
3-Somewhat disagree  6 4.9 
4-Neutral  34 27.9 
5-Somewhat agree  36 29.5 
6-Agree  12 9.8 
7-Strongly agree  5 4.1 
4- People are deceived about vaccine efficacy 
1-Strongly disagree  12 9.8 
2-Disagree  12 9.8 






4-Neutral  44 36.1 
5-Somewhat agree  31 25.4 
6-Agree  11 9.0 
7-Strongly agree  5 4.1 
5- Vaccine efficacy data is often fabricated 
1-Strongly disagree  12 9.8 
2-Disagree  20 16.4 
3-Somewhat disagree  7 5.7 
4-Neutral  42 34.4 
5-Somewhat agree  27 22.1 
6-Agree  12 9.8 
7-Strongly agree  2 1.6 
6- People are deceived about vaccine safety 
1-Strongly disagree  8 6.6 
2-Disagree  16 13.1 
3-Somewhat disagree  10 8.2 
4-Neutral  39 32.0 
5-Somewhat agree  29 23.8 
6-Agree  15 12.3 
7-Strongly agree  5 4.1 
7- The government is trying to cover up the link between vaccines and autism 
1-Strongly disagree  17 13.9 
2-Disagree  13 10.7 
3-Somewhat disagree  9 7.4 
4-Neutral  56 45.9 
5-Somewhat agree  15 12.3 
6-Agree  8 6.6 
7-Strongly agree  4 3.3 
Whole Sample (N=122) 
M whole=2.76, SD=1.42, Min=1, Max=7 
English-Speaking (n=68) M=2.60, SD=1.27, Min=1, Max=7 
Spanish-Speaking (n=54) M =2.95, SD=1.59, Min=1, Max=7 
 
(b) - The 7 Vaccine Hesitancy-Lack of Confidence Items 
 
1- Childhood vaccines are important for my child’s health 
1-Strongly disagree  9 7.4 
2-Disagree  4 3.3 
3-Somewhat disagree  1 .8 
4-Neutral  9 7.4 
5-Somewhat agree  16 13.1 
6-Agree  40 32.8 
7-Strongly agree  43 35.2 
2- Childhood vaccines are effective 
1-Strongly disagree  11 9.0 






3-Somewhat disagree  3 2.5 
4-Neutral  12 9.8 
5-Somewhat agree  17 13.9 
6-Agree  53 43.4 
7-Strongly agree  24 19.7 
3- Having my child vaccinated is important for the health of others in my community 
1-Strongly disagree  11 9.0 
2-Disagree  4 3.3 
3-Somewhat disagree  4 3.3 
4-Neutral  12 9.8 
5-Somewhat agree  13 10.7 
6-Agree  51 41.8 
7-Strongly agree  27 22.1 
4- All childhood vaccines offered by the government program in my community are 
beneficial 
1-Strongly disagree  6 4.9 
2-Disagree  3 2.5 
3-Somewhat disagree  9 7.4 
4-Neutral  30 24.6 
5-Somewhat agree  16 13.1 
6-Agree  37 30.3 
7-Strongly agree  21 17.2 
5-The information I receive about vaccines from the vaccine program is reliable and 
trustworthy 
1-Strongly disagree  4 3.3 
2-Disagree  3 2.5 
3-Somewhat disagree  6 4.9 
4-Neutral  34 27.9 
5-Somewhat agree  29 23.8 
6-Agree  33 27.0 
7-Strongly agree  13 10.7 
6- Getting vaccines is a good way to protect my child/children from disease 
1-Strongly disagree  8 6.6 
2-Disagree  1 .8 
3-Somewhat disagree  0 0 
4-Neutral  14 15.6 
5-Somewhat agree  19 41.0 
6-Agree  50 24.6 
7-Strongly agree  30 6.6 
7- Generally I do what my doctor or health care provider recommends about 
vaccines for my child/children 
1-Strongly disagree  8 6.6 
2-Disagree  4 3.3 
3-Somewhat disagree  4 3.3 
4-Neutral  14 11.5 






6-Agree  48 39.3 
7-Strongly agree  25 20.5 
Whole Sample (N=122) 
M whole=4.48, SD=1.37, Min=1, Max=7 
English-Speaking (n=68) M=4.56, SD=1.42, Min=1, Max=7 
Spanish-Speaking (n=54) M =4.39, SD=1.31, Min=1.50, Max=7 
 
(c) - The 2 Vaccine Hesitancy—Hesitancy-Risks Items 
 
1- I am concerned about serious adverse effects of vaccines 
1-Strongly disagree  3 2.5 
2-Disagree  12 9.8 
3-Somewhat disagree  1 .8 
4-Neutral  33 27.0 
5-Somewhat agree  33 27.0 
6-Agree  26 21.3 
7-Strongly agree  14 11.5 
2- New vaccines carry more risks than older vaccines 
1-Strongly disagree  8 6.6 
2-Disagree  11 9.0 
3-Somewhat disagree  9 7.4 
4-Neutral  50 41.0 
5-Somewhat agree  17 13.9 
6-Agree  18 14.8 
7-Strongly agree  9 7.4 
 
 
The mean score for vaccine conspiracy beliefs for ESP (n=68) was 3.99 for 
closest to neutral (min=1, max=7, SD=1.24) and the mean score for vaccine conspiracy 
beliefs for SSP (n=54) was 3.61 for somewhat disagree (min=1, max=6.29, SD=1.13).  
The mean score for vaccine hesitancy–lack confidence for ESP (n=68) was 2.60 or 
disagree (min=1, max=7, SD=1.27) and the mean score for vaccine hesitancy–lack of 
confidence for SSP (n=54) was 2.95 or closest to somewhat disagree (min=1, max=7, 
SD=1.59). The mean score for vaccine hesitancy—risks for ESP (n=68) was 4.56 for 
neutral (min=1, max=7, SD=1.42) and the mean score for vaccine hesitancy—risks for 
SSP (n=54) was 4.39 for neutral (min=1.50, max=7, SD=1.31).  






S1. Table 12. English-Speaking and Spanish-Speaking Parents’ General Vaccine 
Attitudes, Conspiracy Beliefs, and Vaccine Hesitancy (GVA-CB-HLC-R-16) (N=122) 
  N % 
What are the parents’ general vaccine attitudes, including for (a) conspiracy 
beliefs, (b) vaccine hesitancy—lack of confidence, and (c) vaccine hesitancy—
risks? 
Whole Sample (N=122) 
M whole=3.82, SD=1.20, Min=1, Max=7 
English-Speaking (n=68) M=3.99, SD=1.24, Min=1, Max=7 
Spanish-Speaking (n=54) M=3.61, SD=1.13, Min=1, Max=6.29 
(a) - The 7 Vaccine Conspiracy Beliefs Items 
1- Vaccine safety data is often fabricated 
English-Speaking Sample (N=68)   
1-Strongly disagree  8 11.8 
2-Disagree  7 10.3 
3-Somewhat disagree  7 10.3 
4-Neutral  30 44.1 
5-Somewhat agree  11 16.2 
6-Agree  2 2.9 
7-Strongly agree  3 4.4 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  11 20.4 
2-Disagree  7 13.0 
3-Somewhat disagree  4 7.4 
4-Neutral  23 42.6 
5-Somewhat agree  4 7.4 
6-Agree  5 9.3 
7-Strongly agree  0 0 
2- Negative vaccination effects are covered up 
English-Speaking Sample (N=68)   
1-Strongly disagree  5 7.4 
2-Disagree  8 11.8 
3-Somewhat disagree  5 7.4 
4-Neutral  24 35.3 
5-Somewhat agree  19 27.9 
6-Agree  5 7.4 
7-Strongly agree  2 2.9 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  8 14.8 
2-Disagree  9 16.7 
3-Somewhat disagree  7 13.0 
4-Neutral  15 27.8 
5-Somewhat agree  9 16.7 
6-Agree  5 9.3 






3- Pharmaceutical companies cover up the dangers of vaccines 
English-Speaking Sample (N=68)   
1-Strongly disagree  5 7.4 
2-Disagree  5 7.4 
3-Somewhat disagree  3 4.4 
4-Neutral  19 27.9 
5-Somewhat agree  25 36.8 
6-Agree  8 11.8 
7-Strongly agree  3 4.4 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  11 20.4 
2-Disagree  8 14.8 
3-Somewhat disagree  3 5.6 
4-Neutral  15 27.8 
5-Somewhat agree  11 20.4 
6-Agree  4 7.4 
7-Strongly agree  2 3.7 
4- People are deceived about vaccine efficacy 
English-Speaking Sample (N=68)   
1-Strongly disagree  6 8.8 
2-Disagree  4 5.9 
3-Somewhat disagree  3 4.4 
4-Neutral  24 35.3 
5-Somewhat agree  20 29.4 
6-Agree  7 10.3 
7-Strongly agree  4 5.9 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  6 11.1 
2-Disagree  8 14.8 
3-Somewhat disagree  4 7.4 
4-Neutral  20 37.0 
5-Somewhat agree  11 20.4 
6-Agree  4 7.4 
7-Strongly agree  1 1.9 
5- Vaccine efficacy data is often fabricated 
English-Speaking Sample (N=68)   
1-Strongly disagree  7 10.3 
2-Disagree  10 14.7 
3-Somewhat disagree  3 4.4 
4-Neutral  21 30.9 
5-Somewhat agree  17 25.0 
6-Agree  8 11.8 







Spanish-Speaking Sample (N=54)    
1-Strongly disagree  5 9.3 
2-Disagree  10 18.5 
3-Somewhat disagree  4 7.4 
4-Neutral  21 38.9 
5-Somewhat agree  10 18.5 
6-Agree  4 7.4 
7-Strongly agree  0 0 
6- People are deceived about vaccine safety 
English-Speaking Sample (N=68)   
1-Strongly disagree  6 8.8 
2-Disagree  7 10.3 
3-Somewhat disagree  4 5.9 
4-Neutral  20 29.4 
5-Somewhat agree  20 29.4 
6-Agree  8 11.8 
7-Strongly agree  3 4.4 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  2 3.7 
2-Disagree  9 16.7 
3-Somewhat disagree  6 11.1 
4-Neutral  19 35.2 
5-Somewhat agree  9 16.7 
6-Agree  7 13.0 
7-Strongly agree  2 3.7 
7- The government is trying to cover up the link between vaccines and autism 
English-Speaking Sample (N=68)   
1-Strongly disagree  11 16.2 
2-Disagree  6 8.8 
3-Somewhat disagree  5 7.4 
4-Neutral  30 44.1 
5-Somewhat agree  10 14.7 
6-Agree  4 5.9 
7-Strongly agree  2 2.9 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  6 11.1 
2-Disagree  7 13.0 
3-Somewhat disagree  4 7.4 
4-Neutral  26 48.1 
5-Somewhat agree  5 9.3 
6-Agree  4 7.4 







Whole Sample (N=122) 
M whole=2.76, SD=1.42, Min=1, Max=7 
English-Speaking (n=68) M=2.60, SD=1.27, Min=1, Max=7 
Spanish-Speaking (n=54) M=2.95, SD=1.59, Min=1, Max=7  
 
(b) - The 7 Vaccine Hesitancy-Lack of Confidence Items 
 
1- Childhood vaccines are important for my child’s health 
English-Speaking Sample (N=68)   
1-Strongly disagree  4 5.9 
2-Disagree  1 1.5 
3-Somewhat disagree  0 0 
4-Neutral  5 7.4 
5-Somewhat agree  10 14.7 
6-Agree  21 30.9 
7-Strongly agree  27 39.7 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  5 9.3 
2-Disagree  3 5.6 
3-Somewhat disagree  1 1.9 
4-Neutral  4 7.4 
5-Somewhat agree  6 11.1 
6-Agree  19 35.2 
7-Strongly agree  16 29.6 
2- Childhood vaccines are effective 
English-Speaking Sample (N=68)   
1-Strongly disagree  5 7.4 
2-Disagree  0 0 
3-Somewhat disagree  1 1.5 
4-Neutral  6 8.8 
5-Somewhat agree  9 13.2 
6-Agree  33 48.5 
7-Strongly agree  14 20.6 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  6 11.1 
2-Disagree  2 3.7 
3-Somewhat disagree  2 3.7 
4-Neutral  6 11.1 
5-Somewhat agree  8 14.8 
6-Agree  20 37.0 
7-Strongly agree  10 18.5 
3- Having my child vaccinated is important for the health of others in my community 
English-Speaking Sample (N=68)   
1-Strongly disagree  4 5.9 
2-Disagree  2 2.9 






4-Neutral  4 5.9 
5-Somewhat agree  6 8.8 
6-Agree  33 48.5 
7-Strongly agree  17 25.0 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  7 13.0 
2-Disagree  2 3.7 
3-Somewhat disagree  2 3.7 
4-Neutral  8 14.8 
5-Somewhat agree  7 13.0 
6-Agree  18 33.3 
7-Strongly agree  10 18.5 
4- All childhood vaccines offered by the government program in my community are 
beneficial 
English-Speaking Sample (N=68)   
1-Strongly disagree  2 2.9 
2-Disagree  0 0 
3-Somewhat disagree  7 10.3 
4-Neutral  21 30.9 
5-Somewhat agree  8 11.8 
6-Agree  19 27.9 
7-Strongly agree  11 16.2 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  4 7.4 
2-Disagree  3 5.6 
3-Somewhat disagree  2 3.7 
4-Neutral  9 16.7 
5-Somewhat agree  8 14.8 
6-Agree  18 33.3 
7-Strongly agree  10 18.5 
5-The information I receive about vaccines from the vaccine program is reliable and 
trustworthy 
English-Speaking Sample (N=68)   
1-Strongly disagree  2 2.9 
2-Disagree  1 1.5 
3-Somewhat disagree  3 4.4 
4-Neutral  18 26.5 
5-Somewhat agree  18 26.5 
6-Agree  19 27.9 
7-Strongly agree  7 10.3 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  2 3.7 
2-Disagree  2 3.7 
3-Somewhat disagree  3 5.6 
4-Neutral  16 29.6 






6-Agree  14 25.9 
7-Strongly agree  6 11.1 
6- Getting vaccines is a good way to protect my child/children from disease 
English-Speaking Sample (N=68)   
1-Strongly disagree  3 4.4 
2-Disagree  0 0 
3-Somewhat disagree  0 0 
4-Neutral  7 10.3 
5-Somewhat agree  9 13.2 
6-Agree  31 45.6 
7-Strongly agree  18 26.5 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  5 9.3 
2-Disagree  1 1.9 
3-Somewhat disagree  0 0 
4-Neutral  7 13.0 
5-Somewhat agree  10 18.5 
6-Agree  19 35.2 
7-Strongly agree  12 22.2 
7- Generally I do what my doctor or health care provider recommends about 
vaccines for my child/children 
English-Speaking Sample (N=68)   
1-Strongly disagree  4 5.9 
2-Disagree  0 0 
3-Somewhat disagree  3 4.4 
4-Neutral  7 10.3 
5-Somewhat agree  14 20.6 
6-Agree  26 38.2 
7-Strongly agree  14 20.6 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  4 7.4 
2-Disagree  4 7.4 
3-Somewhat disagree  1 1.9 
4-Neutral  7 13.0 
5-Somewhat agree  5 9.3 
6-Agree  22 40.7 
7-Strongly agree  11 20.4 
Whole Sample (N=122) 
M whole=4.48, SD=1.37, Min=1, Max=7 
English-Speaking (n=68) M=4.56, SD=1.42, Min=1, Max=7 
Spanish-Speaking (n=54) M=4.39, SD=1.31, Min=1.50, Max=7 
 








1- I am concerned about serious adverse effects of vaccines 
English-Speaking Sample (N=68)   
1-Strongly disagree  3 4.4 
2-Disagree  5 7.4 
3-Somewhat disagree  0 0 
4-Neutral  16 23.5 
5-Somewhat agree  21 30.9 
6-Agree  14 20.6 
7-Strongly agree  9 13.2 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  0 0 
2-Disagree  7 13.0 
3-Somewhat disagree  1 1.9 
4-Neutral  17 31.5 
5-Somewhat agree  12 22.2 
6-Agree  12 22.2 
7-Strongly agree  5 9.3 
2- New vaccines carry more risks than older vaccines 
English-Speaking Sample (N=68)   
1-Strongly disagree  4 5.9 
2-Disagree  5 7.4 
3-Somewhat disagree  8 11.8 
4-Neutral  25 36.8 
5-Somewhat agree  10 14.7 
6-Agree  9 13.2 
7-Strongly agree  7 10.3 
Spanish-Speaking Sample (N=54)    
1-Strongly disagree  4 7.4 
2-Disagree  6 11.1 
3-Somewhat disagree  1 1.9 
4-Neutral  25 46.3 
5-Somewhat agree  7 13.0 
6-Agree  9 16.7 
7-Strongly agree  2 3.7 
 
 
Results for Research Question #10 
 
What are the parents’ perceived barriers to their child completing the HPV 
vaccination series?  
 
For the whole sample (n=122), 33.6% experienced the barrier of not knowing how 
often they should take their child for completion of the HPV vaccination series, and 






See Table 13. 
S1. Table 13. Whole Sample: Parents’ Perceived Barriers to Completion of the HPV 
Vaccine Series (PARENTS-PB-CC-HPV-VS-12) (N=122) 
  N % 
What are the parents’ perceived barriers to their child completing the HPV 
vaccination series? 
 
Whole Sample (N=122) 
M whole=1.87, SD=2.43, Min=0, Max=11 
English-Speaking (n=68) M=1.82, SD=2.68, Min=0, Max=11 
Spanish-Speaking (n=54) M=1.93, SD=2.08, Min=0, Max=11 
 
1-not knowing how often I should take my child (whether once, twice or three times) 
Yes  41 33.6 
No  81 66.4 
2-not knowing where to take my child 
Yes  20 16.4 
No  102 83.6 
3-a lack of insurance   
Yes  17 13.9 
No  105 86.1 
4-a lack of finances/money 
Yes  21 17.2 
No  101 82.8 
5-a lack of time, or other demands on my time 
Yes  29 23.8 
No  93 76.2 
6-my work schedule 
Yes  37 30.3 
No  85 69.7 
7-my own health issues (physical or mental) 
Yes  9 7.4 
No  113 92.6 
8-the health issues (physical or mental) of others (e.g. other children, 
husband/partner, babysitter, other family, my parents, etc.) 
Yes  9 7.4 
No  113 92.6 
9-stress in my life 
Yes  19 15.6 
No  103 84.4 
10-language—due to having a provider not communicating in my preferred 
language 
Yes  13 10.7 






11-cultural barriers—due to having a provider not understanding my culture, or not 
being culturally sensitive and appropriate 
Yes  13 10.7 
No  109 89.3 
12-other/something else has been an obstacle/barrier for me (Please indicate in the 
space, below) 
Yes  15 12.3 
No  107 87.7 
 
 
For the ESP sample, 26.5% (n=18) experienced the barrier of not knowing how 
often they should take their child for completion of the HPV vaccination series, and 
30.9% (n=21) experienced the barrier of their work schedule. 
For the SPS sample, 42.6% (n=23) experienced the barrier of not knowing how 
often they should take their child for completion of the HPV vaccination series, and 
29.6% (n=16) experienced the barrier of their work schedule. 
See Table 14. 
S1. Table 14. English-Speaking and Spanish-Speaking Parents’ Perceived Barriers to 
Completion of the HPV Vaccine Series (PARENTS-PB-CC-HPV-VS-12) (N=122) 
  N % 
What are the parents’ perceived barriers to their child completing the HPV 
vaccination series? 
 
Whole Sample (N=122) 
M whole=1.87, SD=2.43, Min=0, Max=11 
English-Speaking (n=68) M=1.82, SD=2.68, Min=0, Max=11 
Spanish-Speaking (n=54) M=1.93, SD=2.08, Min=0, Max=11 
 
1-not knowing how often I should take my child (whether once, twice or three times) 
English-Speaking Sample (N=68)   
Yes  18 26.5 
No  50 73.5 
Spanish-Speaking Sample (N=54) 
Yes  23 42.6 







2-not knowing where to take my child 
English-Speaking Sample (N=68)   
Yes  8 11.8 
No  60 88.2 
Spanish-Speaking Sample (N=54) 
Yes  12 22.2 
No  42 77.8 
3-a lack of insurance   
English-Speaking Sample (N=68)   
Yes  8 11.8 
No  60 88.2 
Spanish-Speaking Sample (N=54) 
Yes  9 16.7 
No  45 83.3 
4-a lack of finances/money 
English-Speaking Sample (N=68)   
Yes  10 14.7 
No  58 85.3 
Spanish-Speaking Sample (N=54) 
Yes  11 20.4 
No  43 79.6 
5-a lack of time, or other demands on my time 
English-Speaking Sample (N=68)   
Yes  18 26.5 
No  50 73.5 
Spanish-Speaking Sample (N=54) 
Yes  11 20.4 
No  43 79.6 
6-my work schedule 
English-Speaking Sample (N=68)   
Yes  21 30.9 
No  47 69.1 
Spanish-Speaking Sample (N=54) 
Yes  16 29.6 
No  38 70.4 
7-my own health issues (physical or mental) 
English-Speaking Sample (N=68)   
Yes  7 10.3 
No  61 89.7 
Spanish-Speaking Sample (N=54) 
Yes  2 3.7 







8-the health issues (physical or mental) of others (e.g. other children, 
husband/partner, babysitter, other family, my parents, etc.) 
English-Speaking Sample (N=68)   
Yes  7 10.3 
No  61 89.7 
Spanish-Speaking Sample (N=54) 
Yes  2 3.7 
No  52 96.3 
9-stress in my life 
English-Speaking Sample (N=68)   
Yes  14 20.6 
No  54 79.4 
Spanish-Speaking Sample (N=54) 
Yes  5 9.3 
No  49 90.7 
10-language—due to having a provider not communicating in my preferred 
language 
English-Speaking Sample (N=68)   
Yes  5 7.4 
No  63 92.6 
Spanish-Speaking Sample (N=54) 
Yes  8 14.8 
No  46 85.2 
11-cultural barriers—due to having a provider not understanding my culture, or not 
being culturally sensitive and appropriate 
English-Speaking Sample (N=68)   
Yes  8 11.8 
No  60 88.2 
Spanish-Speaking Sample (N=54) 
Yes  5 9.3 
No  49 90.7 
12-other/something else has been an obstacle/barrier for me (Please indicate in the 
space, below) 
English-Speaking Sample (N=68)   
Yes  10 14.7 
No  58 85.3 
Spanish-Speaking Sample (N=54) 
Yes  5 9.3 









Results for Research Question #11 
 
Pre-video viewing, what was the parents’ knowledge of HPV, the prevalence 
of parents being in an action or maintenance stage for making sure their children 
received the HPV vaccination—as the Study #1 dependent variable—and, their self-
efficacy for doing this? 
 
For the whole sample (n=122), before watching the video, the mean self-rating 
for level of HPV knowledge (n=122) was 3.01 or fair level of knowledge (min=1-Very 
Poor, max=6-Excellent, SD=1.28). The mean for stage of change for performing the 
HPV-related behaviors indicated was 2.25 (min=1-pre-contemplation, max=5- 
maintenance, SD=1.33) for contemplation stage. The mean self-efficacy for performing 
the HPV-related behaviors was 33.95 or closest to “60% confident” (min=1, max=6,  
SD=1.93) before watching the avatar video. 
See Table 15. 
S1. Table 15. Whole Sample: Pre-video Viewing Parents’ HPV Knowledge, Stage of 
Change, and Self-efficacy for Talking to Providers and Child Receiving the HPV 
Vaccine (PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) (N=122) 
  N % 
Pre-video viewing, what was the parents’ knowledge of HPV, the prevalence of 
parents being in an action or maintenance stage for making sure their children 
received the HPV vaccination—as the Study #1 dependent variable—and, their 
self-efficacy for doing this? 
 
Please rate what you know, or your level of knowledge about the Human 
papillomavirus (HPV) infection HPV, and the HPV vaccination for children: 
1 - Very Poor  16 13.1 
2 – Poor  22 18.0 
3 – Fair  51 41.8 
4 - Good  17 13.9 
5 - Very Good  10 8.2 
6 - Excellent  6 4.9 
Level of HPV Knowledge  
Whole Sample (N=122) 
M whole=2.25, SD=1.33, Min=1, Max=5  
English-Speaking (n=68) M=2.37, SD=1.43, Min=1, Max=5 







Please rate yourself for the behavior of talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection HPV, and the 
HPV vaccination for children—by checking what best describes you, below: 
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 47 38.5 
2-I am thinking about doing this 
behavior. 
 32 26.2 
3-I am preparing to do this behavior.  23 18.9 
4-I have been doing this behavior for 
less than six (6) months. 
 6 4.9 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 14 11.5 
Stage of Change for Having Child Vaccinated  
Whole Sample (N=122) 
M whole=2.61, SD=1.38, Min=1, Max=5  
English-Speaking (n=68) M=2.79, SD=1.47, Min=1, Max=5 
Spanish-Speaking (n=54) M=2.39, SD=1.24, Min=1, Max=5 
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 35 28.7 
2-I am thinking about doing this 
behavior. 
 23 18.9 
3-I am preparing to do this behavior.  38 31.1 
4-I have been doing this behavior for 
less than six (6) months. 
 6 4.9 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 20 16.4 
 
Stage of Change Having Child Receiving all Doses  
Whole Sample (N=122) 
M whole=2.75, SD=1.24, Min=1, Max=5  
English-Speaking (n=68) M=2.57, SD=1.42, Min=1, Max=5 
Spanish-Speaking (n=54) M=2.52, SD=1.23, Min=1, Max=5 
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 38 31.1 
2-I am thinking about doing this 
behavior. 
 18 14.8 
3-I am preparing to do this behavior.  42 34.4 
4-I have been doing this behavior for 
less than six (6) months. 
 9 7.4 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 






Self-efficacy-Talking to Provider  
Whole Sample (N=122) 
M whole=3.66, SD=1.94, Min=1, Max=6 
English-Speaking (n=68) M=3.69, SD=2.00, Min=1, Max=6 
Spanish-Speaking (n=54) M=3.61, SD=1.89, Min=1, Max=6  
And, for doing this I am 
 0% confident  32 26.2 
20% confident  6 4.9 
40% confident  14 11.5 
60% confident  22 18.0 
80% confident  16 13.1 
100% confident  32 26.2 
Self-efficacy- Having Child Vaccinated 
Whole Sample (N=122) 
M whole=3.95, SD=1.93, Min=1, Max=6 
English-Speaking (n=68) M=4.15, SD=1.93, Min=1, Max=6 
Spanish-Speaking (n=54) M=3.70, SD=1.94, Min=1, Max=6 
And, for doing this I am 
 0% confident  27 22.1 
20% confident  6 4.9 
40% confident  11 9.0 
60% confident  19 15.6 
80% confident  20 16.4 
100% confident  39 32.0 
Self-efficacy- Having Child Receiving All Doses 
Whole Sample (N=122) 
M whole=3.99, SD=1.91, Min=1, Max=6 
English-Speaking (n=68) M=4.06, SD=1.95, Min=1, Max=6 
Spanish-Speaking (n=54) M=3.91, SD=1.87, Min=1, Max=6 
And, for doing this I am   
 0% confident  25 20.5 
20% confident  8 6.6 
40% confident  8 6.6 
60% confident  22 18.0 
80% confident  20 16.4 








For ESP (n=68), before watching the video, the mean for stage of change for 
performing the HPV-related behaviors indicated was 2.37 (min=1-pre-contemplation, 
max=5-maintenance, SD=1.43) for contemplation stage. The mean self-efficacy for 
performing the HPV-related behaviors was 3.69 or closest to “60% confident” (min=1, 
max=6, SD=1.93) before watching the avatar video. 
For SSP (n=54), before watching the video, the mean for stage of change for 
performing the HPV-related behaviors indicated was 2.09 (min=1-pre-contemplation, 
max=5-maintenance, SD=1.43) for contemplation stage. The mean self-efficacy for 
performing the HPV-related behaviors was 3.61 or closest to “60% confident” (min=1, 
max=6, SD= 2.02) before watching the avatar video. 
See Table 16. 
S1. Table 16. English-Speaking and Spanish-Speaking Parents: Pre-video Viewing 
Parents’ HPV Knowledge, Stage of Change, and Self-efficacy for Talking to Providers 
and Child Receiving the HPV Vaccine (PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-
HPV-V-7) (N=122) 
  N % 
Please rate what you know, or your level of knowledge about the Human 
papillomavirus (HPV) infection HPV, and the HPV vaccination for children: 
English-Speaking Sample (N=68)   
1 - Very Poor  3 4.4 
2 – Poor  10 14.7 
3 – Fair  36 52.9 
4 – Good  7 10.3 
5 - Very Good  8 11.8 
6 - Excellent  4 5.9 
Spanish-Speaking Sample (N=54) 
1 - Very Poor  13 24.1 
2 – Poor  12 22.2 
3 – Fair  15 27.8 
4 - Good  10 18.5 
5 - Very Good  2 3.7 







HPV Knowledge  
Whole Sample (N=122) 
M whole=2.25, SD=1.33, Min=1, Max=5  
English-Speaking (n=68) M=2.37, SD=1.43, Min=1, Max=5 
Spanish-Speaking (n=54) M=2.09, SD=1.17, Min=1, Max=5 
Please rate yourself for the behavior of talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection HPV, and the 
HPV vaccination for children—by checking what best describes you, below: 
English-Speaking Sample (N=68)   
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 25 36.8 
2-I am thinking about doing this 
behavior. 
 18 26.5 
3-I am preparing to do this behavior.  11 16.2 
4-I have been doing this behavior for 
less than six (6) months. 
 3 4.4 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 11 16.2 
Spanish-Speaking Sample (N=54)    
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 22 40.7 
2-I am thinking about doing this 
behavior. 
 14 25.9 
3-I am preparing to do this behavior.  12 22.2 
4-I have been doing this behavior for 
less than six (6) months. 
 3 5.6 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 3 5.6 
Stage of Change for Having Child Vaccinated  
Whole Sample (N=122) 
M whole=2.61, SD=1.38, Min=1, Max=5  
English-Speaking (n=68) M=2.79, SD=1.47, Min=1, Max=5 
Spanish-Speaking (n=54) M=2.39, SD=1.24, Min=1, Max=5 
English-Speaking (n=68) 
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 18 26.5 
2-I am thinking about doing this 
behavior. 
 12 17.6 
3-I am preparing to do this behavior.  19 27.9 
4-I have been doing this behavior for 
less than six (6) months. 






5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 15 22.1 
Spanish-Speaking Sample (N=54) 
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 17 31.5 
2-I am thinking about doing this 
behavior. 
 11 20.4 
3-I am preparing to do this behavior.  19 35.2 
4-I have been doing this behavior for 
less than six (6) months. 
 2 3.7 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 5 9.3 
Stage of Change Having Child Receiving all Doses  
Whole Sample (N=122) 
M whole=2.75, SD=1.24, Min=1, Max=5  
English-Speaking (n=68) M=2.57, SD=1.42, Min=1, Max=5 
Spanish-Speaking (n=54) M=2.52, SD=1.23, Min=1, Max=5 
English-Speaking (n=68) 
English-Speaking (n=68)    
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 22 32.4 
2-I am thinking about doing this 
behavior. 
 11 16.2 
3-I am preparing to do this behavior.  20 29.4 
4-I have been doing this behavior for 
less than six (6) months. 
 4 5.9 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 
 11 16.2 
Spanish-Speaking Sample (N=54) 
2-For doing this    
1-I am not thinking of doing this 
behavior at all. 
 16 29.6 
2-I am thinking about doing this 
behavior. 
 7 13.0 
3-I am preparing to do this behavior.  22 40.7 
4-I have been doing this behavior for 
less than six (6) months. 
 5 9.3 
5-I have been doing this behavior for 
more than six (6) months up to many 
years. 







Self-efficacy-Talking to Provider  
Whole Sample (N=122) 
M whole=3.66, SD=1.940, Min=1, Max=6 
English-Speaking (n=68) M=3.69, SD=2.00, Min=1, Max=6 
Spanish-Speaking (n=54) M=3.61, SD=1.89, Min=1, Max=6 
English-Speaking (n=68) 
And, for doing this I am 
1-0% confident  20 29.4 
2-20% confident  1 1.5 
3-40% confident  6 8.8 
4-60% confident  13 19.1 
5-80% confident  9 13.2 
6-100% confident  19 27.9 
Spanish-Speaking Sample (N=54) 
1-0% confident  12 22.2 
2-20% confident  5 9.3 
3-40% confident  8 14.8 
4-60% confident  9 16.7 
5-80% confident  7 13.0 
6-100% confident  13 24.1 
Self-efficacy- Having Child Vaccinated 
Whole Sample (N=122) 
M whole=3.95, SD=1.93, Min=1, Max=6 
English-Speaking (n=68) M=4.15, SD=1.93, Min=1, Max=6 
Spanish-Speaking (n=54) M=3.70, SD=1.94, Min=1, Max=6 
English-Speaking (n=68)   
And, for doing this I am 
1-0% confident  15 22.1 
2-20% confident  6 8.8 
3-40% confident  10 14.7 
4-60% confident  13 19.1 
5-80% confident  24 35.3 
6-100% confident  15 22.1 
Spanish-Speaking Sample (N=54) 
1-0% confident  12 22.2 
2-20% confident  6 11.1 
3-40% confident  5 9.3 
4-60% confident  9 16.7 
5-80% confident  7 13.0 
6-100% confident  15 27.8 
Self-efficacy- Having Child Receiving All Doses 
Whole Sample (N=122) 
M whole=3.99, SD=1.91, Min=1, Max=6 
English-Speaking (n=68) M=4.06, SD=1.95, Min=1, Max=6 







English-Speaking (n=68)   
And, for doing this I am 
1-0% confident  15 22.1 
2-20% confident  3 4.4 
3-40% confident  3 4.4 
4-60% confident  13 19.1 
5-80% confident  10 14.7 
6-100% confident  24 35.3 
Spanish-Speaking Sample (N=54) 
1-0% confident  5 9.3 
2-20% confident  5 9.3 
3-40% confident  9 16.7 
4-60% confident  10 18.5 
5-80% confident  15 27.8 
6-100% confident  5 9.3 
 
 
Results for Research Question #12 
 
Was there a change in the parents’ knowledge of HPV, as well as their stage 
of change and self-efficacy for three key behaviors [i.e. (1) talking to a pediatrician 
or family practice medical provider about the Human papillomavirus (HPV) 
infection, and the HPV vaccination for children; (2) making sure their children 
receive the HPV vaccination; and (3) making sure their children receive all the 
required doses (e.g. at least 2 or 3 doses) of the HPV vaccination] when comparing 
their pre-video viewing to post-video viewing mean scores?  
 
For the whole sample, paired t-tests showed all comparisons were statistically 
significant, suggesting the brief video intervention had a positive impact, as follows: 
 The pre-viewing mean score for the whole sample for parents’ HPV 
knowledge was 3.01 or fair (n=115, SD=1.29), versus post-viewing video 
mean score of 4.02 or good (n=115, SD=1.30), as a difference that was 
statistically significant (t=-8.314, df=114, p=.000).  
 The pre-viewing video mean score for stage of change (SOC) for talking to 
Provider (Re: HPV Vaccine for Child) for the whole sample was 2.27 for 
contemplation (n=155, SD=1.35) versus the post-viewing video mean score of 
2.87 for closest to preparation (n=115, SD=1.28), as a difference that was 
statistically significant (t=-5.733, df=114, p=.000).  
 The pre-viewing video mean score for self-efficacy (SE) for Talking to 
Provider (Re: HPV Vaccine for Child) for the whole sample was 3.66 or 
closest to 60% confident (n=115, SD=1.95) versus the post-viewing video 
mean of 4.66 or closest to 80% confident (n=114, SD=1.53), indicating that 






 The pre-viewing video mean score of SOC for Having Child Vaccinated for 
the whole sample was 2.61 or contemplation (n=115, SD=1.39) versus the 
post-viewing video mean 2.89 or closest to preparation (n=115, SD=1.27), 
indicating there was a statistically significant difference (t=-3.267, df=113, 
p=.007).  
 The pre-viewing video mean score for SE for Having Child Vaccinated for 
the whole sample was 3.96 or closest to 60% confident (n=115, SD=1.95) 
versus the post-viewing video mean of 4.77 or closest to 80% confident 
(n=114, SD=1.49), indicating that there was a statistically significant 
difference (t=-5.556, df=114, p=.000). 
 The pre-viewing video mean score for SOC for Having Child Receive All 
HPV Vaccine Doses pre-video for the whole sample was 2.53 or 
contemplation (n=114, SD=1.35) versus the post-viewing video mean of 2.75 
or closest to preparation (n=114, SD=1.25), indicating that there was a 
statistically significant difference (t=-2.728, df=113, p=.007).  
 The pre-viewing video mean score for SE for Having Child Receive All 
Doses for the whole sample was 4.03 or 60% confident (n=114, SD=1.89) 
versus the post-viewing video mean of 4.71 or closest to 80% confident 
(n=114, SD=1.58), indicating that there was a statistically significant 
difference (t=-4.810, df=113, p=.000). 
See Table 17. 
S1. Table 17. Whole Sample: Paired T-Tests (PRE-V-PARENTS-HPV-K-SOC-SE-
FTP-CR-HPV-V-7) (N=115) 
                                                                                                                   t-tests 
  M N SD t df P 
Parents’ HPV Knowledge 
Pre-Video   3.01 115 1.29 -8.314 114 .000*** 
Post-Video   4.02 115 1.30    
SOC for Talking to Provider (Re: HPV Vaccine for Child) 
Pre-Video  2.27 115 1.35 -5.733 114 .000*** 
Post-Video  2.87 115 1.28    
SE for Talking to Provider (Re: HPV Vaccine for Child) 
Pre-Video  3.66 115 1.95 -6.018 114 .000*** 
Post-Video  4.66 115 1.53    
SOC for Having Child Vaccinated 
Pre-Video  2.61 115 1.39 -3.267 113 .001** 
Post-Video  2.89 115 1.27    
SE for Having Child Vaccinated 
Pre-Video  3.96 115 1.96 -5.556 114 .000*** 
Post-Video  4.77 115 1.49     
SOC for Having Child Receive All Doses 
Pre-Video  2.53 114 1.35 -2.728 113 .007** 







SE for Having Child Receive All Doses 
Pre-Video  4.03 114 1.89 -4.810 113 .000*** 
Post-Video  4.71 114 1.58    
*p<.05, **p<.01, ***p<.001 Bonferroni Adjustment Significance (.05/7, p=.007)  
Note: All p values above .007 are considered non-significant, and only those below 
.007 are considered statistically significant 
 
For the ESP sample, findings using paired t-tests were, as follows: 
 The pre-viewing mean score for parents’ HPV knowledge V-PARENTS-
HPV-K-1 for ESP was 3.30 or fair (n=64, SD=1.20), versus post-viewing 
video mean score of 4.38 or good (n=64, SD=1.11), as a difference that was 
statistically significant (t=-6.509, df=63, p=.000).  
 The pre-viewing video mean score for SOC for Talking to Provider (Re: 
HPV Vaccine for Child) for ESP was 2.41or contemplation (n=64, 
SD=1.46) versus the post-viewing video mean score of 3.03 or preparation 
(n=64, SD=1.39), as a difference that was statistically significant (t=-4.465, 
df=63, p=.000).  
 The pre-viewing video mean score for SE for Talking to Provider (Re: HPV 
Vaccine for Child) for the ESP was 3.72 or closest to 60% confident (n=64, 
SD=2.03) versus the post-viewing video mean of 4.84 or closest to 80% 
confident (n=64, SD=1.38), indicating that there was a statistically significant 
difference (t=-4.849, df=63, p=.000).  
 There was not a significant difference between the pre-video mean for SOC 
for Having Child Vaccinated for ESP versus the post video mean (p=.124).  
 The pre-viewing video mean score for SE for Having Child Vaccinated for 
the ESP was 4.16 or 60% confident (n=64, SD=1.97) versus the post-viewing 
video mean of 4.89, or closest to 80% confident (n=64, SD=1.39), indicating 
that there was a statistically significant difference (t=-3.530, df=63, p=.001). 
  The pre-viewing video mean score for SOC for Having Child Receive All 
Doses for the ESP was 2.54 contemplation (n=63, SD=1.44) versus the post-
viewing video mean of 2.83 or closest to preparation (n=63, SD=1.33), 
indicating that there was a statistically significant difference (t=-2.865, df=62, 
p=.006).  
 The pre-viewing video mean score for SE for Having Child Receive All 
Doses for the ESP was 4.14 or 60% confident (n=63, SD=1.95) versus the 
post-viewing video mean of 4.87or closest to 80% confident (n=63, SD=1.48), 
indicating that there was a statistically significant difference (t=-4.810, df=62, 
p=.001). 
 







S1. Table 18. English-Speaking Sample: Paired T-Tests (PRE-V-PARENTS-HPV-K-
SOC-SE-FTP-CR-HPV-V-7) (N=115) 
                                                                                                                   t-tests 
  M N SD t df P 
Parents’ HPV Knowledge 
Pre-Video   3.30 64 1.20 -6.509 63 .000*** 
Post-Video   4.38 64 1.11    
SOC for Talking to Provider (Re: HPV Vaccine for Child) 
Pre-Video  2.41 64 1.46 -4.465 63 .000*** 
Post-Video  3.03 64 1.39    
SE for Talking to Provider (Re: HPV Vaccine for Child) 
Pre-Video  3.72 64 2.03 -4.849 63 .000*** 
Post-Video  4.84 64 1.38    
SOC for Having Child Vaccinated 
Pre-Video  2.77 64 1.49 -1.560 63 .124 
Post-Video  2.97 64 1.357    
SE for Having Child Vaccinated 
Pre-Video  4.16 64 1.97 -3.530 63 .001*** 
Post-Video  4.89 64 1.39     
SOC for Having Child Receive All Doses 
Pre-Video  2.54 63 1.44 -2.865 62 .006*** 
Post-Video  2.83 63 1.33    
SE for Having Child Receive All Doses 
Pre-Video  4.14 63 1.95 -3.436 62 .001*** 
Post-Video  4.87 63 1.48    
*p<.05, **p<.01, ***p<.001 Bonferroni Adjustment Significance (.05/7, p=.007)  
Note: All p values above .007 are considered non-significant, and only those below 
.007 are considered statistically significant 
 
 
For the SPS sample (n=54), paired t-tests showed the following: 
 The pre-video HPV knowledge for SSP was 2.65 for poor (n=51, SD=1.31), 
versus post-viewing video mean score of 3.57 for fair (n=51, SD=1.39), as a 
difference that was statistically significant (t=-5.149, df=50, p=.000).  
 The pre-viewing video mean for SOC for Talking to Provider (Re: HPV 
Vaccine for Child) for SSP was 2.10 or contemplation (n=51, SD=1.19) 
versus the post-viewing video mean score of 2.67 for preparation (n=51, 
SD=1.11), as a difference that was statistically significant (t=-3.575, df=50, 
p=.001). 
 The pre-viewing video mean score for SE for Talking to Provider (Re: HPV 
Vaccine for Child) for the SSP was 3.59 or 40% confident (n=51, SD=1.86) 
versus the post-viewing video mean of 4.43 or 60% confident (n=51, 
SD=1.69), indicating that there was a statistically significant difference  






 The pre-viewing video mean score of SOC for Having Child Vaccinated for 
SSP was 2.41 for contemplation (n=51, SD=1.25) versus the post-viewing 
video mean 2.78 for closest to preparation (n=51, SD=1.15), indicating there 
was a statistically significant difference (t=-3.695, df=50, p=.001).  
 The pre-viewing video mean score for SE for Having Child Vaccinated for 
the SSP was 3.71 or closest to 60% confident (n=51, SD=1.93) versus the 
post-viewing video mean of 4.61 or 60% confident (n=51, SD=1.61), 
indicating that there was a statistically significant difference (t=-4.499, df=50, 
p=.000).  
 There was not a significant difference between the pre-video mean for SOC 
for Having Child Receive All Doses for SSP versus the post-video mean 
(p=.271).  
 The pre-viewing video mean score for SE for Having Child Receive All 
Doses for the SSP was 3.88 or closest to 60% confident (n=51, SD=1.83) 
versus the post-viewing video mean of 4.51 or 60% confident (n=51, 
SD=1.69), indicating that there was a statistically significant difference (t= 
-3.459, df=62, p=.001). 
 
 
See Table 19. 
S1. Table 19. Spanish-Speaking Sample: Paired T-Tests (PRE-V-PARENTS-HPV-K-
SOC-SE-FTP-CR-HPV-V-7) (N=115) 
                                                                                                                   t-tests 
  M N SD t df P 
Parents’ HPV Knowledge 
Pre-Video   2.65 51 1.31 -5.149 50 .000*** 
Post-Video   3.57 51 1.39    
SOC for Talking to Provider (Re: HPV Vaccine for Child) 
Pre-Video  2.10 51 1.19 -3.575 50 .001*** 
Post-Video  2.67 51 1.11    
SE for Talking to Provider (Re: HPV Vaccine for Child) 
Pre-Video  3.59 51 1.86 -3.564 50 .001*** 
Post-Video  4.43 51 1.69    
SOC for Having Child Vaccinated 
Pre-Video  2.41 51 1.25 -3.695 50 .001*** 
Post-Video  2.78 51 1.15    
SE for Having Child Vaccinated 
Pre-Video  3.71 51 1.93 -4.499 50 .000*** 
Post-Video  4.61 51 1.61    
SOC for Having Child Receive All Doses 
Pre-Video  2.51 51 1.26 -1.112 50 .271 







SE for Having Child Receive All Doses 
Pre-Video  3.88 51 1.83 -3.459 50 .001*** 
Post-Video  4.51 51 1.69    
*p<.05, **p<.01, ***p<.001 Bonferroni Adjustment Significance (.05/7, p=.007)  
Note: All p values above .007 are considered non-significant, and only those below 
.007 are considered statistically significant 
 
 
Results for Research Question #13 
 
How do the parents rate the video cartoon?  
 
The mean score for the whole sample (N=122) was 5.04 or very good (min=1,  
max=6, SD=.969). The mean score for the ESP (N=68) was 5.08 or very good (min=1,  
max=6, SD=1.01). The mean score for SSP (N=54) was 4.97 or closest to very good  
(min=3, max=6, SD=.918).  
See Table 20. 
S1. Table 20. Rating the Quality of the Avatar Video (RTV-PARENTS-2) (N=122) 
   N % 
How do the parents rate the video cartoon?  
 
Whole Sample (N=122) 
M whole=5.04, SD=.969, Min=1, Max=6  
English-Speaking (n=68) M=5.08, SD=1.01, Min=1, Max=6 
Spanish-Speaking (n=54) M=4.97, SD=.918, Min=3, Max=6 
 
Please think about the cartoon video you were asked to watch, and please rate the video: 
1. I rate the video as follows: 
1 - Very Poor   1 .8 
2 - Poor   - - 
3 - Fair   2 1.6 
4 - Good   22 18.0 
5 - Very Good   27 22.1 
6 - Excellent   33 27.0 
English-Speaking Sample (N=68)   
1 - Very Poor   1 1.5 
2 - Poor   0 0 
3 - Fair   1 1.5 
4 - Good   11 16.2 
5 - Very Good   18 26.5 






Spanish-Speaking Sample (N=54) 
1 - Very Poor   0 0 
2 - Poor   0 0 
3 - Fair   1 1.9 
4 - Good   11 20.4 
5 - Very Good   9 16.7 
6 - Excellent   12 22.2 
 
 
Results for Research Question #14 
 
Do the parents recommend the video cartoon to other parents?  
 
Some 80.3% (n=98) of parents reported they would recommend the video to other 
parents. Among these 98 parents, 83.8% (n=57) were ESP and 75.9% (n=41) were SSP.  
See Table 21. 
S1. Table 21. Participant Recommendation of the Avatar Video (DOF-UEH-HPV-
PARENTS-1) (N =122) 
  N % 
Would you recommend this video to other parents? 
Whole Sample (N=122) 
Yes  98 80.3 
No  4 3.3 
I feel unable to offer 
a recommendation as 
I was not able to 
watch all the video 
 12 9.8 
English-Speaking Sample (N=68)   
Yes  57 83.8 
No  3 4.4 
I feel unable to offer 
a recommendation as 
I was not able to 
watch all the video 
 3 4.4 
Spanish-Speaking Sample (N=54) 
Yes  41 75.9 
No  1 1.9 
*I feel unable to 
offer a 
recommendation as I 
was not able to 
watch all the video 
 9 16.7 
Note: Recall that this was not a study exclusion criterion. The outcome variable data were 






Dose of exposure to video. Of note, some 66 ESP and 51 SSP reported that they 
watched some or almost all the video. Some 66.2% (n=45) of ESP and 44.4% (n=24) of 
SSP reported that they watched all of the video.  
See Table 22. 
 
S1. Table 22. Dose of Exposure to Video 
                                                                             N                                    % 
How much of the video was watched?               
English-speaking parents (N=68) 
 
1-None of the video  3 4.4 
2-Some of the video  10 14.7 
3-Most of the video  8 11.8 
4 -All of the video  45 66.2 
Spanish-speaking parents (N=54)   
1-None of the video  8 14.8 
2-Some of the video  10 18.5 
3-Most of the video  9 16.7 
4 -All of the video  24 44.4 
 
 
Results for Research Question #15  
 
Are there any significant differences between the responses of the English-
speaking and Spanish-speaking parents on the study measures? 
 
Independent t-tests showed (using p< .001, as per Table 23 footnote), as follows:  
 When comparing ESP (N=67, Mean=4.72, SD=1.90) to SSP (N=54, 
Mean=3.22, SD=1.78) for the level of education, there was a significant 
difference (t=4.429, df=119, p=000)—with the ESP having a higher level of 
education. 
 







S1. Table 23. Independent Sample T-Tests Comparing Dichotomous Groups English- 
and Spanish-Speaking Parents (N=122) 
  N M SD t df p 
Watched all or Most the 
Video 
       
1- ESP  52 5.08 1.01 .495 83 .622 
2- SSP  33 4.97 .918    
Participant age        
1- ESP  68 41.16 6.72 1.916 120 .058 
2- SSP  54 38.72 7.31    
Yearly Household Income        
1- ESP  68 4.57 1.97 3.179 120 .002** 
2- Spanish  54 3.48 1.77    
Level of Education        
1- ESP  67 4.72 1.90 4.429 119 .000*** 
2- SSP  54 3.22 1.78    
Number of children 9-18        
1- ESP  68 1.63 .710 .284 120 .777 
2- SSP  54 1.59 .836    
Exposure to print and 
digital media information 
on HPV 
       
1- ESP  63 2.49 1.66 1.863 114 .065 
2- SSP  53 1.94 1.49    
HPV Knowledge         
1- ESP  68 13.15 6.63 2.031 120 .044* 
2- SSP  54 10.67 6.79    
HPV Vaccine Knowledge        
1- ESP  68 6.03 3.21 1.934 120 .055 
2- SSP  54 4.83 3.61    
Vaccine Conspiracy Beliefs        
1- ESP  68 3.9895 1.24 1.732 120 .086 
2- SSP  54 3.6138 1.13    
Less Confidence in 
Vaccines 
       
1- ESP  68 2.6008 1.26 -1.330 99.41 .187 
2- SSP  54 2.9524 1.59    
Risks from Vaccines        
1- ESP  68 4.5588 1.42 .681 120 .497 
2- Spanish  54 4.3889 1.30    
Barriers to HPV Vaccine        
1- ESP  68 1.82 2.68 -.237 119.95 .813 







Pre-Video Parents’ HPV 
Knowledge 
       
1- ESP  68 3.28 1.17 2.702 120 .008** 
2- SSP  54 2.67 1.33    
Pre-Video SOC for 
Talking to Provider (Re: 
HPV Vaccine for Child) 
       
1- ESP  68 2.37 1.43 1.167 120 .246 
2- SSP  54 2.09 1.17    
Pre-Video SE for Talking 
to Provider (Re: HPV 
Vaccine for Child) 
       
1- ESP  68 3.69 2.00 .225 120 .822 
2- SSP  54 3.61 1.87    
Pre-Video SOC for Having 
Child Vaccinated 
       
1- ESP  68 2.79 1.47 1.620 120 .108 
2- SSP  54 2.39 1.24    
Pre-Video SE for Having 
Child Vaccinated 
       
1- ESP  68 4.15 1.93 1.259 120 .210 
2- Spanish  54 3.70 1.94    
Pre-Video SOC for Having 
Child Receive All Doses 
       
1- ESP  68 2.57 1.42 .226 120 .822 
2- SSP  54 2.52 1.23    
Pre-Video SE for Having 
Child Receive All Doses 
       
1- ESP  68 4.06 1.95 .434 120 .665 
2- SSP  54 3.91 1.87    
Post-Video Parents’ HPV 
Knowledge 
       
1- ESP  64 4.38 1.11 3.467 113 .001** 
2- SSP  51 3.57 1.39    
Post-Video SOC for 
Talking to Provider (Re: 
HPV Vaccine for Child) 
       
1- ESP  64 3.03 1.39 1.525 113 .130 
2- SSP  51 2.67 1.11    
Post-Video SE for Talking 
to Provider (Re: HPV 
Vaccine for Child) 
       
1- ESP  64 4.84 1.38 1.408 95.973 .162 







Post-Video SOC for 
Having Child Vaccinated 
       
1- ESP  64 2.97 1.36 .773 113 .441 
2- SSP  51 2.78 1.15    
Post-Video SE for Having 
Child Vaccinated 
       
1- ESP  64 4.89 1.39 1.008 113 .316 
2- SSP  51 4.61 1.61    
Post-Video SOC for 
Having Child Receive All 
Doses 
       
1- ESP  63 2.83 1.33 .675 112 .501 
2- SSP  51 2.67 1.14    
Post-Video SE for Having 
Child Receive All Doses 
       
1- ESP  63 4.87 1.48 1.225 112 .223 
2- SSP  51 4.51 1.69    
*p<.05, **p<.01, ***p<.001 
Bonferroni Adjustment Significance (.05/26, p=.001)  
Note: All p values above .001 are considered non-significant, and only those below 
.001 are considered statistically significant 
# p<.001 found only for level of education 
 
 
Pearson correlations. Correlations were examined (p<.004, as per footnote in 
Table A), finding no significant correlations among the study variables.  
See Tables A and B in Appendix P, Non-Significant Correlations. 
 
Results for Research Question #16 
 
Controlling for social desirability, what are the significant predictors of 
parents being in an action or maintenance stage for making sure their children 
received the HPV vaccination—as the Study #1 dependent variable?  
 
Backward stepwise regression. In this approach, the model controlled for social 
desirability. All independent variables were entered into the model, as follows: social 
desirability; partner yes/no; age; vaccine risks; confidence in vaccines; born in US 
yes/no; number of children ages 9-18; if child received flu vaccination; if provider 






education in media, etc.; degree of barriers to HPV vaccination; parent believes in value 
of flu vaccination; extent holds conspiracy beliefs about vaccination; if child has already 
received HPV vaccine yes/no; degree of HPV knowledge; annual household income; 
education level; if talked to provider about HPV yes/no; level of HPV vaccination 
knowledge. Then, the program eliminated the variable with the weakest association with 
the dependent variable. This continued (eliminating one variable at a time) until the only 
variables left in the model were statistically significant (i.e., p<.05).  
Using backward stepwise regression analysis, for the whole sample, the 
significant predictors of Study #1 dependent variable of parents being in an action or 
maintenance stage of change for having made the decision and taken action to 
ensure their child received the HPV vaccination—as measured before parents 
watched a linguistically and culturally tailored cartoon video were, as follows: 
 Having a child actually already received the HPV vaccination (β=1.714, 
SEB=.599, p=.000) 
 Having a higher annual household income is (β=.142, SEB=.200, p=.007) 
 
For this model, the R2=.420, and the AdjR2=.405, meaning that 40.5% of the 
variance was explained by this model. 
See Table 24. 
S1. Table 24. Whole Sample: Backward Stepwise Regression Analysis Predicting Higher 
Pre-Video SOC for Having Child Vaccinated (N=122)  
Predictors  b SEB P 
Having a child already actually received HPV vaccination  1.714 .599 .000*** 
Having a higher annual household income is .142 .200 .007* 
*p<.05, **p<.01, ***p<.001 
F=26.838 (p=.000) 








Results for Research Question #17 
 
How do parents respond when asked why they would or would not 
recommend the video, including any comments on the strengths and weaknesses of 
the video, or how could it be improved? 
 
Some 67.2% (n=82) of parents commented on the reasons for recommending the 
avatar video and provided their feedback to help improve the video. Among these 82 
parents, 76.5% (n=52) were ESP and 55.6% (n=30) were SSP.  
Thematic content analysis (see Appendix O, Qualitative Data Analysis Strategy) 
was used to identify emergent themes. 
Among ESP, five emerged themes about the reasons for parents to recommend 
the video to other parents were identified, including: 
Category I-A: Reasons for Recommending the Video among ESP 
Theme 1: Very informative/ educational and linguistically appropriate  
 Subthemes: 
o Simple language  
o Easy to understand  
Theme 2: Improves knowledge and awareness about the HPV infection and HPV vaccine 
Theme 3: Racially and ethnically diverse 
Theme 4: Promotes parental discussion with their child’s healthcare provider about the 
HPV and HPV vaccine 
              Subtheme: 
o Promote HPV-information seeking behavior 
Theme 5: It’s an effective educational tool for parents 
 
See Table 25. 
 
S1. Table 25. ESP Sample’s Reasons for Recommending the E-Health Video (N=122) 
English-Speaking Sample (N=68) 
Emergent Themes Sample Quotes 
Category I-A: Reasons for Recommending 
the Video 
 
Theme 1: Very informative/ 







“I would recommend the video as it offers 
detailed information on the conditions that 
HPV can cause in both men and women as 







       Subthemes: 
a. Simple language  
b. Easy to understand  
 
 
“It uses simple language and answers all 
questions that parents might have.” 
 
“I found it very informative and easy to 
understand.” 
Theme 1: Improve knowledge and 
awareness about the HPV infection and 
HPV vaccine  
“I didn’t know most of those information 
about HPV, this video was very clarify to 
me.” 
 
“The video tells parents like me how the 
vaccine does not affect our children sexual 
life and tells how it can prevent HPV 
cancer. I will recommend the video because 
it explain the benefit of taking a prevention 
vaccine for HPV cancer.” 
 
“I think differently about the HPV vaccine. 
The video made me realize that it can do 
more good than harm to be prepared and 
that preparing kids is just a way of 
protecting them for HVP cancer.” 
Theme 3: Racially and ethnically 
diverse  
 
“…I completely appreciate that it was 
representative of diverse skin tones…” 
 
“…Another positive attribute the video was 
able to convey was the racial makeup of the 
parents and the doctor herself. I’m not sure 
if the Latino or the African American 
population or the was the target audience; 
however, having people of color being 
placed in a primary position usually 
occupied by whites counterparts when it 
come to the creation of media, was very 
pleasing to see. Diversity is essential, and 
even more so on the screen, therefore, this 
video context was able to project a different 
and more positive image to the POC 
communities, rather than, what traditions 








Theme 4: Promote parental discussion 
with their child’s healthcare provider 
about the HPV and HPV vaccine  
   Subtheme 
a. Promote HPV-information 
seeking behavior  
“I still want to ask my doctor” 
 
“I def. need to talk to my kid pediatric” 
Theme 5: It’s an effective educational 
tool for parents  
“I would recommend this video. It is very 
clear and to the point. Easy to understand 
for kids and parents.” 
 
“I like the video and would love to share it 
with my kids.” 
 
“Excellent resource of information. 




Among the SSP, three themes emerged themes for recommending the video: 
Category I-B: Reasons for Recommending the Video among SSP 
Theme 1: Very informative/educational 
Theme 2: Clarifies parents’ concerns and doubts about the HPV vaccine 
Theme 3: Improves knowledge and awareness about HPV infection and HPV 
vaccination 
 
See Table 26. 
S1. Table 26. SSP Sample’s Reasons for Recommending the E-Health Video (N=122) 
Spanish-Speaking Sample (N=54) 
Emergent Themes Sample Quotes 
Category I-B: Reasons for Recommending 
the Video 
 
Theme 1: Very informative/educational  
 
 
“It is educational and very informative.” 
 
“The video was very good and easy to 
understand.” 
Theme 2: Clarifies parents’ concerns 
and doubts about the HPV vaccine 
“The video is very clear and met all my 
expectations and doubts, I would 
recommend it to my friends.” 
 
“The video is very clear, and explains in 
detail what HPV is and the consequences as 
well as the importance of vaccinating 
children from 9 years to 18 years. It cleared 






to take the decision to vaccinate my 
children.” 
Theme 3: Improves knowledge and 
awareness about the HPV infection and 
HPV vaccine 
“Because it explains the importance of 
getting vaccinated and the recommended 
age.” 
“It helped me expand my knowledge.” 
 
 
Results for Research Question #18 
 
What additional thoughts or feelings do the parents share in reaction to the 
video and/or taking the survey?  
 
Three main emergent themes were identified among ESP who provided their 
feedbacks to help improve the video as follows:  
Category 2-A: Reasons for Improving the Video among ESP 
Theme 1: Improve the quality of the video 
                Subthemes: 
o Incorporate more visual image related to HPV  
o Shorten the length of the video 
Theme 2: Include information about HPV vaccine side effects, and whether or not there 
is a recommended HPV test for men 
Theme 3: The video should address the importance of engaging children in sexual health 
education  
               Subtheme 
o Link sexual behavior and health behavior 
 
See Table 27. 
S1. Table 27. ESP Sample’s Recommendation to Improve the E-Health Video (N=122) 
English-Speaking Sample (N=68) 
Emergent Themes Sample Quotes 
Category 2-A: Reasons for Improving the 
Video 
 
Theme 1: Improve the quality of the 
video 
Subthemes: 
a) Incorporate more visual 
image related to HPV  






“I think in the video was informative but very 
dull. Maybe it needed more visuals on the 
virus itself to make it more interesting to 
watch. I would recommend it anyways.” 
 
“I was completely distracted by the skin 








mother. Was this a blended family? So 
odd…” 
 
“I would recommend the video; the pace of 
the video is a little slow.” 
 
Theme 2: Include information about 
HPV vaccine side effects, and whether 
or not there is a recommended HPV 
test for men 
“…the video failed to explain or what 
information may be I did not retain, were an 
explanation of the side effects…” 
 
“Haven’t heard any of the negatives.” 
It doesn’t answer whether or not HPV can be 
tested for in males. 
 
Theme 3: The video should address the 
importance of engaging children in 
sexual health education  
Subthemes: 
a. Link sexual behavior 
and health behavior  
“…Because the HPV virus is a sexually 
transmitted disease, it is necessary to have a 
small amount of information about how 
parents engage their children on this 
particular subject because it falls under 
sexual education, which is a sensitive topic to 
address with children…” 
 
“The video should have included a very small 
discussion between the physician and the 
parents about how a sensitive topic could be 
discussed as well as understood in a family 
dynamic. This is rather important as many 
parents with children between the ages of 9 
and 18 are facing emotional and social 
challenges with their kids…” 
 
“…It is indeed a concern when sharing any 
health videos about sexually transmitted 
diseases to a parent population that more 
integral information pertaining to family 
discussions about sexual behavior is included 









Among SSP who provided their feedbacks to help improve the video, emerged 
theme identified included: 
Category 2-B: Reasons for Improving the Video among SSP: 
Theme 1: Include information about HPV vaccine side effects 
See Table 28. 
S1. Table 28. SSP Sample’s Recommendation to Improve the E-Health Video  
Spanish-Speaking Sample (N=54) 
Emergent Themes Sample Quotes 
Category 2-A: Reasons for Improving 
the Video 
 
Theme 1: Include information about 




“There is no information in the video about 
side effects or reactions that this vaccine in 
children under age can cause ... and long-
term consequences. From my part, it is a 
question which I would like to clarify if there 
are enough studies to verify that this vaccine 
is safe enough to be administered to my son 
or daughter, given that they show that other 
vaccines cause or have caused diseases in 
other children, such as autism.” 
 “I would like to know a little about the side 
effects of the vaccine.” 
 
 
Data Analysis Results by Study Question for Study #2 
Results for Research Question #1 
 
What were the providers’ demographic and background characteristics 
(gender, age, race/ethnicity, US born or not, partner status, annual household 
income, status as a current job title, pediatric or family practitioner, work setting, 
years in current position pediatrics or family practice, years in health care)?  
 
The convenience sample consisted of 19 healthcare providers with 84.2% (n=16) 
females, 26.3% (n=5) non-Hispanic black, 21.1% (n=4) Hispanic, and 31.6% (n=6) were 






Some 63.2% (n=12) were medical doctors. Some 84.2% (n=16) worked in Pediatrics, 
while 26.3% (n=5) worked in Family Medicine Practice. The mean annual household 
income was category 6.05 (min=2, max=8, SD=1.43) for $100,000 to $199,999. 
See Table 29. 
S2. Table 29. Providers’ Demographic Characteristics (N=19) 
  N % 
Gender    
1-Female  16 84.2 
2-Male  3 15.8 
Age    
<30  4 21 
31-40  8 42.1 
41-50  3 15.9 
51-60  2 10.5 
61-72  2 10.5 
M=40.16, SD=12.64, Min=29, Max=71 
Race/Ethnicity    
1-Non-Hispanic Black  5 26.3 
2- Non-Hispanic White  6 31.6 
3-Hispanic/Latino  4 21.1 
4-Asian  5 26.3 
6-Native Hawaiian/Pacific Islander  0 0 
7- Arab American/Middle Eastern  0 0 
8- Other group(s)  0 0 
US-born    
1-Yes  13 68.4 
2-No  6 31.6 
Partner Status    
1-Yes  13 68.4 
2-No  6 31.6 
Level of Education     
1-M.S.N. 1 5.3 
2-MPH 2 10.5 
3-MSW 1 5.3 
4-Nurse Practitioner (NP, FNP, ANP, GNP, etc.) 1 5.3 
5-Physician Assistant (PA) 1 5.3 
6-M.D. (Medical Doctor) 12 63.2 
7-Other (Please explain) 1 5.3 
Employment Status   
1-Full Time 18 94.7 
2-Part Time 0 0 






Annual Household Income   
1-$10,000 to $19,000 1 5.3 
2-$50,000 to $99,999 5 26.3 
3-$100,000 to $199,999 6 31.6 
4-$200,000 to $299,000 4 21.1 
5-$300,000 to $399,000 3 15.8 
M=6.05, SD=1.43, Min=2, Max=8   
Work Setting   
Pediatrics   
1-Yes 16 84.2 
2-No 3 15.8 
Family Practice   
1-Yes 5 26.3 
2-No 14 73.7 
Years in Current Position   
1 year or less 3 15.8 
2-4 years 6 31.6 
8-10 years 3 15.8 
11-15 years 1 5.3 
16-20 years 1 5.3 
26-30 years 2 10.5 
More than 30 years 1 5.3 
 
 
Results for Research Question #2 
 
What was the providers’ (a) level of knowledge about the Human 
papillomavirus (HPV) infection, the available HPV vaccinations, and schedule for 
vaccinating preteen and teen boys and girls—and for the behavior of recommending 
within their medical practice to parents/guardians that they vaccinate their preteen 
and teen boys and girls for HPV—and, also their (b) stage of change, (c) self-
efficacy, and (d) perception of barriers (e.g. time) experienced during a medical visit 
for doing this? 
 
The mean score for providers’ HPV knowledge was 4.53 for between good and 
very good (min=2, max=6, SD=1.12). The mean score for provider’s stage of change for 
recommending HPV vaccination to parents for their children was 4.11 for action stage 
(min=1-precontemplation, max=5-maintance, SD=1.49). The mean self-efficacy for 






The mean score for barriers to recommending HPV vaccination to parents for children 
was 3.32 or low barriers (min=0 non-existent, max=7 extremely high, SD=2.08) or 
closest to low. Some 10.5% (n=2) rated barriers as “extremely high.” 
See Table 30. 
S2. Table 30. Providers’ HPV Knowledge for Recommending HPV Vaccination to 
Parents for Their Child, and Stage of Change, Self-efficacy, and Barriers (N=19) 
   N % 
(a) – HPV Knowledge 
M=4.53, SD=1.12, Min=2, Max=6 
1 – Very Poor   0 0 
2 – Poor   1 5.3 
3 – Fair   2 10.5 
4 – Good   6 31.6 
5 – Very Good   6 31.6 
6 – Excellent   4 21.1 
(b) – Stage of Change for recommending HVP Vaccine 
M=4.11, SD=1.49, Min=1, Max=5 
1-I am not thinking of doing 
this behavior at all. 
  2 10.5 
2-I am thinking about doing 
this behavior. 
  2 10.5 
3-I am preparing to do this 
behavior. 
  1 5.3 
4-I have been doing this 
behavior for LESS than six 
(6) months. 
  1 5.3 
5-I have been doing this 
behavior for MORE than six 
(6) months up to many years. 
  13 68.4 
(c) – Self-Efficacy for Recommending HVP Vaccine 
M=5.32, SD=1.00, Min=2, Max=6 
1-0% confident   0 0 
2-20% confident   1 5.3 
3-40% confident   1 5.3 
4-60% confident   7 36.8 
5-80% confident   10 52.6 







(d) – Degree of Barriers I (e.g. time) Experience in a Medical Visit for Actually 
Doing This is 
M=3.32, SD=2.08, Min=0, Max=7 
1-Non-existent (none at all)   2 10.5 
2-Extremely low   3 15.8 
3-Low   5 26.3 
4-Moderate   5 26.3 
5-High   1 5.3 
6-Very high   1 5.3 
7-Extremely high   2 10.5 
 
 
Results for Research Question #3 
 
How did the providers rate the quality of the cartoon video as a potential 
linguistically and culturally appropriate tool (i.e., available in English and Spanish) 
to support parents in their decision-making about whether or not they make sure 
their preteen or teen child receives the HPV vaccination series? 
 
The mean rating of the video by providers was 4.84 or closest to very good (min= 
3-fair, max=6-excellent, SD=.834). Some 47.4% (n=9) of healthcare providers rated the 
video as “very good,” and 21.1% (n=4) rated the video as “excellent.”  
See Table 31. 
S2. Table 31. Rating the Quality of the Avatar Video (RTV-PROVIDERS-1) (N=19) 
   N % 
How do the providers rate the video cartoon?  
M=4.84, SD=.834, Min=3, Max=6 
Please think about the cartoon video you were asked to watch, and please rate the 
video: 
1. I rate the video as follows: 
1 - Very Poor   0 0 
2 – Poor   0 0 
3 – Fair   1 5.3 
4 – Good   5 26.3 
5 - Very Good   9 47.4 









Results for Research Question #4 
 
Do the providers recommend the cartoon video for parents or to other 
providers so they could share it with parents? 
 
The majority of the sample 89.5% (n=17) of healthcare providers indicated they 
would recommend the video. 
See Table 32. 
S2. Table 32. Providers’ Recommendation of the Avatar Video (N =19) 
  N % 
Would you recommend this video to other parents? 
Whole Sample (N=122) 
Yes  17 89.5 
No  2 10.5 
 
 
Some 78.9% (n=15) of healthcare providers reported that they watched all of the 
video, while some (n=4) of healthcare providers reported that they watched most of the 
video. 
See Table 33. 
S2. Table 33. Dose of Exposure to Video 
         N % 
How much of the video was watched?   
3-Most of the video  4 21.1 
4 -All of the video  15 78.9 
 
 
Results for Research Question #5 
 
How do the providers explain why they would or would not recommend the 
video to parents or other providers, including any comments on the strengths and 
weaknesses of the video, or how could it be improved? 
 
Some 89.5% (n=17) of healthcare providers commented on the video, while the 







Category 3-A: Reasons for Recommending the Video among Providers  
Theme 1: Linguistically appropriate  
     Subthemes  
o Accurate 
o Easy to understand 
o Informative 
o Innovative    
Theme 2: Address parental common concerns about the HPV vaccine 
Theme 3: Representation of diversity  
 
See Table 34. 
S2. Table 34. Provider Reasons for Recommending the E-Health Video (N=17) 
Emergent Themes Sample Quotes 
Category 3: Reasons for Recommending 
the Video 
Theme 1: Linguistically appropriate 
Subthemes:  
a) Accurate 
b) Easy to understand 
c) Informative   
d) Innovation  
 
 
“…information was presented in an 
accurate and simplistic way. I believe 
most families can relate to the questions 
that were brought up in the video.” 
 
“The information was accurate and the 
message was good.” 
“Very informative, easy to watch, not too 
long.” 
 
“Complete and easy to understand 
information.” 
 
“…the clinician did not use a judgmental 
tone.” 
 
“Innovation. Great information” 
Theme 2: Address parental common 
concerns about the HPV vaccine 
“Super helpful and addressed many 
common questions.” 
 
“I think this is a very useful video. It 
explains what HPV is, what it does and 
the need for the vaccine. It also addresses 
common myths.” 
 
“The video was clear and covered all 
FAQs regarding HPV and the vaccine.” 
 







Results for Research Question #6 
 
What additional thoughts or feelings do the providers share in response to 
watching the video and/or taking the survey? 
 
Three emergent themes regarding provider’s recommendations to improve the 
video were identified, as follows: 
Category 3-B: Reasons for Improving the Video among Providers 
Theme 1: Improve the quality of the video 
Subthemes: 
o Use better graphics  
o Shorten the length of the video 
Theme 2: Make it more interactive and engaging 
Subtheme: 
Theme 3: Shift the focus of HPV vaccination away from the route of transmission, 
particularly at the beginning of the video 
Subtheme: 
o Shift focus from STDs to primary prevention of HPV-associated cancers 
 
See Table 35. 
S2. Table 35. Providers’ Recommendation to Improve the E-Health Video (Survey Part-
IX QP-RSP-PROVIDERS-1) (N=17) 
Emergent Themes Sample Quotes 
Category 3-B: Reasons for Improving 
the Video 
 
Theme 1: Improve the quality of 
the video 
Subthemes: 
a) Use better graphics  





“…the graphics weren’t the best…” 
 
“It felt a little long…” 
 
“It seemed very mono-toned and rigid/robotic - 
the physician in particular. I worry that parents 
and teens might be turned off or lose interest.” 
 
“…the dialogue monotone and the pace slow. It 
doesn’t really grab or hold attention.” 
 
“…it is really slow-paced which will likely lead 
to people stopping watching it.” 
 
Theme 2: Make it more interactive 
and engaging  







Theme 3: Shift the focus of HPV 
vaccination away from the route of 
transmission, particularly at the 
beginning of the video 
Subtheme: 
a) Shift focus from STDs to 
primary prevention of HPV-
associated cancers  
“There has been some broader discussion in 
the pediatric field about shifting the focus of 
HPV vaccination away from the route of 
transmission, since this is not a focus on other 
vaccinations.” 
 
“…would definitely not start with HPV as an 
STD- many people believe the whole reason we 
have trouble with HPV vaccination coverage is 
because  
it got billed as an STD vaccine and not what it 




This chapter presented the results of data analysis. Results were organized and 
presented by research questions, providing organization to the chapter. For both Study #1 
and Study #2, findings for both the quantitative and qualitative research questions were 
presented.  
Chapter V provides a summary of the present study and a discussion of results, 











SUMMARY, DISCUSSION, IMPLICATIONS,  
RECOMMENDATIONS, AND CONCLUSION 
 
The present chapter provides a summary of the dissertation research as well as 
implications and recommendations for further research. Lastly, this chapter ends with a 
final conclusion. 
Summary of the Literature Review 
Human papillomavirus (HPV) infection is the most common sexually transmitted 
infection (STI) among women and men in the world (Newman et al., 2018). According to 
Tanveer (2017), HPV is a global health problem. There are more than 150 types of HPV, 
and about 40 types are transmitted through sexual contact, infecting “the anogenital 
region and other mucosa sites of the body” (Dunne et al., 2014, p. 69). Thus, “most 
sexually active persons will acquire HPV in their lifetime” (p. 69).  
Approximately 38,793 HPV-associated cancers are diagnosed in the United States 
annually (CDC, 2016e). The number of reported HPV-associated cancer diagnoses were 
higher among women than among men, at 23,000 and 15,793, respectively. Scientists 
have identified over 120 HPV types (CDC, 2016d). More than 40 types of HPV may 






usually disappear within 2 years (CDC, 2016a). However, persistent infection with 
oncogenic or high-risk HPV types can progress to HPV cancers, such as cancer of the 
cervix, vulva, vagina, penis, or anus (CDC, 2016b; Holman et al., 2014).  
HPV accounts for 99% of all cervical cancer cases (CDC, 2016d; Kessels et al., 
2012). It is estimated that 50% of cervical cancer cases worldwide are caused by HPV 
type 16, while HPV types 16 and 18 are responsible for 70% of cervical cancer diagnoses 
(CDC, 2016d). HPV has also been linked to some oropharyngeal cancers (CDC, 2016c). 
Non-oncogenic or low-risk HPV types 6 and 11 can cause 90% of genital warts and 
abnormal cervical cells (CDC, 2016d; Holman et al., 2014).  
In an effort to address the disparity gap in HPV infection, Healthy People 2020 
sought an 80% increase in the proportion of females and males aged 13 to 15 years who 
complete the HPV vaccination series, with a baseline HPV status of 28.1% and 6.9%, 
respectively (USDHHS, 2019). The U.S. FDA has licensed three vaccines for use in the 
United States: Cervarix, Gardasil, and Gardasil 9 (Fontenot et al., 2015; Meites et al., 
2016). The three vaccines are administered in a three-dose series at intervals of a range of 
0, 1-2, and 6 months (Meites et al., 2016), meaning “1-2 months between dose 1 and 2 
and 6 months between dose 1 and 3” (Wilson et al., 2015, p. 396). The 9vHPV vaccine 
can be administered in a two-dose series schedule for girls and boys from 9 to 14 years 
old (Meites et al., 2016).  
The Advisory Committee on Immunization Practices (ACIP) recommends routine 
vaccination of all three HPV vaccines for girls from ages 11 to 12 years, but the 
vaccination series can be initiated as early as 9 years of age (CDC, 2016a; Trogdon & 






ages 13 to 26 years who have not previously received the vaccine (Laz et al., 2013; 
Trogdon & Ahn, 2015). The ACIP also recommends routine HPV vaccinations of the 
4vHPV and 9vHPV vaccines for teen boys between ages of 11 and 12 years, and through 
age 21 years for those who were not previously vaccinated (CDC, 2016a). For specific 
individuals, such as men who have sex with men (MSM) and for young individuals with 
certain immunocompromised conditions (e.g., HIV), three doses of the HPV vaccine are 
administered, starting at age 9 years and continuing through age 26 years, if not 
vaccinated previously (CDC, 2016a, 2016d, 2016h).  
Despite the ACIP recommendations, HPV vaccine uptake and completion rates 
are lower than expected (Spencer et al., 2018). Data from the 2017 National 
Immunization Survey-Teen (NIS-Teen) showed that 66% of adolescents aged 13 to 17 
years received at least one dose of the HPV vaccine, 69% of girls and 63% of boys 
received their first dose of the HPV vaccine, and only 49% of teens completed all three 
recommended doses (Walker et al., 2018). Clearly, national HPV vaccination completion 
rates are far from meeting the Healthy People 2020 target of 80% of adolescents aged 13 
to 15 years (Katz et al., 2016; Rosen et al., 2018). 
Adolescent girls are more likely to be vaccinated than boys (CDC, 2017e). Data 
from the 2015 NIS-Teen showed that 6 out of 10 girls and 5 out of 10 boys had received 
at least one dose of the HPV vaccine (CDC, 2017e). Only about 43% of teens had 
completed all recommended doses of the HPV vaccine (CDC, 2017h). It is argued that 
delaying “completion of the series places adolescents at risk for acquiring HPV infection 
due to gaps in immunologic protection from the vaccine doses” (Wilson et al., 2015,  






Some studies have reported higher rates of the HPV vaccine initiation among 
African American and Hispanic adolescent girls than their White counterparts (Beavis & 
Levinson, 2016; Nelson et al., 2015; Okafor et al., 2015). Henry et al. (2018) explained 
that higher rates of HPV vaccine uptake among racial/ethnic minority groups (e.g., Non-
Hispanic Black and Hispanics) living in low-income communities could be due in part to 
access to safety-net services which provide free or reduced cost vaccinations, or to the 
availability of long-term targeted interventions. Conversely, higher vaccination rates 
could be due to living among “co-ethnics in segregated areas with similar cultural norms 
that promote vaccination” (p. 2). 
However, African American and Hispanic individuals continue to report lower 
rates of the HPV vaccine completion than those who are White (Beavis & Levinson, 
2016; Jeudin et al., 2014; Nelson et al., 2015; Okafor et al., 2015). In this regard, Henry 
et al. (2018) indicated that economic difficulties and barriers related to access to 
healthcare among individuals living in low-income areas could also result in lower HPV 
vaccine uptake due to limited access to healthcare resources and preventive services. For 
example, language barriers and lack of awareness about the benefits of getting the HPV 
vaccine in racial/ethnic minority communities may result in lower screening rates. Henry 
et al. further stated that, given how “cancer prevention and screening activities are 
generally higher among high-income, more educated populations, conventional wisdom 
suggests that uptake for a recommended vaccine that protects against some cancers would 
also fallow this trend” (p. 2).  
Pérez et al. (2018) reported that after adjusting for healthcare factors, foreign-born 






odds of HPV vaccine initiation and completion than U.S.-born women and men. This 
suggests that immigrants may face barriers other than access to healthcare that contribute 
to lower HPV vaccine initiation than their U.S.-born counterparts. For example, “foreign-
born Latinos have numerous barriers to healthcare, including language, transportation, 
and documentation status, both at the individual and family level” (p. 257). Also, there 
are those immigrants who “may not be familiar with navigating the U.S. healthcare 
system,” or lack knowledge of “U.S. preventive medical guidelines” (p. 257). Also, some 
immigrants may prioritize “treating symptoms rather than seeking regular preventive 
services” (p. 257). Yet, even here, for those immigrants who “seek care, healthcare 
providers have the potential to increase HPV vaccine uptake, as healthcare provider 
recommendation has been associated with HPV vaccination” (p. 257). 
Henry et al. (2018) observed that the higher odds of HPV vaccine in urban areas 
and among racial/ethnic minorities living in high-poverty areas might be due to parental 
acceptability of HPV vaccine, greater proportion of providers recommending the vaccine, 
and parental accessibility to safety net programs. Conversely, lower rates of HPV vaccine 
initiation among boys living in areas with lower levels of poverty, “irrespective of 
race/ethnicity, is also likely to due to less parental support of HPV vaccination as 
compared to parents from lower-SES groups” (p. 11). It is also possible that non-
Hispanic Whites are being exposed to “negative sentiment or vaccination safety 
concerns” and may not pursue vaccinating their sons (p. 11).  
Patel and Berenson (2013) conducted a review on parental vaccine hesitancy and 
explained that parents who refused vaccination tended to be more educated, “have 






(p. 2650). Patel and Berenson further explained the “theory behind this observation,” 
wherein “educated parents are more often more likely to be have access to specific source 
of media, such as Internet, which may expose them to contradictory and possibly 
inaccurate information regarding the HPV vaccine” (p. 2650). Also, those “highly 
educated parents may feel more confident in their ability to interpret complex scientific 
and clinical health information, allowing then to ignore the advice of practitioners if 
contradiction exists” (p. 2650).  
In addition, it is possible that providers in more affluent areas are non-adherent to 
the recommendation guidelines on routinely offering the HPV vaccine to parents for their 
children (Henry et al., 2018). On the other hand, acculturation may play a key role in 
HPV vaccination among Hispanics. For instance, Hispanics who live in low-income 
communities tend to have a lower level of acculturation and are more likely to accept 
HPV vaccine for their children, “which may account for the differences seen among 
Hispanics from low-income compared to Hispanics from wealthier areas” (p. 13).  
Agénor et al. (2018) explained that tailored-education interventions, including 
alerts and reminders, can be used to help providers and parents make an informed 
decision regarding HPV vaccination. Educational interventions should be tailored (e.g., 
be provided in multiple languages) and tested among non-Hispanic Black, Hispanic, and 
non-Hispanic Asian individuals in order to ensure the intervention’s appropriateness and 
effectiveness for those from underserved groups (Agénor et al., 2018).  
Tuong et al. (2014) considered the impact of videos in modifying health 
behaviors, including 28 studies and 12,703 subjects in a systematic review of video 






health behaviors depending on the target behaviors to be influenced,” being less effective 
for influencing addiction behaviors (p. 219).  
Summary of the Statement of the Problem 
The problem that this study addressed is the need to increase HPV vaccination 
initiation and completion for male and female preteens and teens (ages 9 to 18) by virtue 
of the dissertation accomplishing the following: (1) addressing parental hesitancy about 
HPV vaccination and supporting their decision-making to initiate and complete HPV 
vaccination of their children via exposure to an innovative linguistically and culturally 
tailored e-health cartoon video intervention on HPV vaccination; and (2) enhancing 
provider recommendations to parents to vaccinate preteens and teens by providing them 
the new tool of an innovative linguistically and culturally tailored e-health cartoon video 
on HPV vaccination, which they may choose to recommend to parents, augmenting their 
own recommendation to parents to pursue and complete HPV vaccination of children. 
Summary of the Statement of the Purpose 
Study #1: Parents (English or Spanish Speaking)—Predictors of Parents 
Having Decided to Take Action to Vaccinate Child for HPV 
The first purpose of the dissertation research (i.e., Study # 1) was to identify 
significant predictors of the study # 1 dependent variable of parents being in an action or 
maintenance stage of change for having made the decision and taken action to ensure 
their child received the HPV vaccination—as measured before parents watched a 






Study #1: Parents (English or Spanish Speaking)—Cartoon Video as a 
Potential Linguistically and Culturally Tailored Brief Intervention 
A second purpose of the dissertation research (study #1) was to determine if a 
linguistically and culturally tailored (i.e., in English or Spanish) video on HPV and HPV 
vaccination of children can serve as a brief online e-health intervention that promotes 
significant parental movement across the stages of change (i.e., from a precontemplation 
or contemplation stage, to a preparation stage, as per the theory of Prochaska and 
DiClemente [1983]) and, significantly increases self-efficacy (as per the theory of 
Bandura [1977]) for three key behaviors of: (1) talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection, and the HPV 
vaccination for children; (2) making sure their preteen and teen children receive the HPV 
vaccination; and (3) making sure their preteen and teen children receive all the required 
doses (e.g., at least 2 or 3 doses) of the HPV vaccination. This involved a pre-video 
viewing versus post-video viewing comparison of parents’ stage of change and self-
efficacy each of these three key behaviors. In addition, changes in knowledge were 
examined for parents from pre- to post-video viewing. 
Study #1: Parents (English or Spanish Speaking)—Cartoon Video as a 
Potential Linguistically and Culturally Tailored Brief Intervention 
A second purpose of the dissertation research (Study #1) was to determine if a 
linguistically and culturally tailored (i.e., in English or Spanish) video on HPV and HPV 
vaccination of children can serve as a brief online e-health intervention that promotes 
significant parental movement across the stages of change (i.e., from a precontemplation 






DiClemente [1982]) and, significantly increases self-efficacy (as per the theory of 
Bandura [1977]) for three key behaviors of: (1) talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection, and the HPV 
vaccination for children; (2) making sure their preteen and teen children receive the HPV 
vaccination; and (3) making sure their preteen and teen children receive all the required 
doses (e.g. at least 2 or 3 doses) of the HPV vaccination. This involved a pre-video 
viewing versus post-video viewing comparison of parents’ stage of change and self-
efficacy each of these three key behaviors. In addition, changes in knowledge were 
examined for parents from pre- to post-video viewing. 
Study #2: Providers (Pediatricians or Family Practitioners)—Recommending 
the Cartoon Video to Parents or Not 
A third purpose of the dissertation research (i.e., via Study # 2) was to obtain the 
Study #2 dependent variable of pediatricians/family practitioners recommending (yes/no) 
the video to parents and/or other providers so they could share it with parents, in order to 
support parental decision-making about initiating and completing HPV vaccination of 
their preteen and teen children (as per the Diffusion of Innovation Theory of Rogers 
[1995]).  
Summary of the Research Questions for Study #1 
Given an online sample of parents (n=122) who responded to a social media 
campaign (i.e., “Go to <htpps://tinyurl.com/HPV-Video-Study-English> to take the 






win 1 of 3 $100 Amazon gift cards”) and complete the survey, Study #1 sought to answer 
the following research questions: 
1-What are the parents’ demographic characteristics (i.e., selected English or Spanish 
survey and video, gender, age, race/ethnicity, US born or not, partner status, employment 
status, annual household income, level of education, type of medical insurance)? 
Part I: Parent’s Basic Demographics (PARENTS-BD-10) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-What do parents report about their children (i.e., number of children ages 9 to 18, 
number of male and female children, child sexual orientation, type of medical insurance)? 
Part II: About Your Children (AYC-4)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-Do parents report providers having talked to them about HPV and the HPV 
vaccination, and did the providers recommend the HPV vaccination for their child? 
Part III: Parent Report on Provider Recommendation on HPV vaccination for 
Child (PARENT-R-PR-HPV-V-FC-2) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-Do parents report one or more of their children ever having received the HPV 
vaccination? 
Part IV: Parent Report on HPV vaccination for Child (PARENT-R-HPV-V-FC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
5-Do parents report one or more of their children ever having received the flu 
vaccination, and do they believe in the value of an annual (yearly) flu vaccination for 
their children? 
Part V: Parent Report on HPV vaccination for Child (PARENT-R-FLU-V-FC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
6-To what extent have parents been exposed to print or digital media providing 
information on the HPV vaccination for children? 
Part VI: Parent Exposure to Print or Other Media or Information on HPV 
Vaccination for Children (PARENT-EPOMI-HPV-VFC-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 








7-What is the parents’ level of general HPV knowledge? 
Part VII: HPV General Knowledge (HPV-G-K-23) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
8-What is the parents’ level of HPV vaccine knowledge? 
Part VIII: HPV Vaccine Knowledge Scale (HPV-V-K-S-11) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
9-What are the parents’ general vaccine attitudes, including for (a) conspiracy beliefs,  
(b) vaccine hesitancy—lack of confidence, and (c) vaccine hesitancy—risks? 
Part IX: General Vaccine Attitudes-Conspiracy Beliefs, and Hesitancy due to 
Lack of Confidence or Risks (GVA-CB-HLC-R-16) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
10-What are the parents’ perceived barriers to their child completing the HPV 
vaccination series? 
Part X: Parents’ Perceived Barriers to Child’s Completion of the HPV 
vaccination Series (PARENTS-PB-CC-HPV-VS-12) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
11-Pre-video viewing, what was the parents’ knowledge of HPV, the prevalence of 
parents being in an action or maintenance stage for making sure their children received 
the HPV vaccination—as the Study #1 dependent variable—and, their self-efficacy for 
doing this? 
From Item # 4 of Part XII: Pre-Video Parents’ HPV Knowledge and Stage of 
Change and Self-Efficacy for Talking to Provider and Child Receiving the HPV 
Vaccine (PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
12-Was there a change in the parents’ knowledge of HPV, as well as their stage of 
change and self-efficacy for three key behaviors [i.e. (1) talking to a pediatrician or 
family practice medical provider about the Human papillomavirus (HPV) infection, and 
the HPV vaccination for children; (2) making sure their children receive the HPV 
vaccination; and (3) making sure their children receive all the required doses (e.g. at least 
2 or 3 doses) of the HPV vaccination] when comparing their pre-video viewing to post-
video viewing mean scores? 
Part XII: Pre-Video Parents’ HPV Knowledge and Stage of Change and Self-








Part XIV: Post-Video Parents’ HPV Knowledge and Stage of Change and Self-
Efficacy for Talking to Provider and Child Receiving the HPV Vaccine (PRE-V-
PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
Data Analysis Plan: Paired t-tests 
 
13-How do the parents rate the video cartoon? 
Part XV: Rate the Video for Parent (RTV-PARENTS-2) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
14-Do the parents recommend the video cartoon to other parents? 
Part XVI: Diffusion of Innovation using E-Health on HPV by Parents (DOF-
UEH-HPV-PARENTS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
15-Are there any significant differences between the responses of the English-speaking 
and Spanish-speaking parents on the study measures? 
Data Analysis Plan: Independent t-tests 
 
16-Controlling for social desirability, what are the significant predictors of parents being 
in an action or maintenance stage for making sure their children received the HPV 
vaccination—before the video—as the Study #1 dependent variable? 
Data Analysis Plan: Backward stepwise regression 
 
 
Qualitative Portion of Study #1 
 
17-How do parents respond when asked why they would or would not recommend the 
video, including any comments on the strengths and weaknesses of the video, or how 
could it be improved? 
Part XVII: Qualitative Portion on Reasons for Recommending the E-Health Video 
or Not—For Parents (QP-RREHV-PARENTS-1) 
Data Analysis Plan: Identification of emergent themes 
 
18-What additional thoughts or feelings do the parents share in reaction to the video 
and/or taking the survey? 
Part XVIII: Qualitative Portion on Reasons to Study Participation by Parents 
(QP-RSP-PARENTS-1)  







Summary of the Research Questions for Study #2 
Given an online sample of providers (n=19 pediatricians or family practitioners) 
who respond to a social media campaign (i.e., “Click <htpps://tinyurl.com/HPV-Video-
Study-For-Providers> to take 10-12 min Survey for Pediatric & Family Practice 
Providers on HPV vaccination for preteens/teens & rate a cartoon for parents on HPV”) 
and complete the survey, the study #2 answered the following research questions: 
1-What were the providers’ demographic and background characteristics (gender, age, 
race/ethnicity, US born or not, partner status, annual household income, status as a 
current job title, pediatric or family practitioner, work setting, years in current position 
pediatrics or family practice, years in health care)? 
Part I: Provider’s Basic Demographics (PROVIDERS-BD-15)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-What was the providers’ (a) level of knowledge about the Human papillomavirus 
(HPV) infection, the available HPV vaccinations, and schedule for vaccinating preteen 
and teen boys and girls—and for the behavior of recommending within their medical 
practice to parents/guardians that they vaccinate their preteen and teen boys and girls for 
HPV—and, also their (b) stage of change, (c) self-efficacy, and (d) perception of barriers 
(e.g. time) experienced during a medical visit for doing this? 
Part II: Pre-Video Providers’ Overall HPV Knowledge for Recommending HPV 
Vaccination to Parents for their Child—and Stage of Change, Self-efficacy, and 
Barriers (PRE-VIDEO-PROVIDERS-SOC-SE-B-4)  
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-How did the providers rate the quality of the cartoon video as a potential linguistically 
and culturally appropriate tool (i.e., available in English and Spanish) to support parents 
in their decision-making about whether or not they make sure their preteen or teen child 
receives the HPV vaccination series. 
Part III: Rate the Video for Providers (RTV-PROVIDERS-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-Do the providers recommend the cartoon video for parents, or to other providers so 
they could share it with parents? 







Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
 
Qualitative Portion of Study #2 
 
5-How do the providers explain why they would or would not recommend the video to 
parents or other providers, including any comments on the strengths and weaknesses of 
the video, or how could it be improved? 
Part V: Qualitative Portion on Reasons for Recommending the E-Health Video or 
not – for Providers (QP-RREHV-PROVIDERS-1) 
Data Analysis Plan: Identification of emergent themes and categories 
 
6-What additional thoughts or feelings do the providers share in response to watching the 
video and/or taking the survey? 
Part VI: Qualitative Portion on Reactions to Study Participation by Providers 
(QP-RSP-PROVIDERS-1)  
Data Analysis Plan: Identification of emergent themes and categories 
Summary of the Research Instrumentation for Study #1 
The following survey parts were used in Study 1: 
 Part I: Parent’s Basic Demographics (PARENTS-BD-10) 
 Part II: About Your Children (AYC-4)  
 Part III: Parent Report on Provider Recommendation on HPV vaccination for 
Child (PARENT-R-PR-HPV-V-FC-2) 
 Part IV: Parent Report on HPV vaccination for Child (PARENT-R-HPV-V-
FC-1) 
 Part V: Parent Report on HPV vaccination for Child (PARENT-R-FLU-V-
FC-1) 
 Part VI: Parent Exposure to Print or Other Media or Information on HPV 
Vaccination for Children (PARENT-EPOMI-HPV-VFC-1) 
 Part VII: HPV General Knowledge (HPV-G-K-23) 
 Part VIII: HPV Vaccine Knowledge Scale (HPV-V-K-S-11) 
 Part IX: General Vaccine Attitudes-Conspiracy Beliefs, and Hesitancy due to 
Lack of Confidence or Risks (GVA-CB-HLC-R-16) 
 Part X: Parents’ Perceived Barriers to Child’s Completion of the HPV 
vaccination Series (PARENTS-PB-CC-HPV-VS-12) 
 Part XI: More about Social Desirability (MAY-13) 
 Part XII: Pre-Video Parents’ HPV Knowledge and Stage of Change and Self-







 Part XII: Pre-Video Parents’ HPV Knowledge and Stage of Change and Self-
Efficacy for Talking to Provider and Child Receiving the HPV Vaccine (PRE-
V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
  Part XIV: Post-Video Parents’ HPV Knowledge and Stage of Change and 
Self-Efficacy for Talking to Provider and Child Receiving the HPV Vaccine 
(PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
 Part XV: Rate the Video for Parent (RTV-PARENTS-2) 
 Part XVI: Diffusion of Innovation using E-Health on HPV by Parents (DOF-
UEH-HPV-PARENTS-1) 
 Part XVII: Qualitative Portion on Reasons for Recommending the E-Health 
Video or Not—For Parents (QP-RREHV-PARENTS-1) 
 Part XVIII: Qualitative Portion on Reasons to Study Participation by Parents 
(QP-RSP-PARENTS-1)  
Summary of the Research Instrumentation for Study #2 
The following survey parts were used in Study #2: 
 Part I: Provider’s Basic Demographics (PROVIDERS-BD-15) 
 Part II: Pre-Video Providers’ Overall HPV Knowledge-and for 
Recommending HPV vaccination to Parents for their Child, Providers’ Stage 
of Change, Self-efficacy, and Barriers (PRE-VIDEO-OHPVK-PROVIDERS-
SOC-SE-A-M-T-B-7) 
 Part III: Rate the Video for Providers (RTV-PROVIDERS-1) 
 Part IV: Diffusion of Innovation using E-Health on HPV by Providers (DOF-
UEH-HPV-PROVIDERS-1) 
 Part V: Qualitative Portion on Reasons for Recommending the E-Health 
Video or not—for Providers (QP-RREHV-PROVIDERS-1) 
 Part VI: Qualitative Portion on Reactions to Study Participation by Providers 
(QP-RSP-PROVIDERS-1) 
Summary of the Results of Data Analysis for Study #1 
Findings for Parents’ Demographics 
The whole sample consisted of 122 parents who provided electronic informed 
consent and completed the entire online survey. Of the whole sample (n=122), 68 were 
English-speaking parents (ESP) and 54 were Spanish-speaking parents (SSP). Thus, the 






In the whole sample of parents (n=122), 95.9% (n=117) were females and only 
4.1% (n=5) were males. Among ESP, 94.1% (n=64) were females and 5.9% (n=4) were 
males. Among SSP, 98.1% (n=53) were females and 1.9% (n=1) was male. The mean age 
for the whole sample (n=122) was 40.08 years (min=26, max=72, SD=7.06). The mean 
age for ESP (n=68) was 41.16 years (min=27, max=72, SD=6.72). The mean age for SSP 
(n=54) was 38.72 years (min=26, max=55, SD=7.31).  
The mean education for the whole sample (n=121) was 4.05 (min=1, max=9, 
SD=1.98). The mean education for the ESP (n=67) was 4.72 (min=1, max=9, SD=1.88). 
The mean education for the SSP (n=54) was 3.22 (min=1, max=7, SD=1.78).  
Regarding employment status, 73.8% (n=90) of parents reported been employed, 
and of these 90 parents, 79.4% (n=54) were ESP and 66.7% (n=36) were SSP.  
Private insurance plans were the most prevalent source of health coverage 
reported among ESP (58.8%, n=40) and SSP (31.5%, n=17), respectively. Of the 42.6% 
(n=52) parents who were born in the US, 55.9% (n=38) were ESP and 25.9% (n=14) 
were SSP.  
Findings on the Children 
The mean of children aged 9-18 for the whole sample (n=122) was 1.61 (min 1, 
max 4, SD=.765). The mean of children aged 9-18 for ESP (n=68) was 1.63 (min 1, max 
4, SD=.710). The mean of children aged 9-18 for SSP (n=54) was 1.59 (min 1, max 4, 
SD=.836). Also, 48.4% (n=59) of parents reported that their children had a private health 






Findings on Communication With Provider About HPV 
Some 62.3% (n=76) of parents reported that their child’s healthcare provider 
talked to them about the HPV infection and the HPV vaccine. Among these 76 parents, 
64.7% (n=44) were ESP and 59.3% (n=32) were SSP. Also, 55.9% (n=38) of ESP and 
50% (n=27) SSP reported receiving a provider recommendation to vaccinate their child.  
Findings on Vaccination of Children and Related Beliefs 
Some 62.3% (n=76) of parents reported that their child’s healthcare provider 
talked to them about the HPV infection and the HPV vaccine. Among these 76 parents, 
64.7% (n=44) were ESP and 59.3% (n=32) were SSP. Also, 55.9% (n=38) of ESP and 
50% (n=27) SSP reported receiving a provider recommendation to vaccinate their child.  
Some 38.5% (n=47) of parents reported that their child received one or more 
doses of the HPV vaccine. Of the 47 parents, 41.2% (n=28) were ESP and 35.2% (n=19) 
were SSP. Further, 9% (n=12) of parents reported their child received two doses; of 
these, 8.8% (n=6) were ESP and 11.1% (n=6) of SSP. Among 11% (n=9) of parents who 
reported their child received three doses, 11.8% (n=8) were ESP and 5.6% (n=3) of SSP.  
As relevant background, consider how, for the whole sample, 86.1 % (n=105) of 
parents reported that their child received the flu vaccination. Of these 105 parents, 91.2% 
(n=62) were ESP and 79.6% (n=43) were SSP. Also, 52.9% (n=36) of ESP and 83.3% 
(n=45) of SSP indicated that they believe in the value of flu vaccination.  
Findings on Low Exposure to Media on HPV 
The mean score for the whole sample (n=116) was 2.24 for exposed to a very low 






or exposed to a very low amount of information (min 0, max 5, SD=1.66). The mean 
score for SSP (n=54) was 1.94 or closest to being exposed to a very low amount of 
information (min 0, max 5, SD=1.45).  
Findings for General HPV Knowledge and HPV Vaccine Knowledge 
The mean score for the whole sample for general HPV knowledge (n=122) was 
12.05 (min=0, max=23, SD=6.79) for moderate level of general HPV knowledge. The 
mean score for the whole sample for HPV vaccine knowledge (n=122) was 5.50 (min 0, 
max 11, SD=3.43) for a moderate level of HPV vaccine knowledge. 
Findings for General Vaccine Attitudes: Conspiracy Beliefs and Vaccine Hesitancy 
The mean score for vaccine conspiracy beliefs for the whole sample (n=122) was 
3.82 or closest to neutral (min=1, max=7, SD=1.20). The mean score for vaccine 
hesitancy –lack confidence for the whole sample (n=122) was 2.76 or closest to 
somewhat disagree (min=1, max=7, SD=1.42). The mean score for vaccine hesitancy—
hesitancy—risks for the whole sample (n=122) was 4.48 or neutral (min=1, max=7, 
SD=1.37).  
Findings for Perceived Barriers to Child Completing HPV Vaccination Series 
For the whole sample (n=122), 33.6% experienced the barrier of not knowing how 
often they should take their child for completion of the HPV vaccination series, and 







Main Study Findings:  
Positive Impact From the Brief E-Health Video Intervention 
In terms of evaluating the e-health video designed to be culturally and 
linguistically appropriate, the cartoon was rated very good overall; the mean rating for the 
whole sample (N=122) was 5.04 or very good (min=1, max=6, SD=.969), for the ESP 
(N=68) it was 5.08 or very good (min=1, max=6, SD=1.01), and for SSP (N=54) it was 
4.97 or closest to very good (min=3, max=6, SD=.918).  
Most importantly, for the whole sample, paired t-tests showed all comparisons 
were statistically significant, suggesting the brief video intervention had a positive 
impact, as follows: parents’ HPV knowledge was 3.01 or fair (n=115, SD=1.29), versus 
post-viewing video mean score of 4.02 or good (n=115, SD=1.30), as a difference that 
was statistically significant (t=-8.314, df=114, p=.000). Other statistically significant pre-
video to post-video viewing included: the pre-viewing video mean score for stage of 
change (SOC) for talking to Provider (Re: HPV Vaccine for Child) was 2.27 for 
contemplation (n=155, SD=1.35) versus the post-viewing video mean score of 2.87 for 
closest to preparation (n=115, SD=1.28), as a difference that was statistically significant 
(t=-5.733, df=114, p=.000); the pre-viewing video mean score for self-efficacy (SE) for 
Talking to Provider (Re: HPV Vaccine for Child) was 3.66 or closest to 60% 
confident (n=115, SD=1.95) versus the post-viewing video mean of 4.66 or closest to 
80% confident (n=114, SD=1.53), indicating that there was a statistically significant 
difference (t=-6.018, df=114, p=.000); the pre-viewing video mean score of SOC for 
Having Child Vaccinated was 2.61 or contemplation (n=115, SD=1.39) versus the post-
viewing video mean 2.89 or closest to preparation (n=115, SD=1.27), indicating there 






video mean score for SE for Having Child Vaccinated was 3.96 or closest to 60% 
confident (n=115, SD=1.95) versus the post-viewing video mean of 4.77 or closest to 
80% confident (n=114, SD=1.49), indicating that there was a statistically significant 
difference (t=-5.556, df=114, p=.000); the pre-viewing video mean score for SOC for 
Having Child Receive All HPV Vaccine Doses pre-video was 2.53 or contemplation 
(n=114, SD=1.35) versus the post-viewing video mean of 2.75 or closest to preparation 
(n=114, SD=1.25), indicating that there was a statistically significant difference  
(t=-2.728, df=113, p=.007). The pre-viewing video mean score for SE for Having Child 
Receive All Doses was 4.03 or 60% confident (n=114, SD=1.89) versus the post-viewing 
video mean of 4.71 or closest to 80% confident (n=114, SD=1.58), indicating that there 
was a statistically significant difference (t=-4.810, df=113, p=.000). 
As another indicator of the value in the brief intervention, 80.3% (n=98) of 
parents reported they would recommend the video to other parents. Among these 98 
parents, 83.8% (n=57) were ESP and 75.9% (n=41) were SSP.  
Comparing the ESP and SSP 
Regarding any significant differences between the responses of the English-
speaking (ESP) and Spanish-speaking parents (SSP) on the study measures, independent 
t-tests showed (using p<.001) only one finding. When comparing ESP (N=67, 
Mean=4.72, SD=1.90) to SSP (N=54, Mean=3.22, SD=1.78) for the level of education, 
there was a significant difference (t=4.429, df=119, p=000)—with the ESP having a 







Predicting Parental Stage of Change for Vaccinating Child Pre-Video 
Using backward stepwise regression, the model controlled for social desirability. 
Given this was an exploratory study, all independent variables were entered into the 
model, as follows: social desirability; partner yes/no; age; vaccine risks; confidence in 
vaccines; born in US yes/no; number of children ages 9-18; if child received flu 
vaccination; if provider recommended HPV vaccination; if a student; if employed; degree 
of exposure to HPV education in media; degree of barriers to HPV vaccination; parent 
believes in value of flu vaccination; extent holds conspiracy beliefs about vaccination; if 
child has already received HPV vaccine yes/no; degree of HPV knowledge; annual 
household income; education level; if talked to provider about HPV yes/no; level of HPV 
vaccination knowledge. Then, the program eliminated the variable with the weakest 
association with the dependent variable. This continued (eliminating one variable at a 
time) until the only variables left in the model were statistically significant (i.e., p<.05).  
For the whole sample, the significant predictors of Study #1 dependent variable 
of parents being in an action or maintenance stage of change for having made the 
decision and taken action to ensure their child received the HPV vaccination—as 
measured before parents watched a linguistically and culturally tailored cartoon 
video were as follows: having a child actually already received the HPV vaccination 
(β=1.714, SEB=.599, p=.000); and, having a higher annual household income is (β=.142, 
SEB=.200, p=.007). For this model, the R
2=.420, and the AdjR2=.405, meaning that 







Findings Relevant to Diffusion of Innovation Theory 
Some 67.2% (n=82) of parents commented on the reasons for recommending the 
avatar video and provided their feedback to help improve the video. Among these 82 
parents, 76.5% (n=52) were ESP and 55.6% (n=30) were SSP. Among ESP, five 
emerged themes about the reasons for parents to recommend the video to other parents 
were identified including: 
 Very informative/ educational and linguistically appropriate  
o Simple language  
o Easy to understand  
 Improves knowledge and awareness about the HPV infection and HPV 
vaccine 
 Racially and ethnically diverse 
 Promotes parental discussion with their child’s healthcare provider about the 
HPV and HPV vaccine 
o Promote HPV-information seeking behavior 
 It’s an effective educational tool for parents 
Among the SPS, three themes emerged themes for recommending the video: 
 Very informative/educational 
 Clarifies parents’ concerns and doubts about the HPV vaccine 




Findings for Improving the Video 
 
Three main emergent themes were identified among ESP who provided their 
feedback to help improve the video as follows:  
 Improve the quality of the video 
o Incorporate more visual image related to HPV  
o Shorten the length of the video 
 Include information about HPV vaccine side effects, and whether or not there 
is a recommended HPV test for men 
 The video should address the importance of engaging children in sexual health 
education  






Among SSP who provided their feedbacks to help improve the video, emerged 
theme identified included: 
 Include information about HPV vaccine side effects 
Summary of the Results of Data Analysis for Study #2 
Findings for Providers’ Demographics 
The convenience sample consisted of 19 healthcare providers with 84.2% (n=16) 
females, 26.3% (n=5) non-Hispanic Black, 21.1% (n=4) Hispanic, and 31.6% (n=6) were 
non-Hispanic White with a mean age of 40.16 years (min=29, max=71, SD=12.64).  
Some 63.2% (n=12) were medical doctors. Some 84.2% (n=16) worked in 
Pediatrics, while 26.3% (n=5) worked in Family Medicine Practice. The mean annual 
household income was category 6.05 (min=2, max=8, SD=1.43) for $100,000 to 
$199,999. 
Findings on Providers’ HPV Knowledge, Stages of Change, and Self-efficacy 
The mean score for providers’ HPV knowledge was 4.53 for between good and 
very good (min=2, max=6, SD=1.12). The mean score for providers’ stage of change for 
recommending HPV vaccination to parents for their children was 4.11 for action stage 
(min=1-precontemplation, max=5-maintance, SD=1.49). The mean self-efficacy for 
providers was 5.32 for 80% confident or high self-efficacy (min=2, max=6, SD=1.00). 
The mean score for barriers to recommending HPV vaccination to parents for children 
was 3.32 or low barriers (min=0 non-existent, max=7 extremely high, SD=2.08) or 







Findings for Providers’ Ratings of the E-Health Video and Diffusion 
The mean rating of the video by providers was 4.84 or closest to very good (min= 
3-fair, max=6-excellent, SD=.834). Some 47.4% (n=9) of healthcare providers rated the 
video as “very good,” and 21.1% (n=4) rated the video as “excellent.”  
The majority of the sample 89.5% (n=17) of healthcare providers indicated they 
would recommend the video for parents or to other providers so they could share it with 
parents, as diffusion of the innovation of educating parents about HPV using the e-health 
video.  
Findings From Providers’ Qualitative Data 
In response to their being asked to explain why they would or would not 
recommend the video to parents or other providers, including any comments on the 
strengths and weaknesses of the video, or how could it be improved, providers’ open-
ended responses permitted the following emergent themes to be identified: 
o Linguistically appropriate  
o Accurate 
o Easy to understand 
o Informative 
o Innovative    
o Address parental common concerns about the HPV vaccine 
o Representation of diversity  
 
Finally, providers offered their additional thoughts or feelings in response to the 
video, permitting the identification of three emergent themes regarding recommendations 
to improve the video, as follows: 
o  Improve the quality of the video 
o Use better graphics  
o Shorten the length of the video 






o Shift the focus of HPV vaccination away from the route of transmission, 
particularly at the beginning of the video 
o Shift focus from STDs to primary prevention of HPV-associated cancers 
 
Discussion of Study #1 
Discussion of Study #1—Parents’ Demographics 
In the present study, for the whole sample of parents (n=122), 95.9% (n=117) 
were females and only 4.1% (n=5) were males. Among ESP, 94.1% (n =64) were females 
and 5.9% (n=4) were males. In a systematic review, Gilkey and McRee (2016) found that 
studies of parent and adolescent “communication roles in clinical settings consistently 
found” that a parent, “most often mother, was responsible for making the ultimate 
decision about HPV vaccination” (p. 1456). Hence, the convenience sample this study 
obtained may be reflective of those involved in the HPV vaccination decision-making 
process for children in families.  
Independent t-tests showed (using p<.001) comparing ESP and SSP, finding the 
ESP had a higher level of education (N=67, Mean=4.72, SD=1.90) in comparison to the 
SSP (N=54, Mean=3.22, SD=1.78) for the level of education, as a significant difference 
(t=4.429, df = 119, p=000). This is consistent with the study conducted by Ramírez, 
Willis, and Rutten (2017), where Spanish-speaking speaking respondents reported lower 
levels of education compared with the English-speaking respondents.  
The ESP sample of convenience may be comparable to other data, as this sample 
(n=68) attracted participants who were 44.1% (n=30) were Hispanic/Latino. Further, the 
addition SSP sample was 68% (n=83) Hispanic/Latino. This study’s collection of data on 






minority in the USA; in 2014, Hispanics comprised 17.4% of the US population (55.4 
million), and this percentage is expected to increase to 28.6% (119 million) by 2060” 
(Velasco-Mondragon et al., 2016, p. 1). Hispanics in the United States include all those 
native-born and foreign-born from places as varied as South America, the Caribbean, and 
Spain (Velasco-Mondragon et al., 2016).  
Private insurance plan was the most prevalent source of health coverage reported 
among ESP (58.8%, n=40) and SSP and (31.5%, n=17). Hispanics are more likely to be 
uninsured compared to any other racial or ethnic group (USDHHS, Office of Minority 
Health, 2019). Data from the Census Bureau revealed that in 2015, 47% of Hispanics 
have private insurance, while 19.5% of the Hispanic population did not have health 
insurance, as compared to 6.3% of the non-Hispanic White population (USDHHS, Office 
of Minority Health, 2019).  
Discussion of Data on the Children 
Most of studies that assessed factors associated with HPV vaccine initiation and 
completion were mostly based on nationally representative data and often focused on 
girls from ages 13 to 17, and fewer studies included both sexes together (Johnson et al., 
2017). This study included a sample of parents with female and male children aged 9-18.  
Some 48.4% (n=59) parents reported that their children had a private health plan; 
of those 59, 58.8% (n=40) were ESP and 35.2% (n=19) were SSP, with 73.8% (n=90) of 
the whole sample employed, including 79.4% (n=54) ESP and 66.7% (n=36) SSP. Given 
that the majority of parents reported having private insurance plans as compared to 
Medicaid, it could be that children received health coverage through their parents’ private 






children of color tended to receive health insurance coverage through Medicaid or 
Vaccine for Children Program (VFC) (Ylitalo, Lee & Mehta, 2013).  
Discussion on the Key Provider Recommendation 
This study found that more than half 62.3% (n=76) of parents reported that their 
child’s healthcare provider had talked to them about HPV infection and the HPV vaccine. 
Among these 76 parents, 64.7% (n=44) were ESP and 59.3% (n=32) were SSP. Though 
their sample lacked heterogeneity with regard to race and ethnicity, Gilkey and McRee 
(2016) conducted a systematic review and found that “one study examining patients’ 
race/ethnicity suggested disparities in provider communication—with parents of African 
American and Hispanic adolescents” being found to engage in “less often” discussion on 
the “HPV vaccine with a provider or receiving HPV recommendation than parents of 
non-Hispanic adolescents” (p. 1456). In another study, some providers reported difficulty 
discussing sexual health before recommending the HPV vaccine due to the time it takes 
to discuss HPV vaccination, particularly with parents of children aged 11-12 who were 
more likely to refuse vaccination compared to parents of older adolescents (Dempsey  
et al., 2016).  
Although parents’ perceived strength of provider recommendation was not 
assessed in this study, receiving strong provider recommendation of the HPV vaccine has 
been associated with parental vaccine intention and uptake (Meers, Short, Zimet, 
Rosenthal, & Auslander, 2017). Other research showed that when parents perceived 
provider recommendation of the HPV vaccine as optional, then parents preferred to delay 






Over half the parents, 53.3% (n=65), reported receiving a provider 
recommendation to vaccinate their child in the present study, while only 38.5 (n=47) of 
parents reported that their child received one or more doses of the HPV vaccine. Of the 
47 parents, 41.2% (n=28) were ESP and 35.2% (n=19) were SSP. The study sample 
reported vaccine initiation rates lower than the rates reported in the National 
Immunization Survey-Teen (NIS-Teen). For instance, data from the 2017 NIS-Teen 
showed that 66% of adolescents aged 13 to 17 years received at least one dose of the 
HPV vaccine (Walker et al., 2018).   
Further, national data revealed that only 49% of teens completed all three 
recommended doses (Walker et al., 2018). Low completion rates of HPV vaccine are of 
concern. Spencer et al. (2018) examined data from 2004-2014, when the HPV vaccine 
was administered in a three-dose series. The study sample consisted of 1.3 million 
individuals aged 9-26 who had private insurance. The study outcome was receipt of third 
dose within 12 months of the first dose. Spencer et al. found that timely HPV vaccine 
completion follow-through fell over time. This trend was pronounced among females 
(from 67% in 2006 to 38 in 2014) and also among males (from 36% in 2011 to 33% in 
2014). Similar trends persisted when they controlled for age, region, insurance plan type, 
provider type, and seasonal influenza vaccination (Spencer et al., 2018). 
Discussion on Prior Flu Vaccination and Beliefs 
Prior studies have shown that receiving the seasonal flu vaccine in the most recent 
year was positively associated with initiating and completing the HPV vaccine series 
(Donahue et al., 2015; Spencer et al., 2018). In this study, the results showed that some 






vaccine, including 91.2% ESP and 79.6% SSP. Also, 66.4% of parents indicated that they 
believe in the value of seasonal flu vaccination, suggesting that overall, the study sample 
believed in the benefits of the seasonal flu vaccine. The results revealed that more 83.3% 
(n=45) SSP believed in the value of the seasonal flu vaccine compared to 52.9% (n=36) 
ESP. This highlights the importance of the provider recommending the HPV vaccine at 
every medical encounter visit. The latter is of great importance, given that when parents 
do not receive a firm or consistent recommendation for HPV vaccination, then this “led 
to the perception that the vaccine was optional or less important compared to the other 
adolescent vaccines” (Lai et al., 2017, p. 9).  
Discussion of Exposure to Media on HPV 
This study found parents had low to very low exposure to media on HPV. For the 
whole sample (n=116), mean exposure was very low (2.24, SD=1.60). Further, the SSP 
(n=54) mean was 1.94 for closest to a very low amount of information (SD=1.45). Lai et 
al. (2017) discussed how inaccurate information related to HPV vaccine has been 
associated with media sources. Albright et al. (2017) found that, among English-speaking 
parents, a reported distrust of sources of information was a reason for not initiating the 
HPV vaccine. Stevens, Caughy, Lee, Bishop and Tiro (2013) indicated that English 
speakers spent more time using the internet and television compared to Spanish speakers, 
potentially disproportionately exposing them to media on vaccines.  
Discussion of Parental General HPV Knowledge  
Parents in this study correctly responded to over half of the questions in the HPV 






(n=122) was 5.50 (min=0, max=11, SD=3.43) for a moderate level of HPV vaccine 
knowledge; for the ESP sample, it was 6.03 (SD=3.21, min=0, max=11), and for the SSP 
sample, it was 4.83 (SD=3.61, min=0, max 11). Acosta, Bonney, Fost and Green (2013) 
found that most of their study sample of underserved Latinas correctly answered that 
HPV is related to cervical cancer, for example, as evidence of having some knowledge. 
But, the highest level of knowledge was associated with those who were more proficient 
in the English language. Steve 
Stevens et al. (2013) found that English-speaking mothers had higher moderately 
HPV knowledge than did Spanish-speaking mothers, although the results revealed no 
differences in HPV vaccine initiation. In the present study, there was a trend that missed 
the significance level of p<.001 (Bonferroni Adjustment Significance (.05/26, p=.001) for 
the ESP sample having a higher post-video HPV knowledge in comparison to the SSP 
sample (p=.001). Also, in this study, the sample of ESP and SSP parents reported low 
HPV vaccine initiation and completion rates. 
Discussion of Parental HPV Vaccine Knowledge 
Parents in this study correctly responded to over half of the questions in the HPV 
Vaccine Knowledge Scale. For the whole sample (n=122), the mean score sample 
(n=122) was 5.50 (min=0, max=11, SD=3.43) for a moderate level of HPV vaccine 
knowledge; for the ESP sample, it was 6.03 (SD=3.21, min=0, max=11), and for the SSP 
sample, it was lower at 4.83 (SD=3.61, min=0, max=11). 
Evidence has suggested that racial and minority groups are less likely to have 
heard of HPV vaccine, “as women born outside of the United States” (Wisk, Allchin & 






proficiency may contribute to racial and ethnic disparities. Furthermore, evidence has 
suggested that language may moderate information-seeking behavior about HPV vaccine, 
indicating the importance of providing “culturally sensitive information and information 
in a variety of language may improve awareness for vulnerable groups” (p. 5). 
Discussion of General Vaccine Attitudes 
The mean score for vaccine conspiracy beliefs for the whole sample (n=122) was 
3.82 or closest to neutral (min=1, max=7, SD=1.20). The mean score for vaccine 
hesitancy—lack confidence for the whole sample (n=122) was 2.76 or closest to 
somewhat disagree (min=1, max=7, SD=1.42). The mean score for vaccine hesitancy—
hesitancy—risks for the whole sample (n=122) was 4.48 or neutral (min=1, max=7,  
SD=1.37).  
According to Edwards and Smith (2011), social desirability is one of the factors 
that influence the choice of a neutral response. For instance, Krosnick et al. (2002) 
pointed out that  
some people have opinions on any given issue and are aware of possessing those 
opinions, whereas other people do not have opinions and are aware that they do 
not. All of the former individuals are presumed to report their opinions, regardless 
of whether or not a no-opinion response option is offered by a question. But the 
behavior of people without opinions is presumed to be contingent on question 
format. These individuals are presumed to report the fact that they have no 
opinion accurately when a no-opinion option is offered, but when no such option 
is offered, some or all of these people may fabricate reports of “non-attitudes” due 
to pressure to appear opinionated. (p. 373) 
 
In a recent study, Shapiro et al. (2018) assessed vaccine attitudes with validated scales, 
including the Vaccine Conspiracy Beliefs Scale and the Vaccine Hesitancy Scale (i.e., 
one subscale on vaccine hesitancy—lack of confidence, and one subscale on vaccine 






vaccinate stage” had significantly greater odds of having vaccine conspiracy beliefs as 
well as perceived harms from vaccines, a lack of confidence, and perceived risks. 
Discussion of Parental Barriers 
Recall that for the whole sample (n=122) in this study, 33.6% experienced the 
barrier of not knowing how often they should take their child for completion of the HPV 
vaccination series, and 30.3% experienced the barrier of their work schedule. Overall, the 
majority of parents reported low perceived barriers with having their child/children 
completing the recommended doses series. This result was not consistent with prior 
literature that suggested that barriers to HPV vaccine initiation and completion included 
lack of knowledge about the HPV vaccine, lack of knowledge about the association of 
HPV and cervical cancer, concerns about the cost of the vaccine, and low perceived need 
for the vaccine (Albright et al., 2017). Parents had reported lack of time to return for 
another doctor’s visit as a barrier for non-completion of the HPV vaccine series (Holman 
et al., 2014). Others have also documented in the literature that parents reported “being 
unaware of or forgetting about the need for additional doses” as a barrier for vaccine 
incompletion (p. 16).   
Discussion on the Impact of the E-Health Video as a Brief Intervention 
Paired t-tests comparing pre-video to post-video viewing mean scores showed 
statistical increases for all seven independent variables of interest: parents’ HPV 
knowledge, p=.000; SOC for talking to provider about HPV vaccine for child, p=.000;  
SE for talking to provider about HPV vaccine for child, p=.000; SOC for having child 






receive all doses, p=.007; and SE for having child receive all doses, p=.000. This body of 
data suggested that the e-health video, as a brief online intervention, had a positive 
impact insofar as parents significantly increased in knowledge from pre- to post-test, 
while also significantly progressing across the stages of change toward taking action, and 
showing significant increases in self-efficacy to engage in the behaviors of interest. 
Using an avatar video tailored for mother-child dyads on increasing fruit and 
vegetable intake and physical activity levels, Chung (2013) found via 15 paired sample  
t-tests for stage of change, knowledge, and self-efficacy, indicating significant 
improvement across all areas and suggesting the e-health avatar videos served as an 
effective brief online intervention. This is consistent with the impact of an avatar/cartoon 
tailored to be linguistically and culturally appropriate for diverse parents—as in this 
study, while also one of Chung’s (2013) goals with her African American sample. 
This study’s results were also consistent with the finding of Chen et al. (2018) 
who conducted a pilot study to determine the acceptability and feasibility of a computer-
tailored avatar intervention for Latino parents to increase HPV vaccination among 
children aged 11-17. The results showed that the mean HPV-related knowledge scores 
differed significantly from pre-intervention (M=9.3, SD=2.21) to post-intervention 
(M=13.9, SD=0.37); t(41)=-13.77, p<0.001) (Chen et al., 2018). Improving parental 
knowledge of HPV and HPV vaccine has been associated with HPV vaccine intention 
and uptake (Kessels et al., 2012).  
Central to an evaluation of the brief online e-health video intervention was how it 
was highly rated. The mean score for the whole sample (N=122) was 5.04 or very good 






SD=1.01); and SSP (N=54) 4.97 or closest to very good (min=3, max=6, SD=.918). 
Similarly, Chung (2013) also found a high rating of the videos used in that study (Mean = 
8.16, Min=1, Max=10, SD=1.42). 
Another dimension to evaluating this study’s brief online e-health video 
intervention involved whether parents would recommend it others, thereby diffusing the 
innovation of learning about HPV and HPV vaccination via an avatar/cartoon video. In 
this study, 80.3% (n=98) of parents reported they would recommend the video to other 
parents, including 83.8% (n=57) ESP and 75.9% (n=41) SSP. Similarly, Chung (2013) 
found that 84.9% (n=79) of African American mothers would recommend the brief 
online intervention of the video. 
Discussion on Relationships and Predictors of Parents Taking Action  
on HPV Vaccination 
 
There was only one significant difference between the ESP and SSP via 
independent t-tests (using p<.001) for level of education (t=4.429, df=119, p=000)—
with the ESP having a higher level of education. In this study, the results indicated that 
ESP had higher income compared to SSP.  
Also, using backward stepwise regression analysis, for the whole sample, the 
significant predictors of Study #1 dependent variable of parents being in an action or 
maintenance stage of change for having made the decision and taken action to ensure 
their child received the HPV vaccination—as measured before parents watched a 
linguistically and culturally tailored cartoon video were, as follows: (a) having a child 
actually already received the HPV vaccination (β=1.714, SEB=.599, p=.000); and  






model, the R2=.420, and the AdjR2=.405, meaning that 40.5% of the variance was 
explained by this model.  
Chung (2013) sought to predict rating of the video in her regression, as that 
study’s outcome variable, while going on to identify significant predictors of (a) mother 
was currently enrolled as a student (B=.589, p=.008), and (b) mothers having a lower 
education level (B=-.132, p=.05; [AdjR2=123), with 12.3% of the variance accounted for 
in the model. Of note, in the present study, despite the independent t-test finding ESP 
having a significantly higher level of education than SSP, level of education was not a 
significant predictor in the present study. Also, in comparison to Chung, it is important to 
acknowledge how the variables and scales selected in the present study accounted for a 
substantially higher 40.5% of the variance in a model predicting Study #1 dependent 
variable (i.e., parents being in an action or maintenance stage of change for having made 
the decision and taken action to ensure their child received the HPV vaccination)—as 
measured before parents watched a linguistically and culturally tailored cartoon video. 
Discussion of Qualitative Data From Parents 
The results from the qualitative analysis supported the quantitative results 
regarding how most parents rated the video as a brief online intervention as very good. 
Overall, ESP and SSP expressed that the video was very informative and educational; 
here, easy to understand and simple language were identified as subthemes. Sanders, 
Shaw, Guez, Baur and Rudd (2009) pointed out that providing all children and families 
with clear information about health promotion and disease prevention is a “national 
priority” (p. 307). This is of particular importance given that one in three U.S. adults have 






were unable to perform basic child preventive health tasks such as following 
recommendations from a health brochure (Sanders et al., 2009). Thus, the use of e-health 
education interventions can potentially mitigate some of the challenge that individuals 
with low health literacy face when accessing and or seeking health information such as 
HPV and HPV vaccine related information.  
Furthermore, the qualitative results also suggested that this brief e-health 
intervention helped to improve parental knowledge about the HPV and the need for 
vaccinating children by the recommend ages of 11-12. Themes of relevance here from the 
ESP were: improves knowledge and awareness about the HPV infection and HPV 
vaccine; promotes parental discussion with their child’s healthcare provider about the 
HPV and HPV vaccine; it is an effective educational tool for parents. Also, emergent 
themes for SSP were overlapping as follows: very informative/educational; clarifies 
parents’ concerns and doubts about the HPV vaccine; and improves knowledge and 
awareness about HPV infection and HPV vaccination. 
Results from the thematic content analysis revealed that this brief online e-health 
video intervention promoted parent intention to perform the behavior of talking with their 
child provider regarding HPV and HPV vaccine. Thus, the avatar figures/cartoon 
characters appeared to serve as an influential role model for how parents may engage in 
conversation with their child healthcare providers about the HPV and HPV vaccine; 
hence, this is consistent with observational learning within Social Learning Theory 
(Bandura, 1977).  
The results of the qualitative analysis supported Scott, Plotnikoff, Karunamuni, 






Innovation, “innovations that have a clear, unambiguous advantage over the previous 
approach will be more easily adopted and implemented;” including when an innovation 
(compatibility) “fits with the existing values, past experiences, and need of potential 
adapters” (p. 2). 
Regarding feedback for improving the video, among ESP, emergent themes 
identified were: a) improve the quality of the video—subthemes (incorporate more visual 
image related to HPV and shorten the length of the video); (b) include information about 
HPV vaccine side effects, and whether or not there is a recommended HPV test for men; 
and (c) the video should address the importance of engaging children in sexual health 
education—subtheme (link sexual behavior and health behavior). Among SSP, emergent 
theme identified included: (a) include information about HPV vaccine side effects. 
Consistent with previous research, parental concerns about HPV vaccine side effects and 
efficacy have been cited in the literature as common reasons for not vaccinating (Albright 
et al., 2017; Fontenot at al., 2015; Holman et al., 2014).  
Discussion of Study 2 
Discussion of the Providers’ Demographics 
With a focus on providers, Study # 2 obtained a small sample (N=19) with 84.3% 
in pediatrics and 26.3% in family medicine, while the sample was 84.2% (n=16) females, 
26.3% (n=5) non-Hispanic Black, 21.1% (n=4) Hispanic, and 31.6% (n=6) were non-
Hispanic White. The sample had a mean age of 40.16 years (min=29, max=71, 
SD=12.64). Some 63.2% (n=12) were medical doctors where the mean annual household 






The sociodemographic characteristics of the study sample differed from those 
reported for the study sample described by Walker et al. (2017). In Walker et al., the 
sample size was much larger and consisted of 600 pediatricians, 740 family medicine 
practitioners, and 330 nurse practitioners. Participants included in the final analysis were 
75 pediatricians, 136 family practice physicians, and 43 nurse practitioners (Walker et al., 
2017). While the original intent in this study was to recruit N=250 of such diverse 
providers, the barrier of time likely prevented other providers from taking the survey—
even when just a 12-minute research endeavor for them. Providers ended up being 
difficult to recruit, necessitating accepting the value in a small pilot study.  
Discussion on Providers’ Pre-Video Viewing Self-Rating of Knowledge, Stage of 
Change, Self-efficacy, and Barriers during a Medical Visit 
 
Recall the key findings pre-video viewing for providers, as follows in brief. The 
mean score for providers’ HPV knowledge was 4.53 for between good and very good 
(min 2, max 6, SD=1.12). The mean score for provider’s stage of change for 
recommending HPV vaccination to parents for their children was 4.11 for action stage 
(min 1-precontemplation, max=5-maintance, SD=1.49). The mean self-efficacy for 
providers was 5.32 for 80% confident or high self-efficacy (min=2, max=6, SD=1.00). 
The mean score for barriers to recommending HPV vaccination to parents for children 
was 3.32 or low barriers (min=0 non-existent, max=7 extremely high, SD=2.08) or 
closest to low. Some 10.5% (n=2) rated barriers as “extremely high.” 
Findings from a qualitative systematic study showed that providers’ knowledge 
of HPV and HPV vaccine varied (Rosen, Shepard, & Kahn, 2018); for instance, “correct 






responses assessing HPV vaccine knowledge ranged from 17% to 91%.” Providers’ level 
of knowledge about HPV in males was lower compared to their level of knowledge about 
HPV in women; knowledge “was particularly low with respect to understanding of 
vaccine recommendation for men, such as the upper age limit of the recommendation and 
which male HPV-related cancers the vaccines prevent” (p. 57).  
Regarding provider stage of change for recommending the HPV vaccine, the 
majority of healthcare providers were in the action stage, indicating that they are 
recommending the vaccine to children (mean score=4.1, min=1 precontemplation, max=5 
maintenance, SD=1.49). In the study sample, a high proportion 68.4% (n=13) of 
healthcare providers were in a maintenance stage for recommending the HPV vaccine for 
more than 6 months. The results in this study suggested providers’ compliance with 
Advisory Committee on Immunization Practices (ACIP) recommendations for routinely 
recommending the HPV vaccine to children aged 11-12 years.  
According to Rosen et al. (2018), results from the qualitative systematic review 
showed that for “studies that examined intention among clinicians, rates varied widely, 
from 16% to 96%. The mean for intention rates was 66.9 (SD=23) and the median was 
73; the 16% intention rates was an outlier” (p. 57). Walker et al. (2017) pointed out that 
healthcare provider level of knowledge about the HPV vaccines influence their intention 
to recommend the HPV vaccines. Thus, in this study, most healthcare providers rated 
their knowledge as good and the majority of them were in the action stage for 
recommending the vaccine, suggesting that higher level of knowledge about HPV and 
HPV vaccine may contribute to healthcare provider adherence to the ACIP HPV vaccine 






Regarding the providers’ levels of self-efficacy for recommending the HPV 
vaccine, the results showed that the mean score for self-efficacy for healthcare providers 
was 5.32 (min=2, max=6, SD=1.00), indicating 80% confident for recommending the 
HPV vaccines. McRee, Gilkey and Dempsey (2014) asserted that “improving providers’ 
self-efficacy to address parental concerns may be important for supporting 
recommendation practices and ultimately improving HPV vaccine uptake the target aged 
group” (p. 7). Gilkey and McRee (2016) further explained that “providers’ perceptions of 
themselves, self-efficacy to communicate about HPV vaccine was associated with 
recommending and intending to recommend the vaccine” (p. 1456). 
In addition, the mean score for barriers to discussing HPV and HPV vaccination 
of preteens and teens with parents for healthcare providers was 3.32 (min=0 non-existent, 
max=7 extremely high, SD=2.08), indicating that providers perceived low degree of 
barriers that they may experience in a medical visit. This result was not consistent with 
prior studies that indicated that providers reported facing a number of barriers to 
recommending the HPV vaccine including parental hesitancy and/or refusal to vaccinate 
their younger children (aged 11-12), perceived parental concern about vaccine safety, 
difficulty discussing sexual health-related issues that may pertain to HPV vaccination, 
particularly with younger adolescents (Daley et al., 2010; Holman et al., 2014; McRee et 
al., 2014). Also, when providers perceived parents’ refusal or hesitancy to vaccinate, they 
“are reluctant to strongly recommend the vaccine due to concerns about initiating time-
consuming or confrontational debates” (McRee et al., 2014, p. 2). 
In terms of barriers related to the clinical setting, Gilkey and McRee (2016) found 






vaccination” (p. 1463). The providers “identified patient reminder/recall as critical to 
their efforts to recommend HPV vaccination, but many reported that they did not use 
these systems”—and, instead, providers “relied on patients to initiate scheduling”  
(p. 1463). Finally, “providers reported that the time constraints in the clinical encounter” 
were also a “barrier to HPV vaccine communication” (Gilkey & McRee, 2016, p. 1463). 
A body of research indicated that parental refusal or hesitancy regarding the HPV 
vaccine influences healthcare providers’ recommendation practices regarding routinely 
administration of the HPV vaccine to eligible children; also key is the amount of time it 
takes to discuss and address parents’ concerns about the need to vaccinate (Daley et al., 
2010; Holman et al., 2014; McRee et al., 2014). Therefore, this brief health intervention 
could potentially assist providers in addressing parental concerns about the HPV vaccine, 
and may promote and facilitate parent-provider communication about HPV and the HPV 
vaccine—which may potentially lead to parents’ decisions to vaccinate their children. 
Given that the study sample of healthcare providers perceived the benefits of using this 
brief e-health education to increase knowledge and address parental concerns about HPV, 
this may lead to the adoption of this e-health educational intervention among healthcare 
providers.  
Of note, three themes emerged regarding providers’ recommendations to improve 
the video as follows: improve the quality of the video—subthemes (use better graphics 
and shorten the length of the video); make it more interactive and engaging; and shift the 
focus of HPV vaccination away from the route of transmission, particularly at the 
beginning of the video—subtheme (shift the focus from STDs to primary prevention of 






This recommendation is in line with the existing literature that healthcare 
providers perceived parents’ association between HPV vaccine and sexual activity to be 
“a common source of hesitancy” and/or “delay, particularly among children aged 11-12” 
(McRee et al., 2014, p. 7). Some parents of children aged 11-12 believed that their 
children were too fragile and not physiologically mature (e.g., in relation not sexually 
active) to receive the HPV vaccine) (Grandahl et al., 2014).  
This qualitative date indicated the need to use message framing in the context of 
prevention—given how Rwamwejo et al. (2019) conducted a study among providers of 
adolescents from a five-country region (i.e., Argentina, Malaysia, South Africa, South 
Korea, and Spain) to determine the most effective messaging to promote the HPV 
vaccine across these countries. The study results revealed that most providers supported 
use of the most optimal messages emphasizing cancer prevention, strong provider 
recommendation to vaccinate, vaccine safety and efficacy, timely vaccination, and a 
national policy supporting HPV vaccination. Also, framing HPV vaccine “as one of 
several vaccine in the routine schedule” in conjunction with a “strong recommendation” 
revealed that “providers reported low levels of parental hesitancy and higher levels of 
HPV vaccine uptake among parents” (Gilkey & McRee, 2016, p. 1462). 
Implications and Recommendations 
The overall findings of Study #1 and Study #2 have a number of important 







1.  A main study finding is that the e-health online brief avatar/cartoon video 
emerged as having a significant impact from pre-video to post-video viewing for parents 
in the sample, in terms of findings of higher scores post-video viewing. Specifically, 
paired t-tests comparing pre-video to post-video viewing mean scores showed statistical 
increases for all seven independent variables of interest: parents’ HPV knowledge, 
p=.000; SOC for talking to provider about HPV vaccine for child, p=.000; SE for talking 
to provider about HPV vaccine for child, p=.000; SOC for having child vaccinated, 
p=.000; SE for having child vaccinated, p=.000; SOC for having child receive all doses 
p=.007; and SE for having child receive all doses, p=.000. This body of data suggested 
that the e-health video, as a brief online intervention, had a positive impact insofar as 
parents significantly increased in knowledge from pre- to post-test, while also 
significantly progressing across the stages of change toward taking action, and showing 
significant increases in self-efficacy to engage in the behaviors of interest. Implications 
include the need to widely disseminate and utilize the e-health online brief avatar/cartoon 
video in numerous settings and by varied health providers. As the pilot study with the 
small provider sample (n=19) included not only physicians in pediatric or family practice 
medicine, but also nurse practitioners, for example, then diverse providers may use it as 
follows: as a video that plays in waiting areas of hospitals and clinics; as a link that 
providers text-message to clients in advance of their scheduled appointment, especially 
when it is time for the HPV vaccination for a preteen; as a link on a card or brochure that 
is handed out to patients; and as a tool for use when providers hold short education 






2.  Building on the provider pilot data recommending the video, and the data of 
the parents, it is possible to use the findings of Study #1 and Study #2 to apply for a 
major grant to seek to replicate the study with a large nationally representative sample, 
while including funds to support coalitions in communities to come together and 
determine the best uses and adaptations of the video to best meet their community’s 
health needs—including via community-based participatory research models. 
3.  Of great import is how this study found that HPV vaccine initiation and 
completion rates among the study sample were lower than the national rates (i.e., 66% of 
teens have received the first dose, 49% of teens completed the three doses of the HPV 
vaccines) (Walker et al., 2018). Over half the sample (53.3%, n=65) reported receiving a 
provider recommendation to vaccinate their child against the HPV vaccine, while only 
38.5% (n=47) of parents reported that their child received one or more doses of the HPV 
vaccine. Of the 47 parents, 41.2% (n=28) were ESP and 35.2% (n=19) were SSP. 
Provider recommendation of HPV vaccine has been consistently cited in the literature as 
the most important predictor for HPV vaccine uptake and completion (Johnson et al., 
2017; Meites et al., 2017). However, the process of actually initiating behavior, 
maintaining behavior over time, and preventing relapse requires knowledge and skills 
training, as in health educators learning to deploy a brief form of motivational 
interviewing as well as relapse prevention, as described elsewhere (Wallace 2019). 
Implications for health educators involve the need to develop nation-wide strategies 
designed to increase HPV initiation and completion rates for preteens and teens, 






4.  The lack of HPV vaccine completion rates “places adolescents at risk for 
acquiring HPV infection due to gaps in immunologic protection from the vaccine doses” 
(Wilson et al., 2015, p. 396). In the study sample, some 9.8% (n=12) of parents reported 
that their child received two doses of HPV vaccine; of these, 8.8% (n=6) were ESP and 
11.1% (n=6) of SSP; while 9% (n=11) of parents who reported their child received three 
doses, 11.8% (n=8) were ESP and 5.6% (n=3) of SSP. This suggests a serious public 
health challenge that necessitates a national social media campaign that widely 
disseminates the link to the video, ideally as part of a related website. The video may be 
used as part of the workforce development and continuing education aims for the nation, 
including for receipt of continuing education contact hours upon passing a related test or 
quiz. This is consistent with the online focus for the delivery of online interventions in 
this current era—thereby making content readily available nationwide as well as in places 
such as Puerto Rico, the Dominican Republic, South America, and the larger global 
community. Meanwhile, this study has produced a culturally and linguistically 
appropriate e-health video as the basis for all such efforts aimed at avoiding placing 
“adolescents at risk for acquiring HPV infection due to gaps in immunologic protection 
from the vaccine doses” (Wilson et al., 2015, p. 396). 
5.  Given the new brief online e-health avatar/cartoon video, as well as study 
findings, a special focus is warranted on Hispanics/Latinos as a vulnerable immigrant 
population that was found, as the SPS were found, to have a lower level of education in 
comparison to the ESP sample. Targeting the population of Hispanics/Latinos and 
immigrants for special culturally and linguistically appropriate interventions—including 






the larger global community, in the Spanish language—is warranted; this is especially the 
case, given frequent international travel “back home,” and to the United States by parents 
with children; this includes short periods of migration to receive a higher quality health 
care in the United States for those who can afford such travel for healthcare. Exposure 
online to this study’s brief avatar/cartoon video can permit sufficiently broad global 
exposure, as social networks that span the United States and communities “back home” 
disseminate the video. 
6.  Providers have reported a lack of time during a well-child care visit represents 
a barrier to HPV vaccine communication, particularly when the provider faces parents 
who refuse to vaccine their children (Gilkey & McRee, 2016). Providers may not provide 
a strong recommendation to vaccinate when encountering parents who oppose vaccinate 
for their children “due to concerns about initiating time-consuming or confrontational 
debates” (McRee et al., 2014, p. 2). Just as a nurse may take weight, height, blood 
pressure, and temperature before a patient sees the medical provider or nurse practitioner, 
a nurse could have a patient view this study’s short video before going in to see the 
doctor. Thus, as per the McRee et al. (2014) concern, providers may avoid confrontation 
and debate, and instead encounter a parent who by virtue of watching the video enters to 
see the medical provider while having just moved across stages of change from 
contemplation to preparation, as shown in this study. 
7.  Also, findings from the mixed methods supported the feasibility and 
acceptability of using a brief culturally tailored e-health educational intervention to 
educate parents about HPV and HPV vaccine, and promote and facilitate parents’-






daughters and sons. Parents can enter the consultation room with the medical provider in 
a stage of preparation, after just watching 5 minutes of the video with a nurse, or alone—
saving time and sparing the provider confrontation, debate, and related stress. Thus, there 
are implications about the adoption of this innovative brief e-health intervention to 
facilitate parental movement across the stages of change regarding their adoption to HPV 
vaccine.  
8.  Lastly, a longitudinal study is recommended to determine the effect of this  
e-health education intervention in performing the behavior of vaccinating one’s children 
against HPV. This could involve follow-up evaluations at 1 month, 3 months, 6 moths,  
1 year, 2 years, and beyond—in order to capture impacts for younger children as they 
approach and enter the age for HPV vaccination. 
Limitations of the Study 
The study findings should be interpreted in light of some limitations. First, this 
study used self-reported data and causal inferences and associations between awareness 
of and knowledge about HPV and the HPV vaccine; however, inferences about actual 
behavior cannot be made (i.e., taking action for vaccinating children against HPV). Also, 
the study consisted of a convenience sample, which limits the generalizability of findings. 
In addition, the sample consisted mainly of Hispanic/Latino parents suggesting that the 
findings cannot be generalized across racial and ethnic groups. In addition, use of an 
online survey may represent a barrier to some parents who may not have access to the 






to participate in the study may have contributed to low recruitment rates, particularly 
among healthcare providers.  
Conclusion 
The first purpose of the dissertation research (i.e., Study #1) was to identify 
significant predictors of the Study #1 dependent variable of parents being in an action or 
maintenance stage of change for having made the decision and taken action to ensure 
their child received the HPV vaccination—as measured before parents watched a 
linguistically and culturally tailored cartoon video. Using backward stepwise regression 
analysis, the significant predictors of parents being in an higher stage of change (e.g., 
action or maintenance stage) for making sure their children received the HPV vaccination 
was predicted before viewing the video (Whole sample, N=122) by: if a child has 
actually already received HPV vaccination (β=1.714, SEB=.599, p=.000); and a higher 
yearly household income (β=.142, SEB=.200, p=.007). For this model, the R2=.420, and 
the AdjR2=.405, meaning that 40.5% of the variance was explained by this model. 
A second purpose of the dissertation research (Study #1) was to determine if a 
linguistically and culturally tailored (i.e., in English or Spanish) video on HPV and HPV 
vaccination of children can serve as a brief online e-health intervention that promotes 
significant parental movement across the stages of change (i.e., from a precontemplation 
or contemplation stage, to a preparation stage, as per the theory of Prochaska and 
DiClemente [1982]) and significantly increases self-efficacy (as per the theory of Bandura 
[1977]) for three key behaviors of: (1) talking to a pediatrician or family practice medical 






children; (2) making sure their preteen and teen children receive the HPV vaccination; 
and (3) making sure their preteen and teen children receive all the required doses (e.g., at 
least two or three doses) of the HPV vaccination. This involved a pre-video viewing 
versus post-video viewing comparison of parents’ stage of change and self-efficacy each 
of these three key behaviors. In addition, changes in knowledge were examined for 
parents from pre- to post-video viewing.  
For this second purpose, paired t-tests compared the means score for the pre-video 
and post-video. The pre-viewing mean score for parents’ HPV knowledge V-PARENTS-
HPV-K-1 for the whole sample was 3.01 or fair (n=115, SD=1.29), versus post-viewing 
video mean score of 4.02 or good (n=115, SD=1.30), as a difference that was statistically 
significant (t=-8.314, df=114, p=.000). The pre-viewing video mean score for SOC for 
Talking to Provider (Re: HPV Vaccine for Child) for the whole sample was 2.27 or 
contemplation (n=155, SD 1.35) versus the post-viewing video mean score of 2.87 or 
closest to preparation (n=115, SD=1.28), as a difference that was statistically significant 
(t=-5.733, df=114, p=.000). The pre-viewing video mean score for SE for Talking to 
Provider (Re: HPV Vaccine for Child) for the whole sample was 3.66 or closest to 60% 
confident (n=115, SD=1.95) versus the post-viewing video mean of 4.66 or closest to 
80% confident (n=114, SD=1.53), indicating that there was a statistically significant 
difference (t=-6.018, df=114, p=.000). The brief online e-health avatar/cartoon video 
emerged as associated with significant increases in numerous variables, as shown above, 
from pre- to post-video viewing. 
A third purpose of the dissertation research (i.e., via Study #2) was to obtain the 






the video to parents and/or other providers so they could share it with parents, in order to 
support parental decision making about initiating and completing HPV vaccination of 
their preteen and teen children (as per the Diffusion of Innovation Theory of Rogers 
[1995]). The majority 89.5% (n=17) of healthcare providers indicated they would 
recommend the video. 
Both Study #1 and Study #2 were grounded in an integrated theoretical 
framework of health behavior changes such as the Health Belief Model, TTM-stage of 
change, Social Cognitive Theory—Self-efficacy, and Diffusion of Innovation. This study 
was also guided by prior research conducted by the Research Group on Disparities in 
Health (RGDH) and based on validated instruments used in prior studies (Pérez et al., 
2016; Shapiro et al., 2016). In addition, the study followed the standard RGDH protocol 
for conducting e-health research (e.g., Chung, 2013). The recruitment approach consisted 
of conducting a social media campaign and snowballing.  
The theory-based approach has identified the brief online e-health avatar/cartoon 
video intervention as a new evidence-based approach that obtained via a pilot the support 
of providers who overwhelmingly recommended it. 
The resultant evidence-based approach to increasing parental HPV knowledge 
promoting movement across the stages of change toward taking recommended HPV-
related prevention actions for their child and increasing self-efficacy for taking action 
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Study #1 Recruitment Emails 
 
**PARENTS/LEGAL GUARDIANS ARE INVITED** 
DO YOU HAVE CHILDREN AGES 9-18? 
VOLUNTEER FOR A 35-40 MINUTE CONFIDENTIAL STUDY ABOUT 
VACCINATING YOUR CHILDREN AGES 9-18 FOR THE HUMAN 
PAPILLOMAVIRUS (HPV) 
IRB Protocol Number 19-172 
 
The Research Group on Disparities in Health within the Department of Health and 
Behavior Studies at Teachers College, Columbia University, in New York, NY is 
conducting a study to see how parents rate a new cartoon video on the Human 
Papillomavirus (HPV) and what they believe about giving their children ages 9-18 the 
HPV vaccination. 
 
ARE YOU A PARENT OR LEGAL GUARDIAN WHO... 
 Wants to learn about the Human Papillomavirus (HPV) and the recommended 
guidelines for vaccinating preteens and teens for HPV? 
 Is interested in learning more about how to talk to medical providers about HPV? 
 Is age 25 or older and has at least 1 child age 9 to 18 
 Is willing to answer survey questions for about 20-25 minutes 
 Is able to watch a cartoon video for about 5 minutes 
 Willing to rate the cartoon video and answer a final set of survey questions for about 
5-10 minutes? 
To learn more about the study, read the Informed Consent, and proceed 
to study participation, please: 
 
GO TO https://tinyurl.com/HPV-Video-Study-English  if you have a child age 9-18, 
watch the video on the Human Papillomavirus (HPV), rate the video,& complete a survey 
for chance to win one of 3 $100 Amazon gift cards     [If you prefer taking the survey and 
watching the video in Spanish, then Go to  https://tinyurl.com/HPV-Video- Study-
Spanish] 
 
NOTE: Participants have a 3 in 250 chance of winning 1 of 3 $100 Amazon gift cards 
 
For more information about this research study, please contact: 
Alejandrina Canelo Villafana, MS at ac3523@tc.columbia.edu or the Research Sponsor, 
Dr. Barbara Wallace, atbcw3@tc.columbia.edu. 








**SE INVITA A PADRES/MADRES/TUTORES LEGALES** 
¿TIENE NIÑOS DE 9-18 años? 
PARTICIPACIÓN VOLUNTARIA DE 35 A 40 MINUTOS PARA UN ESTUDIO 
CONFIDENCIAL  
SOBRE LA VACUNACIÓN DE SUS HIJOS  
CONTRA EL VIRUS DEL PAPILOMA HUMANO (VPH) 
  
IRB Protocol Number 19-172 
El Grupo de Investigación sobre Disparidades en Salud dentro del Departamento de 
Salud y Estudios de Comportamiento de Teachers College, Columbia University, en 
Nueva York, Nueva York, está llevando a cabo un estudio para ver cómo 
los padres califican un nuevo video de caricaturas sobre el Virus del Papiloma Humano 
(VPH) y sus opiniones. Creer en darles a sus niños de 9 a 18 años la vacuna contra el 
VPH. 
  
¿ES USTED PADRE/MADRE o TUTOR LEGAL QUE... 
 ¿Quiere aprender sobre el virus del papiloma humano (VPH) y las recomendaciones 
para vacunar a pre-adolescentes y adolescentes contra el VPH? 
 ¿Le interesa aprender más acerca de cómo hablar con su proveedor de salud sobre el 
VPH? 
 Tiene 25 años o más y al menos 1 hijo o hija entre 9 y 18 años 
 Está dispuesto a contestar las preguntas de una encuesta durante 20-25 minutos 
 Puede ver un video de dibujos animados durante unos 6 minutos 
 ¿Está dispuesto a calificar el video y contestar una serie de preguntas finales durante 
aproximadamente5-10 minutos? 
 
Para obtener más información sobre el estudio, lea el Consentimiento informado y 
continúe con la participación en el estudio, por favor: 
  
Vaya a https://tinyurl.com/HPV-Video-Study-Spanish si tiene un niño de 9 a 18 años de 
edad, mire el video sobre el virus del papiloma humano (VPH), califique el video y 
complete una encuesta para la oportunidad para ganar una de 3 tarjetas de regalo de 
Amazon de $ 100 
 [Si usted prefiere tomar la encuesta y ver el video en inglés, vaya 
a https://tinyurl.com/HPV-Video-Study-English] 
  
NOTA: Los participantes tienen una probabilidad de 3 en 250 de ganar 1 de 3 tarjetas de 
regalo de Amazon de $ 100 
  
Para obtener más información sobre este estudio de investigación, comuníquese con: 
Alejandrina Canelo Villafana, MS enac3523@tc.columbia.edu o la patrocinadora de la 














MEDICAL PROVIDERS TO YOUTH 
AGES 9-18 
ARE INVITED TO JOIN THE HPV VIDEO STUDY 
***************************************** 
PEDIATRICIANS! FAMILY MEDICAL PROVIDERS! 
PHYSICIAN ASSISTANTS! NURSE PRACTITIONERS! 
VOLUNTEER FOR A CONFIDENTIAL 
SHORT 10-12 MINUTE STUDY 
FOR A CHANCE TO WIN 1 of 3 $100 AMAZON GIFT CARDS 
IRB Protocol Number 19-172 
  
  
The Research Group on Disparities in Health within the Department of Health and 
Behavior Studies at Teachers College, Columbia University, in New York, NY is 
conducting a study to see how medical providers (i.e. pediatricians, family medical 
providers, physician assistants, nurse practitioners) rate a new cartoon video on the 
Human Papillomavirus (HPV) and HPV vaccination that was designed for parents of 
children ages 9-18. The study seeks to determine how medical providers rate and evaluate 
the new cartoon video, and if they recommend it for parents. 
  
To learn more about the study, read the Informed Consent, and proceed 
to study participation, please: 
  
CLICK https://tinyurl.com/HPV-Video-Study-For-Providers if U R a medical provider to 
youth ages 9-18, watch & rate an HPV video, & complete a survey–in just 10-12 
minutes-for chance to win 1 of 3 $100 Amazon gift cards 
  
NOTE: Participants have a 3 in 250 chance of winning 1 of 3 $100 Amazon gift cards 
  
For more information about this research study, please contact: 
Alejandrina Canelo Villafana, MS at ac3523@tc.columbia.edu or the Research Sponsor, 
Dr. Barbara Wallace, at bcw3@tc.columbia.edu.Study contact number: 267-269-7411. 
 
 
THANK YOU FOR YOUR STUDY PARTICIPATION!  
Please text or tweet other medical providers to: 
CLICK https://tinyurl.com/HPV-Video-Study-For-Providers if U R a medical provider to 
youth ages 9-18, watch & rate an HPV video, & complete a survey–in just 10-12 









Study #1 Text/Tweet 
 
GO TO https://tinyurl.com/HPV-Video-Study-English  if you have a child age 9-18, 
watch the video on the Human Papillomavirus (HPV), rate the video,& complete a survey 
for chance to win one of 3 $100 Amazon gift cards     [If you prefer taking the survey and 




Vaya a https://tinyurl.com/HPV-Video-Study-Spanish si tiene un niño de 9 a 18 años de 
edad, mire el video sobre el virus del papiloma humano (VPH), califique el video y 
complete una encuesta para la oportunidad para ganar una de 3 tarjetas de regalo de 
Amazon de $ 100 










Study #2 Text/Tweet 
 
 
GO TO https://tinyurl.com/HPV-Video-Study-For-Providers  if U R a medical provider 
to youth ages 9-18, watch & rate an HPV video, & complete a survey–in just 10-12 








Study #1 Recruitment Flyers 
 
**PARENTS/LEGAL GUARDIANS ARE INVITED** 
VOLUNTEER FOR A 35-40 MINUTE CONFIDENTIAL STUDY ABOUT 
VACCINATING YOUR CHILDREN AGES 9-18 FOR THE HUMAN 
PAPILLOMAVIRUS (HPV) 
 IRB Protocol Number 19-172 
 




ARE YOU A PARENT OR LEGAL GUARDIAN 
WHO... 
• Wants to learn about the Human Papillomavirus 
(HPV) and the recommended guidelines for 
vaccinating pre-teens and teens for HPV? 
• Is interested in learning more about how to talk to 
medical providers about HPV?  
• Is age 25 or older and has at least 1 child age 9 to 
18 
• Is willing to answer survey questions for about 20-
25 minutes 
• Is able to watch a cartoon video for about 5 minutes 
• Willing to rate the cartoon video and answer a final 
set of survey questions for about 5-10 minutes? 
 
	
For more information about this 
research study, please contact: 
Alejandrina Canelo Villafana, MS at 
ac3523@tc.columbia.edu or the 
Research Sponsor, Dr. Barbara 
Wallace, at bcw3@tc.columbia.edu.  
Study contact number: 267-269-7411 
 
The Research Group on Disparities in Health 
within the Department of Health and Behavior 
Studies at Teachers College, Columbia University, 
in New York, NY is conducting a study to see how 
parents rate a new cartoon video on the Human 
Papillomavirus (HPV) and what they believe about 
giving their children ages 9-18 the HPV 
vaccination.   
	
To learn more about the study and read the Informed Consent, please: 
GO TO https://tinyurl.com/HPV-Video-Study-English if you have a child age 9-18, 
watch the video on the Human Papillomavirus (HPV), rate the video, & complete a 
survey for chance to win one of 3 $100 Amazon gift cards    [If you prefer taking the 
survey and watching the video in Spanish, then Go to  https://tinyurl.com/HPV-Video-
Study-Spanish] NOTE: Participants have a 3 in 250 chance of winning 1 of 3 $100 Amazon gift cards 
	
GO TO  
https://tinyurl.com/HPV-Video-Study-English   
if you have a child age 9-18, watch 
the video on the Human 
Papillomavirus (HPV), rate 
the video, & complete a survey for 
chance to win one of 3 $100 
Amazon gift cards 
GO TO  
https://tinyurl.com/HPV-Video-Study-English   
if you have a child age 9-18, watch 
the video on the Human 
Papillomavirus (HPV), rate 
the video, & complete a survey for 
chance to win one of 3 $100 
Amazon gift cards 
GO TO  
https://tinyurl.com/HPV-Video-Study-English   
if you have a child age 9-18, watch 
the video on the Human 
Papillomavirus (HPV), rate 
the video, & complete a survey for 
chance to win one of 3 $100 








**SE INVITA A PADRES/MADRES/TUTORES LEGALES** 
 PARTICIPACIÓN VOLUNTARIA DE 35 A 40 MINUTOS PARA UN ESTUDIO 
CONFIDENCIAL SOBRE LA VACUNACIÓN DE SUS HIJOS CONTRA EL VIRUS 
DEL PAPILOMA HUMANO (VPH) 
 
 IRB Protocol Number 19-172 
 
Arranque una pestaña con el enlace a la encuesta y corra la voz	
	
	
¿ES USTED PADRE/MADRE o TUTOR LEGAL 
QUE... 
• ¿Quiere aprender sobre el virus del papiloma 
humano (VPH) y las recomendaciones para vacunar 
a  
pre-adolescentes y adolescentes contra el VPH? 
• ¿Le interesa aprender más acerca de cómo hablar 
con su proveedor de salud sobre el VPH? 
• Tiene 25 años o más y al menos 1 hijo o hija entre 9 y 
18 años 
• Está dispuesto a contestar las preguntas de una 
encuesta durante 20-25 minutos 
• Puede ver un video de dibujos animados durante 
unos 5 minutos 
• ¿Está dispuesto a calificar el video y contestar una 




Para obtener más información sobre este 
estudio de investigación, comuníquese con: 
Alejandrina Canelo Villafana, MS en 
ac3523@tc.columbia.edu o la patrocinadora 
de la investigación, Dra. Barbara Wallace, en 
bcw3@tc.columbia.edu. 





 si tiene un niño de 9 a 18 años de 
edad, mire el video sobre el virus del 
papiloma humano (VPH), califique el 
video y complete una encuesta para la 
oportunidad para ganar una de 3 
tarjetas de regalo de Amazon de $ 100 
 
El Grupo de Investigación sobre Disparidades en Salud 
dentro del Departamento de Salud y Estudios de 
Comportamiento de Teachers College, Columbia 
University, en Nueva York, Nueva York, está llevando a 
cabo un estudio para ver cómo los padres califican un 
nuevo video de caricaturas sobre el Virus del Papiloma 
Humano (VPH) y sus opiniones. Creer en darles a sus 
niños de 9 a 18 años la vacuna contra el VPH.	
Vaya a 
https://tinyurl.com/HPV-Video-Study-Spanish 
 si tiene un niño de 9 a 18 años de 
edad, mire el video sobre el virus del 
papiloma humano (VPH), califique el 
video y complete una encuesta para la 
oportunidad para ganar una de 3 




 si tiene un niño de 9 a 18 años de 
edad, mire el video sobre el virus del 
papiloma humano (VPH), califique el 
video y complete una encuesta para la 
oportunidad para ganar una de 3 
tarjetas de regalo de Amazon de $ 100 
 
Para obtener más información sobre el estudio y leer el Consentimiento informado, por favor: 
Vaya a https://tinyurl.com/HPV-Video-Study-Spanish si tiene un niño de 9 a 18 años de 
edad, mire el video sobre el virus del papiloma humano (VPH), califique el video y 
complete una encuesta para la oportunidad para ganar una de 3 tarjetas de regalo de 
Amazon de $ 100 [Si usted prefiere tomar la encuesta y ver el video en inglés, vaya a 
https://tinyurl.com/HPV-Video-Study-English]  







Study #1 Informed Consent in English  
 
Teachers College, Columbia University 525 West 120th Street 
New York NY 10027 212 678 3000 
 
INFORMED CONSENT FOR PARENTS 
 
IRB Protocol Number 19-172 
 
 
NOTE: If you prefer taking the survey and watching the video in Spanish, then 
Go to https://tinyurl.com/HPV-Video-Study-Spanish 
 
Protocol Title: VACCINATING CHILDREN FOR THE HUMAN 
PAPILLOMAVIRUS (HPV): PREDICTORS OF PARENTS VACCINATING THEIR 
CHILD AND PROVIDERS RECOMMENDING A NEW LINGUISTICALLY AND 
CULTURALLY TAILORED VIDEO INTERVENTION DESIGNED TO INCREASE 
VACCINATION INITIATION AND COMPLETION 
 
Principal Investigator: Alejandrina Canelo Villafana, MS 
Teachers College, Columbia University; 973-391-4128; ac3523@tc.columbia.edu 
 
INTRODUCTION You are being invited to participate in this research study called 
“VACCINATING CHILDREN FOR THE HUMAN PAPILLOMAVIRUS (HPV): 
PREDICTORS OF PARENTS VACCINATING THEIR CHILD AND PROVIDERS 
RECOMMENDING A NEW LINGUISTICALLY AND CULTURALLY TAILORED 
VIDEO INTERVENTION DESIGNED TO INCREASE VACCINATION 
INITIATION AND COMPLETION.” You may qualify to take part in this research 
study if you are: at least at least 25 years of age; the parent/caregiver or legal guardian 
of at least ONE child between the ages of 9 and 18 years of age; are willing to answer 
survey questions about yourself, your child, what you know about the human 
papillomavirus (HPV), and what you think about having your child vaccinated for 
HPV; and, are able to watch a 5-minute cartoon video aloud (i.e. using a smart phone 
with headphones, or laptop or computer with working speakers). Approximately 250 








WHY IS THIS STUDY BEING DONE? This study is being done to evaluate a new 
cartoon video designed to educate parents about the human papillomavirus (HPV) and 
the decision to have their child vaccinated for HPV. The evaluation will determine if, 
after watching the cartoon video, parents feel more prepared and confident to: (1) talk to  
a medical provider about HPV and the HPV vaccination for children ages 9 to 18; and, 
(2) decide if they will have their children receive the HPV vaccination and all the 
required doses. 
WHAT WILL I BE ASKED TO DO IF I AGREE TO TAKE PART IN THIS 
STUDY? If you decide to participate in this study, you will be asked to: 
 BEFORE WATCHING THE CARTOON: you will spend about 20-25 minutes 
answering a set of questions about you and your child 
 WATCH THE CARTOON: you will spend about 5 minutes watching a 
cartoon using a computer with an Internet connection in a place where you can 
play the cartoon aloud 
 AFTER THE CARTOON: you will spend about 5-10 minutes answering a final 
set of questions, including rating the cartoon and deciding if you would recommend 
it to other parents. 
 
WHAT POSSIBLE RISKS OR DISCOMFORTS CAN I EXPECT FROM TAKING 
PART IN THIS STUDY? This is a minimal risk study, which means the harms or 
discomforts that you may experience are not greater than you would ordinarily 
experience if you were thinking about the health of your child. A participant who 
experiences any emotional discomfort can discontinue answering questions or can 
stop watching the cartoon at any time—without suffering any negative consequences. 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS 
STUDY? There is no direct benefit to you for participating in this study. Participation 
may benefit the field of health education by determining if there is value in a cartoon 
video for educating parents about HPV and the HPV vaccination for children. 
 
WILL I BE PAID FOR BEING IN THIS STUDY? You will not be paid to 
participate. However, when you complete the survey you will be invited to enter your 
email address and to hit a “submit” button—so that you are officially entered into a 
drawing for a chance to receive a prize (i.e., there will be 3 bar coded Amazon gift 
certificates for $100 each). You do not have to enter the lottery drawing to complete the 
survey. Once you submit your email address, then it will automatically be entered into a 
private and secure data base that even the principal investigator cannot access. Once 
250 people have completed the entire survey, you will have a 3 in 250 chance of 
winning one of the 3 bar coded Amazon gift certificates for $100 each. The 
www.Amazon.com gift certificates will be sent to three randomly chosen email 
accounts using a secure online program. This occurs without in any way linking your 
identity to the survey results. The principal investigator is not able to view any of the 









WHEN IS THE STUDY OVER? CAN I LEAVE THE STUDY BEFORE IT ENDS? 
The study is over when you have completed the online survey. However, you can 
discontinue answering the survey questions at any time. You can exit the study at 
any time and delete the link to the study. 
 
PROTECTION OF YOUR CONFIDENTIALITY The study does not involve linking 
your survey responses to any personal information that might identify you, keeping your 
information confidential. Teachers College, Columbia University has determined that 
www.Qualtrics.com provides a secure platform for the online survey you will take. The 
survey data files will also be saved on the primary researcher’s password protected 
computer. Regulations require that research data be kept for at least three years. 
 
For quality assurance, the study team, and/or members of the Teachers College 
Institutional Review Board (IRB) may review the data collected from you as part of this 
study. Otherwise, all information obtained from your participation in this study will be 
held strictly confidential and will be disclosed only with your permission or as required 
by U.S. or State law. 
 
HOW WILL THE RESULTS BE USED? The results of this study will be published 
in journals and presented at academic conferences. This study is being conducted as part 
of the dissertation of the principal investigator. 
 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? 
If you have any questions about taking part in this research study, you should 
contact the principal investigator, Alejandrina Canelo Villafana, MS at 973-391- 
4128 or at ac3523@tc.columbia.edu. You can also contact the faculty advisor, 
Dr. Barbara C. Wallace at (267)-269-7411 or bcw3@tc.columbia.edu. 
 
If you have questions or concerns about your rights as a research subject, you should 
contact the Institutional Review Board (IRB) (the human research ethics committee) 
at 212-678-4105 or email IRB@tc.edu. Or you can write to the IRB at Teachers 
College, Columbia University, 525 W. 120th Street, New York, NY 1002. The IRB is 









Study #1 Informed Consent in Spanish  
Teachers College, Columbia University 
525 West 120th Street 
New York NY 10027 
212 678 3000 
 
CONSENTIMIENTO INFORMADO PARA PADRES 
 
Número de Protocolo IRB 19-172 
 
 




Título del Protocolo: VACUNANDO A LOS NIÑOS  CONTRA EL VIRUS DEL 
PAPILOMA HUMANO (HPV): FACTORES PREDICTORES DE LA RESPUESTA 
DE LOS PADRES PARA VACUNAR A SUS HIJOS E HIJAS Y RECOMENDACION 
DE LOS PROVEEDORES DE SALUD DE UN VIDEO DE INTERVENCION 
ADAPTADO LINGÜÍSTICA Y CULTURALMENTE DISEÑADO PARA LOGRAR 
UN INCREMENTO EN EL INICIO Y FINALIZACION DE LA VACUNACION 
 
Investigador Principal: Alejandrina Canelo Villafana, MS 
Teachers College, Columbia University; 973-391-4128; ac3523@tc.columbia.edu 
 
INTRODUCCION Usted está invitado a participar en este estudio de investigación 
llamado “VACUNANDO A LOS NIÑOS Y NIÑAS CONTRA EL VIRUS DEL 
PAPILOMA HUMANO (VPH): FACTORES PREDICTORES DE LA RESPUESTA 
DE PADRES Y MADRES PARA VACUNAR A SUS HIJOS E HIJAS Y 
RECOMENDACION DE LOS PROVEEDORES DE SALUD DE UN VIDEO DE 
INTERVENCION ADAPTADO LINGÜÍSTICA Y CULTURALMENTE 
DISEÑADO PARA LOGRAR UN INCREMENTO EN EL INICIO Y 
FINALIZACION DE LA VACUNACION.” Los requisitos para poder participar de 
este estudio de investigación son: tener 25 años de edad o más; ser padre, madre o 
tutor legal de al menos UN niño o niña que tenga entre 9 a 18 años de edad; estar 
dispuesto a contestar una encuesta con preguntas acerca de Usted, sus hijos y/o hijas, 
lo que usted conoce a cerca del virus del papiloma humano (VPH), y lo que usted 
piensa sobre tener a sus hijos y/o hijas vacunados contra el virus del papiloma humano 
(VPH); y estar dispuesto a ver un video animado de 5 minutos de duración en volumen 
alto (por ejemplo usando un teléfono inteligente con audífonos, una computadora 
portátil o computadora de escritorio con bocinas que funcionen correctamente). 
Aproximadamente 250 personas podrán formar parte de este estudio y su participación 




¿POR QUÉ SE REALIZARÁ ESTE ESTUDIO? Este estudio se hace para evaluar 
un nuevo video animado diseñado para enseñar a padres, madres o tutores legales a 
cerca del virus del papiloma humano (VPH) y tomar la decisión de vacunar a sus hijos 
y/o hijas contra el VPH. La evaluación determinará si, luego de ver el video animado, 
los padres, madres o tutores legales se sienten más preparados y con mayor confianza 
para: (1) hablar con un proveedor de salud acerca del VPH y la vacuna contra el VPH 
para sus hijos e hijas entre 9 a 18 años de edad; y, (2) decidir si sus hijos e hijas 
recibirán la vacuna contra el VPH y en las dosis necesarias. 
 
¿QUÉ ME PEDIRÁN HACER SI DECIDO PARTICIPAR EN ESTE ESTUDIO? 
Si Usted decide formar parte de esta investigación, se le pedirá: 
 ANTES DE VER EL VIDEO DE DIBUJOS ANIMADOS: deberá contestar una 
serie de preguntas sobre Usted y sus hijos y/o hijas. Esto le tomará 20-25 minutos 
 VER EL VIDEO DE DIBUJOS ANIMADOS: necesitará alrededor de 5 
minutos para mirar el video usando una computadora con conexión a internet en 
un lugar donde pueda reproducir el video en volumen alto. 
 LUEGO DE VER EL VIDEO DE DIBUJOS ANIMADOS: necesitará alrededor 
de 5-10 minutos más para contestar una serie final de preguntas, calificar el video 
y decidir si recomendaría el video a otros padres/madres o tutores legales. 
 
¿QUÉ RIESGOS O MALESTARES SON POSIBLES DE ESPERAR SI FORMO 
PARTE DE ESTE ESTUDIO? Este es un estudio de riesgo mínimo, lo cual significa 
que los daños o malestares que usted pueda experimentar no son mayores a los que 
podría experimentar cualquier persona al pensar en la salud de sus hijos. Si un 
participante experimenta alguna molestia o malestar emocional, puede dejar de contestar 
las preguntas o dejar de mirar el video en cualquier momento—sin sufrir ninguna 
consecuencia negativa. 
 
¿QUÉ BENEFICIOS SON POSIBLES DE ESPERAR POR MI PARTICIPACION 
EN ESTE ESTUDIO? No hay un beneficio directo para usted por participar en este 
estudio. Su participación puede beneficiar al área de educación en salud al determinar 
la utilidad de un video de dibujos animados para enseñar a padres sobre el VPH y la 
vacunación contra el VPH para niños. 
 
¿ME PAGARÁN POR PARTICIPAR EN ESTE ESTUDIO? No se le ofrecerá 
ningún tipo de pago /dinero por participar en este estudio. Sin embargo, cuando usted 
complete la encuesta se le pedirá que ingrese su dirección de correo electrónico y que 
pulse la tecla “enviar”—de esta forma usted ingresará oficialmente a una casilla por la 
posibilidad de recibir un premio (por ejemplo, habrá 3 certificados de regalo de 
Amazon con códigos de barra por un valor de $100 cada uno). Usted no tiene que 
entrar a la casilla de sorteo para completar la encuesta. Una vez que usted envíe su 
dirección de correo electrónico, la misma entrará automáticamente a una base de datos 
privada y segura. Una vez que 250 personas hayan realizado la encuesta completa, 
usted tendrá la posibilidad de 3 en 250 de ganar una de los 3 certificados de regalo de 
Amazon con códigos de barra por un valor de $100 cada uno. Los certificados de 









al azar usando un programa seguro en línea. Esto se realiza sin vincular de ninguna 
manera su identidad a los resultados de la encuesta. La investigadora principal no tiene 
acceso a mirar ninguna de las direcciones de correo electrónico a las cuales se envían 
los certificados de regalo. Sólo los 3 ganadores serán contactados. 
 
¿CUANDO TERMINA MI PARTICIPACIÓN EN EL ESTUDIO? ¿PUEDO 
ABANDONAR EL ESTUDIO ANTES DE TERMINAR? El estudio ha terminado 
cuando haya completado la encuesta en línea. Sin embargo, puede dejar de responder 
las preguntas de la encuesta en cualquier momento. Puede salir del estudio en cualquier 
momento y eliminar el enlace al estudio. 
 
PROTECCION DE SU CONFIDENCIALIDAD El estudio no implica vincular las 
respuestas de su encuesta a ninguna información personal que pueda identificarlo, 
manteniendo su información confidencial. Teachers College, Columbia University ha 
determinado que www.Qualtrics.com proporciona una plataforma segura para la 
encuesta en línea que realizará. Los archivos de datos de la encuesta también se 
guardarán en la computadora protegida por contraseña del investigador principal. Las 
regulaciones requieren que los datos de investigación se mantengan durante al menos 
tres años. 
 
Para garantizar la calidad, el equipo de estudio y / o los miembros de la Junta de 
Revisión Institucional (IRB) de Teachers College pueden revisar los datos recopilados 
de usted como parte de este estudio. De lo contrario, toda la información obtenida de su 
participación en este estudio se mantendrá estrictamente confidencial y se divulgará solo 
con su permiso o según lo exija la ley de los Estados Unidos o del estado. 
 
¿COMO SE UTILIZARÁN LOS RESULTADOS? Los resultados de este estudio 
serán publicados en revistas científicas y serán presentados en conferencias 
académicas. Este estudio se lleva a cabo como parte de la tesis doctoral de la 
investigadora principal. 
 
¿QUIÉN PUEDE CONTESTAR MIS PREGUNTAS O DUDAS A CERCA 
DE ESTE ESTUDIO? 
Si usted tiene alguna duda o pregunta en relación a formar parte de este estudio 
de investigación, deberá ponerse en contacto con la investigadora principal, 
Alejandrina Canelo Villafana, MS al teléfono 973-391-4128 ó a la siguiente 
dirección de correo electrónico ac3523@tc.columbia.edu. Además, puede 












DERECHOS DEL PARTICIPANTE 
 
 He leído el consentimiento informado y tuve oportunidad de realizar preguntas sobre 
investigación (investigadora principal, o tutora académica). 
 He tenido suficiente oportunidad de preguntar sobre los propósitos, procedimientos, 
riesgos y beneficios en relación a este estudio de investigación. 
 Entiendo que mi participación es voluntaria. Puedo rehusarme a participar o 
abandonar mi participación en cualquier momento sin recibir sanción alguna. 
 El investigador puede retirarme de la investigación según su criterio profesional. 
 Si durante el transcurso de la investigación, se encuentra disponible nueva 
información importante que pueda relacionarse con mi predisposición a continuar 
participando, el investigador me proporcionará esta información. 
 Cualquier información correspondiente al proyecto de investigación que pueda 
identificarme no será comunicada o divulgada sin mi consentimiento por separado, 
excepto que sea requerido específicamente por ley. 
 Los datos no identificables pueden ser usada para estudios de investigación futuros, o 
proporcionados a otro investigador para investigaciones futuras sin consentimiento 
informado adicional de la persona o su representante legal.  
 Puedo descargar y guardar una copia de este documento de Consentimiento 
Informado. 
 
Al marcar la casilla a continuación, acepto participar en el estudio y confirmo que 
soy: un adulto de 25 años o más; el padre / cuidador o tutor legal de al menos UN 
niño entre las edades de 9 y 18 años de edad; capaz de leer y entender Español en 
la escuela secundaria; capaz de dedicar entre 35 y 40 minutos a este estudio, 
incluso ver un video de dibujos animados de 5 minutos (por ejemplo usando un 
teléfono inteligente con audífonos, una computadora portátil o computadora de 
escritorio con bocinas que funcionen correctamente ) y responder preguntas de la 
encuesta. 
 













Study #2 Informed Consent 
 
 
Teachers College, Columbia University 
525 West 120th Street 
New York NY 10027 
212 678 3000 
INFORMED CONSENT FOR PROVIDERS 
IRB Protocol Number 19-172 
 
Protocol Title: Vaccinating Children for the Human Papillomavirus (HPV):  
Predictors of Parents Vaccinating their Child and Providers Recommending a New 
Linguistically and Culturally Tailored Video Intervention Designed to Increase 
Vaccination Initiation and Completion 
 
Principal Investigator: Alejandrina Canelo Villafana, MS 
Teachers College, Columbia University; 973-391-4128; ac3523@tc.columbia.edu 
 
INTRODUCTION You are being invited to participate in this research study called 
“Vaccinating Children for the Human Papillomavirus (HPV): Predictors of Parents 
Vaccinating their Child and Providers Recommending a New Linguistically and 
Culturally Tailored Video Intervention Designed to Increase Vaccination Initiation and 
Completion.” You may qualify to take part in this research study if you are a pediatrician 
or family practitioner, or other medical health care provider (e.g. physicians, physician 
assistants, nurse practitioners); you have had direct contact with pediatric patients 
(children, adolescents) within the past six months; and, you will be able to watch and 
listen to a 5-minute cartoon video (i.e. smart phone with headphones, or laptop or 
computer with working speakers). Approximately 250 providers will participate in this 
study and it will take 10-12 minutes of your time to complete. 
 
WHY IS THIS STUDY BEING DONE? This study is being done to evaluate a new 
cartoon video designed to educate parents about the human papillomavirus (HPV) and the 
decision to having their child vaccinated for HPV. The evaluation will determine if, after 
watching the cartoon video, you recommend it for parents in need of education on HPV 
vaccination. 
 
WHAT WILL I BE ASKED TO DO IF I AGREE TO TAKE PART IN THIS 
STUDY? If you decide to participate in this study, you will be asked to spend about 3-4 
minutes answering a set of questions about you and your practice, including your 
knowledge about HPV and extent to which you have discussed HPV vaccination with 









2-3 minutes answering a final set of questions, including rating the cartoon and deciding 
if you would recommend it to for parents. 
 
WHAT POSSIBLE RISKS OR DISCOMFORTS CAN I EXPECT FROM TAKING 
PART IN THIS STUDY? This is a minimal risk study, which means the harms or 
discomforts that you may experience are not greater than you would ordinarily 
experience if you were thinking about the health of children in your practice. A 
participant who experiences any discomfort can discontinue answering questions or can 
stop watching the cartoon at any time—without suffering any negative consequences. 
 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS 
STUDY? There is no direct benefit to you for participating in this study. 
 
WILL I BE PAID FOR BEING IN THIS STUDY? You will not be paid to participate. 
However, when you complete the survey you will be invited to enter your email address 
and to hit a “submit” button—so that you are officially entered into a drawing for a 
chance to receive a prize (i.e., there will be 3 bar coded Amazon gift certificates for $100 
each). You do not have to enter the lottery drawing to complete the survey. Once you 
submit your email address, then it will automatically be entered into a private and secure 
data base that even the principal investigator cannot access. Once 250 people have 
completed the entire survey, you will have a 3 in 250 chance of winning one of the 3 bar 
coded Amazon gift certificates for $100 each. The www.Amazon.com gift certificates 
will be sent to three randomly chosen email accounts using a secure online program. This 
occurs without in any way linking your identity to the survey results. The principal 
investigator is not able to view any of the email addresses to which the gift certificates 
are sent. Only the 3 winners will be contacted. 
 
WHEN IS THE STUDY OVER? CAN I LEAVE THE STUDY BEFORE IT ENDS? 
The study is over when you have completed the online survey. However, you can 
discontinue answering the survey questions at any time. You can exit the study at any 
time and delete the link to the study. 
 
PROTECTION OF YOUR CONFIDENTIALITY The study does not involve linking 
your survey responses to any personal information that might identify you, keeping your 
information confidential. Teachers College, Columbia University has determined that 
www.Qualtrics.com provides a secure platform for the online survey you will take. The 
survey data files will also be saved on the primary researcher’s password protected 
computer. Regulations require that research data be kept for at least three years. For 
quality assurance, the study team, and/or members of the Teachers College Institutional 
Review Board (IRB) may review the data collected from you as part of this study. 
Otherwise, all information obtained from your participation in this study will be held 
strictly confidential and will be disclosed only with your permission or as required by 










HOW WILL THE RESULTS BE USED? The results of this study will be published in 
journals and presented at academic conferences. This study is being conducted as part of 
the dissertation of the principal investigator. 
 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? If you have any 
questions about taking part in this research study, you should contact the principal 
investigator, Alejandrina Canelo Villafana, MS at 973-391-4128 or at 
ac3523@tc.columbia.edu. You can also contact the faculty advisor, Dr. Barbara C. 
Wallace at (267)-269-7411 or bcw3@tc.columbia.edu. 
 
If you have questions or concerns about your rights as a research subject, you should 
contact the Institutional Review Board (IRB) (the human research ethics committee) at 
212-678-4105 or email IRB@tc.edu. Or you can write to the IRB at Teachers College, 
Columbia University, 525 W. 120th Street, New York, NY 1002. The IRB is the committee 
that oversees human research protection for Teachers College, Columbia University. 
 
PARTICIPANT’S RIGHTS 
 I have read the Informed Consent Form and have been offered the opportunity to 
discuss the form with the researcher. 
 I have had ample opportunity to ask questions about the purposes, procedures, risks 
and benefits regarding this research study. 
 I understand that my participation is voluntary. I may refuse to participate or 
withdraw participation at any time without penalty. 
 The researcher may withdraw me from the research at his or her professional 
discretion. I understand that if I take the survey more than once I will be 
eliminated from the study. 
 If, during the course of the study, significant new information that has been 
developed becomes available which may relate to my willingness to continue my 
participation, the researcher will provide this information to me. 
 Any information derived from the research study that personally identifies me will 
not be voluntarily released or disclosed without my separate consent, except as 
specifically required by law. 
 I should receive a copy of the Informed Consent Form document. (I 
understand that I can download it). 
 
By checking the box below, I agree to participate in the study and I am confirming 
that I am: a medical health care provider (e.g. physician, physician assistant, nurse 
practitioner) who works in a pediatric or family care practice—while having had 
direct contact with pediatric patients (children, adolescents) within the past 6 
months; and, able to devote about 10-12 minutes to this study, including watching a 
5-minute cartoon video (i.e. using a smart phone with headphones, or laptop or 
computer with working speakers) and answering survey questions. 















ENGLISH VERSION OF FINAL SCRIPT FOR 
TOMAS GETS HIS FIRST HPV VACCINATION SHOT 
(5 Minute Avatar/Cartoon Video) 
NOTE: 675 words = 5.7 minutes 
 
CAST: 
D = Dr. James 
T = Tomas, age 11 
M = Mother 
F = Father 
S = Simone, Sister of Tom, age 12 
 
SCENE – Doctor’s Office 
 
D: How are you Mr. Ramirez? And you, Mrs. Ramirez? 
M: Great, Dr. James.  
F: Great. We have a birthday boy, here! 
D: Tomas, Happy Birthday! 
T: Thank you! I’m 11 now! 
S: I’m still older! 
D: It’s time for your son, Tomas, to get a number of recommended vaccines for those age 
11 to 12.  
F: Yes, I know about the vaccines for flu, tdap and meningococcal. But, I wanted to learn 
more about the HPV vaccine.  
S: I remember getting the HPV vaccine last year. I came here with Mom. 
D: Yes. HPV vaccine is recommended for all 11 to 12 year old girls and boys—or can 
start as early as age 9. I recommend that Tomas receive the HPV vaccination, today. 
S: Just like me! 
 
[Children are in a corner looking at books, toys, etc.., being distracted, and not listening 
to the adults’ conversation] 
 
F: So, Dr. James, please tell me more about HPV. 
D: Certainly. 
F: I know HPV is a sexually transmitted disease. 
D: Yes! HPV is the most common sexually transmitted disease. HPV is transmitted by 
having vaginal, anal or oral sex with someone who has the virus. Almost all sexually 









M: And most people will never even know they have HPV.  
F: But, my son is not sexually active. He’s just 11! 
D: It is because he is not yet sexually active that we recommend the HPV vaccination at 
his age. By vaccinating for HPV today, your child will have the best protection possible 
BEFORE the start of any kind of sexual activity. 
F: Really? 
D: Yes. We vaccinate people well BEFORE they are exposed to an infection. 
M: Dr. James, please share with my husband what you told me before: why the HPV 
vaccine is so important.  
D: The HPV vaccine is very important because it helps prevent cancer. 
F: I remember hearing that the HPV vaccine was important for girls to receive, in order to 
help prevent cervical cancer. 
D: HPV not only causes many of the cancers of the cervix, vagina and vulva in women, 
but also of the penis in men. Both men and women can get genital warts and cancers of 
the anus, mouth, and throat from HPV. The HPV vaccine can help prevent these cancers. 
F: I just remembered my boss saying the cause of his cancer of the mouth was most likely 
HPV!  
M: So, there is a good reason to vaccinate preteens and teens BEFORE they become 
sexually active! 
D: Research shows that vaccinating preteens and teens does not make them more likely to 
become sexually active. Other research shows the HPV vaccine to be extremely effective 
in reducing infections caused by HPV. 
M: Have you vaccinated your children? 
D: Yes. I strongly believe in the importance of this cancer-preventing vaccine. I follow 
the recommendations of the American Academy of Pediatrics and many other experts. 
F: Well, let’s get Tomas vaccinated! I’m convinced that HPV vaccination is important. 
 
(Children hear this declaration and return to the area where the adults are talking) 
 
S: Is Thomas going to have to come back for his second HPV shot? 
D: Yes. 
M: Just like you did last year. 
T: So, I get one HPV shot today, and then I have to come back for another one? 
D: Yes. Because you are under age 15, you get two doses of the HPV vaccine. You will 
get the second dose 6-12 months from now. 
M: Do some children get 3 doses? 
D: Yes, the 3-dose schedule is recommended for children starting the HPV vaccination 
series on or after their 15th birthday. For those teens the second dose is given 1-2 months 
after the first, and the third dose is administered 6 months after the first dose. 
F: What happens if a child does not receive all of their doses? 
D: They can still complete the vaccine series. I just saw a 16 year old teen who had his 
first HPV dose at age 13 when he lived in another state. His Dad brought him in for dose 










D: This reflects the recommendation that all parents with children ages 9 to 18 under 
their care have their children complete ALL the doses in the HPV vaccination series. 
M: I’ll make the appointment for Tomas’s second HPV shot before we leave here today. 
S: Just like I got my second shot! 
M: Yes! 
D: Are you ready for your first HPV shot, Tomas? 
T: I’m ready! 
  
Final Page: 
This video was brought to you by: 
Research Group on Disparities in Health (RGDH) 
Department of Health and Behavior Studies 
Teachers College, Columbia University 
New York, NY 
 
Contact Persons:  
Alejandrina Canelo Villafana, MS, (Doctoral Candidate), Fellow of the RGDH 













Video Script in Spanish 
 
VERSION FINAL EN ESPAÑOL DEL GUIÓN PARA 
TOMAS RECIBE SU PRIMERA DOSIS DE VACUNA VPH 
 (Avatar/Video Animado de 5 Minutos) 
NOTA: 675 (948) palabras = 6.25 minutos 
 
PERSONAJES: 
D = Dr. James 
T = Tomas, 11 años 
M = Madre 
P = Padre 
S = Simone, Hermana de Tomy, 12 años 
 
ESCENA – Consultorio del Doctor 
 
D: ¿Cómo está usted Sr. Ramirez? Y usted, Sra. Ramirez? 
M: Muy bien, Dr. James.  
P: Muy bien. ¡Tenemos un niño de cumpleaños, aquí está! 
D: ¡Tomas, Feliz Cumpleaños! 
T: ¡Gracias! ¡Ahora tengo 11! 
S: ¡Todavía soy mayor que tú!   
D: Es tiempo que su hijo, Tomas, reciba una serie de vacunas recomendadas para niños 
quienes tienen de 11 a 12 años de edad. 
P: Si, conozco sobre las vacunas para la gripe, dTap y meningococo. Pero quiero 
aprender más sobre las vacunas contra el virus del papiloma humano (VPH). 
S: Yo recuerdo que recibí la vacuna VPH el año pasado. Vine acá con Mamá. 
D: Si. La vacuna VPH se recomienda para todos los niños y niñas de 11 a 12 años de 
edad—o se puede comenzar tan pronto como a la edad de 9 años. Yo recomiendo que 
Tomás reciba la vacuna del VPH, hoy. 
S: ¡Igual que yo! 
 
[Los niños están en un rincón mirando libros, juguetes, etc., están distraídos y no 
escuchan la conversación de los adultos] 
 
P: Entonces, Dr. James, dígame sobre el VPH. 
D: Por supuesto. 
P: Sé que el VPH es una enfermedad de transmisión sexual. 
D: ¡Exacto! El VPH es la más común de las enfermedades de transmisión sexual. El VPH 
se transmite por tener sexo vaginal, anal u oral con alguien que tiene el virus. Casi todas 
las personas sexualmente activas contraerán el VPH en algún momento de sus vidas. 









P: Pero, mi hijo no es sexualmente activo. ¡Tiene solo 11 años! 
D: Justamente, es porque él no ha estado aun sexualmente activo es que recomendamos 
la vacunación contra el VPH a esta edad. Si se vacuna contra el VPH hoy, su hijo tendrá 
la mejor protección posible ANTES del inicio de cualquier tipo de actividad sexual. 
P: ¿De verdad?  
D: Si. Nosotros vacunamos a las personas justo ANTES de que estén expuestas a una 
infección. 
M: Dr. James, por favor cuéntele a mi marido lo que usted me dijo antes: por qué la 
vacuna contra el VPH es tan importante. 
D: La vacuna contra el VPH es muy importante porque ayuda a prevenir los tipos de 
cáncer relacionados con el VPH. 
P: Recuerdo haber escuchado que la vacuna contra el VPH era importante para las niñas, 
para prevenir cáncer cervical. 
 
D: el VPH no sólo causa muchos de los canceres de cuello uterino, vagina y vulva en 
mujeres, sino también produce cáncer de pene en hombres. Tanto hombres como mujeres 
pueden tener verrugas genitales y canceres de ano, boca y garganta por VPH. La vacuna 
contra el VPH puede ayudar a prevenir estos canceres. 
P: ¡Justo recordé que mi jefe dijo que la causa de su cáncer de boca fue lo más probable 
por VPH! 
M: ¡Entonces, hay una buena razón para vacunar a los pre-adolescentes y adolescentes 
ANTES que lleguen a ser sexualmente activos! 
D: Las investigaciones demuestran que el vacunar a los pre-adolescentes y adolescentes 
no los hace más propensos a ser sexualmente activos. Otros estudios muestran que la 
vacuna contra el VPH es extremadamente efectiva al reducir las infecciones causadas por 
el VPH 
M: ¿Ha vacunado usted a sus hijos? 
D: Si. Creo firmemente en la importancia de esta vacuna para prevenir el cáncer. Yo sigo 
las recomendaciones de la Academia Americana de Pediatría (American Academy of 
Pediatrics) y muchos otros expertos. 
P: Bien, vacunemos a Tomás! Estoy convencido que la vacunación contra el VPH es 
importante. 
 
(Los niños escuchan esta afirmación y regresan al área donde los adultos están 
hablando) 
 
S: Tomás tiene que regresar para su segunda dosis de VPH?  
D: Si. 
M: Igual que tú lo hiciste el año pasado. 
T: ¿Entonces, recibo una dosis de la vacuna VPH hoy, y después tengo que regresar para 
otra dosis? 
D: Si. Como tú tienes menos de 15 años, recibes 2 dosis de la vacuna VPH. Recibirás la 
segunda dosis dentro de 6 a 12 meses a partir de ahora. 









D: Si, La vacuna se administra como una serie de 3 dosis a niños que comienzan la serie 
de vacunación VPH a los 15 años o después de esa edad. Para esos adolescentes, la 
segunda dosis se da 1 a 2 meses después de la primera dosis, y la tercera dosis se 
administra 6 meses después de la primera dosis.  
P: ¿Qué pasa si un niño no recibe todas sus dosis? 
D: Igual pueden completar su serie de vacunas. Justamente vi a un adolescente de 16 años 
que tuvo su primera dosis a los 13 años cuando vivía en otro estado. Su papá lo trajo para 
la dosis número 2. 
M: Wow 
D: Esto muestra la recomendación que todos los padres con hijos de 9 a 18 años de edad 
bajo su cuidado hayan completado TODAS las dosis de la serie de vacunación contra el 
VPH. 
M: Pediré una cita para la segunda dosis de VPH de Tomás antes de salir de acá hoy. 
S: ¡Del mismo modo que yo tuve mi segunda dosis! 
M: ¡Si! 
D: ¿Estás listo para tu primer dosis de VPH, Tomás? 
T: ¡Estoy listo! 
  
Página Final: 
Este video llegó a Usted a través de:  
Research Group on Disparities in Health (RGDH) 
Department of Health and Behavior Studies 
Teachers College, Columbia University 
New York, NY 
 
Personas de Contacto:  
Alejandrina Canelo Villafana, MS, (Candidata a Doctorado), Fellow del RGDH 













Screenshots of Video 
 






















































SCREENING TOOL IN ENGLISH FOR IRB PROTOCOL # 19-172 
 
1-Are you at least at least 25 years of age? 
 Yes___ No____ 
 
2-Are you the parent/caregiver or legal guardian of at least ONE child between the ages 
of 9 and 18 years of age? 
Yes___ No____ 
 
3-Are you able to read and understand English on a 12
th
 grade level? 
Yes___ No____ 
 
4-Are you able to devote about 35-40 minutes to this study at this time—for a chance to 
win one of three $100 Amazon gift cards? 
Yes___ No____ 
 




6-Second, are you willing to spend about 5 minutes watching a cartoon video? This 
means using a computer with an Internet connection in a convenient location that will 
allow you to play the cartoon aloud? 
Yes___ No____ 
 
7-Third, after you watch the cartoon, are you willing to rate it and answer a final set of 
questions for about another 5-10 minutes? 
Yes___ No____ 
 
If they answered YES to all of the above questionsà they access survey. 
If they answered NO to any of the above questionsà they receive this message: 
Thank you for your time, but, unfortunately you are not qualified to participate in this study.  
 
Feel free to invite other parents who have children between the ages of 9 to 18 to participate in 















SURVEY FOR PARENTS ON HPV VACCINATION FOR CHILDREN 
 
FOR ENGLISH SPEAKING PARENTS 
(To be translated into Spanish for Spanish Speaking Parents) 
 
Please choose to take this survey and watch a video in English or Spanish 
__I choose English  ___I choose Spanish 
 
Instructions. Please answer the following questions by either placing a check mark next 
to your answer, or filling in the blank space. 
---------------------------------------------------------------------------------------------- 
PART I: PARENT’S BASIC DEMOGRAPHICS (PARENTS-BD-10) 
[NOTE: This is a standard tool commonly used by Research Group on Disparities in 
Health RGDH)] 
1)   MY gender is: ___Female  ___Male ___Other (Please explain________) 
2)  MY age is: _______ (USE DROP DOWN MENU OF 18 to 85) 
3)  MY race/ethnicity is as follows: (Please mark all that apply) 
__Black/African American  
__White / Caucasian / European American 
__Hispanic / Latino (including Dominican, Puerto Rican, Mexican, Mexican American, 
Chicano, Cuban, other Spanish)  
    __Asian (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, or other 
Asian)  
__American Indian / Alaska Native 
__Native Hawaiian / Pacific Islander 
__Arab American / Middle Eastern 
__Other group(s) (Please specify)  
4)  Do you live in the United States? _Yes    _No If NO—EXIT SURVEY 
If yes, what is your current zip code? ¬¬¬_____________________________ 
5) Were you born in the United States?  
If you answered “No,” where was YOUR place of birth or country of origin? 
b-1. Country of_____________________[Drop down menu] 
b-2. And, at what age did YOU come to the US? [Drop down menu 1-70] 
6) I AM currently:  
a. ___Single   b. ___Married c. ___Separated  d. ___Divorced 
e. ___Widowed  f. ___In Domestic Partnership g. ___Living with Significant 
Other 
7). I am currently (check all that apply) 
a.  ____part-time undergraduate student 
b. ____ full-time undergraduate student 
c. ____ part-time graduate student 
d. ____ full-time graduate student 
e. ____employed  










h. ____on Welfare 
i. ____receiving Social Security Income 
j. ____receiving Social Security Disability Income 
k.  ____receiving Worker’s Compensation 
l.  ____retired  
m.  ____Other (please explain________________________) 
8). MY yearly household income is:  
 1-Less than $920,000 
 2-$10,000 to $19,000  
 3-$20,000 to $39,000  
 4-$40,000 to $49,000 
 5-$50,000 to $99,999 
 6-$100,000 to $199,999 
 7-$200,000 to $299,000 
 8-$300,000 to $399,000 
 9-$400,000 to $499,000 
 10-$500,000 to $799,000 
 11-$800,000 or More 
9). MY highest education level is:  
□ Less than high school 
□ High school or high school equivalent (GED) 
□ Some college or a Certificate Program 
□ 2 year college degree (Associates) 
□ 4 year college degree (Bachelor’s) 
□ Masters degree 
□ J.D. - Lawyer 
□ Doctoral Degree (Ph.D., Ed.D, etc.). 
□ Medical Degree (M.D., D.D.S., etc.) 
10) My type of medical insurance is (check all that apply) 
a) Private insurance plan (e.g. Blue Cross/Blue Shield, Aetna, Oxford, etc…) 
b) HMO   c) Medicaid   d) Medicare.. e) Not Applicable, I have no medical insurance 
---------------------------------------------------------------------------------------------- 
PART II: ABOUT YOUR CHILDREN (AYC-4) 
 
1-How many children do you have in your care between the ages of 9 to 18?  
[Drop down menu 0-10]  
2- How many of your children were born [3 Drop down menus 0-10 for each option] 
___Male  ___Female ___Other  
3- How many of your children are [2 Drop down menus 0-10 for each option] 
___heterosexual  ___other sexual orientation (e.g. LGBTQ)  ___I don’t know 
4-Please indicate the types of medical insurance that your children have—and check all 









a) Private insurance plan (e.g. Blue Cross/Blue Shield, Aetna, Oxford, etc…) 
b) HMO    
c) Medicaid 
d) Medicare 
e) Not Applicable, no medical insurance 
----------------------------------------------------------------------------------------------- 
PART III: PARENT REPORT ON PROVIDER RECOMMENDATION ON HPV 
VACCINATION FOR CHILD (PARENT-R-PR-HPV-V-FC-2) 
Has a pediatrician or family practice medical provider ever…. 
1-talked to you about the Human papillomavirus (HPV) infection? __Yes __No __Not 
sure/Don’t know 
HPV2- recommended that your child receive the HPV vaccination? __Yes __No __Not 
sure/Don’t know 
------------------------------------------------------------------------------------------------- 
PART IV: PARENT REPORT ON HPV VACCINATION FOR CHILD (PARENT-
R-HPV-V-FC-1) 
1-Has one or more of your children ever received the HPV vaccination? 
1__Yes 0__No ___I’m not sure  
2-For the HPV vaccination given to your child, please indicate how many doses your 
child received (i.e. returned to medical provider for dose or doses: 
___I’m not sure    ___1 dose   ____2 doses    _____3 doses 
------------------------------------------------------------------------------------------------- 
PART V: PARENT REPORT ON FLU VACCINATION FOR CHILD (PARENT-
R-FLU-V-FC-1) 
[This is a new scale created by the Principal Investigator and her dissertation sponsor, Dr. 
Barbara Wallace, for use by the Research Group on Disparities in Health (RGDH).] 
1-Has one or more of your children ever received the flu vaccination 
1__Yes 0__No I’m not sure 
2-Do you believe in the value of an annual (yearly) flu vaccination for your child? 
1__Yes 0__No I’m not sure 
------------------------------------------------------------------------------------------------- 
PART VI: PARENT EXPOSURE TO PRINT OR OTHER MEDIA OR 
INFORMATION ON HPV VACCINATION FOR CHILDREN (PARENT-EPOMI-
HPV-VFC-1) 
1-Have you ever read anything, or watched a video, or seen anything on television, or 
Facebook, or on the Internet about the Human papillomavirus (HPV) infection and the 
HPV vaccination for children? 
0__No, no information at all   
1__Yes, I was exposed to a very low amount of information 
2_Yes, I was exposed to a low amount of information  
3_Yes, I was exposed to a moderate amount of information 
4_Yes, I was exposed to a large amount of information 
5_Yes, I was exposed to a very large amount of information 










PART VII: HPV GENERAL KNOWLEDGE (HPV-G-K-23) 
[Source: Pérez, S., Tatar, O., Ostini, R., Shapiro, G. K., Waller, J., Zimet, G., & 
Rosberger, Z. (2016). Extending and validating a human papillomavirus (HPV) 
knowledge measure in a national sample of Canadian parents of boys. Preventive 
Medicine, 91, 43-49.]Note. As per Shapiro et al (2018), as recommended by Pérez et al 
(2016), two items from the original General Knowledge scale administration (‘HPV 
usually doesn’t need any treatment’ and ‘HPV can cause herpes’) were deleted from the 
Shapiro et al (2018) study because the psychometric evaluation found that when removed 
the reliability of the scale improved.] 
 
Please indicate whether the following items are True or False, or if you Don’t Know. 
Score 1=true 
1 HPV is very rare  (FALSE)   _T _F _Don’t Know 
2 HPV always has visible signs or symptoms (FALSE) _T _F _Don’t Know 
3 HPV can cause cervical cancer (TRUE) _T _F _Don’t Know 
4 HPV can be transmitted through genital skin-to-skin contact (TRUE) _T _F       
_Don’t Know 
5 There are many types of HPV (TRUE) _T _F _Don’t Know 
6 HPV can cause HIV/AIDS (FALSE – etc……….) _T _F _Don’t Know 
7 HPV can be passed on during sexual intercourse ((TRUE) _T _F _Don’t Know 
8 HPV can cause genital warts (TRUE) _T _F _Don’t Know 
9 Men cannot get HPV (FALSE) _T _F _Don’t Know 
10 Using condoms reduces the chances of HPV transmission (TRUE) _T _F _Don’t 
Know 
11 HPV can be cured with antibiotics (FALSE) _T _F _Don’t Know 
12 Having many sexual partners increases the risk of getting HPV (TRUE) _T _F 
_Don’t Know 
13 Most sexually active people will get HPV at some point in their lives (TRUE) _T 
_F _Don’t Know 
14 A person could have HPV for many years without knowing it (TRUE) _T _F 
_Don’t Know 
15 Having sex at an early age increases the risk of getting HPV (TRUE) _T _F 
_Don’t Know 
16 HPV can cause anal cancer (TRUE) _T _F _Don’t Know 
17 HPV is a bacterial infection (FALSE) _T _F _Don’t Know 
18 HPV can be transmitted through oral sex (TRUE) _T _F _Don’t Know 
19 HPV can cause cancer of the penis (TRUE) _T _F _Don’t Know 
20 HPV can be transmitted through anal sex (TRUE) _T _F _Don’t Know 
21 HPV infections always leads to health problems (FALSE) _T _F _Don’t Know 
22 HPV can cause oral cancer (TRUE) _T _F _Don’t Know 












PART VIII: HPV VACCINE KNOWLEDGE SCALE (HPV-V-K-S-11) 
[Source: Pérez, S., Tatar, O., Ostini, R., Shapiro, G. K., Waller, J., Zimet, G., & 
Rosberger, Z. (2016). Extending and validating a human papillomavirus (HPV) 
knowledge measure in a national sample of Canadian parents of boys. Preventive 
Medicine, 91, 43-49.] 
Note. As per Shapiro et al (2018), in their study’s administration of the Vaccine 
Knowledge Scale, ‘vaccines’ was changed to ‘vaccine’ to make the measure consistently 
in the singular. Slight adaptations were also made to ensure the items were gender-neutral 
(rather than directed at parents of males only) and updated based on policy 
recommendations and current generation vaccines. 
NOTE: Questions # 10 and 11 were specific to Canada, being deleted and replaced with 
new items # 10 and #11] 
 
Please indicate whether the following items are True or False, or if you Don’t Know. 
Score 1=true 
 
1-The HPV vaccine requires at least 2 doses (TRUE) _T _F _Don’t Know 
2-The HPV vaccines offers protection against all sexually transmitted infections (FALSE, 
etc) _T _F _Don’t Know 
3-The HPV vaccines are most effective if given to people who’ve never had sex (TRUE) 
_T _F _Don’t Know 
4-Someone who has had the HPV vaccine cannot develop cervical cancer (FALSE) _T 
_F _Don’t Know 
5-The HPV vaccines offer protection against cervical cancers (TRUE) _T _F _Don’t 
Know 
6-The HPV vaccine offers protection against genital warts (TRUE) _T _F _Don’t Know 
7-Girls who have had an HPV vaccine do not need a Pap test when they are older 
(FALSE) _T _F _Don’t Know 
8-The HPV vaccine protects you from every type of HPV (FALSE) _T _F _Don’t Know 
9-You can cure HPV by getting the HPV vaccine (FALSE) _T _F _Don’t Know 
10-HPV vaccination is most effective when given to preteens and teens before they 
become sexually active (TRUE) _T _F _Don’t Know 
11-Sexually active individuals can still benefit from getting the HPV vaccines  (TRUE) 
_T _F _Don’t Know 
 
----------------------------------------------------------------------------------------------- 
PART IX: GENERAL VACCINE ATTITUDES—CONSPIRACY BELIEFS, AND 
HESITANCY DUE TO LACK OF CONFIDENCE  
OR RISKS (GVA-CB-HLC-R-16) 
[Sources: 1 Shapiro GK, Holding A, Pérez S, Amsel R, Rosberger Z. (2016). Validation 
of the vaccine conspiracy belief scale. Papillomavirus Research 2016; 2: 167-72.  
2 Shapiro GK, Tatar O, Dube E, et al. (2018) The Vaccine Hesitancy Scale: Psychometric 









Note. * One item from the original scale (‘immunizing children is harmful and this fact is 
covered up’) was modified slightly in the Shapiro et al (2016) study’s administration (to 
‘negative vaccination effects are covered up’) as this was a double-barrelled question. (R) 
Indicates items that were reverse coded.] 
[Note: Each of the three subscales, A, B, or C is scored 1 to 5, as follows] 
Please answer the following questions, using this rating scale (Note: likert scale options 
to appear under every question, below in qualtrics version): 
1__strongly disagree   2__disagree   3__somehwhat disagree 
4__neutral 5__somewhat agree . 6__agree   7. __strongly agree 
 
(A) VACCINE CONSPIRACY BELIEFS SUBSCALE 1 
1-Vaccine safety data is often fabricated 1 2 3 4 5 6 7 
2-Negative vaccination effects are covered up * 1 2 3 4 5 6 7 
3-Pharmaceutical companies cover up the dangers of vaccines 1 2 3 4 5 6 7 
4-People are deceived about vaccine efficacy 1 2 3 4 5 6 7 
5-Vaccine efficacy data is often fabricated 1 2 3 4 5 6 7 
6-People are deceived about vaccine safety 1 2 3 4 5 6 7 
7-The government is trying to cover up the link between vaccines and autism. 1 2 3 4 5 6 
7 
(B) VACCINE HESITANCY SUBSCALE—LACK OF CONFIDENCE 2 
1-Childhood vaccines are important for my child’s health (R=Reverse Coded) 1 2 3 4 5 6 
7 
2-Childhood vaccines are effective (R) 1 2 3 4 5 6 7 
3-Having my child vaccinated is important for the health of others in my 
 community (R) 1 2 3 4 5 6 7 
4-All childhood vaccines offered by the government program in my  
community are beneficial (R) 1 2 3 4 5 6 7 
5-The information I receive about vaccines from the vaccine program is  
reliable and trustworthy (R) 1 2 3 4 5 6 7 
6-Getting vaccines is a good way to protect my child/children from disease (R) 1 2 3 4 5 
6 7 
7-Generally I do what my doctor or health care provider recommends about  
vaccines for my child/children (R) 1 2 3 4 5 6 7 
 
(C) VACCINE HESITANCY SUB-SCALE—RISKS 1 
1-I am concerned about serious adverse effects of vaccines 1 2 3 4 5 6 7 
2-New vaccines carry more risks than older vaccines 1 2 3 4 5 6 7 
----------------------------------------------------------------------------------------------- 
PART X: PARENTS’ PERCEIVED BARRIERS TO CHILD’S COMPLETION OF 
THE HPV VACCINATION SERIES (PARENTS-PB-CC-HPV-VS-12) 
[This is a new scale created in 2018 for use by the Research Group on Disparities in 
Health (RGDH). This is scored as a continuous scale of 0-12, where 0= no barriers and 










Please think about ALL of your children and indicate if you have experienced any of the 
following barriers or obstacles or challenges that have prevented you from having any of 
your children vaccinated with the HPV vaccine. Please select Yes or No, as your answer 
 
1. __ not knowing how often I should take my child (whether once, twice or three 
times)__YES (1) __NO (0) 
2. __ not knowing where to take my child __YES (1) __NO (0) 
3. __ a lack of insurance  __YES (1) __NO (0) 
4. __ a lack of finances/money __YES (1) __NO (0) 
5. __ a lack of time, or other demands on my time __YES (1) __NO (0) 
6. __ my work schedule __YES (1) __NO (0) 
7. __ my own health issues (physical or mental) __YES (1) __NO (0) 
8. __ the health issues (physical or mental) of others (e.g. other children,    
           husband/partner, babysitter, other family, my parents, etc) __YES (1) __NO (0) 
9. __ stress in my life __YES (1) __NO (0) 
10. __language—due to having a provider not communicating in my preferred 
language __YES (1) __NO (0) 
11. __cultural barriers—due to having a provider not understanding my culture, or not 
being culturally sensitive and appropriate __YES (1) __NO (0) 
12. __ other/something else has been an obstacle/barrier for me (Please indicate in the 
space, below) __YES (1) __NO (0) Explain__________________________ 
------------------------------------------------------------------------------------------------- 
PART XI: MORE ABOUT YOU (SOCIAL DESIRABILITY) (MAY-13) 
same as all prior analyses this year 
Read each item below and decide whether the statement is true or false as it pertains to 
you personally. Circle T for True or F for false. 
1. It is sometimes hard for me to go on with my work if I am not encouraged.  T  F 
2. I sometimes feel resentful when I don’t get my way.     T  F 
3. On a few occasions, I have given up doing something because I thought  
too little of my ability.         T  F 
4. There have been times when I felt like rebelling against people in authority even 
though I knew they were right.       T  F 
5. No matter who I’m talking to, I’m always a good listener.   T  F 
6. There have been occasions when I took advantage of someone.   T  F 
7. I’m always willing to admit it when I make a mistake.    T  F 
8. I sometimes try to get even rather than forgive and forget.   T  F 
9. I am always courteous, even to people who are disagreeable   T  F 
10. I have never been irked when people expressed ideas very different from  
my own.          T  F 
11. There have been times when I was quite jealous of the good fortune of  
others.           T  F 
12. I am sometimes irritated by people who ask favors of me.   T  F 









“GO TO <LINK> to take the African American Women’s Breast Cancer Survivors’ 




PART XII: PRE-VIDEO PARENTS’ HPV KNOWLEDGE AND STAGE OF 
CHANGE AND SELF-EFFICACY FOR TALKING TO PROVIDERS AND 
CHILD RECEIVING THE HPV VACCINE (PRE-V-PARENTS-HPV-K-SOC-SE-
FTP-CR-HPV-V-7) 
[This is a new scale created by the Principal Investigator and her dissertation sponsor, Dr. 
Barbara Wallace, for use by the Research Group on Disparities in Health (RGDH).  
The scale provides a continuous score for the sub-scales of: (1) self-rating of level of 
HPV knowledge [K-item # 1]; (2) stage of change for performing the HPV-related 
behaviors indicated [SOC-items # 2, 4, 6], and (3) self-efficacy for performing the HPV-
related behaviors indicated [SE-items # 3, 5, 7]] 
 
1-Please rate what you know, or your level of knowledge about the Human 
papillomavirus (HPV) infection HPV, and the HPV vaccination for children: 
 
Very Poor Poor Fair Good Very Good Excellent 
1 2 3 4 5 6 
 
Please rate yourself for the behavior of talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection HPV, and the HPV 
vaccination for children – by checking what best describes you, below: 
2-For doing this 
1_____I am not thinking of doing this behavior at all. 
2_____I am thinking about doing this behavior. 
3_____I am preparing to do this behavior. 
4_____I have been doing this behavior for less than six (6) months. 
5_____I have been doing this behavior for more than six (6) months up to many   
          years 
_____I cannot answer, because I do not know enough about the HPV vaccination  
3-And, for doing this I am 
1____0% confident                2____20% confident              3  ____40% confident  
4____60% confident             5____80% confident                6 ____100% confident  
_____I cannot answer, because I do not know enough about the HPV vaccination 
 
NOTE: ITEM # 4 action and maintenance stages (less than 6 months and more than 6 
months up to many year) = Study # 1 Dependent Variable: 
Please rate yourself for the behavior of making sure your children receive the HPV 
vaccination– by checking what best describes you, below: 










_____I am not thinking of doing this behavior at all. 
_____I am thinking about doing this behavior. 
_____I am preparing to do this behavior. 
_____I have been doing this behavior for less than six (6) months. 
_____I have been doing this behavior for more than six (6) months up to many   
          years 
_____I cannot answer, because I do not know enough about the HPV vaccination 
5- And, for doing this I am 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident  
_____I cannot answer, because I do not know enough about the HPV vaccination 
 
Please rate yourself for the behavior of making sure your child receives all the required 
doses (e.g. at least 2 or 3 doses) of the HPV vaccination – by checking what best 
describes you, below: 
6-For doing this 
_____I am not thinking of doing this behavior at all. 
_____I am thinking about doing this behavior. 
_____I am preparing to do this behavior. 
_____I have been doing this behavior for less than six (6) months. 
_____I have been doing this behavior for more than six (6) months up to many   
          years 
_____I cannot answer, because I do not know enough about the HPV vaccination  
7- And, for doing this I am 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident 




PARENTS PLEASE CLICK ON THE LINK TO WATCH THE CARTOON  
(for approximately 5 minutes) 
 
************************************************************* 
PART XIII: POST-VIDEO VIEWING ADHERENCE SURVEY FOR 
PROVIDERS (PVV-AS-PROVIDERS– 1) 
[This is a common scale used by the Research Group on Disparities in Health (RGDH).] 
 
Answer the following questions, please: 
1-How much of the video was watched? 











PART XIV: POST-VIDEO PARENTS’ HPV KNOWLEDGE AND STAGE OF 
CHANGE AND SELF-EFFICACY FOR TALKING TO PROVIDERS AND 
CHILD RECEIVING THE HPV VACCINE (PRE-V-PARENTS-HPV-K-SOC-SE-
FTP-CR-HPV-V-7) 
[See description under PART XII. This is the same scale, but for post-video] 
 
1-Please rate what you know, or your level of knowledge about the Human 
papillomavirus (HPV) infection, and the HPV vaccination for children: 
 
Very Poor Poor Fair Good Very Good Excellent 
1 2 3 4 5 6 
 
Please rate yourself for the behavior of talking to a pediatrician or family practice 
medical provider about the Human papillomavirus (HPV) infection, and the HPV 
vaccination for children – by checking what best describes you, below: 
2-For doing this 1-5 
_____I am not thinking of doing this behavior at all. 
_____I am thinking about doing this behavior. 
_____I am preparing to do this behavior. 
_____I have been doing this behavior for less than six (6) months. 
_____I have been doing this behavior for more than six (6) months up to many years 
_____I cannot answer, because I do not know enough about the HPV vaccination  
3-And, for doing this I am 1-6 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident  
_____I cannot answer, because I do not know enough about the HPV vaccination 
 
Please rate yourself for the behavior of making sure your children receive the HPV 
vaccination– by checking what best describes you, below: 
4-For doing this  
_____I am not thinking of doing this behavior at all. 
_____I am thinking about doing this behavior. 
_____I am preparing to do this behavior. 
_____I have been doing this behavior for less than six (6) months. 
_____I have been doing this behavior for more than six (6) months up to many years 
_____I cannot answer, because I do not know enough about the HPV vaccination 
5- And, for doing this I am 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident  
_____I cannot answer, because I do not know enough about the HPV vaccination 
 
Please rate yourself for the behavior of making sure your child receives all the required 
doses (e.g. at least 2 or 3 doses) of the HPV vaccination – by checking what best 









6-For doing this 
_____I am not thinking of doing this behavior at all. 
_____I am thinking about doing this behavior. 
_____I am preparing to do this behavior. 
_____I have been doing this behavior for less than six (6) months. 
_____I have been doing this behavior for more than six (6) months up to many years 
_____I cannot answer, because I do not know enough about the HPV vaccination 
7- And, for doing this I am 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident 
_____I cannot answer, because I do not know enough about the HPV vaccination 
------------------------------------------------------------------------------------------------------------ 
PART XV: RATE THE VIDEO FOR PARENTS (RTV-PARENTS-2) 
[This is a common scale used by the Research Group on Disparities in Health (RGDH).] 
 
Please think about the cartoon video you were asked to watch, and please rate the video: 
1. I rate the video as follows: 
Very Poor Poor Fair Good Very Good Excellent 
1 2 3 4 5 6 
___I feel unable to rate the video - I was not able to watch all the video 
------------------------------------------------------------------------------------------------------------ 
PART XVI: DIFFUSION OF INNOVATION USING E-HEALTH ON HPV BY 
PARENTS (DOF-UEH-HPV-PARENTS-1) 
[This is a common scale used by the Research Group on Disparities in Health (RGDH).] 
Score 1=yes 
1. Would you recommend this video to other parents with children? 
__Yes __No  ______I feel unable to offer a recommendation – as I was not able to watch 
all the video 
------------------------------------------------------------------------------------------------------------ 
PART XVII: QUALITATIVE PORTION ON REASONS FOR REOMMENDING 
THE E-HEALTH VIDEO OR NOT—FOR PARENTS (QP-RREHV-PARENTS-1) 
[This is a common scale used by the Research Group on Disparities in Health (RGDH).] 
 
1- Please explain why you would or would not recommend the video. Feel free to offer 
your comments on the strengths and weaknesses of the video, or how could it be 
improved. 
___I feel unable to comment on the video – as I was not able to watch all the video 















PART XVIII: QUALITATIVE PORTION ON REACTIONS TO STUDY 
PARTICIPATION BY PARENTS (QP-RSP-PARENTS-1) 
[This is a new question created by the Principal Investigator and her dissertation sponsor, 
Dr. Barbara Wallace, for use by the Research Group on Disparities in Health (RGDH).] 
 
1-What thoughts or feelings might you share in response to watching the video and/or 

























SCREENING TOOL IN SPANISH FOR IRB PROTOCOL # 19-172 
Herramienta de evaluación para padres que hablan español  
1- ¿Tiene usted al menos 25 años de edad? 
Si___ No____ 
2-  ¿Es usted padre/madre, cuidador/a o tutor/a legal de algún niño/a que tenga entre 9 y 18 años 
de edad? 
Si___ No____ 
3-¿Puede usted leer y entender inglés al nivel de 12° grado?  
Si___ No____ 
4-¿Dispone usted de 35 a 40 minutos para participar en este estudio en este momento y tener la 
posibilidad de ganar una de las tres tarjetas de regalo por $100 de Amazon? 
Si___ No____ 
5-¿Más específicamente, en primer lugar, podrá disponer de 20 a 25 minutos de su tiempo para 
contestar una serie de preguntas? 
Si___ No____ 
6-Segundo, ¿está usted dispuesto a pasar unos 5 minutos viendo un video animado? Para ello se 




7-Tercero, después de ver el video, ¿estaría dispuesto a calificarlo y contestar una serie de 




Si respondieron SÍ a todas las preguntas anteriores, acceden a la encuesta. Si contestaron NO a 
cualquiera de las preguntas anteriores, reciben este mensaje: Gracias por su tiempo, pero 
desafortunadamente no está calificado para participar en este estudio. 
 
Siéntase en la libertad de invitar a otros padres  que tengan niños entre las edades de 9 a 18 años 










ENCUESTA PARA PADRES SOBRE LA VACUNACIÓN DEL VPH PARA 
NIÑOS 
PARA PADRES EN ESPANOL 
 
Por favor, elija tomar esta encuesta y ver un video en inglés o español. 
__Elijo inglés ___Elijo español 
 
Instrucciones. Por favor responda a las siguientes preguntas colocando una  marca de verificación a 
continuación 
----------------------------------------------------------------------------------------------- 
PARTE I: INFORMACION DEMOGRAFICA BASICA DE LOS PADRES 
(PADRES-BD-10) 
1- Soy:      A. Mujer     B. Hombre     C. Otro (Por favor explique________) 
2- Mi edad es: _______  (UTILIZE EL MENÚ DE DESCENSO DE 18 A 85)  
3- Mi raza u origen étnico es:  
(Por favor marcar todas las opciones adecuadas)  
 Negra    Afro descendente  
 Blanca   Caucásico/a   Europeo descendente 
 Hispano    Latino (incluyendo Dominicano, Puertorriqueño, Mejicano,  
Mejicano Americano, Chicano,  Cubano, otro Latinos) 
 Asiática (Indo asiático, Chino, Filipino, Japonés, Koreano, Vietnames, u otro 
origen asiático)   
 Nativo Americano  Nativo de Alaska 
 Hawaiano nativo    de las Islas del Pacifico 
 Árabe   Medio oriente 
 Otra raza/ tipo étnico (Por favor, explique)   _____________________ 
4- ¿Vive usted en los Estados Unidos? _Si _No, Si respondió NO — POR FAVOR   
SALGA DE LA ENCUESTA 
SI respondió SI, indique su código postal_________ 
5- ¿Nació usted en los Estados Unidos? _Si _No 
Si respondió “No”, ¿Cuál fue su lugar de nacimiento o país de origen? 
b-1. País de _____________________ [Menú desplegable] 
b-2. ¿Y a qué edad vino usted a los Estados Unidos? [UTILIZE EL MENÚ DE 
DESCENSO 1-70] 
6- Ahora estoy: A.  Soltero/a        B.   Casado/a         
C.  Separado/a       D.  Divorciado/a         E. Viudo/a         F.  Compañero/a 
doméstico (En pareja de hecho)  G.  Viviendo con mi pareja        
H.  Otra forma (Explicar) ________________________ 
7- Estoy actualmente (marque todas las opciones que correspondan): 
a. Estudiante de tiempo parcial en la universidad  
b. Estudiante dedicación completa en la universidad  










d. Estudiante dedicación completa en la Maestría de la universidad o 
Maestría pos graduado. 
e. Empleado 
f. Desempleado 
g. Ama de casa  
h. Recibe planes de Welfare (bienestar social del gobierno) 
i. Recibe planes sociales SSI (subsidio de seguro social) 
j. Recibe planes sociales SSD (subsidio o seguro social por discapacidad) 
k. Compensación de trabajador/a  
l. Jubilado 
m. Otro (por favor especifique) _______________________________ 
8- El ingreso total de toda la familia anual: 
1- Menos de $9,000  
2- $10,000  to  $19,000 
3- $20,000  to  $39,000 
4- $40,000  to  $49,000 
5- $50,000  to  $99,999 
6- $100,000 to $199,999 
7- $200,000 to $299,000 
8- $300,000 to $399,000 
9- $400,000 to $499,000 
10- $500,000 to $799,000 
11- $800,000 o Más 
9- Mi nivel más alto de educación es: 
  Escuela secundaria incompleta. 
  Escuela superior o escuela secundaria o terciaria o su equivalente (GED, etc…) 
completa. 
  La universidad no completada o título técnico. 
  Universidad o título técnico incompleto. 
  Grado asociado (2 años de duración en la universidad).  
  Bachillerato de la universidad o Licenciatura de 4 años o más de la 
universidad.  
  Maestría de la universidad o Maestría pos graduado.  
  Doctor en Jurisprudencia - Abogado (J.D.). 
  Doctorado (Ph.D., Ed.D, etc.) o (filosofía, educación, ciencias sociales, 
ciencias). 
  Doctorado de Medicina  (M.D., D.D.S., .D.O. etc.). 
 
10-  Mi tipo de seguro de salud o seguro médico es (marque todas las opciones que 
correspondan) 
a) Plan de seguro privado (por ejemplo, Blue Cross / Blue Shield, Aetna, Oxford, 
etc.) 










PARTE II: CUESTIONARIO SOBRE SUS HIJOS (AYC-4) 
[Este es un formulario nuevo creado por la Investigadora Principal y su Directora de 
Investigación, Dra. Barbara Wallace, para ser usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
1- ¿Cuántos hijos de 9 a 18 años tiene bajo su responsabilidad? 
 [Abra el menú de opciones 0-10]  
2- ¿Cuántos de sus hijos nacieron: [Abra el menú 1, 2, o 3 y marce la opción de 0-10] 
___Sexo masculino  ___Sexo femenino ___Otro 
3- ¿Cuántos de sus hijos son: [Abra el menú 1, 2, o 3 y marce la opción de 0-10] 
___heterosexuales  ___otra orientación sexual (ejemplo: LGBTQ)  ___No lo sé 
4-Por favor indique el tipo de cobertura médica que tienen sus hijos - y marque todas las 
que correspondan para todos sus hijos entre las edades de 9 y 18 años) 
a) Plan privado de cobertura (por e j. Blue Cross/Blue Shield, Aetna, Oxford, etc…) 
b) HMO    
c) Medicaid 
d) Medicare 
e) No corresponde, sin cobertura médica 
----------------------------------------------------------------------------------------------- 
PARTE III: CUESTIONARIO A LOS PADRES SOBRE LAS 
RECOMENDACIONES DEL PROVEEDOR DE SERVICIOS MEDICOS SOBRE 
LA VACUNA CONTRA EL VPH PARA SUS HIJOS (PARENT-R-PR-HPV-V-FC-
2) 
[Este es un formulario nuevo creado por la Investigadora Principal y su Directora de 
Investigación, Dra. Barbara Wallace, para ser usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
 
Un pediatra o médico de familia alguna vez… 
1-¿le habló sobre la infección por el virus del papiloma humano (VPH)? __Si __No 
 __No estoy seguro/a. No lo sé 
2-¿le recomendó que su hijo reciba la vacuna contra el VPH? __Si __No __No estoy 
seguro/a. No lo sé 
------------------------------------------------------------------------------------------------- 
PARTE IV: CUESTIONARIO A LOS PADRES SOBRE LA VACUNA CONTRA 
EL VPH PARA SUS HIJOS (PARENT-R-HPV-V-FC-1) 
[Este es un formulario nuevo creado por la Investigadora Principal y su Directora de 
Investigación, Dra. Barbara Wallace, para ser usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
  
1-Uno o más de sus hijos han recibido alguna vez la vacuna contra el VPH? 
__Si __No ___No estoy seguro/a 
2- Para la vacuna que recibió su hijo/a, por favor indique cuántas dosis recibió su hijo/a 
(por ejemplo si regresó a su proveedor de salud para otra u otras dosis: 










PARTE V: CUESTIONARIO A LOS PADRES SOBRE LA VACUNA CONTRA 
LA INFLUENZA PARA SUS HIJOS (PARENT-R-FLU-V-FC-1) 
[Este es un formulario nuevo creado por la Investigadora Principal y su Directora de 
Investigación, Dra. Barbara Wallace, para ser usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
1-¿Uno o más de sus hijos han recibido alguna vez la vacuna contra la influenza? 
__Si __No ___No estoy seguro/a 
2-¿Cree Usted en la importancia de vacunar anualmente (una vez al año) a sus hijos? 
__Si __No ___No estoy seguro/a 
------------------------------------------------------------------------------------------------- 
PARTE VI: ACCESO DE LOS PADRES A INFORMACIÓN EN MEDIOS DE 
COMUNICACIÓN O IMPRESA SOBRE LA VACUNA CONTRA EL HPV PARA 
NIÑOS (PARENT-EPOMI-HPV-VFC-1) 
[Este es un formulario nuevo creado por la Investigadora Principal y su Directora de 
Investigación, Dra. Barbara Wallace, para ser usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
 
1-¿Alguna vez leyó, miró un video o vio algo en televisión o Facebook o en Internet 
sobre la infección por el virus del papiloma humano (VPH) y la vacuna contra el VPH 
para niños? 
0__No, ningún tipo de información 
1__Si, recibí muy poca información 
2__Si, recibí poca información 
3__Si, recibí una cantidad moderada de información 
4__Si, recibí mucha información 
5__Si, recibí una gran cantidad de información 
 __No corresponde - No estoy seguro/a de haber recibido alguna información  
--------------------------------------------------------------------------------------------------------- 
PARTE VII: CONOCIMIENTOS GENERALES SOBRE EL VPH (HPV-G-K-23) 
[Source: Pérez, S., Tatar, O., Ostini, R., Shapiro, G. K., Waller, J., Zimet, G., & 
Rosberger, Z. (2016). Extending and validating a human papillomavirus (HPV) 
knowledge measure in a national sample of Canadian parents of boys. Preventive 
Medicine, 91, 43-49.]Note. As per Shapiro et al (2018), as recommended by Pérez et al 
(2016), two items from the original General Knowledge scale administration (‘HPV 
usually doesn’t need any treatment’ and ‘HPV can cause herpes’) were deleted from the 
Shapiro et al (2018) study because the psychometric evaluation found that when removed 
the reliability of the scale improved.]  
Por favor indique si las siguientes declaraciones son verdaderos o falsos o si no lo sabe. 
1 El VPH  es muy raro (FALSO)   _V _F _No lo sé 
2 El VPH  siempre presenta signos y síntomas visibles (FALSO)   _V _F _No lo sé 
3 El VPH  puede causar cáncer cervical (VERDADERO)  _V _F _No lo sé 
4 El VPH  puede transmitirse por contacto genital de piel a piel (VERDADERO)  









5 Hay muchos tipos de  VPH  (VERDADERO)  _V _F _No lo sé 
6 El  VPH  puede causar HIV/SIDA (FALSO) _V _F _No lo sé 
7 El  VPH  se puede transmitir durante las relaciones sexuales (VERDADERO)  _V 
_F _No lo sé  
8 El  VPH  puede producir verrugas genitales (VERDADERO)  _V _F _No lo sé 
9 Los hombres no se infectan con el  VPH  (FALSO) _V _F _No lo sé 
10 El uso de preservativo disminuye la posibilidad de contagio por  VPH 
(VERDADERO)  _V _F _No lo sé 
11 El  VPH se puede curar con antibióticos (FALSO)  _V _F _No lo sé 
12 Tener múltiples parejas sexuales incrementa el riesgo de contagio por  VPH  
(VERDADERO)  _V _F _No lo sé 
13 La mayoría de las personas sexualmente activas contraerán el VPH en algún 
momento de su vida (VERDADERO)  _V _F _No lo sé 
14 Una persona puede tener el VPH durante varios años sin saberlo (VERDADERO)  
_V _F _No lo sé 
15 Tener relaciones sexuales a edad temprana aumenta el riesgo de tener el VPH  
(VERDADERO)  _V _F _No lo sé 
16 El  VPH  puede causar cáncer anal (VERDADERO)  _V _F _No lo sé 
17 El VPH es una infección bacteriana (FALSO)  _V _F _No lo sé  
18 El VPH  se puede transmitir por sexo oral (VERDADERO)  _V _F _No lo sé 
19 El VPH  puede causar cáncer de pene (VERDADERO)  _V _F _No lo sé 
20 El VPH  se puede transmitir por sexo anal (VERDADERO)  _V _F _No lo sé 
21 La infección por  VPH  siempre causa problemas de salud (FALSO)  _V _F _No 
lo sé 
22 El  VPH  puede causar cáncer de boca (VERDADERO)  _V _F _No lo sé 
23 Una persona que no tiene síntomas no puede transmitir la infección por  VPH 




PARTE VIII: MEDICION DEL CONOCIMIENTO SOBRE LA VACUNA 
CONTRA EL VPH (HPV-V-K-S-11) 
[Source: Pérez, S., Tatar, O., Ostini, R., Shapiro, G. K., Waller, J., Zimet, G., & 
Rosberger, Z. (2016). Extending and validating a human papillomavirus (HPV) 
knowledge measure in a national sample of Canadian parents of boys. Preventive 
Medicine, 91, 43-49.] 
Note. As per Shapiro et al (2018), in their study’s administration of the Vaccine 
Knowledge Scale, ‘vaccines’ was changed to ‘vaccine’ to make the measure consistently 
in the singular. Slight adaptations were also made to ensure the items were gender-neutral 
(rather than directed at parents of males only) and updated based on policy 
recommendations and current generation vaccines. 
NOTE: Questions # 10 and 11 were specific to Canada, being deleted and replaced with 










Por favor indique si las siguientes declaraciones son verdaderos o falsos o si no lo sabe. 
 
1-La vacuna contra el VPH requiere al menos 2 dosis (VERDADERO)  _V _F _No lo sé 
2-La vacuna contra el VPH protege contra todas las enfermedades de transmisión sexual 
(FALSO)  _V _F _No lo sé 
3-La vacuna contra el VPH es más efectiva si se administran a personas que nunca han 
tenido relaciones sexuales (VERDADERO)  _V _F _No lo sé 
4-Si alguien recibe la vacuna contra el VPH no puede desarrollar cáncer cervical 
(FALSO)  _V _F _No lo sé 
5-La vacuna contra el VPH protege contra el cáncer cervical (VERDADERO)  _V _F 
_No lo sé 
6- La vacuna contra el VPH protege de las verrugas genitales (VERDADERO)  _V _F 
_No lo sé 
7-Las niñas que han recibido una vacuna contra el VPH no necesitan hacerse la prueba 
del Pap cuando sean mayores (FALSO)  _V _F _No lo sé 
8- La vacuna contra el VPH lo protege contra todos los tipos de HPV (FALSO)  _V _F 
_No lo sé 
9-La infección por VPH se puede curar con la vacuna contra el HPV (FALSO)  _V _F 
_No lo sé 
10- La vacuna contra el VPH es más efectiva si se administra a preadolescentes y 
adolescentes antes que sean sexualmente activos (VERDADERO)  _V _F _No lo sé 
11-Las personas sexualmente activas se pueden beneficiarse de recibir la vacuna contra el 
VPH (VERDADERO)  _V _F _No lo sé  
 
----------------------------------------------------------------------------------------------- 
PARTE IX: ACTITUDES GENERALES FRENTE A LA VACUNA__ 
CREENCIAS CONSPIRATIVAS, DUDAS POR FALTA DE CONFIANZA O 
RIESGOS (GVA-CB-HLC-R-16) 
[Sources: 1 Shapiro GK, Holding A, Pérez S, Amsel R, Rosberger Z. (2016). Validation 
of the vaccine conspiracy belief scale. Papillomavirus Research 2016; 2: 167-72.  
2 Shapiro GK, Tatar O, Dube E, et al. (2018) The Vaccine Hesitancy Scale: Psychometric 
properties and validation. Vaccine 2018; 36: 545-52. 
Note. * One item from the original scale (‘immunizing children is harmful and this fact is 
covered up’) was modified slightly in the Shapiro et al (2016) study’s administration (to 
‘negative vaccination effects are covered up’) as this was a double-barrelled question. (R) 
Indicates items that were reverse coded.] 
[Note: Each of the three subscales, A, B, or C is scored 1 to 5, as follows]  
 
Por favor, conteste las preguntas a continuación usando la siguiente escala de medición 
(Nota: las opciones de la escala Likert aparecen debajo de cada pregunta, más abajo en la 
versión qualtrics): 
1__totalmente en desacuerdo  2__en desacuerdo   3__parcialmente en desacuerdo 










(A) SUBESCALA1 SOBRE CREENCIAS CONSPIRATIVAS A CERCA DE LA 
VACUNA 
1-Los datos de seguridad de las vacunas muchas veces son inventados 1 2 3 4 5 6 7 
2-Los efectos negativos de las vacunas se ocultan* 1 2 3 4 5 6 7 
3-Las empresas farmacéuticas ocultan los peligros de las vacunas 1 2 3 4 5 6 7 
4-La gente es engañada a cerca de la eficacia de las vacunas 1 2 3 4 5 6 7 
5-La información sobre eficacia de las vacunas muchas veces es inventada 1 2 3 4 5 6 7 
6- La gente es engañada a cerca de la seguridad de las vacunas 1 2 3 4 5 6 7 
7-El gobierno está tratando de ocultar la relación entre las vacunas y el autismo 1 2 3 4 5 
6 7 
 
(B) SUBESCALA SOBRE DUDAS__FALTA DE CONFIANZA HACIA LA 
VACUNA2 
1-Las vacunas en la niñez son importantes para la salud de mis hijos (R=código reverso/ 
opuesto) 1 2 3 4 5 6 7 
2-Las vacunas en la niñez son efectivas (R) 1 2 3 4 5 6 7 
3-Es importante para la salud de otros en mi comunidad que mi hijo/a esté vacunado (R) 
1 2 3 4 5 6 7 
4-Todas las vacunas para la niñez que ofrece el programa del gobierno en mi comunidad 
son beneficiosas (R) 1 2 3 4 5 6 7 
5-La información que recibo del programa de vacunación sobre las vacunas es segura y 
confiable (R) 1 2 3 4 5 6 7 
6-Vacunar a mis hijos es una buena manera de protegerlos de enfermedades (R) 1 2 3 4 5 
6 7 
7-Generalmente hago lo que mi médico o proveedor de salud me recomienda a cerca de 
las vacunas para mis hijos (R) 1 2 3 4 5 6 7 
 
(C) SUBESCALA SOBRE DUDAS__RIESGOS DE LA VACUNA 1 
1-Estoy preocupado/a por los graves efectos adversos de las vacunas 1 2 3 4 5 6 7 
2-Las nuevas vacunas presentan más riesgos que las vacunas de antes 1 2 3 4 5 6 7 
----------------------------------------------------------------------------------------------- 
PARTE X: BARRERAS PERCIBIDAS POR LOS PADRES PARA COMPLETAR LA 
SERIE DE VACUNACION CONTRA EL VPH(PARENTS-PB-CC-HPV-VS-12) 
[This is a new scale created in 2018 for use by the Research Group on Disparities in 
Health (RGDH). This is scored as a continuous scale of 0-12, where 0= no barriers and 
12=highest barriers. This version added items on language and culture.] 
 
Por favor, piense en TODOS sus hijos e indique si usted ha experimentado alguna de las 
siguientes barreras u obstáculos o desafíos que le han impedido de vacunar a alguno de 
sus hijos con la vacuna contra el VPH. Por favor seleccione Si o No, como su respuesta  
 
1.13. __ no saber con qué frecuencia debo traer a mi hijo (ya sea una, dos o tres veces) 
__SI (1) __NO (0) 









3.15. __ falta de seguro medico __ SI (1) __NO (0) 
4.16. __ falta de subsidio/dinero __ SI (1) __NO (0) 
5.17. __ falta de tiempo, o otras exigencias en mis horarios __ SI (1) __NO (0) 
6.18. __ mi horario de trabajo __ SI (1) __NO (0) 
7.19. __ problemas con mi salud (física o mental) __ SI (1) __NO (0) 
8.20. __ problemas de salud (física o mental) de otros (ej. otros hijos, esposo/pareja, 
niñera, otro familiar, mis padres, etc. __ SI (1) __NO (0) 
9.21. __ Estrés en mi vida __ SI (1) __NO (0) 
10.22. __idioma—debido a que mi proveedor de salud no se comunica en mi idioma 
preferido __SI (1) __NO (0) 
11.23. __barreras culturales—debido a que mi proveedor de salud no entiende mi cultura 
o no es culturalmente sensible y adecuado __SI (1) __NO (0) 
12.24. __ otro/algo más que ha sido un obstáculo/barrera para mí (por favor indicar en el 
espacio abajo) __SI (1) __NO (0) 
Explique_______________________________________________ 
----------------------------------------------------------------------------------------------------------- 
PARTE XI: MAS A CERCA DE USTED. (SOCIALMENTE DESEABLE) (MAY-
13) 
[Using a short form, arising from the original work of: Crowne, D. and Marlowe, D. 
(1960). A new scale of social desirability independent of psychopathology. Journal of 
Consulting Psychology, 24(4):349‐354. More details will be presented in dissertation] 
  
Lea cada declaración abajo y decida si la frase es verdadera o falsa en relación a usted. 
Marcar con un círculo la V para Verdadero y la F para Falso 
1. A veces es difícil para mí continuar con mi trabajo si no estoy motivado V  F 
2. A veces me siento resentido cuando no tengo lo que quiero (cuando no me salgo con la 
mía)           V  F 
3. En pocas ocasiones, me dí por vencido porque pensé que tenía poca capacidad 
           V  F 
4. Ha habido ocasiones en la que me sentí con ganas de rebelarme contra personas de 
autoridad aunque yo sabía que ellos tenían razón.     V  F 
5. No importa con quien hable, siempre soy bueno escuchando   V  F 
6. Ha habido ocasiones en las que me aproveché de alguien   V  F 
7. Siempre estoy dispuesto a admitir cuando cometo un error   V  F 
8. Algunas veces trato de vengarme en lugar de perdonar y olvidar             V  F 
9. Siempre soy amable, aún con personas desagradables    V  F 
10. Nunca me molesté cuando la gente expresaba ideas muy diferentes a las mías V F 
11. Ha habido ocasiones en la que me sentí envidioso de la buena suerte de otros V  F 
12. A veces me molesta la gente que me pida favores    V  F 












PARTE XII: PREVIO AL VIDEO: CONOCIMIENTO DE LOS PADRES SOBRE 
EL VPH, ETAPA DE CAMBIO Y AUTOEFICACIA PARA HABLAR CON 
PROVEEDORES DE SALUD Y QUE LOS NIÑOS RECIBAN LA VACUNA 
CONTRA EL VPH (PRE-V-PARENTS-HPV-K-SOC-SE-FTP-CR-HPV-V-7) 
[This is a new scale created by the Principal Investigator and her dissertation sponsor, Dr. 
Barbara Wallace, for use by the Research Group on Disparities in Health (RGDH). The 
scale provides a continuous score for the sub-scales of: (1) self-rating of level of HPV 
knowledge [K-item # 1]; (2) stage of change for performing the HPV-related behaviors 
indicated [SOC-items # 2, 4, 6], and (3) self-efficacy for performing the HPV-related 
behaviors indicated [SE-items # 3, 5, 7]] 
 
1-Por favor, califica lo que sabes o tu nivel de conocimiento a cerca de la infección por el 
virus del papiloma humano y la vacuna contra el virus VPH para chicos: 
 
Muy poco Poco Intermedio Bueno Muy Bueno Excelente 
1 2 3 4 5 6 
 
Por favor, califícate a ti mismo por el comportamiento al hablar con un pediatra o médico 
de familia a cerca de la infección por el virus del papiloma humano y la vacuna contra el 
virus VPH para niños. Marca abajo lo que mejor te describa: 
2-Por hacer esto 
_____No pienso realizar este comportamiento para nada. 
_____Estoy pensando en realizar este comportamiento. 
_____Me estoy preparando para realizar este comportamiento. 
_____Estuve realizando este comportamiento durante menos de seis (6) meses. 
_____ Estuve realizando este comportamiento durante más de seis (6) meses hasta varios 
años. 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna contra el 
VPH. 
3-Y, por hacer esto me siento 
____0% seguro               ____20% seguro                 ____40% seguro  
____60% seguro             ____80% seguro                 ____100% seguro 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna 
 
NOTE: ITEM # 4 action and maintenance stages (less than 6 months and more than 6 
months up to many year) = Study # 1 Dependent Variable: 
 
Por favor, califícate a ti mismo por el comportamiento de asegurarte que tus hijos reciban  
la vacuna contra el virus VPH. Marca abajo lo que mejor te describa: 
 
4-Por hacer esto 
_____No pienso realizar este comportamiento para nada. 
_____Estoy pensando en realizar este comportamiento. 









_____Estuve realizando este comportamiento durante menos de seis (6) meses. 
_____ Estuve realizando este comportamiento durante más de seis (6) meses hasta varios 
años. 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna contra el 
VPH. 
5-Y, por hacer esto me siento 
____0% seguro               ____20% seguro                 ____40% seguro  
____60% seguro             ____80% seguro                 ____100% seguro 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna  
 
Por favor, califícate a ti mismo por el comportamiento de asegurarte que tus hijos reciban 
todas las dosis necesarias (ej. al menos 2 o 3 dosis) de la vacuna contra el virus VPH. 
Marca abajo lo que mejor te describa: 
6-Por hacer esto 
_____No pienso realizar este comportamiento para nada. 
_____Estoy pensando en realizar este comportamiento. 
_____Me estoy preparando para realizar este comportamiento. 
_____Estuve realizando este comportamiento durante menos de seis (6) meses. 
_____ Estuve realizando este comportamiento durante más de seis (6) meses hasta varios 
años. 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna contra el 
VPH. 
7-Y, por hacer esto me siento 
____0% seguro               ____20% seguro                 ____40% seguro  
____60% seguro             ____80% seguro                 ____100% seguro 




PADRES, POR FAVOR HAGAN CLICK EN EL EN EL ENLACE PARA VER EL 
DIBUJOS ANIMADOS  
 (durante aproximadamente 5 minutos) 
 
************************************************************* 
PARTE XIII: ENCUESTA DE ADHERENCIA PARA PROVEEDORES DE 
SALUD LUEGO DE VER EL VIDEO (PVV-AS-PROVIDERS– 1) 
[Este es un formulario de medición comúnmente usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
 
Por favor, conteste las siguientes preguntas:  
1- ¿Cuánto vio del video? 










PARTE XIV: DÉSPUES AL VIDEO: CONOCIMIENTO DE LOS PADRES 
SOBRE EL VPH, ETAPA DE CAMBIO Y AUTOEFICACIA PARA HABLAR 
CON PROVEEDORES DE SALUD Y QUE LOS NIÑOS RECIBAN LA VACUNA 
CONTRA EL HPV (PRE (((isn’t it POST))))-V-PARENTS-HPV-K-SOC-SE-FTP-
CR-HPV-V-7) 
[See description under PART XII. This is the same scale, but for post-video] 
 
1-Por favor, califica lo que sabes o tu nivel de conocimiento a cerca de la infección por el 
virus del papiloma humano y la vacuna contra el virus VPH para chicos: 
 
Muy poco Poco Intermedio Bueno Muy Bueno Excelente 
1 2 3 4 5 6 
 
Por favor, califícate a ti mismo por el comportamiento al hablar con un pediatra o médico 
de familia a cerca de la infección por el virus del papiloma humano y la vacuna contra el 
virus VPH para niños. Marca abajo lo que mejor te describa: 
2-Por hacer esto 
_____No pienso realizar este comportamiento para nada. 
_____Estoy pensando en realizar este comportamiento. 
_____Me estoy preparando para realizar este comportamiento. 
_____Estuve realizando este comportamiento durante menos de seis (6) meses. 
_____ Estuve realizando este comportamiento durante más de seis (6) meses hasta varios 
años. 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna contra el 
VPH. 
3-Y, por hacer esto me siento 
____0% seguro               ____20% seguro                 ____40% seguro  
____60% seguro             ____80% seguro                 ____100% seguro 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna 
 
Por favor, califícate a ti mismo por el comportamiento de asegurarte que tus hijos reciban  
la vacuna contra el virus VPH. Marca abajo lo que mejor te describa: 
 
4-Por hacer esto 
_____No pienso realizar este comportamiento para nada. 
_____Estoy pensando en realizar este comportamiento. 
_____Me estoy preparando para realizar este comportamiento. 
_____Estuve realizando este comportamiento durante menos de seis (6) meses. 
_____ Estuve realizando este comportamiento durante más de seis (6) meses hasta varios 
años. 











5-Y, por hacer esto me siento 
____0% seguro               ____20% seguro                 ____40% seguro  
____60% seguro             ____80% seguro                 ____100% seguro 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna  
 
Por favor, califícate a ti mismo por el comportamiento de asegurarte que tus hijos reciban 
todas las dosis necesarias (ej. al menos 2 o 3 dosis) de la vacuna contra el virus VPH. 
Marca abajo lo que mejor te describa: 
6-Por hacer esto 
_____No pienso realizar este comportamiento para nada. 
_____Estoy pensando en realizar este comportamiento. 
_____Me estoy preparando para realizar este comportamiento. 
_____Estuve realizando este comportamiento durante menos de seis (6) meses. 
_____ Estuve realizando este comportamiento durante más de seis (6) meses hasta varios 
años. 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna contra el 
VPH. 
7-Y, por hacer esto me siento 
____0% seguro               ____20% seguro                 ____40% seguro  
____60% seguro             ____80% seguro                 ____100% seguro 
_____No puedo contestar porque no conozco suficiente a cerca de la vacuna 
------------------------------------------------------------------------------------------------------------ 
 
PARTE XV: CALIFICA EL VIDEO PARA PADRES (RTV-PARENTS-2) 
[Este es un formulario de medición comúnmente usado por el Grupo de Estudios 
sobre Desigualdades en Salud (RGDH).] 
 
Por favor, piense en el video de dibujos animados que le solicitamos mirar y califique el 
video: 
1. Yo califico el video como: 
Muy malo Malo Intermedio Bueno Muy bueno Excelente 
1 2 3 4 5 6 
___No me siento capaz de calificar el video – No pude ver todo el video  
------------------------------------------------------------------------------------------------------------ 
PARTE XVI: DIFUSION DE LA INNOVACION DE USAR E-SALUD SOBRE 
VPH PARA PADRES (DOF-UEH-HPV-PARENTS-1) 
[Este es un formulario de medición comúnmente usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
 
1. ¿Recomendaría usted este video a otros padres con niños? 
__Si __No  ______No me siento capaz de ofrecer una recomendación – ya que no pude 










PARTE XVII: SECCION CUALITATIVA SOBRE LAS RAZONES PARA 
RECOMENDAR O NO, EL VIDEO DE E-SALUD PARA PADRES (QP-RREHV-
PARENTS-1) 
[Este es un formulario de medición comúnmente usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
 
1- Por favor explique por qué recomendaría o no el video. Siéntase libre de comentar 
sobre lo positivo y lo negativo del video, o cómo se podría mejorar el video. 
___No me siento capaz de comentar sobre el video ya que no pude ver el video completo 








PARTE XVIII: SECCION CUALITATIVA SOBRE LAS REACCIONES DE LOS 
PADRES FRENTE A SU PARTICIPACION EN EL ESTUDIO (QP-RSP-
PARENTS-1) 
[Esta es una nueva pregunta creado por la Investigadora Principal y su Directora de 
Investigación, Dra. Barbara Wallace, para ser usado por el Grupo de Estudios sobre 
Desigualdades en Salud (RGDH).] 
1- ¿Qué pensamientos o sentimientos podría usted compartir como resultado de ver el 

























SCREENING TOOL FOR PROVIDERS  
FOR IRB PROTOCOL # 19-172 
 
1-Are you a medical health care provider (e.g. physicians, physician assistants, 
nurse practitioners)? ___Yes ___No 
 
2-Do you work in a pediatric or family care practice? ___Yes ___No 
 
3-Have you had direct contact with patients within the past six months? 
___Yes ___No 
 
4-Are you at least 24 years of age? 
___Yes ___No 
 
5-Are you able to devote about 10-12 minutes to this study at this time, including 
watching a 5-minute avatar/cartoon video and stating if you recommend it to other 




If they answered YES to all of the above questionsà they access survey. 
If they answered NO to any of the above questionsà they receive this message: 
Thank you for your time, but, unfortunately you are not qualified to participate in 
this study.  
 
Feel free to invite medical providers for children to participate in this study. Send them 


















HPV SURVEY FOR PEDIATRIC AND FAMILY 
PRACTICE PROVIDERS 
 
Instructions. Please answer the following questions by either placing a check mark next 
to your answer, or filling in the blank space. 
---------------------------------------------------------------------------------------------- 
PART I: PROVIDERS’ BASIC DEMOGRAPHICS (PROVIDERS-BD-125)  
[This is a common tool used by the Research Group on Disparities in Health (RGDH). 
Questions have been added specific to medical providers for this study.] 
1)   MY gender is: ___Female  ___Male ___Other (Please explain________) 
2)  MY age is: _______ (USE DROP DOWN MENU OF 18 to 85) 
3)  MY race/ethnicity is as follows: (Please mark all that apply) 
__Black/African American  
__White / Caucasian / European American 
__Hispanic / Latino (including Dominican, Puerto Rican, Mexican, Mexican American, 
Chicano, Cuban, other Spanish)  
    __Asian (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, or other 
Asian)  
__American Indian / Alaska Native 
__Native Hawaiian / Pacific Islander 
__Arab American / Middle Eastern 
__Other group(s) (Please specify)  
4)  Do you live in the United States? _Yes    _No If NO—EXIT SURVEY 
If yes, what is your current zip code? ¬¬¬_____________________________ 
5) Were you born in the United States?  
If you answered “No,” where was YOUR place of birth or country of origin? 
b-1. Country of_____________________[Drop down menu] 
b-2. And, at what age did YOU come to the US? [Drop down menu 1-70] 
6) Do you have a partner? ___Yes __NoI AM currently:  
a. ___Single   b. ___Married c. ___Separated  d. ___Divorced 
e. ___Widowed  f. ___In Domestic Partnership g. ___Living with Significant 
Other 
7). My annual household income is:  
 1-Less than $920,000 
 2-$10,000 to $19,000  
 3-$20,000 to $39,000  
 4-$40,000 to $49,000 
 5-$50,000 to $99,999 
 6-$100,000 to $199,999 
 7-$200,000 to $299,000 
 8-$300,000 to $399,000 
 9-$400,000 to $499,000 
 10-$500,000 to $799,000 









8) My highest education level/degrees obtained is: (check all that apply) 
 ___Nursing Diploma.  
___ M.S.N 
___MPH    
___MSW  
 ___Nurse Practitioner (NP, FNP, ANP, GNP, etc…) 
___ Physician Assistant (PA) 
___M.D. (Medical Doctor) 
___DO (Doctor of Osteopathic Medicine) 
___Other (Please explain______________) 
9- My current job title is: _____________________________________ 
9 10-My employment status is: a. ___Full Time      b. ___Part Time      c_Per Diem 
 c.___Unemployed for a period of ___________ 
 d.___Retired for a period of ____________ 
11-Do you work in pediatrics? ___Yes __No 
12-Do you work in a family practice? ___Yes ___No 
13. In terms of the type of health care setting in which I work, it may best be described as 
a: 
__Hospital or medical center 
__outpatient medical clinic 
__outpatient medical primary care practice office 
__outpatient community clinic 
__outpatient private practice  
__outpatient mobile medical van 
__emergency room 
__other (explain)________________ 
14. I have worked in my current position for a period of  








__more than 30 years 
135. In terms of my career, I have worked in pediatrics or a family practice some type of 
health care setting (hospital, medical center, clinic, emergency room, etc…) for a total 
period of 
















__more than 30 years 
------------------------------------------------------------------------------------------------------------ 
PART II: PRE-VIDEO PROVIDERS’ OVERALL HPV KNOWLEDGE FOR 
RECOMMENDING HPV VACCINATION TO PARENTS FOR THEIR CHILD— 
AND STAGE OF CHANGE, SELF-EFFICACY, AND BARRIERS (PRE-VIDEO-
PROVIDERS-SOC-SE-B-4) 
 
[This is a new scale created by the Principal Investigator and her dissertation sponsor, Dr. 
Barbara Wallace, for use by the Research Group on Disparities in Health (RGDH).] 
 
1-Please rate what you know, or your level of knowledge about the Human 
papillomavirus (HPV) infection, the available HPV vaccinations, and the schedule for 
vaccinating preteen and teen boys and girls? 
 
Very Poor Poor Fair Good Very Good Excellent 
1 2 3 4 5 6 
 
Please rate yourself for the behavior of recommending within my medical practice to 
parents/guardians that they vaccinate their preteen and teen boys and girls for HPV– by 
checking what best describes you, below 
2-For doing this 1-5 
_____I am not thinking of doing this behavior at all. 
_____I am thinking about doing this behavior. 
_____I am preparing to do this behavior. 
_____I have been doing this behavior for less than six (6) months. 
_____I have been doing this behavior for more than six (6) months up to many   
          years 
_____I cannot answer, because I do not know enough about the HPV vaccination  
3-And, for doing this I am 1-6 
____0% confident                ____20% confident                ____40% confident  
____60% confident             ____80% confident                 ____100% confident  
_____I cannot answer, because I do not know enough about the HPV vaccination 
4-And, the degree of barriers I (e.g. time) experience in a medical visit for actually doing 
this is  
__(0) non-existent (none at all) __(1) extremely low __(2) very low  __(2) low __(3) 
moderate __(4) high ___(5) very high  __(6) extremely high 
------------------------------------------------------------------------------------------------ 
************************************************************* 
PROVIDERS PLEASE CLICK ON THE LINK TO WATCH THE CARTOON  










PART III: POST-VIDEO VIEWING ADHERENCE SURVEY FOR PROVIDERS 
(PVV-AS-PROVIDERS– 1) 
 
Answer the following questions, please: 
1-How much of the video was watched? 
3__All of the video  2__Most of the video  1_Some of the video  0_None of the video 
------------------------------------------------------------------------------------------------------------ 
PART IV: RATE THE VIDEO FOR PROVIDERS (RTV-PROVIDERS-1) 
[This is a common scale used by the Research Group on Disparities in Health (RGDH).] 
 
Please think about the cartoon video you were asked to watch. Please rate this cartoon as 
a potential linguistically and culturally appropriate tool (i.e. available in English and 
Spanish) to support parents in their decision-making about whether or not they make sure 
their preteen or teen child receives the HPV vaccination series. 
 
1. I rate the video as follows: 
Very Poor Poor Fair Good Very Good Excellent 
1 2 3 4 5 6 
___NA/Unable to rate - I was not able to watch the video 
------------------------------------------------------------------------------------------------------------ 
PART V: DIFFUSION OF INNOVATION USING E-HEALTH ON HPV BY 
PROVIDERS (DOF-UEH-HPV-PROVIDERS-1) 
 
NOTE: This is the study # 2 dependent variable of pediatricians/family practitioners 
recommending (yes/no) the video to parents and/or other providers so they could share it 
with parents. 
 
1- Would you recommend this cartoon video for parents, or to other providers so they 
could share it with parents? 
1-__Yes _0-_No  ___NA/Unable - I was not able to watch the video 
------------------------------------------------------------------------------------------------------------ 
PART VI: QUALITATIVE PORTION ON REASONS FOR REOMMENDING 
THE E-HEALTH VIDEO OR NOT—FOR PROVIDERS (QP-RREHV-
PROVIDERS-1) 
 [NOT A REQUIRED QUESTION IN QUALTRICS] 
 
1- Please explain why you would or would not recommend the video. Feel free to offer 
your comments on the strengths and weaknesses of the video, or how could it be 
improved. 
___I feel unable to comment on the video – as I was not able to watch all the video 












PART VII: QUALITATIVE PORTION ON REACTIONS TO STUDY 
PARTICIPATION BY PROVIDERS (QP-RSP-PROVIDERS-1) 
 [NOT A REQUIRED QUESTION IN QUALTRICS] 
 
1-What other thoughts or feelings might you share in response to watching the video 
and/or taking this survey? 
















S1. Table A-Correlations Between Selected Variables and Pre-Video SOC for Having Child 
Vaccinated and Rating of the Video (Watched All or Most) 
 Pre-Video SOC for Having 
Child Vaccinated 
 Rating of the Video 
Variables selected N Pearson 
Correlation 
P  N Pearson 
Correlation 
P 
Participant age 122 .196 .031*  85  .225 .038* 
Yearly Household 
Income 
122 .154 .091  85 -.073 .507 




122 .132 .147  85 .122 .267 
Exposure to print 
and digital media 
information on 
HPV 
116 .221 .017*  80 .188 
 
.096 
HPV Knowledge 122 .287 .001***  85 .014  .897 
HPV Vaccine 
Knowledge 












122 -.049 .589  85 -.003 .981 
Perceived 
barriers 
174 -.020 .826  85 .072 .512 
Social desirability 122 -.174 .055  85 .041 .713 
*p<.05, **p<.01, ***p<.001 
Bonferroni Adjustment Significance (.05/12, p= .004)  
Note: All p values above .004 are considered non-significant, and only those below .004 










S1. Table B. Correlation Between Selected Variables and Pre-Video SOC for Having Child 
Vaccinated and Rating of the Video (Watched All or Most) 
   Pre-Video SOC for Having 
Child Vaccinated 
Rating of the Video 
Variables selected N Pearson 
Correlation 
P  N Pearson 
Correlation 
p 
Participant age        
1-ESP 68 .169 .167  52 .180 .20
2 




        
1-ESP 68 .113 .358  52 -.149 .29
2 
2- SSP 54 .129 .354  33 .007 .97
0 
Educational level         
1-ESP 67 .124 .317  51 .002 .991 
2- SSP 54 -.006 .967  33 .124 .490 
Number of children 
aged 9-18 
        
1-ESP 68 .226 .063  52 .263 .060 
2- SSP 54 .010 .942  33 -.057 .753 
Exposure to print 
and digital media 
information on 
HPV 
        
1-ESP 63 .078 .542  48 .156 .289 
2- SSP 53 .386 .004**  32 .219 .228 
HPV Knowledge        
1-ESP 68 .194 .112  52 .058 .683 
2- SSP 54 .378 .005**  33 -.095 .599 
HPV Vaccine 
Knowledge 
        
1-ESP 68 .232 .057  52 .072 .610 
2- SSP 54 .282 .039*  33 .024 .896 
Vaccine 
Conspiracy Beliefs 
        
1-ESP 68 -.077 .530  52 -.250 .074 













        
1-ESP 68 -.167 .173  52 -.087 .541 
2- SSP 54 -.301 .027*  33 -.033 .853 
Vaccine hesitancy-
hesitancy risks 
        
1-ESP 68 -.134 .278  52 -.118 .406 
2- SSP 54 .062 .654  33 .243 .173 
Perceived barriers          
1-ESP 68 -.043 .725  52 .214 .127 
2- SSP 54 .033 .810  33 -.255 .152 
Social desirability          
1-ESP 68 -.192 .117  52 .067 .635 
2- SSP 54 -.088 .527  33 .006  .975 
*p<.05, **p<.01, ***p<.001 
Bonferroni Adjustment Significance (.05/12, p= .004)  
Note: All p values above .004 are considered non-significant, and only those below .004 













Internal Consistency of the Study Scales 
 
 
*S1. Table C. Internal Consistency of Scales (GVA-CB-HLC-R-16) (N=122) 
Scale  #of 
items  
Cronbach’s Alpha 
Whole Sample (N=122)   
(a) –The General Vaccine Attitudes- Conspiracy Beliefs, 
and Hesitancy due to Lack of Confidence or Risks Scale 
(GVA-CB-HLC-R-16) 
7 .890 
(b) –The General Vaccine Attitudes- Conspiracy Beliefs, 
and Hesitancy due to Lack of Confidence or Risks Scale 
(GVA-CB-HLC-R-16) 
7 .943  
(c) –The General Vaccine Attitudes- Conspiracy Beliefs, 
and Hesitancy due to Lack of Confidence or Risks Scale 
(GVA-CB-HLC-R-16) 
2 .765 
ESP: (N=64)   
(a) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .915 
(b) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .931 
(c) - The General Vaccine Attitudes- Conspiracy Beliefs 
and Hesitancy due to Lack of Confidence or Risks Scale 
(GVA-CB-HLC-R-16) 
2 .795 
SSP (N=54)   
(a) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .851 
(b) - The General Vaccine Attitudes- Conspiracy 
Beliefsand Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .953 
(c) - The General Vaccine Attitudes- Conspiracy Beliefs 
and Hesitancy due to Lack of Confidence or Risks  
Scale (GVA-CB-HLC-R-16) 
2 .720 
Note: Regarding Research Question # 9-What are the parents’ general vaccine attitudes, 











S1. Table C. Internal Consistency of the Scale (GVA-CB-HLC-R-16) (N=122) 
Scale  #of 
items  
Cronbach’s Alpha 
Whole Sample (N=122)   
(a) - The General Vaccine Attitudes- Conspiracy 
Beliefs,    and Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .890 
(b) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks  
        Scale (GVA-CB-HLC-R-16) 
7 .943  
(c) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks  
        Scale (GVA-CB-HLC-R-16)) 
2 .765 
ESP: (N=64)   
(a) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks  
        Scale (GVA-CB-HLC-R-16) 
7 .915 
(b) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks  
        Scale (GVA-CB-HLC-R-16) 
7 .931 
(c) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks  
        Scale (GVA-CB-HLC-R-16) 
2 .795 
SSP (N=54)   
(a) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .851 
(b) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 
Risks Scale (GVA-CB-HLC-R-16) 
7 .953 
(c) - The General Vaccine Attitudes- Conspiracy 
Beliefs, and Hesitancy due to Lack of Confidence or 














Qualitative Data Analysis Strategy 
 
ANALYZING QUALITATIVE DATA 
 
The Research Group on Disparities in Health (RGDH) highly values mixed 
methods dissertations that combine quantitative and qualitative methods. Professor 
Barbara Wallace, Director of the RGDH, has provided this step-by-step guide for the 
analysis of qualitative data. Typically, a dissertation is rooted in three to four theories 
(e.g. stages of change, self-efficacy, diffusion of innovation) and surveys collecting 
quantitative data have a rationale in corresponding theory. Meanwhile, all surveys end 
with open-ended questions (1-3) that are analyzed for themes; some students use a 
qualitative data analysis package for this task. However, I recommend the following steps 
for analyzing qualitative data: 
 
Myth: you do not need to read all of your qualitative data 
Truth: you DO need to follow all these steps 
 
START WITH YOUR FIRST QUALITATIVE RESEARCH QUESTION 
 
1) ORGANIZE- copy and paste qualitative data from survey monkey into one file--
organizing by question asked 
2) HIGHLIGHT - as you read it, highlight in yellow quotes that stand out--and, after 
you read about twenty answers, go back to the first highlighted yellow and in brackets at 
the end put an emergent theme: 
3) CREATE ACTION PHRASES - ITALICIZE AND BOLD - the emergent theme in 
brackets should be an action phrase--such as perceiving the need for 
supervision/training 
or striving to achieve positive outcomes or pursuing objectives by taking action 
4) LIST DOCUMENT FOR EMERGENT THEMES -as you continue to read beyond 
the first twenty answers, have a second document where you are copying and pasting 
your emergent themes--creating a LIST; as you read your twentieth to fortieth answer, 
start to just copy and paste the relevant emergent theme from your LIST, placing it in 
brackets where it applies 
5) THEMES EXPAND TO ACCOMMODATE MORE DATA - feel free to elaborate 
on the emergent theme to accommodate the answers you see (twentieth to fortieth 
answers); for example, perceiving the need for supervision/training/new 
curriculum or striving to achieve positive outcomes/goals/highest potential, or pursuing 
objectives by taking action/engaging in advocacy 
6) SEE HOW EXPANDED THEMES ACCOMMODATE ALL DATA - the new 
elaborated emergent themes now encompass ALL the examples (#1-20, 21-40)  
7) CLASSIFY ALL DATA BY THEMES - continue to go through all of your data 









the emergent theme in brackets; put any NEW emergent themes in your second document 
where you are copying and pasting your emergent themes--creating a LIST 
8) QUICKLY CONTINUE TO CLASSIFY ALL DATA BY THEMES - if you have a 
LOT of data, eyeball and read quickly examples (101-200)--searching for every place 
you can highlight in yellow a new emergent theme (e.g. feeling the focus is 
unnecessary/rebelling/not caring)--to place on your LIST; or, quickly copy and paste 
where the new emergent theme fits in (e.g. #104 reflects the theme of perceiving the 
need for supervision/training/new curriculum) 
9) CREATE TABLE AND ORGANIZE BY REDUCED CATEGORIES THAT 
ENCOMPASS GROUPS OF THEMES: turn your final LIST of emergent themes (e.g. 
20) into a TABLE; search for CATEGORIES OF THEMES  that may accommodate 3-5 
of your emergent themes (fit under it like an umbrella); organize the LIST of emergent 
themes so groups appear under the higher order CATEGORIES. For example, there may 
be just 3 categories of solutions, or strategies, or complaints might each encompass 3-4 
themes. 
10) ENTER FREQUENCY AND PERCENTAGE IN TABLE: go back and count the 
number of times each emergent theme appeared in your data; add to your TABLE n and 
% for number of times the emergent theme appeared--even as it it now under a 
CATEGORY in your table. 
 
 
